[
  {
    "text": "Scottish Dental\nSDcep\nClinical Effectiveness Programme\nDrug Prescribing For Dentistry\nDental Clinical Guidance\nThird Edition\nJanuary 2016",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 1
  },
  {
    "text": "Scottish Dental\nSDcep\nClinical Effectiveness Programme\nThe Scottish Dental Clinical Effectiveness Programme (SDCEP)\nis an initiative of the National Dental Advisory Committee\n(NDAC) in partnership with NHS Education for Scotland. The\nprogramme provides user-friendly, evidence-based guidance\non topics identified as priorities for oral health care.\nSDCEP guidance aims to support improvements in patient care\nby bringing together, in a structured manner, the best available\ninformation that is releva",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 2
  },
  {
    "text": "nt to the topic, and presenting\nthis information in a form that can interpreted easily and\nimplemented.\nSupporting the provision of safe, effective, person-centred care",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 2
  },
  {
    "text": "Scottish Dental\nSDcep\nClinical Effectiveness Programme\nDrug Prescribing For Dentistry\nDental Clinical Guidance\nThird Edition\nJanuary 2016",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 3
  },
  {
    "text": "Drug Prescribing For Dentistry\nDisclaimer\nThis product contains information from the British National Formulary (BNF). For more\ncomprehensive prescribing and drug information, refer to the complete current edition of the\nBritish National Formulary or www.bnf.org.\nThe BNF is jointly owned by the Royal Pharmaceutical Society of Great Britain and the BMJ Publishing\nGroup Ltd (jointly referred to as “The Publisher”). The BNF provides UK healthcare professionals\nwith authoritative and practical infor",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 4
  },
  {
    "text": "mation on the selection and clinical use of medicines in a\nclear, concise and accessible manner. The BNF is designed for prescribers, pharmacists and other\nhealthcare professionals, situated within the United Kingdom. The Publisher works to ensure that\nthe information provided in the BNF is accurate and up-to-date as at the date of publication, but\nchanges do regularly occur and the Publisher does not warrant that it is accurate.\nThe BNF is designed as a digest for rapid reference and it may not",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 4
  },
  {
    "text": " always include all information\nnecessary for prescribing or dispensing. Also less detail is given on certain specialties since those\ninvolved are expected to have specialist knowledge and access to specialist literature. The BNF\nshould be interpreted in light of professional knowledge and supplemented as necessary with\nspecialist publications and by reference to product literature. Information is also available from\nmedicines information services.\nTo the fullest extent permitted by law the Publ",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 4
  },
  {
    "text": "isher assumes no responsibility for any aspect of\nhealthcare administered with the aid of this information or any other use of this information. The\nPublisher does not exclude any liability for death or personal injury resulting from negligence,\nfraud, or any liability which cannot be excluded by applicable law.\n© Scottish Dental Clinical Effectiveness Programme\nSDCEP operates within NHS Education for Scotland. You may copy or reproduce the\ninformation in this document for use within NHSScotland",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 4
  },
  {
    "text": " and for non-commercial\neducational purposes.\nUse of this document for commercial purposes is not permitted.\nISBN 978-1-905829-28-6\nFirst published 2008\nThird edition published January 2016\nScottish Dental Clinical Effectiveness Programme\nDundee Dental Education Centre, Frankland Building, Small’s Wynd, Dundee DD1 4HN\nEmail scottishdental.cep@nes.scot.nhs.uk\nTel 01382 425751 / 425771\nWebsite www.sdcep.org.uk",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 4
  },
  {
    "text": "Drug Prescribing For Dentistry\nDrug Prescribing For Dentistry\n1 Introduction 1\n1.1 Scope of this Guidance 1\n1.1.1 Medical Emergency Information 2\n1.1.2 Prescribing Information 2\n1.1.3 Drug Interactions 3\n1.1.4 Prescribing For Specific Patient Groups 3\n1.1.5 Off-label Prescribing 4\n1.1.6 Local Measures 4\n1.2 Statement of Intent 4\n1.3 Prescription Writing 5\n1.4 Adverse Reactions to Drugs 6\n2 Medical Emergencies in Dental Practice 7\n2.1 Anaphylaxis 10\n2.2 Treatment of Milder Forms of Allergy 11\n2.3",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 5
  },
  {
    "text": " Asthma 13\n2.4 Cardiac Emergencies 14\n2.4.1 Acute Coronary Syndromes (Angina and Myocardial Infarction) 14\n2.4.2 Cardiac Arrest 15\n2.5 Epilepsy 16\n2.6 Faint 18\n2.7 Hypoglycaemia 19\n2.8 Other Medical Emergencies 21\n2.8.1 Stroke 21\n2.8.2 Aspiration and Choking 22\n3 Anxiety 25\n4 Bacterial Infections 27\n4.1 Antibiotics and Contraception 28\n4.2 Infective Endocarditis 29\n4.3 Dental Abscess 29\n4.4 Necrotising Ulcerative Gingivitis and Pericoronitis 35\n4.5 Sinusitis 36\n5 Fungal Infections 39\n5.1 Pseudom",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 5
  },
  {
    "text": "embranous Candidosis and Erythematous Candidosis 39\n5.2 Denture Stomatitis 41\n5.3 Angular Cheilitis 43\n6 Viral Infections 45\n6.1 Herpes Simplex Infections 45\n6.2 Varicella-zoster Infections 48\niii",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 5
  },
  {
    "text": "Drug Prescribing For Dentistry\n7 Odontogenic Pain 49\n8 Facial Pain 55\n8.1 Trigeminal Neuralgia 55\n8.2 Other Facial Pain 56\n9 Mucosal Ulceration and Inflammation 57\n9.1 Simple Mouthwashes 57\n9.2 Antimicrobial Mouthwashes 58\n9.3 Local Analgesics 60\n9.4 Topical Corticosteroids 62\n10 Dry Mouth 63\n10.1 Local Measures 63\n10.2 Artificial Saliva Preparations 63\n10.3 Topical Fluoride 66\n11 Dental Caries 67\n12 Clinical Governance, CPD and Training 69\n12.1 Recommendations for Self Audit 70\n12.2 National Au",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 6
  },
  {
    "text": "dit 70\nAppendix 1 Guidance Development 71\nThe Scottish Dental Clinical Effectiveness Programme 71\nThe Programme Development Team 71\nThe Guidance Development Group 72\nGuidance Development Methodology 73\nReview and Updating 74\nSteering Group 74\nConflict of Interest 74\nAppendix 2 List of Drugs 75\nAppendix 3 Useful Sources of Information 77\nAppendix 4 Drug Interactions 80\nAppendix 5 Bacterial Infections Management Guide 82\nIndex 83\nReferences 85\niv",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 6
  },
  {
    "text": "Drug Prescribing For Dentistry\n1 Introduction\nRegistered dentists are legally entitled to prescribe from the entirety of the British National\nFormulary (BNF) and BNF for Children (BNFC). However, dental prescribing within the National\nHealth Service (NHS) is restricted to those drugs contained within the List of Dental Preparations\nin the Dental Practitioners Formulary (DPF). Since 2005 the DPF, which was formerly a distinct\npublication, has been incorporated into the body of the British Nationa",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 7
  },
  {
    "text": "l Formulary and the BNF\nfor Children. Both the BNF and BNFC are available as print and online editions, with an updated\nvolume of the BNF print edition issued every six months and an updated volume of the BNFC print\nedition issued yearly. The online editions of both the BNF and BNFC are updated monthly which\nenables access to the latest prescribing information (www.bnf.org).\nTo facilitate easy access to information that is most relevant to drug prescribing for dentistry,\nthe Scottish Dental Clin",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 7
  },
  {
    "text": "ical Effectiveness Programme (SDCEP; www.sdcep.org.uk) convened a\nGuidance Development Group in 2005 to produce guidance that brings together the essential\ninformation from the BNF and BNFC. Further details about SDCEP and the development of this\nguidance are given in Appendix 1. Edition one of this guidance was published in April 2008, with\nupdates provided periodically. A second edition was published in August 2011. This third edition\nof the Drug Prescribing For Dentistry guidance is based on ",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 7
  },
  {
    "text": "BNF 701 and BNFC 2015-162 and\nsupersedes the first two editions and their updates. An app, (Dental Prescribing) was released in\n2012 and is regularly updated in line with changes to the print editions of the BNF.\nThe list of drugs that can be prescribed by dentists within the NHS in Scotland includes all drugs\nin this guidance (see List of Dental Preparations in BNF 701). Although dentists can prescribe\nadditional drugs within the NHS, they have a duty to prescribe only within their competence a",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 7
  },
  {
    "text": "nd\nto adhere to guidance from their local formulary committees.\n1.1 Scope of this Guidance\nThis guidance aims to facilitate drug prescribing within primary care dental practice by bringing\ntogether advice on dental prescribing from the BNF and BNFC and presenting it in a readily\naccessible, problem-orientated style. The information on drug prescribing contained in this\nguidance is based on BNF 701 and BNFC 2015-16,2 whose advice is constructed from the clinical\nliterature and reflects, as far as",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 7
  },
  {
    "text": " possible, an evaluation of the evidence from diverse sources. The\ndrugs recommended in this guidance were identified by the Guidance Development Group as\nmost relevant to primary care dental practice.\nAdvice on drugs used to manage medical emergencies is also provided. This advice is based on\ninformation provided in BNF 701 and BNFC 2015-16,2 and guidance published by the National\nDental Advisory Committee (NDAC) in 2015.3\nThe diagnosis of dental disease is outwith the scope of this guidance an",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 7
  },
  {
    "text": "d is not discussed in\ndetail. The SDCEP Management of Acute Dental Problems4 guidance provides more information\non the diagnosis, initial management and subsequent care for a wide variety of conditions that\nmay present in primary care.\n1",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 7
  },
  {
    "text": "Drug Prescribing For Dentistry\n1 Introduction\nThis guidance is suitable for informing dental practitioners in the primary care sector, and applies\nto all patients, including adults, children and those with special needs, who would normally be\ntreated in the primary care sector. The guidance does not include advice on prescribing for those\nin a secondary care environment or for practitioners with special expertise who may prescribe a\nwider range of drugs.\nDrug regimens with dosages are included b",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 8
  },
  {
    "text": "ut the intention is for this guidance to be used in\nconjunction with the BNF and BNFC. Consult the most up-to-date volume of the BNF (www.\nbnf.org) before prescribing for adults and be aware that prescribing for some patient groups,\nincluding the elderly, patients who are immunocompromised or with hepatic or renal problems,\npatients who are pregnant and nursing mothers, might differ (see Section 1.1.4). Consult the\nmost up-to-date volume of the BNFC (www.bnf.org) before prescribing for children.",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 8
  },
  {
    "text": "\n1.1.1 Medical Emergency Information\nAll general dental practitioners and dental care professionals are required to be able to manage\nmedical emergencies, which includes the administration of drugs in a life threatening situation.\nA list of drugs for use in medical emergencies is included in Section 2, together with information\nabout their administration. This list reflects the emergency drugs recommended in BNF 701\nand included in NDAC guidance3 published in 2015. In addition, brief details of ",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 8
  },
  {
    "text": "the signs and\nsymptoms of medical emergencies that might occur in primary care dental practice are provided.\nInformation regarding administration of drugs used in medical emergencies is provided in white\nboxes on the left, with any differences in the doses or formulations for children provided in blue\nboxes on the right.\nThis advice is based on information provided in BNF 701 and BNFC 2015-2016,2 and guidance\npublished by the NDAC.3 Refer to guidance from the Resuscitation Council (UK)5-7 for de",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 8
  },
  {
    "text": "tails of\nthe equipment and training required to be able to deal with cardiorespiratory arrest effectively.\nThe SDCEP Practice Support Manual8 (www.psm.sdcep.org.uk) also contains further information\nand guidance concerning medical emergencies and life support.\n1.1.2 Prescribing Information\nIn Sections 3–11, prescribing information is presented for all patients: information is provided\nfor adults in yellow boxes on the left, and differences in the doses and formulations used for\ndifferent age ran",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 8
  },
  {
    "text": "ges of children are provided in blue boxes on the right.¥ For those drugs where a\nrange in the dose or frequency of administration is provided by the BNF, a dose and frequency of\nadministration that is most relevant to primary care dental practice is recommended based on the\n¥Be aware that, for clarity and to aid selection of the correct dose, age and weight ranges for children have been\nadjusted in the most recent versions of the BNF and BNFC so that they no longer overlap. This change is refle",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 8
  },
  {
    "text": "cted in\nthis edition of the guidance.\n2",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 8
  },
  {
    "text": "Drug Prescribing For Dentistry\n1 Introduction\nopinion of experienced practitioners. Advisory notes and cautions are provided in footnotes to the\nprescribing boxes to help inform the decision of the practitioner. For more detailed information\non cautions, contraindications and side-effects, refer to the BNF and BNFC (www.bnf.org).\nFor practical reasons, the frequency of administration of each drug is generally given as ‘X times\ndaily’. However, it is advisable to inform patients that they should ",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 9
  },
  {
    "text": "take the drug at regular intervals\nthat are as spaced out as possible.\nIn some cases a drug of choice is recommended for a given dental condition. However, in\nmany cases drug regimens are not listed in order of preference so that the choice of the clinical\npractitioner is not limited. The availability of sugar-free preparations, as indicated in the BNF, is\nhighlighted; for further details, refer to the BNF and BNFC. A list of all the drugs recommended\nin this guidance is provided in Appendix 2.\n",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 9
  },
  {
    "text": "1.1.3 Drug Interactions\nCommon drug interactions that could have serious consequences are identified within the\nguidance and include:\n• interaction of non-steroidal anti-inflammatory drugs (NSAIDs), carbamazapine, azole\nantifungals, metronidazole and macrolide antibiotics with warfarin.\n• incidence of myopathy after prescribing azoles and clarithromycin in those taking statins.\n• asthma symptoms exacerbated following the use of NSAIDs.\nIt is important that dentists are aware of potential drug in",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 9
  },
  {
    "text": "teractions. Further information on\ncommon drug interactions that may be encountered in dental practice is provided in Appendix 4\nof this guidance. However, it is recommended that dentists refer to Appendix 1 of the BNF and\nBNFC (www.bnf.org) for comprehensive information on drug interactions.\nNote that antibiotics which do not induce liver enzymes are no longer thought to reduce the\nefficacy of combined oral contraceptives.9 See Section 4.1 for further information.\n1.1.4 Prescribing For Specific",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 9
  },
  {
    "text": " Patient Groups\nBe aware that special care may be required when prescribing for certain groups who may have\nadditional or complex needs, such as the elderly, patients who are immunocompromised, patients\nwho are pregnant and nursing mothers. Also note that dentists need to be aware of whether any\npatient suffers from an unrelated medical condition (e.g. renal or liver impairment) or is taking\nother medication because modification to the management of the patient’s dental condition\nmight be requir",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 9
  },
  {
    "text": "ed.10 Refer to the BNF and BNFC (www.bnf.org) for further details.\n3",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 9
  },
  {
    "text": "DDrruugg PPrreessccrriibbiinngg FFoorr DDeennttiissttrryy\n1 Introduction\n1.1.5 Off-label Prescribing\nSome drugs, although licensed, are recommended for use outside the terms of their licence\n(‘off-label’ use). Some of these drugs have been found to be effective in dental practice and\nalthough their specific use in dentistry has not been licensed, their use in the management of\ncertain dental conditions has been endorsed by the BNF. Also, certain drugs which are licensed\nfor use in adults are not",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 10
  },
  {
    "text": " licensed for use in children. As most drugs are not usually tested on\nchildren, pharmaceutical companies cannot apply to license them for paediatric use. The use of\nthese drugs is, however, sometimes necessary in the treatment of children. For more details see\nthe General Medical Council website: www.gmc-uk.org/guidance/ethical_guidance/14327.asp.\nThe responsibility for prescribing drugs ‘off-label’ and any other drugs lies with the practitioner\nwho signs the prescription. Note that prescribing",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 10
  },
  {
    "text": " or administering drugs that are unlicensed\nfor a particular condition or for use in children alters (and probably increases) the practitioner’s\nprofessional responsibility and potential liability, and the practitioner should be able to justify and\nfeel competent in using such drugs (see BNF; www.bnf.org). For information, these drugs are\nindicated within the text.\n1.1.6 Local Measures\nDrug therapy is only part of the management of dental conditions, which also includes surgical\nand local measur",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 10
  },
  {
    "text": "es. In some cases, local measures are sufficient to treat a given dental condition,\nwhereas in other cases drug therapy in addition to local measures is necessary. Information\nregarding common local measures to be used in the first instance is provided in green boxes\nbefore prescribing information.\n1.2 Statement of Intent\nThis guidance is based on information contained in BNF 701 and BNFC 2015-20162 and the\nopinion of experts and experienced practitioners, and reflects current relevant legislati",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 10
  },
  {
    "text": "on and\nprofessional regulations. It should be used in conjunction with the BNF and BNFC and be taken\ninto account when making decisions about a particular clinical procedure or treatment plan in\ndiscussion with the patient and/or guardian or carer.\nNote that drug therapy is only part of the management of dental conditions, which also includes\nsurgical and local measures.\nAs guidance, the information presented here does not override the individual responsibility of the\nhealth professional to make",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 10
  },
  {
    "text": " decisions appropriate to the individual patient. However, it is advised\nthat significant departures from this guidance be fully documented in the patient’s case notes at\nthe time the relevant decision is made.\nAlthough primarily provided for dental practitioners in Scotland, this guidance is also likely to be\nof relevance elsewhere. If using the guidance outside Scotland, it may also be necessary to consult\nother local or national guidance and to be aware of other prescribing practice initiativ",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 10
  },
  {
    "text": "es.\n4",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 10
  },
  {
    "text": "Drug Prescribing For Dentistry\n1 Introduction\n1.3 Prescription Writing\nDental practitioners should only prescribe within their competence and must make an appropriate\nassessment of the patient’s condition, taking into account their medical history and any current\nmedication, when prescribing. Dentists may only write NHS prescriptions for drugs which appear\nin the Dental Practitioners’ Formulary (DPF), which is incorporated in the BNF and BNFC (both\navailable at www.bnf.org). NHS prescriptions ar",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 11
  },
  {
    "text": "e written on a specified form (e.g. GP14 in\nScotland). If the medicine to be prescribed is not included in the DPF, a private prescription\nmay be provided. Private patients who require medicine as part of their treatment should also\nbe provided with a private prescription, even if the required drug is included in the DPF. Private\nprescriptions may be written on practice headed notepaper following the same recommendations\nas for NHS prescriptions. Dental practitioners may only prescribe using the",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 11
  },
  {
    "text": " non-proprietary name\nof the drug. Exceptions to this are detailed in the text under individual drugs. An example of a\ncompleted prescription form can be found in the section Guidance on Prescribing in general BNF\nguidance (www.bnf.org).\nWrite prescriptions legibly in ink, stating the date, the name and address of the patient\nand the practice address.\nIt is preferable that the age and date of birth of the patient is also stated; this is a legal\nrequirement in the case of prescription-only medici",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 11
  },
  {
    "text": "nes for children under 12 years.\nWrite the names of drugs and preparations clearly using approved titles only. Do not\nuse abbreviations.\nState the pharmaceutical form to be dispensed (i.e. tablet, capsule, liquid) and the\nrequired strength; this is particularly important for liquid preparations.\n• It is acceptable to abbreviate ‘milligrams’ to ‘mg’ but do not abbreviate ‘micrograms’\nor ‘nanograms’; these must be written in full.\nState the dose and the dose frequency.\nState the quantity or volume",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 11
  },
  {
    "text": " to be supplied; this may also be indicated by stating the\nnumber of days of treatment required in the box provided on NHS forms.\n• Where a liquid formulation is prescribed, the volume to be dispensed will be\ncalculated by the dispenser provided that the number of days of treatment required\nis included. Sugar-free versions, where available, should be prescribed.\nIn the case of preparations to be taken ‘as required’, specify a minimum dose interval\nand the total quantity to be supplied.\nSign the ",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 11
  },
  {
    "text": "prescription in ink.\n5",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 11
  },
  {
    "text": "Drug Prescribing For Dentistry\n1 Introduction\nThere is no statutory requirement for the dental surgeon to communicate with a patient’s medical\npractitioner when prescribing for dental use. There are, however, occasions when this would be\nin the patient’s interest and such communication is encouraged.\nThere are no clinical indications for drugs which have controlled drug prescription requirements\nto be prescribed in primary dental care.\nNHS prescription pads must be kept secure to prevent misuse ",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 12
  },
  {
    "text": "or theft. The Practitioner Services\ndivision of NHS National Services Scotland has produced guidance for all prescribers across\nScotland. This discusses a range of measures available to prevent and tackle the problem of\nprescription form theft and misuse at a local level and outlines the recommended action when\nan incident occurs (see www.psd.scot.nhs.uk/professionals/pharmacy/documents/security_of_\nprescription_form_guidance-final_July2012_000.pdf).\nFurther advice on prescription writing is giv",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 12
  },
  {
    "text": "en in the BNF and BNFC (www.bnf.org).\n1.4 Adverse Reactions to Drugs\nAdverse or unwanted reactions might occur after use of any drug. The Medicines and Healthcare\nproducts Regulatory Agency (MHRA; www.mhra.gov.uk) monitors suspected adverse drug\nreactions through the Yellow Card Scheme (www.yellowcard.gov.uk). Healthcare professionals\nare advised to record and report any adverse drug reactions using the scheme. Patients and carers\ncan also report suspected adverse reactions to the MHRA using the",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 12
  },
  {
    "text": " scheme. More information is\navailable from the BNF (www.bnf.org).\nIt is also important when prescribing to discuss with the patient any potential side effects, such as\nnausea or diarrhoea, which may occur.\n6",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 12
  },
  {
    "text": "Drug Prescribing For Dentistry\n2 Medical Emergencies in Dental Practice\nEach dental practice must stock, and regularly check, a core list of drugs and equipment for use\nin medical emergencies. All general dental practitioners and dental care professionals are required\nto ensure that they are competent in the use of both the drugs and the equipment and are able to\nrecognise medical emergencies.5,6 The SDCEP Practice Support Manual8 (www.psm.sdcep.org.uk)\ncontains further information on emergency ",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 13
  },
  {
    "text": "medical equipment and storage of emergency drugs.\nBrief details of the drugs used in the management of medical emergencies are provided\nhere. Refer to guidance from the Resuscitation Council (UK),5-7 the National Dental Advisory\nCommittee3 and the BNF1 for more-detailed advice on how to recognise, assess and manage\nmedical emergencies and for details of the equipment and training required to be able to deal\nwith medical emergencies and cardio-pulmonary resuscitation (CPR) effectively. It is impo",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 13
  },
  {
    "text": "rtant\nto undertake regular training in the management of medical emergencies within the dental\nenvironment to keep up to date with current guidance. Training in medical emergencies is a\ncore element of continuing professional development (CPD) for dentists and all dental care\nprofessionals and the GDC recommend at least 10 hours of such training every CPD cycle (2 hours\nper year). Ensuring that you have an up-to-date full medical history for all patients will facilitate\nthe management of medical",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 13
  },
  {
    "text": " emergencies.\nRefer to Appendix 1 of the BNF and BNFC for further details of drug interactions. 7",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 13
  },
  {
    "text": "Drug Prescribing For Dentistry\n2 Medical Emergencies in Dental Practice\nThe current recommended drugs for medical emergencies are:\n• Adrenaline, 1-ml ampoules or prefilled syringes of 0.5 ml of 1:1000 solution for\nintramuscular (i.m.) injection§\n• Aspirin, 300 mg dispersible tablets\n• Glucagon, for i.m. injection of 1 mg\n• Glyceryl trinitrate (GTN) spray, 400 micrograms per metered dose\n• Midazolam oromucosal solution, 5 mg/ml, for topical buccal administration¥\n• Oral glucose (there are several",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 14
  },
  {
    "text": " alternative forms, including non-diet fizzy drinks,\nglucose gel, powdered glucose and sugar lumps)\n• Oxygen cylinder, two size D or two size CD or one size E‡\n• Salbutamol inhaler, 100 micrograms per actuation\nAlthough the above list includes midazolam for topical administration, parenteral midazolam is a\nsuitable alternative for use by appropriately trained individuals.\n§Note that pre-filled syringes are convenient in an emergency situation due to their ease of use but those provided\nfor patie",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 14
  },
  {
    "text": "nt use (e.g. EpiPen® etc.) may contain less adrenaline than recommended for the management of medical\nemergencies.\n¥Midazolam oromucosal solution is available as pre-filled oral syringes; several sizes are available to allow for exact\ndosing for different age groups. Midazolam oromucosal solution is not licensed for use in children <3 months or in\nadults >18 years.\n‡Ensure the supply of oxygen contained in the cylinders will enable adequate flow rates (15 litres/minute) to be\nmaintained until th",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 14
  },
  {
    "text": "e arrival of the ambulance or the patient recovers fully (at least 30 minutes supply). A full size D\ncylinder contains nominally 340 litres of oxygen and therefore should provide oxygen for up to ~22 minutes; a full size\nCD cylinder contains nominally 460 litres of oxygen and therefore should provide oxygen for up to ~30 minutes; a full\nsize E cylinder contains nominally 680 litres of oxygen and therefore should provide oxygen for up to ~45 minutes.\nFor rural practices, it may be prudent to reta",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 14
  },
  {
    "text": "in two size E cylinders to allow for longer ambulance response times.\n8 Refer to Appendix 1 of the BNF and BNFC for further details of drug interactions.",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 14
  },
  {
    "text": "Drug Prescribing For Dentistry\n2 Medical Emergencies in Dental Practice\nNote that the British National Formulary, Volume 70 (BNF 70)1 recommends buccal midazolam as\nan emergency drug for the management of status epilepticus in dental practice. Midazolam is a\nSchedule 3 controlled drug (CD). This means that:\n• prescriptions or requisitions for midazolam must comply with the full CD regulations;\n• records of midazolam usage do not need to be kept in a CD register;\n• invoices for midazolam need to ",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 15
  },
  {
    "text": "be retained for 2 years;\n• midazolam (as other Schedule 3 drugs) should be denatured before being placed in waste\ncontainers; see SDCEP Practice Support Manual8 (www.psm.sdcep.org.uk) for guidance on\nthe denaturation of midazolam;\n• midazolam is exempt from the safe custody requirements and will not legally require storage\nin a CD cabinet;\n• BNF 701 includes the CD3 symbol against midazolam preparations. Information on the legal\nstatus of midazolam is also shown in the section Controlled Drugs a",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 15
  },
  {
    "text": "nd Drug Dependence in\ngeneral BNF guidance.\nIn addition, dental practices might wish to stock the following to aid the\nmanagement of patients with mild allergic reactions:\n• Cetirizine 10 mg tablets or oral solution (5 mg/5 ml)\n• Chlorphenamine, 4 mg tablets or oral solution (2 mg/5 ml)\n• Loratadine, 10 mg tablets or syrup (5 mg/5 ml)\nUse these drugs in the following emergencies in the order stated. Where a patient requires transfer\nto hospital, ensure that you provide full and complete handover",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 15
  },
  {
    "text": " notes with details of any treatment\ncarried out and/or drugs administered.\nRefer to Appendix 1 of the BNF and BNFC for further details of drug interactions. 9",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 15
  },
  {
    "text": "Drug Prescribing For Dentistry\n2 Medical Emergencies in Dental Practice\n2.1 Anaphylaxis\nKey signs of anaphylaxis: Symptoms include:\n• Marked upper airway (laryngeal) • Abdominal pain, vomiting, diarrhoea,\noedema and bronchospasm, causing and a sense of impending doom\nstridor and wheezing • Flushing, but pallor might also occur\n• Tachycardia (heart rate > 110 per • Patients may also display symptoms\nminute) and increased respiratory rate of mild allergy (see Section 2.2)\nManagement\nThe priority i",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 16
  },
  {
    "text": "s to transfer the patient to hospital as an emergency.\nAssess the patient.\nCall for an ambulance.\nSecure the patient’s airway and help to restore their blood pressure by laying the patient\nflat and raising their feet.\nRemove the source of anaphylaxis, if known, using suction if required.\nFor children:\nAdminister 100% oxygen\n– flow rate: 15 litres/minute. As for adults\nAdminister adrenaline, 0.5 ml For children:\n(1:1000), i.m. injection repeated Adrenaline (1:1000)11\nafter 5 minutes if needed.11 ",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 16
  },
  {
    "text": "6 months-5 years 0.15 ml\n6-11 years 0.3 ml\n12-17 years¥ 0.5 ml\n¥Use 0.3 ml adrenaline for children aged 12–17 years if the child is small or prepubertal.\nIf cardiac arrest follows an anaphylactic reaction, initiate basic life support (BLS)\nand carry out early defibrillation where defibrillator is available.§\n[Refer to Resuscitation Council (UK) guidance7 for details of BLS for adults and children.]\n§In August 2014 the Scottish Government commenced roll-out of defibrillators to NHS dental practic",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 16
  },
  {
    "text": "es in Scotland. All\ndental teams should be trained in the use of these devices.\n10 Refer to Appendix 1 of the BNF and BNFC for further details of drug interactions.",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 16
  },
  {
    "text": "Drug Prescribing For Dentistry\n2 Medical Emergencies in Dental Practice\n2.2 Treatment of Milder Forms of Allergy\nKey signs of mild allergy:\n• Urticaria and rash, particularly of chest, • Mild bronchospasm without evidence\nhands and feet of severe shortness of breath\n• Rhinitis, conjunctivitis\nManagement\nFor children:\nAdminister 1 Cetirizine Tablet,\n10 mg. Cetirizine‡ Tablet, 10 mg or\nOral Solution, 5mg/5 ml\n6-11 years 5 mg\n12-17 years As for adults\nNB: Although drowsiness is rare, advise patient",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 17
  },
  {
    "text": "s not to drive.\nUse with caution in patients with hepatic impairment or epilepsy.\n‡Cetirizine tablets are not licensed for use in children under 2 years (see Section 1.1.5).\nor\nFor children:\nAdminister 1 Chlorphenamine\nTablet, 4 mg. Chlorphenamine Tablet‡, 4 mg\nor Oral Solution¥, 2 mg/5 ml\n2-5 years 1 mg\n6-11 years 2 mg\n12-17 years 4 mg\nNB: Chlorphenamine can cause drowsiness. Advise patients not to drive.\nUse with caution in patients with hepatic impairment, prostatic hypertrophy, epilepsy, uri",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 17
  },
  {
    "text": "nary retention,\nglaucoma or pyloroduodenal obstruction. Avoid use in children with severe liver disease.\nDo not give to children under 2 years, except on specialist advice, because the safety of the use of\nchlorphenamine has not been established.\n‡Chlorphenamine tablets are not licensed for use in children under 6 years (see Section 1.1.5).\n¥Chlorphenamine oral solution (syrup) is not licensed for use in children under 1 year (see Section 1.1.5).\nor\nRefer to Appendix 1 of the BNF and BNFC for fu",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 17
  },
  {
    "text": "rther details of drug interactions. 11",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 17
  },
  {
    "text": "Drug Prescribing For Dentistry\n2 Medical Emergencies in Dental Practice\nAdminister 1 Loratadine For children:\nTablet, 10 mg. Loratadine Tablet, 10 mg or Syrup, 5 mg/ml\n2-11 years\n5 mg\nbody weight <30 kg\n2-11 years\nAs for adults\nbody weight ≥30 kg\n12-17 years As for adults\nNB: Although drowsiness is rare advise patients not to drive.\nUse with caution in patients with hepatic impairment or epilepsy.\nIf the patient displays signs of mild bronchospasm:\nFor children:\nAdminister a salbutamol inhaler,\n",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 18
  },
  {
    "text": "4 puffs (100 micrograms per actuation), Salbutamol inhaler\nthrough a large-volume spacer, 12-17 years 1 puff via a spacer\nrepeat as needed. every 15 seconds (max.\n10 puffs), repeat above\nregime at 10-20 minute\nintervals as needed.\nRefer the patient to their general medical practitioner.\nTreatment with antihistamines is only suitable in cases of mild allergy; severe allergic reactions\nmust be treated as stated in Section 2.1.\n12 Refer to Appendix 1 of the BNF and BNFC for further details of drug ",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 18
  },
  {
    "text": "interactions.",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 18
  },
  {
    "text": "Drug Prescribing For Dentistry\n2 Medical Emergencies in Dental Practice\n2.3 Asthma\nKey signs of life-threatening asthma Key signs of acute severe asthma\n• Cyanosis or respiratory rate <8 per • Inability to complete sentences in one\nminute breath\n• Bradycardia (heart rate <50 per minute) • Respiratory rate >25 per minute\n• Exhaustion, confusion, decreased • Tachycardia (heart rate >110 per\nconscious level minute)\nManagement\nThe priority is to transfer a patient displaying symptoms of\nlife-threate",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 19
  },
  {
    "text": "ning asthma to hospital immediately as an emergency.\nAssess the patient.\nSit patient upright.\nFor children:\nAdminister 100% oxygen\n– flow rate: 15 litres/minute. As for adults\nFor children:\nAdminister the patient’s own\nbronchodilator (2 puffs); if Salbutamol inhaler\nunavailable, administer a salbutamol 2-17 years 1 puff via a spacer\ninhaler, 4 puffs (100 micrograms per every 15 seconds (max.\nactuation), through a large-volume 10 puffs), repeat above\nspacer, repeat as needed. regime at 10-20 minu",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 19
  },
  {
    "text": "te\nintervals as needed.\nIf a patient suffering from a severe episode of asthma does not respond\nto treatment with bronchodilators within 5 minutes of administration,\nthey should also be transferred to hospital as an emergency.\nRefer to Appendix 1 of the BNF and BNFC for further details of drug interactions. Refer to Appendix 1 of the BNF and BNFC for further details of drug interactions. 13",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 19
  },
  {
    "text": "Drug Prescribing For Dentistry\n2 Medical Emergencies in Dental Practice\n2.4 Cardiac Emergencies\n2.4.1 Acute Coronary Syndromes\n(Angina and Myocardial Infarction)\nKey sign: Symptoms include:\n• Progressive onset of severe, crushing • Shortness of breath\npain in the centre and across the front • Increased respiratory rate\nof chest; the pain might radiate to the\n• Skin becomes pale and clammy\nshoulders and down the arms (more\ncommonly the left), into the neck and • Nausea and vomiting are common\njaw",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 20
  },
  {
    "text": " or through to the back • Pulse might be weak and blood\npressure might fall\nManagement\nAssess the patient.\nFor children:\nAdminister 100% oxygen\n– flow rate: 15 litres/minute. Not relevant for children\nFor children:\nAdminister glyceryl trinitrate (GTN)\nspray, 2 puffs (400 micrograms per Not relevant for children\nmetered dose) sublingually, repeated\nafter 3 minutes if chest pain remains.\nIf the patient does not respond to GTN treatment then the priority\nis to transfer the patient to hospital as an",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 20
  },
  {
    "text": " emergency.\nCall for an ambulance.\n14 Refer to Appendix 1 of the BNF and BNFC for further details of drug interactions.",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 20
  },
  {
    "text": "Drug Prescribing For Dentistry\n2 Medical Emergencies in Dental Practice\nAdminister aspirin, 300 mg For children:\ndispersible tablet, orally. Do not use in children because, rarely,\nit can cause Reye’s syndrome‡\nNB: The aspirin tablet should be chewed or dispersed in water.\nIf aspirin is given, send a note with the patient to inform the hospital staff.\n‡Aspirin is not licensed for use in children under 16 years (see Section 1.1.5).\nIf the patient becomes unresponsive, check for signs of life (bre",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 21
  },
  {
    "text": "athing and circulation),\nand if there are no signs of life or no normal breathing, initiate basic life support (BLS)\nand carry out early defibrillation where a defibrillator is available.¥ [Refer to Resuscitation\nCouncil (UK) guidance7 for details of BLS for adults and children.]\n2.4.2 Cardiac Arrest\nKey signs:\n• Loss of consciousness • Loss of pulse\n• Absence of normal breathing • Dilation of pupils\nMan agement\nThe priority is to transfer the patient to hospital as an emergency.\nCall for an amb",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 21
  },
  {
    "text": "ulance.\nFor children:\nInitiate BLS§, using 100% oxygen\nor ventilation – flow rate: As for adults, with minor\n15 litres/minute. modifications to BLS for children§\n§Refer to Resuscitation Council (UK) guidance7 for details of BLS for adults and children.\nWhere a defibrillator is available, carry out early defibrillation.¥\n¥In August 2014 the Scottish Government commenced roll-out of defibrillators to NHS dental practices in Scotland. All\ndental teams should be trained in the use of these devices.\n",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 21
  },
  {
    "text": "Refer to Appendix 1 of the BNF and BNFC for further details of drug interactions. 15",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 21
  },
  {
    "text": "Drug Prescribing For Dentistry\n2 Medical Emergencies in Dental Practice\n2.5 Epilepsy\nKey signs: Symptoms include:\n• Sudden loss of consciousness, patient • Brief warning or ‘aura’\nmay become rigid, fall, might give a cry • Frothing from the mouth and urinary\nand becomes cyanosed (tonic phase) incontinence\n• Jerking movements of the limbs; the\ntongue might be bitten (clonic phase)\nNB: Fitting might be associated with other conditions (e.g. hypoglycaemia, fainting).\nManagement\nAssess the patient.\n",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 22
  },
  {
    "text": "Do not try to restrain convulsive movements.\nEnsure the patient is not at risk from injury.\nSecure the patient’s airway.\nFor children:\nAdminister 100% oxygen\n– flow rate: 15 litres/minute. As for adults\nThe seizure will typically last a few minutes; the patient might then become floppy but remain\nunconscious. Once the patient regains consciousness they may remain confused.\nHowever, if the epileptic fit is repeated or prolonged (5 minutes or longer), continue administering\noxygen and:\n16 Refer to",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 22
  },
  {
    "text": " Appendix 1 of the BNF and BNFC for further details of drug interactions.",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 22
  },
  {
    "text": "Drug Prescribing For Dentistry\n2 Medical Emergencies in Dental Practice\nFor children:\nAdminister 10 mg midazolam (use\n2 ml oromucosal solution, 5 mg/ml) Midazolam oromucosal solution (5 mg/ml)¥\ntopically into the buccal cavity.‡ 6-11 months 2.5 mg\n1-4 years 5 mg\n5-9 years 7.5 mg\n10-17 years 10 mg\n‡Midazolam oromucosal solution is not licensed for use in adults in status epilepticus (see Section 1.1.5) but is\nrecommended by the BNF to manage these patients (see www.bnf.org).\n¥Midazolam oromucosal",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 23
  },
  {
    "text": " solution (5 mg/ml) pre-filled syringes are available in several sizes to allow for exact\ndosing in different age groups\nAfter convulsive movements have subsided, place the patient in the recovery position and\ncheck the airway. Do not send the patient home until they have recovered fully.\nOnly give medication if convulsive seizures are prolonged (last for 5 minutes or longer) or\nrecur in quick succession. In these cases and if this was the first episode of epilepsy for\nthe patient, the convulsio",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 23
  },
  {
    "text": "n was atypical, injury occurred or there is difficulty monitoring\nthe patient, call for an ambulance.\nRefer to Appendix 1 of the BNF and BNFC for further details of drug interactions. 17",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 23
  },
  {
    "text": "Drug Prescribing For Dentistry\n2 Medical Emergencies in Dental Practice\n2.6 Faint\nKey signs: Symptoms include:\n• Patient feels faint, dizzy, light-headed • Pallor and sweating\n• Slow pulse rate • Nausea and vomiting\n• Loss of consciousness\nManagement\nAssess the patient.\nLay the patient flat and, if the patient is not breathless, raise the patient’s feet. Loosen any\ntight clothing around the neck.\nFor children:\nAdminister 100% oxygen –\nflow rate: 15 litres/minute until As for adults\nconsciousness",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 24
  },
  {
    "text": " is regained.\n18 Refer to Appendix 1 of the BNF and BNFC for further details of drug interactions.",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 24
  },
  {
    "text": "Drug Prescribing For Dentistry\n2 Medical Emergencies in Dental Practice\n2.7 Hypoglycaemia\nKey signs: Symptoms include:\n• Aggression and confusion • Shaking and trembling\n• Sweating • Difficulty in concentration/vagueness\n• Tachycardia (heart rate >110 per min) • Slurring of speech\n• Headache\n• Fitting\n• Unconsciousness\nManagement\nAssess the patient.\nFor children:\nAdminister 100% oxygen\n– flow rate: 15 litres/minute. As for adults\nIf the patient remains conscious and cooperative:\nFor children:\nAd",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 25
  },
  {
    "text": "minister oral glucose (10-20 g),\nrepeated, if necessary, after As for adults\n10-15 minutes.\nRefer to Appendix 1 of the BNF and BNFC for further details of drug interactions. 19",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 25
  },
  {
    "text": "Drug Prescribing For Dentistry\n2 Medical Emergencies in Dental Practice\nIf the patient is unconscious or uncooperative:\nFor children:\nAdminister glucagon, 1 mg, i.m.\ninjection. Glucagon, i.m. injection\n2-17 years\n0.5mg\nbody-weight <25 kg\n2-17 years\n1mg\nbody-weight ≥25 kg\nand\nFor children:\nAdminister oral glucose (10–20 g)\nwhen the patient regains As for adults\nconsciousness.\nIf the patient does not respond or any difficulty is experienced, call for an ambulance.\n20 Refer to Appendix 1 of the BNF",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 26
  },
  {
    "text": " and BNFC for further details of drug interactions.",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 26
  },
  {
    "text": "Drug Prescribing For Dentistry\n2 Medical Emergencies in Dental Practice\n2.8 Other Medical Emergencies\n2.8.1 Stroke\nKey signs:\n• Facial weakness; one eye may droop or • Communication problems; slurred\npatient may only be able to move one speech; patient is unable to understand\nside of mouth what is being said to them\n• Arm weakness\nManagement\nThe priority is to transfer the patient to hospital as an emergency\nAssess the patient.\nFor children:\nAdminister 100% oxygen\n– flow rate: 15 litres/minute. ",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 27
  },
  {
    "text": "As for adults\nIf the patient is unconscious and breathing, secure their airway and place in the recovery\nposition.\nCall for an ambulance.\nRefer to Appendix 1 of the BNF and BNFC for further details of drug interactions. Refer to Appendix 1 of the BNF and BNFC for further details of drug interactions. 21",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 27
  },
  {
    "text": "Drug Prescribing For Dentistry\n2 Medical Emergencies in Dental Practice\n2.8.2 Aspiration and Choking\nDental patients are susceptible to choking and aspiration due to the presence of blood and\nsecretions in their mouths for prolonged periods, suppressed pharyngeal reflexes due to local\nanaesthesia or the presence of impression material or dental equipment in their mouths.\nSigns and symptoms include:\n• Patient may develop ‘paradoxical’\n• Patient may cough and splutter\nchest or abdominal movements\n",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 28
  },
  {
    "text": "• Patient may complain of breathing\n• Patient may become cyanosed and\ndifficulty\nlose consciousness\n• Breathing may become noisy on\ninspiration (stridor)\nManagement\nAspiration\nEncourage patient to cough vigorously.\nFor children:\nAdminister 100% oxygen\n– flow rate: 15 litres/minute. As for adults\nFor children:\nAdminister a salbutamol inhaler,\n4 puffs (100 micrograms per actuation), Salbutamol inhaler\nthrough a large-volume spacer, 2-17 years 1 puff via a spacer\nrepeat as needed. every 15 seconds ",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 28
  },
  {
    "text": "(max.\n10 puffs), repeat above\nregime at 10-20 minute\nintervals as needed.\n22 Refer to Appendix 1 of the BNF and BNFC for further details of drug interactions.",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 28
  },
  {
    "text": "Drug Prescribing For Dentistry\n2 Medical Emergencies in Dental Practice\nIf you suspect that a large fragment has been inhaled or swallowed but there are no\nsigns or symptoms, refer the patient to hospital for x-ray and removal of the fragment if\nnecessary.\nIf the patient is symptomatic following aspiration, refer them to hospital as an\nemergency.\nChoking\nRemove any visible foreign bodies in the mouth and pharynx.\nEncourage the patient to cough.\nIf the patient is unable to cough but remains consc",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 29
  },
  {
    "text": "ious, commence back blows followed\nby abdominal thrusts.\nIf the patient becomes unconscious, basic life support (BLS) should be started immediately;\nthis may also help to dislodge the foreign body.\nCall an ambulance and transfer patient to hospital as an emergency.\nRefer to Appendix 1 of the BNF and BNFC for further details of drug interactions. 23",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 29
  },
  {
    "text": "Drug Prescribing For Dentistry\n24",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 30
  },
  {
    "text": "Drug Prescribing For Dentistry\n3 Anxiety\nAn oral dose of a benzodiazepine may be used as premedication to aid anxiety management\nbefore dental treatment. However, note that benzodiazepines are addictive and susceptible to\nabuse and therefore only the minimum number of tablets required should be prescribed. Advise\nthe patient that they will require an escort and that they should not drive.\nNote that such premedication is not a definitive sedation technique. The Scottish Dental Clinical\nEffectiven",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 31
  },
  {
    "text": "ess Programme (SDCEP) has provided separate guidance on the provision of conscious\nsedation in dentistry.12\nAn appropriate regimen to aid anxiety management is:\nDiazepam Tablets, 5 mg For children:\nSend: 1 tablet Not recommended because it has an\nunpredictable effect in children\nLabel: 1 tablet 2 hours before procedure\nNB: The dose of diazepam can be increased to 10 mg if necessary.\nHalve the adult dose for elderly or debilitated patients.\nAdvise all patients that they will require an escort and",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 31
  },
  {
    "text": " that they should not drive.\nRefer to Appendix 1 of the BNF and BNFC for further details of drug interactions. 25",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 31
  },
  {
    "text": "Drug Prescribing For Dentistry\n26",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 32
  },
  {
    "text": "Drug Prescribing For Dentistry\n4 Bacterial Infections\nProlonged courses of antibiotic treatment can encourage the development of drug resistance and\ntherefore the prescribing of antibiotics must be kept to a minimum and used only when\nthere is a clear need.\nThe emergence and spread of antibiotic resistance is a global concern and is a major threat to\npublic health. The indiscriminate use of antimicrobials in primary care, including dentistry, has\nbeen identified as one of the drivers of antibiot",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 33
  },
  {
    "text": "ic resistance. Dental antimicrobial prescribing in\nScotland has been increasing year on year and although in 2013/14 there was a 5.5% reduction\nin items dispensed compared to the previous year, dental prescriptions still accounted for almost\n9% of all oral antibacterials dispensed in NHS primary care.13 It has been estimated from clinical\naudit that around 50% of dental prescriptions for antibacterials are inappropriate.14,15 Prudent,\nappropriate use of antibacterials will slow the emergence of ",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 33
  },
  {
    "text": "bacterial resistance and will preserve\nthe usefulness of existing drugs for future generations.\nThe use of broad-spectrum antibiotics has also been associated with the rise in Clostridium\ndifficile–associated disease observed in both primary and secondary care. Care should therefore\nbe taken when prescribing these antibiotics to vulnerable groups, such as the elderly and those\nwith a history of gastrointestinal disease, including those using proton pump inhibitor (PPI) drugs\nfor dyspepsia and ga",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 33
  },
  {
    "text": "stro-oesophageal reflux diseases.\nAs a first step in the treatment of bacterial infections, use local measures. For example, drain pus\nif present in dental abscesses by extraction of the tooth or through the root canals, and attempt\nto drain any soft-tissue pus by incision. However, do not attempt to drain a cellulitis-type swelling.\nAntibiotics are only appropriate for oral infections where there is evidence of spreading infection\n(cellulitis, lymph node involvement, swelling) or systemic invol",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 33
  },
  {
    "text": "vement (fever, malaise). In addition,\nother indications for antibiotics are cases of necrotising ulcerative gingivitis or pericoronitis where\nthere is systemic involvement or persistent swelling despite local treatment. Antibiotics are also\nappropriate for sinusitis where there are persistent symptoms and/or purulent discharge lasting\nat least seven days or where symptoms are severe. Use antibiotics in conjunction with, and not as\nan alternative to, local measures.\nNote that patients who have re",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 33
  },
  {
    "text": "cently taken a course of antibiotics (within the preceding six\nweeks) have an increased risk of harbouring bacteria resistant to that drug and should therefore\nbe prescribed an alternative. Where there is significant trismus, floor-of-mouth swelling or\ndifficulty breathing, transfer patients to hospital as an emergency. A guide which outlines the\nmanagement of bacterial infections is presented in Appendix 5.\nThere is no evidence to support the prescription of antibiotics for the treatment of pul",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 33
  },
  {
    "text": "pitis or the\nprevention of dry socket in patients undergoing non-surgical dental extractions. Dental pain arising\nfrom these conditions is due primarily to an inflammatory response which should be managed by\nthe appropriate use of analgesics and local measures. Antibiotics should not be used as prophylactic\nprescriptions to prevent infections after a routine dental surgical procedure.\nRefer to Appendix 1 of the BNF and BNFC for further details of drug interactions. 27",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 33
  },
  {
    "text": "Drug Prescribing For Dentistry\n4 Bacterial Infections\nA poster for dental practices, which explains to patients that drainage and analgesics are often\nthe most effective treatments for dental infections, is available to download from the Scottish\nMedicines Consortium website (see www.scottishmedicines.org.uk/files/sapg/Dental_poster.pdf).\nBefore prescribing antibiotics, refer to the BNF and BNFC for drug interactions (www.bnf.org).\nAdvise patients to space out doses as much as possible throughou",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 34
  },
  {
    "text": "t the day. Review patients with\nbacterial infections who have been treated with local measures or who have received a course of\nantibiotic treatment within two to seven days.\n4.1 Antibiotics and Contraception\nUntil recently, some broad-spectrum antibiotics were thought to reduce the efficacy of combined\noral contraceptives and contraceptive patches or rings. However in Drug Interactions with\nHormonal Contraception: Clinical Guidance,9 the Faculty of Sexual and Reproductive Healthcare\nof the Roya",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 34
  },
  {
    "text": "l College of Obstetricians and Gynaecologists states that additional contraceptive\nprecautions are no longer necessary when antibacterials that do not induce liver enzymes are\ntaken with combined oral contraceptives, unless diarrhoea or vomiting occurs. Also, no additional\ncontraceptive precautions are required when contraceptive patches or vaginal rings are used with\nantibacterials that do not induce liver enzymes. These recommendations are reflected in BNF\n70.1 The antibiotics included in this",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 34
  },
  {
    "text": " publication do not induce liver enzymes therefore additional\ncontraceptive precautions are not required for patients taking short courses of these drugs unless\ndiarrhoea or vomiting occurs.\n28 Refer to Appendix 1 of the BNF and BNFC for further details of drug interactions.",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 34
  },
  {
    "text": "Drug Prescribing For Dentistry\n4 Bacterial Infections\n4.2 Infective Endocarditis\nPreviously, in dentistry, antibiotics were prescribed as prophylaxis for the prevention of infective\nendocarditis. In 2008, the National Institute for Health and Care Excellence (NICE) issued Clinical\nGuideline 6416 which states that antibiotic prophylaxis against infective endocarditis is not\nrecommended for people undergoing dental procedures. In 2015, a NICE standing committee\nreviewed the recommendations and pub",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 35
  },
  {
    "text": "lished an addendum to the guideline which reiterated\nthat there is no evidence that antibiotic prophylaxis prior to dental treatment is of any benefit\nto patients. In addition, there is no evidence that prophylaxis is of any benefit in patients with\nprosthetic joints and it is unacceptable to expose patients to the potential adverse effects of\nantibiotics in these circumstances.\n4.3 Dental Abscess\nDental abscesses are usually infected with viridans Streptococcus spp. or Gram-negative organisms.\n",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 35
  },
  {
    "text": "Treat dental abscesses in the first instance by using local measures to achieve drainage, with\nremoval of the cause where possible. A guide which outlines the management of dental abscess\nis presented in Appendix 5.\nAntibiotics are not appropriate in cases where the infection is localised to the peri-radicular tissues as\nthis indicates that the infection is being adequately managed by the immune system. Also, in these\ncases the abscess is mostly isolated from the circulation, resulting in very l",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 35
  },
  {
    "text": "ittle antibiotic penetration.\nAntibiotics are only required if immediate drainage is not achieved using local measures or in\ncases of spreading infection (swelling, cellulitis, lymph node involvement) or systemic involvement\n(fever, malaise), all of which suggest that the immune system alone is not able to adequately\nmanage the infection.\nIt is good practice to measure the temperature of patients with suspected bacterial infections,\nwith temperatures <36oC or >38oC indicative of systemic involve",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 35
  },
  {
    "text": "ment. However be aware that the\nabsence of pyrexia does not preclude the prescribing of antibiotics if other signs and symptoms of\nspreading infection or systemic involvement are present.\nAmoxicillin is usually effective at treating such infections, and is as effective as phenoxymethyl-\npenicillin (penicillin V) but is better absorbed. The duration of treatment depends on the severity\nof the infection and the clinical response, but drugs are usually given for 5 days. However, do not\nprolong cour",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 35
  },
  {
    "text": "ses of treatment unduly because this can encourage the development of resistance.\nFor severe infections the dose of amoxicillin, phenoxymethylpenicillin and metronidazole should\nbe doubled. Severe infections include those cases where there is extra-oral swelling, eye closing or\ntrismus but it is a matter of clinical judgement. Where there is significant trismus, floor-of-mouth\nswelling or difficulty breathing, transfer patients to hospital as an emergency. If the patient does\nnot respond to the ",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 35
  },
  {
    "text": "prescribed antibiotic, check the diagnosis and consider referral to a specialist.\nRefer to Appendix 1 of the BNF and BNFC for further details of drug interactions. 29",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 35
  },
  {
    "text": "Drug Prescribing For Dentistry\n4 Bacterial Infections\nDental abscesses should be treated with local measures in the first instance.\nLocal Measures – to be used in the first instance\nIf pus is present in a dental abscess, drain by extraction of the tooth or through the\nroot canals.\nIf pus is present in any soft tissue, attempt to drain by incision.\nIf local measures have proved ineffective or there is evidence of cellulitis, spreading infection or\nsystemic involvement, one of the following first-",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 36
  },
  {
    "text": "line antibiotics can be prescribed. The antibiotic\ndoses recommended in this guidance are based on the doses recommended by the BNF. However\ndentists should be aware that local formulary recommendations may differ.\nAn appropriate 5-day regimen is a choice of:\nAmoxicillin Capsules, 500 mg For children:\nSend: 15 capsules Amoxicillin Capsules, 250 mg, or Oral\nSuspension*, 125 mg/5 ml or 250 mg/5 ml\nLabel: 1 capsule three times daily\n6-11 months 125mg three\ntimes daily\n1-4 years 250 mg three\ntimes d",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 36
  },
  {
    "text": "aily\n5-11 years 500 mg three\ntimes daily\n12-17 years 500 mg three\ntimes daily\nNB: The dose of amoxicillin should be doubled in severe infection in adults and children aged 12-17 years. In\nsevere infection in children aged 6 months to 11 years, the dose of amoxicillin should be increased up to\n30 mg/kg (max 1 g) three times daily.\nAmoxicillin, like other penicillins, can result in hypersensitivity reactions, including rashes and anaphylaxis,\nand can cause diarrhoea. Do not prescribe amoxicillin t",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 36
  },
  {
    "text": "o patients with a history of anaphylaxis, urticaria or\nrash immediately after penicillin administration as these individuals are at risk of immediate hypersensitivity.\n*Sugar-free preparation is available.\nor\n30 Refer to Appendix 1 of the BNF and BNFC for further details of drug interactions.",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 36
  },
  {
    "text": "Drug Prescribing For Dentistry\n4 Bacterial Infections\nPhenoxymethylpenicillin Tablets, For children:\n250 mg Phenoxymethylpenicillin Tablets,\nSend: 40 tablets 250 mg, or Oral Solution*, 125 mg/5 ml\nor 250 mg/5 ml\nLabel: 2 tablets four times daily\n6-11 months 62.5 mg four\ntimes daily\n1-5 years 125 mg four\ntimes daily\n6-11 years 250 mg four\ntimes daily\n12-17 years 500 mg four\ntimes daily\nNB: For severe infection in adults, the dose of phenoxymethylpenicillin should be doubled. For severe infection ",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 37
  },
  {
    "text": "in\nchildren up to 11 years, increase dose up to 12.5 mg/kg four times daily. For severe infection in children aged\n12-17 years increase dose up to 1 g four times daily.\nPhenoxymethylpenicillin, like other penicillins, can result in hypersensitivity reactions, including rashes and\nanaphylaxis, and can cause diarrhoea. Do not prescribe phenoxymethylpenicillin to patients with a history\nof anaphylaxis, urticaria or rash immediately after penicillin administration as these individuals are at risk of",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 37
  },
  {
    "text": "\nimmediate hypersensitivity.\n*Sugar-free preparation is available\nRefer to Appendix 1 of the BNF and BNFC for further details of drug interactions. 31",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 37
  },
  {
    "text": "Drug Prescribing For Dentistry\n4 Bacterial Infections\nMetronidazole is effective against anaerobic bacteria and is a suitable alternative for the\nmanagement of dental abscess in patients who are allergic to penicillin. It can also be used as an\nadjunct to amoxicillin in patients with spreading infection or pyrexia. (NB: Both drugs are used in\nthe same doses as when administered alone.)\nIn patients who are allergic to penicillin, an appropriate 5-day regimen is:\nMetronidazole Tablets, 200 mg For ",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 38
  },
  {
    "text": "children:\nSend: 15 tablets Metronidazole‡ Tablets, 200 mg,\nor Oral Suspension, 200 mg/5 ml\nLabel: 1 tablet three times daily\n1-2 years 50 mg three\ntimes daily\n3-6 years 100 mg twice\ndaily\n7-9 years 100 mg three\ntimes daily\n10-17 years 200 mg three\ntimes daily\nNB: For severe infection, the dose of metronidazole should be doubled in adults and children aged 12-17 years.\nFor severe infection in children up to 11 years, increase dose up to 7.5 mg/kg (max. 400 mg) three times daily.\nAdvise patient to",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 38
  },
  {
    "text": " avoid alcohol (metronidazole has a disulfiram-like reaction with alcohol).\nDo not prescribe metronidazole for patients taking warfarin.\n‡ Metronidazole is not licensed for use in children under 1 year (see Section 1.1.5).\n32 Refer to Appendix 1 of the BNF and BNFC for further details of drug interactions.",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 38
  },
  {
    "text": "Drug Prescribing For Dentistry\n4 Bacterial Infections\nSecond-line antibiotics for dental abscess\nThe empirical use of other antibiotics such as clindamycin, co-amoxiclav and clarithromycin offers\nno advantage over the first line drugs amoxicillin, phenoxymethylpenicillin and metronidazole for\nmost dental patients. Their routine use in dentistry is unnecessary and could contribute to the\ndevelopment of antimicrobial resistance. Also the use of broad-spectrum antibiotics is associated\nwith the inc",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 39
  },
  {
    "text": "rease in Clostridium difficile infection observed in both primary and secondary care.\nHowever, if a patient has not responded to the first-line antibiotic prescribed, check the diagnosis\nand either refer the patient or consider speaking to a specialist before prescribing clindamycin,\nco-amoxiclav or clarithromycin.\nClindamycin is active against Gram-positive cocci, including streptococci and penicillin-resistant\nstaphylococci, and can be used if the patient has not responded to amoxicillin or me",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 39
  },
  {
    "text": "tronidazole.\nIt should be noted, however, that clindamycin can cause the serious adverse effect of antibiotic-\nassociated colitis more frequently than other antibiotics.\nCo-amoxiclav is active against beta-lactamase-producing bacteria that are resistant to amoxicillin,\nand can be used to treat severe dental infection with spreading cellulitis or dental infection that\nhas not responded to first-line antibacterial treatment.\nClarithromycin is active against beta-lactamase-producing bacteria.\nAs th",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 39
  },
  {
    "text": "e use of broad-spectrum antibiotics, especially co-amoxiclav and clindamycin, can result in\nClostridium difficile infection, use of these drugs should be restricted to second-line treatment of\nsevere infections only.\nIf patients do not respond to first-line amoxicillin or metronidazole treatment, or in\ncases of severe infection with spreading cellulitis, an appropriate 5-day regimen is:\nClindamycin Capsules, 150 mg For children:\nSend: 20 capsules 12-17 years As for adults\nLabel: 1 capsule four t",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 39
  },
  {
    "text": "imes daily,\nswallowed with water\nNB: Advise patient that capsule should be swallowed with a glass of water.\nDo not prescribe clindamycin to patients with diarrhoeal states.\nAdvise patient to discontinue use immediately if diarrhoea or colitis develops as clindamycin can cause the\nside-effect of antibiotic-associated colitis.\nor\nRefer to Appendix 1 of the BNF and BNFC for further details of drug interactions. 33",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 39
  },
  {
    "text": "Drug Prescribing For Dentistry\n4 Bacterial Infections\nCo-amoxiclav 250/125 Tablets For children:\nSend: 15 tablets 12-17 years As for adults\nLabel: 1 tablet three times daily\nNB: Co-amoxiclav 250/125 tablets are amoxicillin 250 mg as trihydrate and clavulanic acid 125 mg as potassium\nsalt.\nCholestatic jaundice can occur either during or shortly after the use of co-amoxiclav; this condition is more\ncommon in patients above the age of 65 years and in men. Do not prescribe co-amoxiclav to patients w",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 40
  },
  {
    "text": "ho\nhave a history of co-amoxiclav-associated or penicillin-associated jaundice or hepatic dysfunction.\nCo-amoxiclav, like other penicillins, can result in hypersensitivity reactions, including rashes and anaphylaxis,\nand can cause diarrhoea. Do not prescribe co-amoxiclav to patients with a history of anaphylaxis, urticaria or\nrash immediately after penicillin administration as these individuals are at risk of immediate hypersensitivity.\nor\nAn appropriate 7-day regimen is:\nClarithromycin Tablets,",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 40
  },
  {
    "text": " 250 mg For children:\nSend: 14 tablets Clarithromycin Tablets, 250 mg\nor Oral Suspension 125 mg/5ml\nLabel: 1 tablet two times daily\nor 250 mg/5 ml\n1-11 years 62.5 mg two\nBody weight 8-11 kg times daily\n1-11 years 125 mg two\nBody weight 12-19 kg times daily\n1-11 years 187.5 mg two\nBody weight 20-29 kg times daily\n1-11 years 250 mg two\nBody weight 30-40 kg times daily\n12-17 years 250 mg two\ntimes daily\nNB: Use with caution in patients who are predisposed to QT interval prolongation including elect",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 40
  },
  {
    "text": "rolyte\ndisturbances and those with hepatic impairment or renal impairment. Do not prescribe for pregnant\nwomen or nursing mothers. Do not prescribe clarithromycin for patients taking warfarin or statins.\nFor more information on the clinical management of dental abscess, refer to the SDCEP guidance\nManagement of Acute Dental Problems,4 which is available to download at www.sdcep.org.uk.\nA web app of the guidance is also available at http://madp.sdcep.org.uk/.\n34 Refer to Appendix 1 of the BNF and",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 40
  },
  {
    "text": " BNFC for further details of drug interactions.",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 40
  },
  {
    "text": "Drug Prescribing For Dentistry\n4 Bacterial Infections\n4.4 Necrotising Ulcerative Gingivitis and Pericoronitis\nNecrotising ulcerative gingivitis (NUG) is a painful, superficial infection of the gingival margins\nassociated with anaerobic fuso-spirochaetal bacteria and is more common in patients who\nsmoke, the immuno-suppressed and those with poor oral hygiene. In mild cases of NUG, local\nmeasures (see below) may be sufficient but more severe cases may also require treatment with\nantibiotics, metro",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 41
  },
  {
    "text": "nidazole being the drug of first choice\nPericoronitis is a superficial infection of the operculum, with occasional local spread, that is often\nassociated with anaerobic bacteria. In most cases treatment with local measures will be sufficient\nfor resolution of the symptoms. However, where there is systemic involvement or persistent\nswelling despite local measures, a three day course of metronidazole can be prescribed.\nA suitable alternative for both conditions is amoxicillin. A guide which outlin",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 41
  },
  {
    "text": "es the management\nof necrotising ulcerative gingivitis and pericoronitis is presented in Appendix 5.\nLocal Measures – to be used in the first instance\nIn the case of necrotising ulcerative gingivitis, remove supra-gingival and sub-gingival\ndeposits and provide oral hygiene advice.\n• Due to the pain associated with NUG, the patient may only be able to tolerate\nlimited debridement in the acute phase.\nIn the case of pericoronitis, carry out irrigation and debridement.\nIf drug treatment is required,",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 41
  },
  {
    "text": " an appropriate 3-day regimen is:\nMetronidazole Tablets, 200 mg For children:\nSend: 9 tablets Metronidazole‡ Tablets, 200 mg,\nor Oral Suspension, 200 mg/5 ml\nLabel: 1 tablet three times daily\n1-2 years 50 mg three\ntimes daily\n3-6 years 100 mg twice\ndaily\n7-9 years 100 mg three\ntimes daily\n10-17 years 200 mg three\ntimes daily\nNB: Advise patient to avoid alcohol (metronidazole has a disulfiram-like reaction with alcohol).\nDo not prescribe metronidazole for patients taking warfarin.\n‡Metronidazole ",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 41
  },
  {
    "text": "is not licensed for use in children under 1 year (see Section 1.1.5).\nRefer to Appendix 1 of the BNF and BNFC for further details of drug interactions. 35",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 41
  },
  {
    "text": "Drug Prescribing For Dentistry\n4 Bacterial Infections\nor\nAmoxicillin Capsules, 500 mg For children:\nSend: 9 capsules Amoxicillin Capsules, 250 mg, or\nOral Suspension*, 125 mg/5 ml\nLabel: 1 capsule three times daily\nor 250 mg/5 ml\n6-11 months 125 mg three\ntimes daily\n1-4 years 250 mg three\ntimes daily\n5-11 years 500 mg three\ntimes daily\n12-17 years 500 mg three\ntimes daily\nNB: The dose of amoxicillin should be doubled in severe infection in adults and children aged 12-17 years. In\nsevere infectio",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 42
  },
  {
    "text": "n in children aged 6 months to 11 years, the dose of amoxicillin should be increased up to\n30 mg/kg (max 1g) three times daily.\nAmoxicillin, like other penicillins, can result in hypersensitivity reactions, including rashes and anaphylaxis,\nand can cause diarrhoea. Do not prescribe amoxicillin to patients with a history of anaphylaxis, urticaria or\nrash immediately after penicillin administration as these individuals are at risk of immediate hypersensitivity.\n*Sugar-free preparation is available",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 42
  },
  {
    "text": ".\nFor more information on the clinical management of necrotising ulcerative gingivitis and\nperiocoronitis, refer to the SDCEP guidance Management of Acute Dental Problems,4 which is\navailable to download at www.sdcep.org.uk. A web app of the guidance is also available at http://\nmadp.sdcep.org.uk/. The SDCEP guidance Prevention and Treatment of Periodontal Diseases in\nPrimary Care17 also provides advice on the management of these conditions.\n4.5 Sinusitis\nSinusitis is a generally self-limiting c",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 42
  },
  {
    "text": "ondition that has an average duration of 2½ weeks. Therefore,\nin suspected cases of sinusitis local measures should be advised in the first instance. Antibiotic\ntherapy should only be used for persistent symptoms and/or purulent discharge lasting at least\nseven days or if symptoms are severe. A guide which outlines the management of sinusitis\npresented in Appendix 5.\nLocal Measures – to be used in the first instance\nAdvise the patient to use steam inhalation‡\n‡not recommended for children.\n36 Re",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 42
  },
  {
    "text": "fer to Appendix 1 of the BNF and BNFC for further details of drug interactions.",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 42
  },
  {
    "text": "Drug Prescribing For Dentistry\n4 Bacterial Infections\nIf drug treatment is required, an appropriate regimen is:\nEphedrine Nasal Drops, 0.5% For children:\nSend: 10 ml Ephedrine Nasal Drops‡, 0.5%\nLabel: 1 drop into each nostril up to 12-17 years As for adults\nthree times daily when required\nNB: Advise patient to use for a maximum of 7 days. In adults and children over 12 years, the dose of ephedrine\nnasal drops can be increased to 2 drops 3 or 4 times daily, if required.\nDo not use in patients wi",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 43
  },
  {
    "text": "th high blood pressure.\n‡Not licensed for use in children under 12 years (see Section 1.1.5).\nIf an antibiotic is required, an appropriate 7-day regimen is a choice of:\nAmoxicillin Capsules, 500 mg For children:\nSend: 21 capsules Amoxicillin Capsules, 250 mg, or\nOral Suspension*, 125 mg/5 ml\nLabel: 1 capsule three times daily\nor 250 mg/5 ml\n6-11 months 125 mg three\ntimes daily\n1-4 years 250 mg three\ntimes daily\n5-11 years 500 mg three\ntimes daily\n12-17 years 500 mg three\ntimes daily\nNB: The dose",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 43
  },
  {
    "text": " of amoxicillin should be doubled in severe infection in adults and children aged 12-17 years. In\nsevere infection in children aged 6 months to 11 years, the dose of amoxicillin should be increased up to 30\nmg/kg (max 1 g) three times daily.\nAmoxicillin, like other penicillins, can result in hypersensitivity reactions, including rashes and anaphylaxis, and\ncan cause diarrhoea. Do not prescribe amoxicillin to patients with a history of anaphylaxis, urticaria or rash\nimmediately after penicillin a",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 43
  },
  {
    "text": "dministration as these individuals are at risk of immediate hypersensitivity.\n*Sugar-free preparation is available.\nor\nRefer to Appendix 1 of the BNF and BNFC for further details of drug interactions. 37",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 43
  },
  {
    "text": "Drug Prescribing For Dentistry\n4 Bacterial Infections\nDoxycycline Capsules§, 100 mg For children:\nSend: 8 capsules Doxycyline‡ Capsules§, 100 mg\nLabel: 2 capsules on the first day, <12 years Not recommended\nfollowed by 1 capsule daily for use because it\ncauses intrinsic\nstaining of developing\nteeth‡\n≥12 years As for adults\nNB: Advise patient to swallow capsules whole with plenty of fluid during meals, while sitting or standing.\nFor severe infection in adults and children aged 12 years and over, ",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 44
  },
  {
    "text": "2 capsules daily can be given.\nUse with caution in patients with hepatic impairment or those receiving potentially hepatotoxic drugs. Do\nnot prescribe for pregnant women, nursing mothers or children under 12 years, as it can deposit on growing\nbone and teeth (by binding to calcium) and cause staining and, occasionally, dental hypoplasia.\nDoxycycline can cause nausea, vomiting, diarrhoea, dysphagia, oesophageal irritation and photosensitivity.\nDo not prescribe doxycycline for patients taking warf",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 44
  },
  {
    "text": "arin.\n§Doxycycline is also available as doxycyline dispersible tablets.\n‡ Doxycycline is not licensed for use in children under 12 years (see Section 1.1.5).\nFor more information on the clinical management of sinusitis, refer to the SDCEP guidance\nManagement of Acute Dental Problems,4 which is available to download at www.sdcep.org.uk.\nA web app of the guidance is also available at http://madp.sdcep.org.uk/.\n38 Refer to Appendix 1 of the BNF and BNFC for further details of drug interactions.",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 44
  },
  {
    "text": "Drug Prescribing For Dentistry\n5 Fungal Infections\nSuperficial fungal infections can be treated in a primary care setting. However, chronic hyperplastic\ncandidosis (candidal leukoplakia) is potentially premalignant and therefore refer patients with this\ncondition for specialist treatment. Treatment with a topical antifungal agent, such as nystatin, is\neffective against superficial infections but compliance is poor because of its unpleasant taste. Thus,\nmiconazole or the systemically absorbed dru",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 45
  },
  {
    "text": "g fluconazole are preferred unless contraindicated.\nNote that fluconazole interacts with many drugs, including warfarin and statins, and therefore\ndo not give fluconazole to patients taking these drugs. In addition, avoid the use of miconazole,\na topical azole antifungal agent, in such patients because sufficient drug is absorbed to cause\nsimilar interactions.\n5.1 Pseudomembranous Candidosis and\nErythematous Candidosis\nSeveral patient groups are predisposed to pseudomembranous candidosis and ery",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 45
  },
  {
    "text": "thematous\ncandidosis infections (e.g. patients taking inhaled corticosteroids, cytotoxics or broad-spectrum\nantibacterials, diabetic patients, patients with nutritional deficiencies, or patients with serious\nsystemic disease associated with reduced immunity such as leukaemia, other malignancies and\nHIV infection). If the patient does not respond to appropriate local measures and a course of drug\ntreatment, or there is no identifiable cause, refer the patient to a specialist or the patient’s gene",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 45
  },
  {
    "text": "ral\nmedical practitioner for further investigation. Fungal infections in immunocompromised patients\nwith serious systemic disease are likely to need intravenous systemic treatment; therefore, refer\nsuch patients to a specialist or the patient’s general medical practitioner.\nWhen these infections are associated with the use of inhaled corticosteroids for lung disease, use\nlocal measures in the first instance to try to avoid the problem.\nLocal Measures - to be used in the first instance\nAdvise pat",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 45
  },
  {
    "text": "ients who use a corticosteroid inhaler to rinse their mouth with water or\nbrush their teeth immediately after using the inhaler.\nRefer to Appendix 1 of the BNF and BNFC for further details of drug interactions. 39",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 45
  },
  {
    "text": "Drug Prescribing For Dentistry\n5 Fungal Infections\nIf drug treatment is required, an appropriate 7-day regimen is a choice of:\nFluconazole Capsules, 50 mg For children:\nSend: 7 capsules Fluconazole Capsules 50 mg or\nOral Suspension, 50 mg/5 ml\nLabel: 1 capsule daily\n6 months-11 years 3-6 mg/kg\non first day and\nthen 3 mg/kg\n(max. 50 mg) daily\n12-17 years 50 mg daily\nNB: Fluconazole can be administered for a maximum of 14 days for the treatment of oropharyngeal candidosis.\nDo not prescribe flucona",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 46
  },
  {
    "text": "zole for patients taking warfarin or statins.\nor\nMiconazole Oromucosal Gel*, For children:\n20 mg/g Miconazole Oromucosal Gel*,\nSend: 80 g tube 20 mg/g\nLabel: Apply a pea-sized amount after 2-17 years As for adults\nfood four times daily\nNB: Advise patient to continue use for 7 days after lesions have healed.\nDo not prescribe miconazole for patients taking warfarin or statins.\n*Sugar-free preparation is available.\n40 Refer to Appendix 1 of the BNF and BNFC for further details of drug interactions.",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 46
  },
  {
    "text": "Drug Prescribing For Dentistry\n5 Fungal Infections\nIf fluconazole and miconazole are contraindicated, an appropriate regimen is:\nNystatin Oral Suspension, 100,000 For children:\nunits/ml\nAs for adults\nSend: 30 ml\nLabel: 1 ml after food four times daily for\n7 days\nNB: Advise patient to rinse suspension around mouth and then retain suspension near lesion for 5 minutes before\nswallowing.\nAdvise patient to continue use for 48 hours after lesions have healed.\nFor more information on the clinical manag",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 47
  },
  {
    "text": "ement of candidal infections, refer to the SDCEP\nguidance Management of Acute Dental Problems,4 which is available to download at\nwww.sdcep.org.uk. A web app of the guidance is also available at http://madp.sdcep.org.uk/.\n5.2 Denture Stomatitis\nDenture stomatitis can be treated effectively by local measures (see below). However, antifungal\nagents can be used as an adjunct to these local measures, particularly to reduce palatal\ninflammation before taking impressions for new dentures. Chlorhexidin",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 47
  },
  {
    "text": "e mouthwash is also\neffective against fungal infections.\nLocal Measures – to be used in the first instance\nAdvise the patient to:\n• brush the palate daily to treat the condition;\n• clean their dentures thoroughly (by soaking in chlorhexidine mouthwash or\nsodium hypochlorite for 15 minutes twice daily; note that hypochlorite should\nonly be used for acrylic dentures);\n• leave their dentures out as often as possible during the treatment period.\nIf dentures themselves are identified as contributing ",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 47
  },
  {
    "text": "to the problem, ensure the dentures are\nadjusted or new dentures are made to avoid the problem recurring.\nRefer to Appendix 1 of the BNF and BNFC for further details of drug interactions. 41",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 47
  },
  {
    "text": "Drug Prescribing For Dentistry\n5 Fungal Infections\nIf drug treatment is required, an appropriate 7-day regimen is a choice of:\nFluconazole Capsules, 50 mg For children:\nSend: 7 capsules Fluconazole Capsules 50 mg or\nOral Suspension, 50 mg/5 ml\nLabel: 1 capsule daily\n6 months-11 years 3-6 mg/kg\non first day and\nthen 3 mg/kg\n(max. 50 mg) daily\n12-17 years 50 mg daily\nNB: Fluconazole can be administered for a maximum of 14 days for the treatment of denture stomatitis.\nDo not prescribe fluconazole f",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 48
  },
  {
    "text": "or patients taking warfarin or statins.\nor\nMiconazole Oromucosal Gel*, For children:\n20 mg/g Miconazole Oromucosal Gel*,\nSend: 80 g tube 20 mg/g\nLabel: Apply a pea-sized amount to 2-17 years As for adults\nfitting surface of upper denture\nafter food four times daily\nNB: Advise patient to remove upper denture, apply gel sparingly to fitting surface and then reinsert.\nAdvise patient to continue use for 7 days after lesions have healed.\nDo not prescribe miconazole for patients taking warfarin or sta",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 48
  },
  {
    "text": "tins.\n*Sugar-free preparation is available.\n42 Refer to Appendix 1 of the BNF and BNFC for further details of drug interactions.",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 48
  },
  {
    "text": "Drug Prescribing For Dentistry\n5 Fungal Infections\nIf fluconazole and miconazole are contraindicated, an appropriate regimen is:\nNystatin Oral Suspension, For children:\n100,000 units/ml\nAs for adults\nSend: 30 ml\nLabel: 1 ml after food four times daily for\n7 days\nNB: Advise patient to remove dentures before using drug, rinse suspension around mouth and then retain\nsuspension near lesion for 5 minutes before swallowing.\nAdvise patient to continue use for 48 hours after lesions have healed.\n5.3 Ang",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 49
  },
  {
    "text": "ular Cheilitis\nAngular cheilitis in denture-wearing patients is usually caused by infection with Candida spp. and\nthere is an associated denture stomatitis that should be treated concurrently. In those without\ndentures, angular cheilitis is more likely to be caused by infection with Streptococcus spp. or\nStaphylococcus spp.\nMiconazole cream is effective against both Candida and Gram-positive cocci and is therefore\nappropriate to use for all patients, except those taking warfarin or statins. Wher",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 49
  },
  {
    "text": "e the condition is\nclearly bacterial in nature, sodium fusidate (fusidic acid) ointment can be used. Note that creams\nare normally used on wet surfaces whereas ointments are normally used on dry surfaces.\nUnresponsive cases can be treated with miconazole and hydrocortisone cream or ointment,\nexcept those patients taking warfarin or statins. Continue treatment until clinical resolution is\nachieved. A lack of clinical response might indicate predisposing factors such as a concurrent\nhaematinic def",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 49
  },
  {
    "text": "iciency or diabetes. Refer such cases to a specialist or the patient’s general medical\npractitioner.\nIf dentures themselves are identified as contributing to the problem, ensure the dentures are\nadjusted or new dentures are made to avoid the problem recurring.\nRefer to Appendix 1 of the BNF and BNFC for further details of drug interactions. 43",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 49
  },
  {
    "text": "Drug Prescribing For Dentistry\n5 Fungal Infections\nAn appropriate regimen is a choice of:\nMiconazole Cream, 2% For children:\nSend: 20 g tube As for adults\nLabel: Apply to angles of mouth twice\ndaily\nNB: Advise patient to continue use for 10 days after lesions have healed.\nDo not prescribe miconazole for patients taking warfarin or statins.\nor\nSodium Fusidate Ointment, 2% For children:\nSend: 15 g tube As for adults\nLabel: Apply to angles of mouth\nfour times daily\nNB: To avoid the development of r",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 50
  },
  {
    "text": "esistance, do not prescribe sodium fusidate for longer than 10 days.\nAn appropriate regimen for unresponsive cases is a choice of:\nMiconazole (2%) and Hydrocortisone For children:\n(1%) Cream\nAs for adults\nSend: 30 g tube\nLabel: Apply to angles of mouth\ntwice daily\nNB: Advise patient to continue use for a maximum of 7 days.\nDo not prescribe miconazole for patients taking warfarin or statins.\nor\nMiconazole (2%) and Hydrocortisone For children:\n(1%) Ointment\nAs for adults\nSend: 30 g tube\nLabel: App",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 50
  },
  {
    "text": "ly to angles of mouth\ntwice daily\nNB: Advise patient to continue use for a maximum of 7 days.\nDo not prescribe miconazole for patients taking warfarin or statins.\n44 Refer to Appendix 1 of the BNF and BNFC for further details of drug interactions.",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 50
  },
  {
    "text": "Drug Prescribing For Dentistry\n6 Viral Infections\n6.1 Herpes Simplex Infections\nPrimary herpetic gingivostomatitis [as a result of herpes simplex virus (HSV)] is best managed\nby symptomatic relief [i.e. nutritious diet, plenty of fluids, bed rest, use of analgesics and\nantimicrobial mouthwashes (either chlorhexidine or hydrogen peroxide)]. The use of antimicrobial\nmouthwashes controls plaque accumulation if toothbrushing is painful and also helps to control\nsecondary infection in general.\nTreat ",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 51
  },
  {
    "text": "infections in immunocompromised patients and severe infections in non-\nimmunocompromised patients with a systemic antiviral agent, the drug of choice being aciclovir.\nGive patients analgesics regularly to minimise oral discomfort; a topical benzydamine hydrochloride\n(oromucosal) spray might provide additional relief from oral discomfort and is particularly helpful\nin children. Refer immunocompromised patients (both adults and children) with severe infection\nto hospital.\nMild infection of the lip",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 51
  },
  {
    "text": "s [herpes labialis (cold sores)] in non-immuncompromised patients is\ntreated with a topical antiviral drug (aciclovir cream).\nBell’s palsy is sometimes associated with herpes simplex. Refer patients with Bell’s palsy to a\nspecialist or the patient’s general medical practitioner for treatment.\nLocal Measures – to be used in the first instance\nAdvise the patient to avoid dehydration and alter their diet (to include soft food and\nadequate fluids) and use analgesics and an antimicrobial mouthwash.\nR",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 51
  },
  {
    "text": "efer to Appendix 1 of the BNF and BNFC for further details of drug interactions. 45",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 51
  },
  {
    "text": "Drug Prescribing For Dentistry\n6 Viral Infections\nAn appropriate mouthwash is a choice of:\nChlorhexidine Mouthwash, 0.2% For children:\nSend: 300 ml As for adults\nLabel: Rinse mouth for 1 minute with\n10 ml twice daily\nNB: Advise patient to spit out mouthwash after rinsing and use until lesions have resolved and patient can carry\nout good oral hygiene.\nChlorhexidine gluconate might be incompatible with some ingredients in toothpaste; advise patient to\nleave an interval of at least 30 minutes betwe",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 52
  },
  {
    "text": "en using mouthwash and toothpaste. Also advise patient that\nchlorhexidine mouthwash can be diluted 1:1 with water with no loss in efficacy.\nor\nHydrogen Peroxide Mouthwash, 6% For children:\nSend: 300 ml As for adults\nLabel: Rinse mouth for 2 minutes with\n15 ml diluted in half a tumbler of\nwarm water three times daily\nNB: Advise patient to spit out mouthwash after rinsing and use until lesions have resolved and patient can carry\nout good oral hygiene.\nHydrogen peroxide mouthwash can be used as a r",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 52
  },
  {
    "text": "inse for up to 3 minutes, if required.\n46 Refer to Appendix 1 of the BNF and BNFC for further details of drug interactions.",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 52
  },
  {
    "text": "Drug Prescribing For Dentistry\n6 Viral Infections\nFor infections in immunocompromised patients and severe infections in non-\nimmunocompromised patients, an appropriate 5-day regimen is:\nAciclovir Tablets, 200 mg For children:\nSend: 25 tablets Aciclovir Tablets, 200 mg, or Oral\nSuspension*, 200 mg/5 ml\nLabel: 1 tablet five times daily\n6 months-1 year 100 mg five\ntimes daily\n2-17 years 200 mg five\ntimes daily\nNB: In both adults and children, the dose can be doubled in immunocompromised patients or",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 53
  },
  {
    "text": " if absorption is\nimpaired.\n*Sugar-free preparation is available.\nAntiviral creams such as aciclovir can be used to treat herpes labialis in non-immunocompromised\npatients. Administer this topical agent at the prodromal stage of a herpes labialis lesion to\nmaximise its benefit.\nAn appropriate regimen is:\nAciclovir Cream, 5% For children:\nSend: 2 g As for adults\nLabel: Apply to lesion every 4 hours (five\ntimes daily) for 5 days\nNB: Aciclovir cream can be applied for up to 10 days, if required.\nRe",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 53
  },
  {
    "text": "fer to Appendix 1 of the BNF and BNFC for further details of drug interactions. 47",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 53
  },
  {
    "text": "Drug Prescribing For Dentistry\n6 Viral Infections\n6.2 Varicella-zoster Infections\nIn patients with herpes zoster (shingles), systemic antiviral agents reduce pain and reduce the\nincidence of post-herpetic neuralgia and viral shedding. Aciclovir is the drug of choice. However,\nvalaciclovir and famciclovir are suitable alternatives (although they can only be prescribed using\na private prescription). Start treatment ideally at diagnosis or within 72 hours of the onset of the\nrash; even after this p",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 54
  },
  {
    "text": "oint antiviral treatment can reduce the severity of post-herpetic neuralgia. In\naddition, refer all patients with herpes zoster to a specialist or their general medical practitioner.\nAn appropriate 7-day regimen is:\nAciclovir Tablets, 800 mg (shingles For children:\ntreatment pack)\nNot relevant for children in dental setting‡\nSend: 35 tablets\nLabel: 1 tablet five times daily\n‡Aciclovir tablets and oral suspension are not licensed for the treatment of herpes zoster in children (see\nSection 1.1.5).",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 54
  },
  {
    "text": "\nFor more information on the clinical management of viral infections, refer to the SDCEP guidance\nManagement of Acute Dental Problems,4 which is available to download at www.sdcep.org.uk.\nA web app of the guidance is also available at http://madp.sdcep.org.uk/.\n48 Refer to Appendix 1 of the BNF and BNFC for further details of drug interactions.",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 54
  },
  {
    "text": "Drug Prescribing For Dentistry\n7 Odontogenic Pain\nMost odontogenic pain can be relieved effectively by non-steroidal anti-inflammatory drugs\n(NSAIDs), such as ibuprofen and aspirin, which have anti-inflammatory activity. Paracetamol is\nalso effective in the management of odontogenic or post-operative pain but has no demonstrable\nanti-inflammatory activity. Aspirin is a potent and useful NSAID but avoid its use in children and\nthose with an aspirin allergy, and do not prescribe following a dental",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 55
  },
  {
    "text": " extraction or other minor\nsurgery. Pyrexia in children can be managed using paracetamol or ibuprofen. Both drugs can\nbe given alternately to control ongoing pyrexia without exceeding the recommended dose or\nfrequency of administration for either drug.\nCautions\nParacetamol is a safe, well tolerated drug with few side effects when used as directed. However,\nstaggered overdose, where an excessive dose of paracetamol or paracetamol-containing\npreparations is ingested over a period of hours, can lea",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 55
  },
  {
    "text": "d to hepatotoxicity. Acute dental pain\nmay lead to such unintentional overdose, as patients may unknowingly take more than one\nparacetamol-containing preparation in order to control their discomfort.\nAll patients, including children, should be referred to an emergency department if they have\ningested paracetamol at a dose of 75 mg/kg or greater, either as a single acute dose or staggered\nacross a 24 hour period.18 Patients who are uncertain about the timing of doses or the total\namount ingested ",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 55
  },
  {
    "text": "should also be referred. Note that patients who have taken the appropriate\nrecommended therapeutic dose (e.g. for adults this 8 x 500 mg paracetamol tablets in 24 hours)\ndo NOT need to be referred. However an adult patient, for example, who weighs 60 kg (9 stone 6\nlbs) or less and has ingested nine paracetamol tablets within a 24 hour period should be referred.\nFor more information, see the National Poisons Information Service (www.npis.org).\nAvoid the use of all NSAIDs in patients with a histor",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 55
  },
  {
    "text": "y of hypersensitivity to aspirin or any other\nNSAID, including those in whom attacks of asthma, angioedema, urticaria or rhinitis have been\nprecipitated by aspirin or any other NSAID. All NSAIDs cause gastrointestinal irritation and\ntherefore avoid in patients with previous or active peptic ulcer disease. However, if NSAIDs are\nrequired to provide pain relief in these patients, a proton pump inhibitor can be prescribed in\nconjunction with the NSAID. In addition, use NSAIDs with caution in the el",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 55
  },
  {
    "text": "derly, patients with\nallergic disorders, pregnant women, nursing mothers, those taking oral anticoagulants such as\nwarfarin, those with coagulation defects and those with an inherited bleeding disorder. NSAIDs\nmight impair renal function and so use with caution in patients with renal, cardiac or hepatic\nimpairment. Some patients may already take a daily low-dose of aspirin, in these cases do not\nprescribe NSAIDs as these can increase the risk of gastro-intestinal side-effects. More information\no",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 55
  },
  {
    "text": "n potential NSAID drug interactions is provided in Appendix 4.\nRefer to Appendix 1 of the BNF and BNFC for further details of drug interactions. 49",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 55
  },
  {
    "text": "Drug Prescribing For Dentistry\n7 Odontogenic Pain\nThe NSAID diclofenac is also effective against moderate inflammatory or post-operative pain.\nHowever, be aware that diclofenac is contra-indicated in ischaemic heart disease, cerebrovascular\ndisease, peripheral arterial disease and mild to severe heart failure and should be used with caution\nin patients with a history of cardiac failure, left ventricular disfunction, hypertension, in patients with\noedema for any other reason, and in patients with",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 56
  },
  {
    "text": " other risk factors for cardiac events.\nThe BNF (BNF 701) does not recommend the use of dihydrocodeine as it is relatively\nineffective against dental pain and also causes nausea and constipation. There is also\nthe potential for abuse of dihydrocodeine; therefore, if the drug is to be used, prescribe\nonly the minimum number of tablets required.\nPrescribe analgesics only as a temporary measure for the relief of pain, and ensure the underlying\ncause is managed. Base the choice of analgesic on its s",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 56
  },
  {
    "text": "uitability for the patient. If the following\nregimens are ineffective, refer the patient to their general medical practitioner.\n50 Refer to Appendix 1 of the BNF and BNFC for further details of drug interactions.",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 56
  },
  {
    "text": "Drug Prescribing For Dentistry\n7 Odontogenic Pain\nFor mild to moderate odontogenic or post-operative pain, an appropriate 5-day\nregimen is:\nParacetamol Tablets, 500 mg For children:\nSend: 40 tablets Paracetamol Tablets or Soluble\nTablets, 500 mg, or Oral Suspension*,\nLabel: 2 tablets four times daily\n120 mg/5 ml or 250 mg/5 ml\n6 months- 120 mg four times\n1 year daily (max. 4 doses\nin 24 hours)\n2-3 years 180 mg four times\ndaily (max. 4 doses\nin 24 hours)\n4-5 years 240 mg four times\ndaily (max. 4 ",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 57
  },
  {
    "text": "doses\nin 24 hours)\n6-7 years 240-250 mg four times\ndaily (max. 4 doses\nin 24 hours)\n8-9 years 360-375 mg four times\ndaily (max. 4 doses\nin 24 hours)\n10-11 years 480-500 mg four times\ndaily (max. 4 doses\nin 24 hours)\n12-15 years 480-750 mg four times\ndaily (max. 4 doses\nin 24 hours)\n16-17 years 500 mg-1 g four\ntimes daily (max. 4 doses\nin 24 hours)\nNB: Advise patients that paracetamol can be taken at 4-hourly intervals but not to exceed the recommended daily\ndose (maximum of 4 g for adults). Over",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 57
  },
  {
    "text": "dose with paracetamol is dangerous because it can cause hepatic\ndamage that is sometimes not apparent for 4-6 days and can be fatal. Note that a patient who ingests a\ntherapeutic excess (defined as more than the recommended daily dose [8 x 500 mg tablets for adults] AND\nmore than or equal to 75 mg/kg in any 24 hour period) should be referred for assessment in an emergency\ndepartment (for more information see page 49).\n*Sugar-free preparation is available.\nRefer to Appendix 1 of the BNF and BNFC ",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 57
  },
  {
    "text": "for further details of drug interactions. 51",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 57
  },
  {
    "text": "Drug Prescribing For Dentistry\n7 Odontogenic Pain\nFor mild to moderate odontogenic, post-operative or inflammatory pain, an appropriate\n5-day regimen is:\nIbuprofen Tablets, 400 mg For children:\nSend: 20 tablets Ibuprofen Oral Suspension*, 100 mg/\n5 ml or Ibuprofen Tablets, 200 mg\nLabel: 1 tablet four times daily,\npreferably after food 6-11 months 50 mg four times\ndaily, preferably after\nfood\n1-3 years 100 mg three times\ndaily, preferably after\nfood\n4-6 years 150 mg three times\ndaily, preferably ",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 58
  },
  {
    "text": "after\nfood\n7-9 years 200 mg three times\ndaily, preferably after\nfood\n10-11 years 300 mg three times\ndaily, preferably after\nfood\n12-17 years 300-400 mg four\ntimes daily,\npreferably after food\nNB: In adults, the dose of ibuprofen can be increased, if necessary, to a maximum of 2.4 g daily.\nAvoid use in those with a hypersensitivity to aspirin or any other NSAID, including those in whom attacks\nof asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID. Do no",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 58
  },
  {
    "text": "t\nprescribe for patients taking a low dose of aspirin daily. Avoid use in pregnant patients and avoid in those\nwith previous or active peptic ulcer disease, unless a proton pump inhibitor is co-prescribed (see page 54).\nUse with caution in the elderly, patients with allergic disorders, nursing mothers, those taking oral\nanticoagulants such as warfarin, those with coagulation defects, those with an inherited bleeding disorder,\nand those with renal, cardiac or hepatic impairment. Restrict ibuprofe",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 58
  },
  {
    "text": "n use to 5 days or less in those patients\ntaking antihypertensive drugs. See Appendix 4 for more information on potential drug interactions.\n*Sugar-free preparation is available.\nIn cases where paracetamol or ibuprofen alone is not effective, both paracetamol and ibuprofen\ncan be given alternately (i.e. ibuprofen can be taken first and then paracetamol 2 hours later,\nand so on, using the normal daily doses given in the prescription boxes above). This regimen\ncontrols ongoing pain and pyrexia wit",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 58
  },
  {
    "text": "hout exceeding the recommended dose or frequency of\nadministration for either drug.\n52 Refer to Appendix 1 of the BNF and BNFC for further details of drug interactions.",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 58
  },
  {
    "text": "Drug Prescribing For Dentistry\n7 Odontogenic Pain\nFor mild to moderate odontogenic or inflammatory pain, an appropriate 5-day regimen\nis:\nAspirin Dispersible Tablets, 300 mg For children:\nSend: 40 tablets <16 years Do not use in children\nbecause, rarely, it\nLabel: 2 tablets four times daily,\ncan cause Reye’s\npreferably after food\nsyndrome‡\n≥16 years As for adults\nNB: Advise patient that aspirin can be taken at 4-hourly intervals but not to exceed the recommended daily\ndose. In adults and childre",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 59
  },
  {
    "text": "n 16 years and over, up to 3 tablets (900 mg) can be given in one dose\n(maximum daily dose of 4 g).\nDo not prescribe aspirin following a dental extraction or other minor surgery.\nAvoid use in those with a known allergy to aspirin or hypersensitivity to aspirin or any other NSAID, including\nthose in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any\nother NSAID. Avoid use in nursing mothers and patients with previous or active peptic ulcer disease a",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 59
  },
  {
    "text": "nd use\nwith caution in the elderly, patients with allergic disorders, pregnant women, those taking oral anticoagulants\nsuch as warfarin, those with coagulation defects, those with an inherited bleeding disorder, and those with\nrenal, cardiac or hepatic impairment. See Appendix 4 for more information on potential drug interactions.\n‡Aspirin is not licensed for use in children under 16 years (see Section 1.1.5).\nDiclofenac is also effective against moderate inflammatory or post-operative pain.\nAn ",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 59
  },
  {
    "text": "appropriate 5-day regimen is:\nDiclofenac Sodium Tablets, 50 mg For children:\nSend: 15 tablets Not recommended for dental use in\nchildren‡\nLabel: 1 tablet three times daily\nNB: Advise patient not to exceed the recommended daily dose (maximum of 150 mg).\nDiclofenac is contra-indicated in ischaemic heart disease, cerebrovascular disease, peripheral arterial disease\nand mild to severe heart failure. It should be used with caution in patients with a history of cardiac failure,\nleft ventricular disfun",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 59
  },
  {
    "text": "ction, hypertension, in patients with oedema for any other reason, and in patients\nwith other risk factors for cardiac events. Avoid use in those with a hypersensitivity to aspirin or any other\nNSAID, including those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated\nby aspirin or any other NSAID. Do not prescribe for patients taking a low dose of aspirin daily. Avoid use\nin pregnant patients and avoid in those with previous or active peptic ulcer disease, unless",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 59
  },
  {
    "text": " a proton pump\ninhibitor is co-prescribed (see page 54). Use with caution in the elderly, patients with allergic disorders,\nnursing mothers, those taking oral anticoagulants such as warfarin, those with coagulation defects, those\nwith an inherited bleeding disorder, and those with renal, cardiac or hepatic impairment. See Appendix 4 for\nmore information on potential drug interactions.\nDiclofenac tablets are enteric coated and should be swallowed whole, not chewed or crushed.\n‡Diclofenac tablets ",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 59
  },
  {
    "text": "of >25 mg are not licensed for use in children (see Section 1.1.5).\nRefer to Appendix 1 of the BNF and BNFC for further details of drug interactions. 53",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 59
  },
  {
    "text": "Drug Prescribing For Dentistry\n7 Odontogenic Pain\nIn patients who have a history of previous or active peptic ulcer disease where paracetamol alone\nis not sufficient for the treatment of odontogenic pain, and a NSAID (i.e. ibuprofen or diclofenac)\nis required, prescribe a proton pump inhibitor (i.e. lansoprazole and omeprazole) in conjunction\nwith the NSAID. Prescribe the proton pump inhibitor for the duration of the analgesic course to\nprevent the occurrence of gastric problems.\nIn patients who",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 60
  },
  {
    "text": " have a history of previous or active peptic ulcer disease and require a\nNSAID for the treatment of odontogenic pain, an appropriate 5-day regimen to prevent\ngastric problems is:\nLansoprazole Capsules, 15 mg For children:\nSend: 5 capsules Not licensed for children\nLabel: 1 capsule once daily\nNB: Use with caution in patients with liver disease, in pregnancy and in patients who are breast-feeding.\nor\nGastro-resistant Omeprazole Capsules, For children:\n20 mg\nNot licensed for children\nSend: 5 capsul",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 60
  },
  {
    "text": "es\nLabel: 1 capsule once daily\nNB: Use with caution in patients with liver disease, in pregnancy and in patients who are breast-feeding.\n54",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 60
  },
  {
    "text": "Drug Prescribing For Dentistry\n8 Facial Pain\nBefore treatment, ensure the pain is not odontogenic in nature. Non-odontogenic facial pain can\nbe organic or neurogenic in nature. Most non-odontogenic organic facial pain requires specialist\ncare.\n8.1 Trigeminal Neuralgia\nIf a patient with trigeminal neuralgia presents in primary care, control quickly by treatment with\ncarbamazepine. A positive response confirms the diagnosis. Make an urgent referral to a specialist\nor the patient’s general medical ",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 61
  },
  {
    "text": "practitioner for a full blood count and liver function tests.\nAn appropriate 10-day regimen is:\nCarbamazepine Tablets, 100 mg For children:\nSend: 20 tablets Not relevant for children\nLabel: 1 tablet twice daily\nNB: Advise patient to space out doses as much as possible throughout the day.\nCarbamazepine has the potential to react with multiple other medicines; check Appendix 1 of BNF for\ninteractions.\nCarbamazepine can cause reversible blurring of vision, dizziness and unsteadiness (dose-related).",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 61
  },
  {
    "text": "\nRefer to the BNF for advice which should be given to patients prescribed carbamazepine.\nFor more information on the clinical management of trigeminal neuralgia, refer to the\nSDCEP guidance Management of Acute Dental Problems,4 which is available to download at\nwww.sdcep.org.uk. A web app of the guidance is also available at http://madp.sdcep.org.uk/.\nRefer to Appendix 1 of the BNF and BNFC for further details of drug interactions. 55",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 61
  },
  {
    "text": "Drug Prescribing For Dentistry\n8 Facial Pain\n8.2 Other Facial Pain\nTemporomandibular dysfunction usually responds to reassurance and local therapy; advise the\npatient to have a soft diet and avoid chewing gum, and consider making an occlusal splint for the\npatient. Acute temporomandibular dysfunction might respond to analgesics such as ibuprofen\n(see Section 7 for drug regimen) or a short course of diazepam as a muscle relaxant. However,\nas benzodiazepines are addictive and susceptible to abuse ",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 62
  },
  {
    "text": "only the minimum number of tablets\nrequired should be prescribed.\nAn appropriate 5-day regimen is:\nDiazepam Tablets, 2 mg For children:\nSend: 15 tablets Not recommended because it has an\nunpredictable effect in children\nLabel: 1 tablet three times daily\nNB: The dose can be increased if necessary to 15 mg daily.\nHalve the adult dose for elderly or debilitated patients.\nAdvise all patients that they should not drive.\nIf the patient does not respond, refer the patient to a specialist or the patient",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 62
  },
  {
    "text": "’s general medical\npractitioner.\nChronic neuropathic facial pain and oral dysaesthesia might require to be managed with\nneuropathic painkillers. Refer such cases to a specialist or the patient’s general medical\npractitioner.\nFor more information on the clinical management of temperomandibular joint conditions, refer\nto the SDCEP guidance Management of Acute Dental Problems,4 which is available to download\nat www.sdcep.org.uk. A web app of the guidance is also available at http://madp.sdcep.org.u",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 62
  },
  {
    "text": "k/.\n56 Refer to Appendix 1 of the BNF and BNFC for further details of drug interactions.",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 62
  },
  {
    "text": "Drug Prescribing For Dentistry\n9 Mucosal Ulceration and Inflammation\nMucosal ulceration and inflammation can arise as a result of several different conditions.\nA diagnosis must be established because the majority of lesions require specific therapy in\naddition to topical symptomatic therapy. Such specific therapy usually involves specialist care.\nTemporary relief using topical, symptomatic therapy involves simple mouthwashes, antimicrobial\nmouthwashes, local analgesics or topical corticosteroids",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 63
  },
  {
    "text": ". Review the patient to assess the status\nof ulcers. If ulcers remain unresponsive to treatment, refer the patient to a specialist. Any ulcer\nthat persists for more than three weeks must be referred for biopsy.\nThe following treatments are not listed in order of preference so the choice of the clinical\npractitioner is not limited and so that patient preferences can be taken into consideration when\nprescribing.\n9.1 Simple Mouthwashes\nLocal Measures – to be used in the first instance\nAdvise the pa",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 63
  },
  {
    "text": "tient to rinse their mouth with a salt solution prepared by dissolving half\na teaspoon of salt in a glass of warm water to relieve pain and swelling.\nAlternatively, compound sodium chloride mouthwashes made up with warm water can be\nprescribed.\nAn appropriate regimen is:\nSodium Chloride Mouthwash, For children:\nCompound\nAs for adults\nSend: 300 ml\nLabel: Dilute with an equal volume of\nwarm water\nNB: Advise patient to spit out mouthwash after rinsing.\nRefer to Appendix 1 of the BNF and BNFC for fu",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 63
  },
  {
    "text": "rther details of drug interactions. 57",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 63
  },
  {
    "text": "Drug Prescribing For Dentistry\n9 Mucosal Ulceration and Inflammation\n9.2 Antimicrobial Mouthwashes\nAntimicrobial mouthwashes can reduce secondary infection and are particularly useful when pain\nlimits other oral hygiene measures.\nAn appropriate regimen is a choice of:\nChlorhexidine Mouthwash, 0.2% For children:\nSend: 300 ml As for adults\nLabel: Rinse mouth for 1 minute with\n10 ml twice daily\nNB: Advise patient to spit out mouthwash after rinsing and use until lesions have resolved and patient ca",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 64
  },
  {
    "text": "n carry\nout good oral hygiene.\nChlorhexidine gluconate might be incompatible with some ingredients in toothpaste; advise patient to\nleave an interval of at least 30 minutes between using mouthwash and toothpaste. Also advise patient that\nchlorhexidine mouthwash can be diluted 1:1 with water with no loss in efficacy.\nor\nHydrogen Peroxide Mouthwash, 6% For children:\nSend: 300 ml As for adults\nLabel: Rinse mouth for 2 minutes with\n15 ml diluted in half a glass of\nwarm water three times daily\nNB: Ad",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 64
  },
  {
    "text": "vise patient to spit out mouthwash after rinsing, and use until lesions have resolved and patient can carry\nout good oral hygiene.\nHydrogen peroxide mouthwash can be used as a rinse for up to 3 minutes, if required.\n58 Refer to Appendix 1 of the BNF and BNFC for further details of drug interactions.",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 64
  },
  {
    "text": "Drug Prescribing For Dentistry\n9 Mucosal Ulceration and Inflammation\nA tetracycline mouthwash is effective in some patients with recurrent aphthous stomatitis.\nDoxycycline can be used as a rinse and is usually given for three days. Enough medication to treat\nseveral episodes of ulceration can be provided.\nAn appropriate regimen is:\nDoxycycline Dispersible Tablets§, For children:\n100 mg <12 years Not recommended\nSend: 48 tablets for use because it\ncauses intrinsic\nLabel: 1 tablet to be dissolved ",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 65
  },
  {
    "text": "in water\nstaining of developing\nand rinsed around the mouth for\nteeth‡\n2 minutes four times daily for\nthree days at the onset of ≥12 years As for adults\nulceration\nNB: Advise patient to spit out mouthwash after rinsing.\nUse with caution in patients with hepatic impairment or those receiving potentially hepatotoxic drugs. Do\nnot prescribe for pregnant women, nursing mothers or children under 12 years, as it can deposit on growing\nbone and teeth (by binding to calcium) and cause staining and, occa",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 65
  },
  {
    "text": "sionally, dental hypoplasia.\nThe anticoagulant effect of warfarin might be enhanced by doxycycline.\n§Doxycycline is also available as doxycycline capsules.\n‡Doxycycline is not licensed for use in children under 12 years and doxycycline dispersible tablets are not licensed\nfor oral ulceration in adults or children (see Section 1.1.5).\nRefer to Appendix 1 of the BNF and BNFC for further details of drug interactions. 59",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 65
  },
  {
    "text": "Drug Prescribing For Dentistry\n9 Mucosal Ulceration and Inflammation\n9.3 Local Analgesics\nLocal analgesics cannot relieve pain continuously but are helpful in severe pain (e.g. major\naphthae) to enable eating or sleeping. Lidocaine 5% ointment can be directly applied to the ulcer\nor lidocaine 10% solution, provided as a spray, can be applied to the ulcer using a cotton bud.\nBenzydamine hydrochloride mouthwash or spray can also reduce mucosal discomfort.\nAn appropriate regimen is a choice of:\nBen",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 66
  },
  {
    "text": "zydamine Mouthwash, 0.15% For children:\nSend: 300 ml ≤12 years Not recommended for\nuse because of local\nLabel: Rinse or gargle using 15 ml every\nanaesthetic properties\n1½ hours as required\n13-17 years As for adults\nNB: Advise patient that benzydamine mouthwash can be diluted with an equal volume of water if stinging\noccurs.\nAdvise patient to spit out mouthwash after rinsing.\nThe mouthwash is usually given for not more than 7 days.\nor\nBenzydamine Oromucosal Spray, For children:\n0.15% Benzydamine ",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 66
  },
  {
    "text": "Oromucosal Spray, 0.15%\nSend: 30 ml\n6 months- 1 spray per 4 kg\nLabel: 4 sprays onto affected area every 5 years body-weight\n1½ hours (max. 4 sprays) every\n1½ hours\n6-17 years 4 sprays every 1½ hours\nNB: In adults and children of 12 years and over, up to 8 sprays of benzydamine oromucosal spray can be applied\nat any one time.\nor\n60 Refer to Appendix 1 of the BNF and BNFC for further details of drug interactions.",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 66
  },
  {
    "text": "Drug Prescribing For Dentistry\n9 Mucosal Ulceration and Inflammation\nLidocaine Ointment, 5% For children:\nSend: 15 g As for adults\nLabel: Rub sparingly and gently on\naffected areas\nNB: Advise patient to take care with the application to avoid producing anaesthesia of the pharynx before meals\nas this might lead to choking.\nor\nLidocaine Spray, 10%‡ For children:\nSend: 50 ml As for adults\nLabel: Apply as necessary with a\ncotton bud\nNB: Advise patient to take care with the application to avoid produ",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 67
  },
  {
    "text": "cing anaesthesia of the pharynx before meals\nas this might lead to choking.\n‡Lidocaine Spray, 10%, is not licensed for oral ulceration (see Section 1.1.5).\nRefer to Appendix 1 of the BNF and BNFC for further details of drug interactions. 61",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 67
  },
  {
    "text": "Drug Prescribing For Dentistry\n9 Mucosal Ulceration and Inflammation\n9.4 Topical Corticosteroids\nTopical corticosteroids can be used to treat mucosal ulceration and inflammation. Carefully\ncontrol chronic use to prevent systemic effects. The choice of preparation depends on the extent\nand location of the lesions. Hydrocortisone oromucosal tablets can be allowed to dissolve next to\nthe lesion. Beclometasone diproprionate inhaler (Clenil Modulite®) sprayed twice daily onto the\naffected site is sui",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 68
  },
  {
    "text": "table for tongue lesions and accessible areas. Betamethasone tablets, dissolved\nin water and used as a mouthwash, are suitable for extensive inflammation or ulceration but\nshould not be swallowed to minimise the risks of systemic effects.\nAn appropriate regimen is a choice of:\nClenil Modulite®‡, 50 micrograms/ For children:\nmetered inhalation (beclometasone\n≥2 years As for adults\npressurised inhalation, CFC-free)\nSend: One 200-dose unit\nLabel: 1-2 puffs directed onto ulcers\ntwice daily\n‡Clenil M",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 68
  },
  {
    "text": "odulite® inhaler is not licensed for oral ulceration (see Section 1.1.5).\nor\nBetamethasone Soluble Tablets‡, For children:\n500 micrograms\n<12 years Not appropriate for\nSend: 100 tablets use because\nof risk of swallowing\nLabel: 1 tablet dissolved in 10 ml water\nas a mouthwash four times daily ≥12 years As for adults\nNB: Advise patient to spit out mouthwash after rinsing.\n‡Betamethasone soluble tablets are not licensed for oral ulceration (see Section 1.1.5).\nor\nHydrocortisone Oromucosal Tablets, ",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 68
  },
  {
    "text": "For children:\n2.5 mg <12 years Prescribe only on\nSend: 20 tablets medical advice\nLabel: 1 tablet dissolved next to lesion ≥12 years As for adults\nfour times daily\nFor more information on the clinical management of mucosal ulceration and inflammation, refer\nto the SDCEP guidance Management of Acute Dental Problems,4 which is available to download\nat www.sdcep.org.uk. A web app of the guidance is also available at http://madp.sdcep.org.uk/.\n62 Refer to Appendix 1 of the BNF and BNFC for further de",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 68
  },
  {
    "text": "tails of drug interactions.",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 68
  },
  {
    "text": "Drug Prescribing For Dentistry\n10 Dry Mouth\nThe subjective feeling of a dry mouth (xerostomia) can arise as a result of loss of the mucous layer\nwithout clinical evidence of dryness. There is usually little relief with artificial saliva preparations\nor mucosal gel preparations in these patients. Dry mouth can also be caused by drugs that have\nantimuscarinic effects (tricyclic antidepressants, antipsychotics), diuretic drugs, irradiation of the\nhead and neck region or by damage or disease of the ",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 69
  },
  {
    "text": "salivary glands (e.g. Sjögren’s syndrome).\nIn these cases, artificial saliva preparations can provide useful relief.\n10.1 Local Measures\nSimple local measures (see below) might provide symptomatic relief in patients with subjective\ndryness but good saliva volume. However, in these patients artificial saliva preparations or mucosal\ngel preparations usually provide little relief and therefore the use of artificial saliva preparations\nis discouraged.\nLocal Measures – to be used in the first instanc",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 69
  },
  {
    "text": "e\nAdvise the patient to take frequent sips of cool drinks, suck pieces of ice or sugar-free\nfruit pastilles, or use sugar-free chewing gum to provide symptomatic relief.\n10.2 Artificial Saliva Preparations\nPatients with dry mouth induced by drug treatment, head and neck radiotherapy or a disease of the\nsalivary glands may obtain symptomatic relief from the use of artificial salivas or other proprietary\nsaliva-promoting medication. However, the effects tend to be of short duration. Where there is",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 69
  },
  {
    "text": "\na considerable reduction in saliva production the use of lubricant gel preparations, applied to the\noral mucosa, can give more-prolonged relief. Local measures such as those described in Section\n10.1 can also be helpful. Topical fluoride should also be prescribed for these patients (see Section\n10.3) and dietary advice provided.\nNote that some proprietary artificial saliva or mucosal gel preparations may only be prescribed\nfor patients with dry mouth that is associated with head and neck radiot",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 69
  },
  {
    "text": "herapy or autoimmune\nxerostomias such as sicca (primary Sjögren’s) syndrome. Also, saliva stimulating tablets may only\nbe prescribed for patients with salivary gland impairment and patent (open) salivary ducts.\nThe following treatments are not listed in order of preference. The choice of the clinical practitioner\nis not limited in order that patient preferences can be taken into consideration when prescribing.\nNote that saliva-stimulating tablets and artificial saliva pastilles contain citric an",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 69
  },
  {
    "text": "d/or malic acid and\ntherefore a high frequency of use might lead to dental erosion.\nThe artificial saliva preparations denoted • lack a generic alternative and should therefore be\nprescribed by brand name.\nRefer to Appendix 1 of the BNF and BNFC for further details of drug interactions. 63",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 69
  },
  {
    "text": "Drug Prescribing For Dentistry\n10 Dry Mouth\nAn appropriate regimen is a choice of:\nAn appropriate regimen is a choice of:\nArtificial Saliva Gel For children:\nSend: 50 g Not relevant for children in dental setting\nLabel: Apply to oral mucosa as required\nNB: Avoid use with toothpastes containing detergents (including foaming agents).\nor\nArtificial Saliva Oral Spray* For children:\nSend: 100 ml Not relevant for children in dental setting\nLabel: Spray as required\n*Sugar-free preparation available\nor\n",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 70
  },
  {
    "text": "Artificial Saliva Pastilles* For children:\nSend: 50 pastilles Not relevant for children in dental setting\nLabel: 1 pastille sucked as required\n*Sugar-free preparation is available\nor\nAS Saliva Orthana® Oral Spray* For children:\nSend: 50 ml Not relevant for children in dental setting\norLabel: Sprayed three times onto oral\nmucosa as required\n*This preparation includes limited fluoride supplementation\nor\n64 Refer to Appendix 1 of the BNF and BNFC for further details of drug interactions.",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 70
  },
  {
    "text": "Drug Prescribing For Dentistry\n10 Dry Mouth\n• BioXtra® Gel For children:\nSend: 40 ml Not relevant for children in dental setting\nLabel: Apply to oral mucosa as required\nN.B. May only be prescribed for dry mouth associated with radiotherapy or sicca syndrome\nor\n• Glandosane® Aerosol Spray For children:\nSend: 50 ml Not relevant for children in dental setting\nor\nLabel: Spray onto oral and pharyngeal\nmucosa as required\nNB: May only be prescribed for dry mouth associated with radiotherapy or sicca sy",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 71
  },
  {
    "text": "ndrome\nGlandosane Aerosol Spray® has a pH of 5.75 and may be inappropriate for dentulous patients.\nor\nSaliva-stimulating Tablets* For children:\nSend: 100 tablets Not relevant for children in dental setting\nLabel: 1 tablet sucked as required\nNB: May only be prescribed for dry mouth associated with impaired salivary gland function and patent salivary ducts.\n*Sugar-free preparation is available.\nor\n• Saliveze® Oral Spray For children:\nSend: 50 ml Not relevant for children in dental setting\nLabel: 1",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 71
  },
  {
    "text": " spray onto oral mucosa as required\nNB: May only be prescribed for dry mouth associated with radiotherapy or sicca syndrome\nRefer to Appendix 1 of the BNF and BNFC for further details of drug interactions. 65",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 71
  },
  {
    "text": "Drug Prescribing For Dentistry\n10 Dry Mouth\n10.3 Topical Fluoride\nPatients who have a true saliva deficit, such as those undergoing head and neck radiotherapy,\nare at high risk from dental caries and opportunistic infections. These patients should use topical\nfluoride preparations regularly (e.g. fluoride mouthwash, high-fluoride toothpaste) in addition to\na saliva substitute or saliva-promoting medication.\nAn appropriate regimen is a choice of:\nSodium Fluoride Toothpaste, 0.619% For children:\n(",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 72
  },
  {
    "text": "2800 ppm)\n<10 years Not indicated for use\nSend: 75 ml because of risk of\nswallowing and\nLabel: Brush teeth for 1 minute after\npossible poisoning\nmeals using 1 cm, before spitting\nout, twice daily ≥10 years As for adults\nNB: Advise patient to avoid rinsing mouth, drinking or eating for 30 minutes after use, and advise patient\nthat this 2800 ppm sodium fluoride toothpaste is a medicine and is only to be used by the person for\nwhom it is prescribed.\nor\nSodium Fluoride Toothpaste, 1.1% For children:",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 72
  },
  {
    "text": "\n(5000 ppm) < 16 years Not indicated for use\nSend: 51 g because of risk of\nswallowing and\nLabel: Brush teeth for 3 minutes after\npossible poisoning\nmeals using 2 cm, before spitting\nout, three times daily ≥ 16 years As for adults\nNB: Advise patient to avoid rinsing mouth, drinking or eating for 30 minutes after use, and advise patient that\nthis 5000 ppm sodium fluoride toothpaste is a medicine and is only to be used by the person for whom it is\nprescribed.\nor\nSodium Fluoride Mouthwash, 0.05% For",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 72
  },
  {
    "text": " children:\nSend: 250 ml <6 years Not indicated for use\nbecause of risk of\nLabel: Rinse mouth once daily with 10\nswallowing and\nml for 1 minute and spit out\npossible poisoning\n(preferably at a different time\nfrom brushing) ≥6 years As for adults\nNB: Advise patient to avoid rinsing mouth, drinking or eating for 15 minutes after use.\n66 Refer to Appendix 1 of the BNF and BNFC for further details of drug interactions.",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 72
  },
  {
    "text": "Drug Prescribing For Dentistry\n11 Dental Caries\nFluoride confers significant resistance to dental caries, with the topical action of fluoride on enamel\nand plaque considered more important in this effect than the systemic action. Additional fluoride\ntreatment may be prescribed for patients who are at increased risk of dental caries or are medically\ncompromised. The decision to prescribe additional fluoride treatment must take into account several\nfactors, including whether the patient lives in a",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 73
  },
  {
    "text": "n area where water is fluoridated, whether fluoride\nvarnish has been applied and whether the patient already uses a fluoride mouthwash. Further advice\nis provided in the SDCEP Prevention and Management of Dental Caries in Children19 guidance.\nAn appropriate regimen is a choice of:\nSodium Fluoride Toothpaste, 0.619% For children:\nor\n(2800 ppm)\n<10 years Not indicated for use\nSend: 75 ml because of risk of\nswallowing and\nLabel: Brush teeth for 1 minute after\npossible poisoning\nmeals using 1 cm, be",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 73
  },
  {
    "text": "fore\nspitting out, twice daily ≥10 years As for adults\nNB: Advise patient to avoid rinsing mouth, drinking or eating for 30 minutes after use, and advise patient that\nthis 2800 ppm sodium fluoride toothpaste is a medicine and is only to be used by the person for whom it is\nprescribed.\nor\nSodium Fluoride Toothpaste, 1.1% For children:\n(5000 ppm) <16 years Not indicated for use\nSend: 51 g because of risk of\nswallowing and\nLabel: Brush teeth for 3 minutes after\npossible poisoning\nmeals using 2 cm, ",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 73
  },
  {
    "text": "before spitting\nout, three times daily ≥16 years As for adults\nNB: Advise patient to avoid rinsing mouth, drinking or eating for 30 minutes after use, and advise patient that\nthis 5000 ppm sodium fluoride toothpaste is a medicine and is only to be used by the person for whom it is\nprescribed.\nor\nRefer to Appendix 1 of the BNF and BNFC for further details of drug interactions. Refer to Appendix 1 of the BNF and BNFC for further details of drug interactions. 67",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 73
  },
  {
    "text": "Drug Prescribing For Dentistry\n11 Dental Caries\nSodium Fluoride Mouthwash, 0.05% For children:\nSend: 250 ml Sodium Fluoride Mouthwash, 0.05%\nLabel: Rinse mouth once daily with <6 years Not indicated for use\n10 ml for 1 minute and spit because of risk of\nout (preferably at a different swallowing and\ntime from brushing) possible poisoning\n≥6 years As for adults\nNB: Advise patient to avoid rinsing mouth, drinking or eating for 15 minutes after use.\n68 Refer to Appendix 1 of the BNF and BNFC for fur",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 74
  },
  {
    "text": "ther details of drug interactions.",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 74
  },
  {
    "text": "Drug Prescribing For Dentistry\n12 Clinical Governance, CPD and Training\nIt is a requirement of clinical governance and fundamental good clinical practice that all health\nprofessionals work to monitor and constantly strive to improve the quality of care that they and\ntheir teams provide to patients.\nIt is recommended that:\n• all general dental practitioners and dental care professionals involved in dealing with medical\nemergencies undertake appropriate annual training and continuing professional ",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 75
  },
  {
    "text": "development\n(CPD); this is a practice inspection requirement and a minimum of 10 hours per CPD cycle is\nrecommended by the General Dental Council (GDC);\n• general dental practitioners who prescribe drugs ensure they are up to date with any changes\nin prescribing recommendations of the British National Formulary1 (BNF) and BNF for Children2\n(BNFC); updates will be posted on the Scottish Dental Clinical Effectiveness Programme\n(SDCEP; www.sdcep.org.uk) website if required following publication of ",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 75
  },
  {
    "text": "new editions of the\nBNF and BNFC, but practitioners should also refer to the BNF and BNFC (www.bnf.org) for\ndetails;\n• general dental practitioners who prescribe drugs seek to audit their practice regularly, and\nassess prescribing appropriateness and accuracy; examples of audit topics are provided in\nSection 12.1;\n• general dental practitioners who prescribe drugs carry out significant event analyses (SEAs) as\nappropriate.\nFurther information on the training requirements for dealing with medical",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 75
  },
  {
    "text": " emergencies can be\nfound in the SDCEP Practice Support Manual8 (www.psm.sdcep.org.uk). Guidance concerning audit\nand significant event analysis can also be found in the Practice Support Manual8 or is available via\nNHS Education for Scotland (www.nes.scot.nhs.uk/education-and-training/by-discipline/dentistry/\nareas-of-education/professional-development/clinical-audit-and-sea.aspx).\n69",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 75
  },
  {
    "text": "Drug Prescribing For Dentistry\n12 Clinical Governance, CPD and Training\n12.1 Recommendations for Self Audit\nThe terms of service for dentists in Scotland20 state that GDPs should undertake at least 15\nhours of clinical audit within each three year period, the most recent of which commenced on\n1st August 2013. Drug prescribing is an area where audit can be a particularly useful tool for\nimproving patient care, enabling practitioners to review current prescribing practices, consider\nalternatives t",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 76
  },
  {
    "text": "o antibiotic prescribing and to implement changes to meet best practice guidance\nrecommendations, if required.\nTopics for audit and review should be chosen carefully to provide information that will improve\nthe quality of drug prescribing within dentistry and ensure patient safety. Examples include:\n• the appropriateness of prescribing (i.e. is the prescribed drug appropriate for the condition?);\n• the accuracy and completeness of prescriptions (i.e. is the correct dose and frequency\nincluded, a",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 76
  },
  {
    "text": "nd are all relevant details included?).\n12.2 National Audit\nNHS Education for Scotland (NES) will, from time to time, publish pre-approved audit projects,\nnormally in relation to national priorities such as Antibiotic Prescribing, Infection Control and\nDecontamination, Oral Health Assessment, Patient Experience and other relevant topics. More\ninformation is available from the NES Portal (www.portal.scot.nhs.uk).\n70",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 76
  },
  {
    "text": "Drug Prescribing For Dentistry\nAppendix 1 Guidance Development\nThe Scottish Dental Clinical Effectiveness Programme\nThe Scottish Dental Clinical Effectiveness Programme (SDCEP) is an initiative of the National Dental\nAdvisory Committee (NDAC) in partnership with NHS Education for Scotland (NES).\nThe NDAC comprises representatives of all branches of the dental profession and acts in an advisory\ncapacity to the Chief Dental Officer. It considers issues that are of national importance in Scottish\nd",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 77
  },
  {
    "text": "entistry and also provides feedback to other bodies within the Scottish Government on related,\nrelevant healthcare matters.\nSDCEP was established in 2004 under the direction of the NDAC to give a structured approach to\nproviding clinical guidance for the dental profession. Since then, SDCEP has become established\nwithin the Dental Directorate of NES and provides and important link between best practice\nguidance and dental education and training. The programme’s primary aim is to develop guidance",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 77
  },
  {
    "text": "\nthat supports dental teams to provide quality patient care. SDCEP brings together the best available\ninformation that is relevant to priority areas in dentistry, and presents guidance on best practice in\na form that can be interpreted easily and implemented. The guidance recommendations may be\nbased on a variety of sources of information, including research evidence, guidelines, legislation,\npolicies and expert opinion as appropriate to the subject. SDCEP guidance takes a variety of forms\nto su",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 77
  },
  {
    "text": "it the diverse topics being addressed.\nRecognising that publication of guidance alone is likely to have a limited influence on practice,\nSDCEP also contributes to the research and development of interventions to enhance the translation\nof guidance recommendations into practice through its participation in the TRiaDS (Translation\nResearch in a Dental Setting) collaboration (www.triads.org.uk).\nSDCEP is funded by NHS Education for Scotland and has made important contributions to the\nimplementation",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 77
  },
  {
    "text": " of the Scottish Government’s Dental Action Plan, which aims to both modernise\ndental services and improve oral health in Scotland.\nThe Programme Development Team\nThe Programme Development Team operates within NHS Education for Scotland and is responsible\nfor the methodology of guidance development. Working with members of the Guidance\nDevelopment Group, the team facilitates all aspects of guidance development by providing project\nmanagement and administrative support, searching and appraising i",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 77
  },
  {
    "text": "nformation and evidence,\nconducting research, liaising with external organisations, editing the guidance, and managing the\npublication and dissemination of guidance materials. For up-to-date information on the SDCEP\nProgramme Development Team, refer to the SDCEP website (www.sdcep.org.uk).\n71",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 77
  },
  {
    "text": "Drug Prescribing For Dentistry\nAppendix 1 Guidance Development\nThe Guidance Development Group\nA Guidance Development Group, comprising individuals from a range of branches of the dental\nprofession that have a role in dental drug prescribing, was convened to develop and write this\nguidance.\nDavid Wray (Chair) Dean and Professor of Oral Medicine, Dubai College of Dental\nMedicine\nAlex Crighton Consultant in Oral Medicine, Glasgow Dental Hospital and School;\nmember of the Scottish Antimicrobial Pres",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 78
  },
  {
    "text": "cribing Group\nColin Fergusson Community Pharmacist, Glasgow\nSarah Manton Consultant in Restorative and Special Care Dentistry and Honorary\nSenior Lecturer, Dundee Dental Hospital and School\nTracy McFee Speciality Dentist and Honorary Clinical Teacher, Dundee Dental\nHospital and School\nStuart McLaren General Dental Practitioner, Rutherglen; Emergency Physician,\nVictoria Infirmary, Glasgow\nLiz Payne Administrator, Scottish Dental Clinical Effectiveness Programme\nColin Ritchie Core Trainee 2, Unive",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 78
  },
  {
    "text": "rsity Hospital Crosshouse, Kilmarnock\nSamantha Rutherford Research and Development Manager, Scottish Dental Clinical\nEffectiveness Programme\nPetrina Sweeney Senior Lecturer/Honorary Consultant in Special Care Dentistry,\nUniversity of Glasgow Dental School\nRobin Thompson General Dental Practitioner, Linlithgow\n72",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 78
  },
  {
    "text": "Drug Prescribing For Dentistry\nAppendix 1 Guidance Development\nGuidance Development Methodology\nSDCEP endeavours to use a methodology for guidance development that mirrors that used to\ndevelop high-quality guidelines. It aims to be transparent, systematic and to adhere as far as\npossible to international standards set out by the Appraisal of Guidelines Research and Evaluation\n(AGREE) Collaboration (www.agreecollaboration.org/).\nFor the majority of SDCEP guidance publications, the guidance recomm",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 79
  },
  {
    "text": "endations are informed\nby a thorough literature search and quality appraisal of the available evidence. However, for this\nguidance on drug prescribing, the British National Formulary1 and BNF for Children2 were used as\nthe main sources of information. These publications aim to provide prescribers, pharmacists and\nother healthcare professionals with sound up-to-date information about the use of medicines.\nInformation about drugs included in these publications is drawn from the manufacturers’ prod",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 79
  },
  {
    "text": "uct\nliterature, medical and pharmaceutical literature, regulatory authorities and professional bodies.\nAdvice is constructed from the clinical literature and reflects, as far as possible, an evaluation\nof the evidence from diverse sources. The Guidance Development Group identified information\nfrom the BNF and BNFC, and consulted with experts and experienced practitioners to develop\nguidance of specific relevance to primary care dental practice. For those drugs where a range\nin the dose or freque",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 79
  },
  {
    "text": "ncy of administration is provided by the BNF, a dose and frequency of\nadministration that is most relevant to primary care dental practice is recommended based on the\nopinion of experienced practitioners.\nOther references used in the production of the current guidance are cited in the reference list.\nPrior to the development of the third edition, SDCEP conducted a survey to ascertain dentists’\nattitudes towards the guidance and to garner feedback on how they felt it could be improved.\n295 genera",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 79
  },
  {
    "text": "l dental practitioners responded to the survey and suggestions for improvements were\nconsidered during the updating of the guidance.\nFor the first edition of this guidance, a wide consultation was conducted prior to peer review and\npublication. This included a wide range of individuals and organisations with particular interests in\ndental prescribing, representatives of end-users and those involved in the organisation of dental\nservices or dental education in Scotland.\nThe content and presentati",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 79
  },
  {
    "text": "on of the second and third editions of the guidance does not vary\nsignificantly from that of edition one; therefore, it was concluded that in depth consultation was\nnot required. The updated guidance was reviewed by the Guidance Development Group before\npeer review by a range of experts comprising general dental practitioners, academic dentists,\npharmacists and medical professionals, including paediatricians. Comments received during peer\nreview were considered carefully by the Guidance Developm",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 79
  },
  {
    "text": "ent Group and further amendments\nwere made to the guidance before publication.\nFurther information about the methodology used to develop this guidance is available on our\nwebsite: www.sdcep.org.uk.\n73",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 79
  },
  {
    "text": "Drug Prescribing For Dentistry\nAppendix 1 Guidance Development\nReview and Updating\nA review of all aspects of the context of this guidance (regulations, legislation, trends in working\npractices and evidence) will take place three years after publication and, if this has changed\nsignificantly, the guidance will be updated accordingly. As with editions one and two, the\nprescribing guidance in edition three will be reviewed as each new edition of the BNF and BNFC is\nreleased, with updates available",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 80
  },
  {
    "text": " on the SDCEP website (www.sdcep.org.uk) and, if required, as a\nhard copy to be stored in the pocket at the rear of this publication. SDCEP will always endeavour\nto provide guidance updates in as timely a manner as possible. However, be aware that due to the\ntime required to prepare and release updates, the guidance may not always reflect the information\navailable in the latest version of the BNF.\nSteering Group\nThe Steering Group oversees all the activities of the SDCEP and includes representat",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 80
  },
  {
    "text": "ives of guidance\ndevelopment groups and the dental institutions in Scotland. For up-to-date membership of the\nSteering Group, refer to the SDCEP website (www.sdcep.org.uk).\nConflict of Interest\nAll contributors to SDCEP are required to declare their financial, intellectual and other relevant\ninterests. At each group meeting, participants are asked to confirm whether there are any changes\nto these. Should any potential conflicts of interest arise, these are discussed and actions for their\nmanagem",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 80
  },
  {
    "text": "ent agreed. Declarations of interest and decisions about potential conflicts of interest are\navailable on request.\n74",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 80
  },
  {
    "text": "Drug Prescribing For Dentistry\nAppendix 2 List of Drugs\nThe following drugs are included in the third edition of Drug Prescribing For Dentistry. All drugs\nin this guidance can be prescribed by dentists within the NHS in Scotland (see List of Dental\nPreparations in BNF 701).\nPlease refer to Appendix 1 of the British National Formulary and BNF for Children (www.bnf.org) for\nfurther details of drug interactions. Report any suspected adverse interactions to the Medicines and\nHealthcare products Regu",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 81
  },
  {
    "text": "latory Agency (see the BNF for details).\nAciclovir Cream Co-amoxiclav Tablets 250/125 (amoxicillin\n250 mg as trihydrate, clavulanic acid\nAciclovir Oral Suspension, 200 mg/5 ml\n125 mg as potassium salt)\nAciclovir Tablets, 200 mg\nDiazepam Tablets\nAciclovir Tablets, 800 mg\nDiclofenac Sodium Tablets\nAmoxicillin Capsules\nDoxycycline Capsules, 100 mg\nAmoxicillin Oral Suspension\nDoxycycline Dispersible Tablets\nArtificial Saliva Gel\nEphedrine Nasal Drops\nArtificial Saliva Oral Spray\nFluconazole Capsules",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 81
  },
  {
    "text": ", 50 mg\nArtificial Saliva Pastilles\nFluconazole Oral Suspension, 50 mg/5 ml\nAspirin Tablets, Dispersible\nGlandosane® Aerosol Spray\nAS Saliva Orthana® Oral Spray\nHydrocortisone Oromucosal Tablets\nBeclometasone Diproprionate Aerosol\nHydrogen Peroxide Mouthwash 6%\nInhalation, 50 micrograms/metered dose as\nClenil Modulate® Ibuprofen Oral Suspension, sugar-free\nBenzydamine Mouthwash, 0.15% Ibuprofen Tablets\nBenzydamine Oromucosal Spray, 0.15% Lansoprazole Capsules\nBetamethasone Soluble Tablets, Lidoc",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 81
  },
  {
    "text": "aine 5% Ointment\n500 micrograms\nLidocaine Spray 10%\nBioXtra® Gel\nMetronidazole Oral Suspension\nCarbamazepine Tablets\nMetronidazole Tablets\nChlorhexidine Mouthwash\nMiconazole Cream\nClarithromycin Oral Suspension, 125 mg/5 ml\nMiconazole Oromucosal Gel\nClarithromycin Oral Suspension 250 mg/5 ml\nMiconazole and Hydrocortisone Cream\nClarithromycin Tablets\nMiconazole and Hydrocortisone Ointment\nClindamycin Capsules\nNystatin Oral Suspension\n75",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 81
  },
  {
    "text": "Drug Prescribing For Dentistry\nAppendix 2 List of Drugs\nOmeprazole Gastro-Resistant Capsules Saliva-stimulating Tablets\nParacetamol Oral Suspension Saliveze® Oral Spray\nParacetamol Tablets Sodium Chloride Mouthwash, Compound\nParacetamol Tablets, Soluble Sodium Fluoride Mouthwash\nPhenoxymethylpenicillin Oral Solution Sodium Fluoride Toothpaste 0.619%\nPhenoxymethylpenicillin Tablets Sodium Fluoride Toothpaste 1.1%\nSodium Fusidate (fusidic acid) Ointment\n76",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 82
  },
  {
    "text": "Drug Prescribing For Dentistry\nAppendix 3 Useful Sources of Information\nThe British National Formulary1 (BNF) and BNF for Children2 (BNFC) have been the main information\nsources used in the development of this guidance. In addition to providing information on drug\nprescribing and drugs used to manage medical emergencies, the BNF (www.bnf.org) also contains\nother useful information, including:\n• Contact details for medicines information services (also see overleaf) and poisons information\nservice",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 83
  },
  {
    "text": "s\n• Guidance on prescribing\n• Information on prescription writing\n• Details of controlled drugs and drug dependence\n• Advice on adverse reactions, including the oral side-effects of drugs, and how to report new\nadverse reactions to the Medicines and Healthcare products Regulatory Agency\n• Information on:\n- prescribing for children\n- prescribing for patients with liver disease\n- prescribing for patients with renal impairment\n- prescribing for pregnant patients\n- prescribing for breastfeeding pati",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 83
  },
  {
    "text": "ents\n- prescribing for the elderly\n• Information on drug interactions (Appendix 1 of BNF and BNFC)\n• A table showing the mean weights of children by age (also see overleaf)\nIn addition information on prescribing for specific patient groups is included in the relevant chapters,\neither under the specific drug or in the prescribing notes.\n77",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 83
  },
  {
    "text": "Drug Prescribing For Dentistry\nAppendix 3 Useful Sources of Information\nMedicines Information Services\nInformation on any aspect of drug therapy can be obtained from regional and local Medicines\nInformation Services. For example, the Information Services can provide advice on the choice of\ndrugs, interactions, adverse reactions and restrictions on drug prescribing.\nDetails of the local services provided within Scotland can be obtained from the directory on the\nUK Medicines Information website (w",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 84
  },
  {
    "text": "ww.ukmi.nhs.uk) or by telephoning one of the following\nregional numbers.\nAberdeen: 01224 552 316\nDundee: 01382 632 351 or 01382 660 111 Extn. 32351\nEdinburgh: 0131 242 2920\nGlasgow: 0141 211 4407\nInformation on drug therapy relating to dental treatment can be obtained by telephoning the\nNorth West Medicines Information Centre\n(www.ukmi.nhs.uk/activities/specialistServices)\nLiverpool: 0151 794 8206\n78",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 84
  },
  {
    "text": "Drug Prescribing For Dentistry\nAppendix 3 Useful Sources of Information\nPrescribing for Children – Mean Weights\nThe information in the table below has been extracted from BNFC 2015-20162. The table shows\nthe mean values for weight by children’s age. These values can be used to calculate doses in\nthe absence of actual measurements. However, note that the child’s actual weight might vary\nconsiderably from the values in the table and it is important to see the child to ensure that the\nvalue chosen ",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 85
  },
  {
    "text": "is appropriate. In most cases, the child’s actual weight should be obtained as soon\nas possible and the dose re-calculated.\nAge Weight (kg)\n6 months 7.6\n1 year 9\n3 years 14\n5 years 18\n7 years 23\n10 years 32\n12 years 39\n14 year old boy 49\n14 year old girl 50\nAdult male 68\nAdult female 58\n79",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 85
  },
  {
    "text": "Drug Prescribing For Dentistry\nAppendix 4 Drug Interactions\nWhen two or more drugs are given at the same time, they may exert their effects independently\nor they may interact. With the increase in the number of older patients who have retained some\nor all of their teeth and who may be on one or more long-term medications, identifying potential\ndrug interactions that may occur between drugs prescribed in dental practice and the patient’s\ncurrent medication is increasingly important.\nDrug interact",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 86
  },
  {
    "text": "ions can involve a variety of mechanisms, including those where the normal\nconcentration of a drug in tissue fluid is either reduced or increased due to the effects of a\nsecond drug on its ADME (absorption, distribution, metabolism, excretion) properties or those\nwhere the pharmacological effects of the first drug are modified (reduced or enhanced) due to\nthe pharmacological effects of the second drug. See Seymour21 and Dawoud et al.22 for more\ninformation on the principles of drug interactions ",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 86
  },
  {
    "text": "in dentistry.\nNot all drug interactions have serious consequences. However it is important that dentists are\naware of potentially harmful interactions when prescribing.\nThe most frequent interactions and side effects observed with drugs commonly prescribed in\ndentistry are:\n• interactions of non-steroidal anti-inflammatory drugs (NSAIDs), carbamazapine, azole\nantifungals and antibiotics with warfarin;\n• incidence of myopathy after prescribing azoles and clarithromycin in those taking statins;\n• ",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 86
  },
  {
    "text": "asthma symptoms exacerbated following the use of NSAIDs.\nDrug interactions can be minimised by ensuring that the patient’s medical history, including\ninformation on current medication, is up to date and by using alternative drugs where indicated.\nThe table overleaf lists the most common potential drug interactions likely to be encountered\nwhen prescribing in dental practice. However, always consult Appendix 1 of the BNF1 or BNFC2\n(www.bnf.org) for more comprehensive information on drug interacti",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 86
  },
  {
    "text": "ons.\nNHS Education for Scotland and the Yellow Card Centre Scotland (Centre for Adverse Reactions\nto Drugs Scotland) have developed a resource for healthcare professionals, including dentists,\nabout Adverse Drug Reactions (ADRs), their incidence and public health implications. The\nresource comprises six online modules and includes interactive learning tasks and case studies.\nThe resource can be accessed from www.nes.scot.nhs.uk/education-and-training/by-discipline/\npharmacy/about-nes-pharmacy/ed",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 86
  },
  {
    "text": "ucational-resources/resources-by-topic/clinical-governance/\npatient-safety-adverse-drug-reactions.aspx\n80",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 86
  },
  {
    "text": "Drug Prescribing For Dentistry\nAppendix 4 Drug Interactions\nDental drug Common interacting drug(s) Recommendation\nMetronidazole Alcohol Advise patients to avoid alcohol\nWarfarin Do not prescribe metronidazole\nfor patients taking warfarin\nMacrolide antibiotics Calcium channel blockers (e.g. Do not prescribe macrolide\n(e.g. clarithromycin) nifedipine), carbamazepine, antibiotics for patients taking\nciclosporin, domperidone, these drugs\nstatins (e.g. simvastatin),\ntheophylline, warfarin\nAzole antif",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 87
  },
  {
    "text": "ungals Statins, warfarin, theophylline Do not prescribe azole antifungals\n(e.g. fluconazole, for patients taking these drugs\nmiconazole)\nNon-steroidal Antihypertensive drugs esp. Avoid prescribing NSAIDs or\nanti-inflammatories beta-blockers (e.g. altenolol), ensure course is for 5 days or less\n(e.g. ibuprofen, ACE inhibitors (e.g. lisinopril) and\ndiclofenac) diuretics\nAnticoagulants (e.g. warfarin, Do not prescribe NSAIDs for\ndabigatran) patients taking these drugs\nAspirin Do not prescribe NSAID",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 87
  },
  {
    "text": "s for\npatients taking a daily low dose\nof aspirin\nLithium Do not prescribe NSAIDs\nMethotrexate Avoid prescribing NSAIDs\nSelective serotonin reuptake Avoid prescribing NSAIDs\ninhibitors (SSRIs e.g. fluoxetine)\nSystemic corticosteroids Only prescribe NSAIDs\nin combination with a\nproton-pump inhibitor\nAspirin Alcohol Advise patients to avoid alcohol\nfor 12 hours after taking aspirin\nClopidogrel Avoid prescribing aspirin\nNon-steroidal anti-inflammatories Do not prescribe aspirin for\n(e.g. ibuprofen,",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 87
  },
  {
    "text": " diclofenac) patients taking these drugs\nSelective serotonin reuptake Avoid prescribing aspirin\ninhibitors (SSRIs e.g. fluoxetine)\nSystemic corticosteroids Only prescribe aspirin\nin combination with a\nproton-pump inhibitor\nWarfarin Do not prescribe aspirin for\npatients taking warfarin\nRefer to Appendix 1 of the BNF and BNFC for further details of drug interactions. 81",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 87
  },
  {
    "text": "Drug Prescribing For Dentistry\nAppendix 5 Bacterial Infections Management Guide\nDental Abscess Necrotic Ulcerative Pericoronitis Sinusitis\n(See Section 4.3) Gingivitis (NUG) (See Section 4.4) (See Section 4.5)\n(See Section 4.4)\nIs there spreading infection Is there persistent swelling Are there persistent symptoms\n(cellulitis, swelling) or or systemic symptoms and purulent discharge\nsystemic involvement despite local measures? lasting at least seven days\n(fever, malaise)?* or severe symptoms?\nIf",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 88
  },
  {
    "text": " the answer is:\nNO YES\nAntibiotics are not required. Treat with local measures and prescribe a\nTreat with local measures. suitable antibiotic as detailed below.\nAdvise on appropriate analgesia where required. Advise on appropriate analgesia where required.\n* If there is significant trismus, floor of mouth swelling or difficulty\nbreathing, transfer patients to hospital as an emergency.\nDental abscess NUG/Pericoronitis Sinusitis\nA choice of: A choice of: A choice of:\nAmoxicillin Metronidazole Amox",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 88
  },
  {
    "text": "icillin\nPhenoxymethylpenicillin Amoxicillin Doxycycline\nMetronidazole\nN.B. Review patients with bacterial infections who have been treated with local\nmeasures, or who have received a course of antibiotic treatment, within 2 to 7 days\nBase infection management on clinical findings. Refer to the specified sections of the guidance\nfor advice on local measures, appropriate analgesia and, where required, recommended\nantibiotic doses for adults and children. A poster of this guide is available to down",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 88
  },
  {
    "text": "load from\nthe SDCEP website (www.sdcep.org.uk).\n82",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 88
  },
  {
    "text": "Drug Prescribing For Dentistry\nAppendix 5 Bacterial Infections Management Guide Index\nPrincipal page references are highlighted in bold (e.g. pages on which prescription boxes for a\nparticular drug are presented and pages on which a particular condition is discussed).\nAbscess, dental 29, 32, 33 Cardiac arrest 15\nlocal measures 30 Cardiac emergencies 14\nAciclovir 45, 47, 48 Cetirizine 9, 11\nAcute coronary syndrome Chlorhexidine mouthwash 41, 46, 58\nsee Angina and Myocardial Infarction Chlorphenam",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 89
  },
  {
    "text": "ine 9, 11\nAdrenaline 8, 10 Choking 22, 23\nAllergy 11 Clarithromycin 33, 34\nAmoxicillin 29, 30, 33, 35, 36, 37 Clindamycin 33\nAnaphylaxis 10 Clostridium difficile 27, 33\nAngina 14 Co-amoxiclav 33, 34\nAngular cheilitis 43 Contraceptives 3, 28\nAntibiotic prophylaxis 29 Corticosteroids 57, 62\nAntibiotics 28, 29, 33 Dental caries 67\nAntifungal agents 39, 41 Diazepam 25, 56\nAntihistamine 12 Diclofenac 50, 53\nAnxiety 25 Doxycycline 38\nArtificial saliva preparations 63 mouthwash 59\ngel 64 Dry mouth 63\no",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 89
  },
  {
    "text": "ral spray 64 local measures 63\npastilles 64 Dry socket 27\nAspiration 22 Ephedrine 37\nAspirin 8, 15, 49, 53 Epilepsy 16\nAsthma 13 Faint 18\nAS Saliva Orthana® Oral Spray 64 Famciclovir 48\nBeclometasone diproprionate Fluconazole 39, 40, 42\nClenil Modulite® 62 Fluoride\nBell’s palsy 45 Mouthwash 66, 68\nBenzodiazepine 25 Toothpaste 66, 67\nBenzydamine Gingivitis\nmouthwash 60 see Necrotising ulcerative\noromucosal spray 45, 60 Glandosane® Aerosol Spray 65\nBetamethasone 62 Glucagon 8, 20\nBioXtra® Gel 65 G",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 89
  },
  {
    "text": "lucose, oral 8, 19, 20\nCandidal leukoplakia 39 Glyceryl trinitrate (GTN) 8, 14\nCandidosis, chronic hyperplastic 39 Herpes labialis 45, 47\nCandidosis, erythematous 39 Herpes simplex virus 45\nlocal measures 39 local measures 45\nCandidosis, pseudomembranous 39 Herpes zoster 48\nlocal measures 39 Herpetic gingivostomatitis 45\nCarbamazepine 55 Hydrocortisone 62\n83",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 89
  },
  {
    "text": "Drug Prescribing For Dentistry\nIndex\nHydrogen Peroxide Mouthwash 45, 46, 58 Oxygen 8, 10, 13, 14, 15, 16, 18, 19, 21, 22\nHypoglycaemia 19 Pain\nIbuprofen 49, 52, 56 Facial 55\nInfection Inflammatory 50, 52, 53\nBacterial 27 Neuropathic 56\nFungal 39 Odontogenic 49, 51, 52, 53\nViral 45 Oral dysaesthesia 56\nInfective endocarditis 29 Post-operative 49, 51, 52, 53\nInflammation Paracetamol 49, 51, 52\nMucosal 57, 62 Penicillin 31, 33\nPalatal 41 Pericoronitis 27, 35\nLansoprazole 54 local measures 35\nLidoca",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 90
  },
  {
    "text": "ine 60, 61 Phenoxymethylpenicillin 29, 31, 33\nLocal analgesics 57, 60 Premedication 25\nLoratadine 9, 12 Pulpitis 27\nMedical emergencies 2, 7 Pyrexia 29, 32, 49, 52\nMetronidazole 32, 33, 35 Salbutamol 8, 12, 13, 22\nMiconazole 39, 43 Saliva-stimulating tablets (SSTs) 63, 65\ncream 44 Saliveze® Oral Spray 65\noromucosal gel 40, 42 Sedation 25\nMiconazole and Hydrocortisone 43 Shingles see Herpes zoster\ncream 44 Sinusitis 27, 36\nointment 44 local measures 36\nMidazolam 8, 9, 17 Sodium fusidate (fusidic ",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 90
  },
  {
    "text": "acid) 43, 44\nMouthwash Stomatitis, aphthous 59\nBenzydamine 60 Stomatitis, denture 41, 43\nChlorhexidine 41, 46, 58 local measures 41\nDoxycycline 59 Stroke 21\nHydrogen peroxide 45, 46, 58 Swelling 27, 29, 35\nSodium chloride 57 Temporomandibular dysfunction 56\nSodium fluoride 66, 68 Topical corticosteroids see Corticosteroids\nTetracycline 59 Trigeminal neuralgia 55\nMyocardial infarction 14 Trismus 27, 29\nNecrotising ulcerative gingivitis 27, 35 Ulceration, mucosal 57, 62\nlocal measures 35 local mea",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 90
  },
  {
    "text": "sures 57\nNSAID 49, 54 Valaciclovir 48\nNystatin 39, 41, 43 Xerostomia (dry mouth) 63\nOmeprazole, gastro-resistant 54\n84",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 90
  },
  {
    "text": "Drug Prescribing For Dentistry\nReferences\n1. Joint Formulary Committee British National Formulary. Edn 70. London: BMJ Group and\nPharmaceutical Press; 2015.\n(www.bnf.org. Accessed 01/10/15)\n2. Joint Formulary Committee BNF for Children. BNJ Group, Pharmaceutical Press and RCPCH\nPublications Limited 2015-2016.\n(www.bnf.org. Accessed 01/10/15)\n3. Emergency Drugs and Equipment in Primary Dental Care. National Dental Advisory Committee; 2015.\n(www.scotland.gov.uk/Resource/0046/00469019.pdf. Accessed",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 91
  },
  {
    "text": " 01/10/15)\n4. Management of Acute Dental Problems: Dental Clinical Guidance. Scottish Dental Clinical\nEffectiveness Programme; 2013.\n(www.sdcep.org.uk/published-guidance/management-of-acute-dental-problems-madp.\nAccessed 01/10/15)\n5. Quality standards for cardiopulmonary resuscitation practice and training - Primary Dental Care.\nResuscitation Council (UK); 2013.\n(www.resus.org.uk/pages/QSCPR_PrimaryDentalCare.htm. Accessed 01/10/15)\n6. Minimum equipment list for cardiopulmonary resuscitation - P",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 91
  },
  {
    "text": "rimary Dental Care. Resuscitation\nCouncil (UK); 2013.\n(www.resus.org.uk/pages/QSCPR_PrimaryDentalCare_Equip.htm. Accessed 01/10/15)\n7. Resuscitation Guidelines 2015. Resuscitation Council (UK); 2015.\n(www.resus.org.uk/pages/guide.htm. Accessed 15/10/2015)\n8. Practice Support Manual: Dental Practice Guidance. Scottish Dental Clinical Effectiveness\nProgramme; 2015.\n(www.psm.sdcep.org.uk. Accessed 01/10/15)\n9. Drug Interactions with Hormonal Contraception: Clinical Guidance. Faculty of Sexual and\nR",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 91
  },
  {
    "text": "eproductive Healthcare, Royal College of Obstetricians and Gynaecologists; 2012.\n(www.fsrh.org/pdfs/CEUGuidanceDrugInteractionsHormonal.pdf. Accessed 01/10/15)\n10. Oral Health Management of Patients Prescribed Bisphosphonates: Dental Clinical Guidance.\nScottish Dental Clinical Effectiveness Programme; 2011.\n(www.sdcep.org.uk/published-guidance/bisphosphonates. Accessed 01/10/15)\n11. Emergency Treatment of Anaphylactic Reactions. Guidelines for Healthcare Providers.\nResuscitation Council (UK); 20",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 91
  },
  {
    "text": "08.\n(www.resus.org.uk/pages/reaction.pdf. Accessed 01/10/15)\n85",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 91
  },
  {
    "text": "Drug Prescribing For Dentistry\nReferences\n12. Conscious Sedation in Dentistry: Dental Clinical Guidance. Second Edition. Scottish Dental\nClinical Effectiveness Programme; 2012.\n(www.sdcep.org.uk/published-guidance/sedation. Accessed 01/10/15)\n13. Primary Care Prescribing Indicators Annual Report 2013-14. Scottish Antimicrobial Prescribing\nGroup, Health Protection Scotland, NHS National Services Scotland; 2014.\n(www.scottishmedicines.org.uk/SAPG/News/2014-10-14-SAPG-Primary-Care-PI-2013-14-\nRepor",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 92
  },
  {
    "text": "t.pdf. Accessed 01/10/15)\n14. Palmer NA, Dailey YM, Martin MV. Can audit improve antibiotic prescribing in general dental\npractice? British Dental Journal. 2001;191(5):253-255.\n(www.nature.com/bdj/journal/v191/n5/pdf/4801156a.pdf. Accessed 01/10/15)\n15. Chate RA, White S, Hale LR, et al. The impact of clinical audit on antibiotic prescribing in\ngeneral dental practice. British Dental Journal. 2006;201(10):635-641.\n(www.nature.com/bdj/journal/v201/n10/pdf/4814261a.pdf. Accessed 01/10/15)\n16. NICE",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 92
  },
  {
    "text": " Guideline 64. Prophylaxis against infective endocarditis: Antimicrobial prophylaxis\nagainst infective endocarditis in adults and children undergoing interventional procedures.\nNational Institute for Health and Care Excellence; 2008. Updated 2015.\n(www.nice.org.uk/guidance/cg64. Accessed 01/10/15)\n17. Prevention and Treatment of Periodontal Diseases in Primary Care: Dental Clinical Guidance\nScottish Dental Clinical Effectiveness Programme; 2014.\n(www.sdcep.org.uk/published-guidance/periodontal-m",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 92
  },
  {
    "text": "anagement. Accessed 01/10/15)\n18. Statement from the National Dental Advisory Committee (NDAC) On Acute Paracetamol\nOverdose. National Dental Advisory Committee; 2013.\n(www.psd.scot.nhs.uk/professionals/dental/schedulearchive/NDACAdviceonthe\nmanagementofparacetamol.pdf. Accessed 01/10/15)\n19. Prevention and Management of Dental Caries in Children: Dental Clinical Guidance. Scottish\nDental Clinical Effectiveness Programme; 2010.\n(www.sdcep.org.uk/published-guidance/caries-in-children. Accessed 01",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 92
  },
  {
    "text": "/10/15)\n20. Terms of Service for Dentists. Schedule 1 of The National Health Service (General Dental\nServices)(Scotland) Regulations 2010. SSI 2010/208. Scottish Government Health Directorates;\n2010.\n(www.legislation.gov.uk/ssi/2010/208/schedule/1/made. Accessed 01/10/15)\n86",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 92
  },
  {
    "text": "Drug Prescribing For Dentistry\nReferences\n21. Seymour RA. Drug interactions in dentistry. Dental Update. 2009;36(8):458-470.\n(www.dental-update.co.uk/articleMatchListArticle.asp?aKey=761. Accessed 01/10/15)\n22. Dawoud BE, Roberts A, Yates JM. Drug interactions in general dental practice--considerations\nfor the dental practitioner. British Dental Journal. 2014;216(1):15-23.\n(www.nature.com/bdj/journal/v216/n1/pdf/sj.bdj.2013.1237.pdf. Accessed 01/10/15)\n87",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 93
  },
  {
    "text": "Drug Prescribing For Dentistry\nNotes\n88",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 94
  },
  {
    "text": "The SDCEP Dental Prescribing app\nThe Dental Prescribing app brings SDCEP’s\npopular Drug Prescribing For Dentistry\nguidance to your mobile device. A key\nfeature is the inclusion of direct links to\nthe BNF website for drug interaction\ninformation.\nBased on the latest version of the British\nNational Formulary (BNF) and BNF for Children\n(BNFC), the app includes local measures and drug prescriptions for the\nmanagement of a range of dental conditions for both adults and children.\nInformation on the ma",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 95
  },
  {
    "text": "nagement of medical emergencies is also provided,\nincluding drug administration.\nFurther details are available on the SDCEP website: www.sdcep.org.uk",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 95
  },
  {
    "text": "The Scottish Dental Clinical Effectiveness Programme (SDCEP) is an\ninitiative of the National Dental Advisory Committee in partnership\nwith NHS Education for Scotland. The Programme aims to provide user-\nfriendly, evidence-based guidance on topics identified as priorities for\noral health care.\nSDCEP guidance aims to support improvements in patient care by\nbringing together, in a structured manner, the best available information\nthat is relevant to the topic, and presenting this information in a ",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 96
  },
  {
    "text": "form\nthat can be interpreted easily and implemented.\nThe third edition of Drug Prescribing For Dentistry aims to facilitate\ndrug prescribing within primary care dental practice. Advice on dental\nprescribing from the British National Formulary (BNF) and BNF for\nChildren is presented in a readily accessible, problem-oriented style.\nScottish Dental Clinical Effectiveness Programme\nDundee Dental Education Centre, Frankland Building,\nSmall’s Wynd, Dundee DD1 4HN\nEmail scottishdental.cep@nes.scot.nhs.",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 96
  },
  {
    "text": "uk\nTel 01382 425751 / 425771\nWebsite www.sdcep.org.uk\nsetadpU",
    "source": "03. Drug Prescribing For Dentistry – Dental Clinical Guidance author Scottish Dental Clinical Effectiveness Programme.pdf",
    "page": 96
  },
  {
    "text": "Ministry of Public Health and Sanitation\nThe National Diabetes Prevention and Control Program\nDIABETES PREVENTION\nAND MANAGEMENT\nA guide for community health workers\nMarch 2012\nCommunity Diabetes Prevention and Management Page I 1",
    "source": "2. Diabetes Prevention and Management Author World Diabetes Foundation Fighting Diabetes Worldwide.pdf",
    "page": 1
  },
  {
    "text": "ACKNOWLEDGEMENTS\nThis guide for community health workers on diabetes prevention and\nmanagement was prepared with the active participation of diabetes and\ncommunity experts from different organizations in Kenya.\nThis guide was prepared in line with the community health worker train-\ning curriculum developed at the division of community health services.\nThe Process of developing of this guide was supported by the World\nDiabetes Foundation\nThe participation of the following individuals and organiza",
    "source": "2. Diabetes Prevention and Management Author World Diabetes Foundation Fighting Diabetes Worldwide.pdf",
    "page": 2
  },
  {
    "text": "tion is grate-\nfully appreciated\n• Dr. William Maina – Head, Division of Non-communicable Diseases\n(MOPHS)\n• Dr. Joseph Kibachio - Division of Non-communicable Diseases\n(MOPHS)\n• Zachary Ndegwa - Division of Non-communicable Diseases (MOPHS)\n• Scholastica Owondo - Division of Non-communicable Diseases\n(MOPHS)\n• Dr. Carol Ngunu - Division of Non-communicable Diseases (MOPHS)\n• Edward Ndungu – Division of Non-communicable Diseases (MOPHS)\n• Simion Ndemo – Division of Community Health Services (MOP",
    "source": "2. Diabetes Prevention and Management Author World Diabetes Foundation Fighting Diabetes Worldwide.pdf",
    "page": 2
  },
  {
    "text": "HS)\n• Rosemary Ngaruro – Head, Division of Clinical Nutrition (MOMS)\n• Phylis Kiiru – Kenyatta National Hospital (MOMS)\n• Purity Maina – Embu Provincial General Hospital (MOMS)\n• Eva Muchemi - Kenya Diabetes Management and Information Centre\n• Lilian Karugu - Kenya Diabetes Management and Information Centre\n• Joseph Mwangi – Kenya Diabetes Management and Information\nCentre\n• Vincent Mbugua - Kenya Diabetes Management and Information\nCentre\n• James Mwangi – Kenya Diabetes Management and Informati",
    "source": "2. Diabetes Prevention and Management Author World Diabetes Foundation Fighting Diabetes Worldwide.pdf",
    "page": 2
  },
  {
    "text": "on Centre\n• Monica Mukiira – Chaaria Diabetes Support Group, Meru\n• Reuben Magoko – Nyeri Diabetes Support Group\n• Geoffrey Baraza – Nakuru Diabetes Support Group\n2 I Page Community Diabetes Prevention and Management",
    "source": "2. Diabetes Prevention and Management Author World Diabetes Foundation Fighting Diabetes Worldwide.pdf",
    "page": 2
  },
  {
    "text": "AFYA YAKO YATEGEMEA\nVYAKULA UNAVYOKULA\nCHUMVI\nMAFUTA YA\nKUPIKIA\nCommunity Diabetes Prevention and Management Page I 3",
    "source": "2. Diabetes Prevention and Management Author World Diabetes Foundation Fighting Diabetes Worldwide.pdf",
    "page": 3
  },
  {
    "text": "INTRODUCTION\nWhat is diabetes?\nDiabetes is a lifelong condition characterized by high blood sugar resulting\nfrom:\n- Lack or insufficient production of insulin\n- Insulin resistance (inaction)\n- Both\n• Our body needs glucose (from food) to make energy.\n• Insulin is a chemical produced by the pancreas which helps the body to\nutilize glucose. It acts like a key that opens the body cells for glucose to\nenter so that it can be used for energy production.\n• When cells do not take up glucose it overflow",
    "source": "2. Diabetes Prevention and Management Author World Diabetes Foundation Fighting Diabetes Worldwide.pdf",
    "page": 4
  },
  {
    "text": "s and floods the blood\nsystem, this is then referred to as high blood sugar or hyperglycemia.\nTYPES OF DIABETES\nThere are 3 Main types of Diabetes\nType 1\n• Results from absolute lack of insulin\n• It is of a sudden onset and can develop at any age but usually occurs\nbefore the age of 30, and especially in childhood. The causes of this\nare when the pancreas cannot produce insulin. Account for about 5 to 10%\nof all cases of diabetes.\n• People with type 1 diabetes need insulin for survival.\nType 2\n•",
    "source": "2. Diabetes Prevention and Management Author World Diabetes Foundation Fighting Diabetes Worldwide.pdf",
    "page": 4
  },
  {
    "text": " Type 2 diabetes develops when the body cannot make enough insulin or\nwhen the insulin that is produced does not work properly (known as\ninsulin resistance).\n• Usually appears in people over the age of 40, but it is becoming more\ncommon in the young.\n• It can be controlled by a healthy diet, increased physical activity and oral\ndrugs and later may eventually require insulin for control.\nDiabetes during Pregnancy (Gestational diabetes)\n• Diabetes detected for the first time during pregnancy.\n• GD",
    "source": "2. Diabetes Prevention and Management Author World Diabetes Foundation Fighting Diabetes Worldwide.pdf",
    "page": 4
  },
  {
    "text": "M occurs because the body cannot produce enough insulin to meet the\nextra needs of pregnancy.\n• GDM usually disappears after giving birth and may indicate an increased\nrisk of Type 2 diabetes\n4 I Page Community Diabetes Prevention and Management",
    "source": "2. Diabetes Prevention and Management Author World Diabetes Foundation Fighting Diabetes Worldwide.pdf",
    "page": 4
  },
  {
    "text": "Community Diabetes Prevention and Management Page I 5",
    "source": "2. Diabetes Prevention and Management Author World Diabetes Foundation Fighting Diabetes Worldwide.pdf",
    "page": 5
  },
  {
    "text": "Signs and Symptoms of Diabetes\nThey include:\n• Frequent urination\n• Excessive thirst\n• Extreme hunger\n• Unexplained weight loss\n• Increased fatigue\n• Irritability\n• Blurred vision\n• Itching of the private parts in women\n• Slow healing of cuts and wounds\n• Impotence-failure to sustain an erection.\n• Numbness, burning sensations ,pins and needles of the feet and\nhands\nNB: a person can be living with diabetes without experiencing the\nsymptoms, thus regular blood sugar testing is recommended.\n6 I Pa",
    "source": "2. Diabetes Prevention and Management Author World Diabetes Foundation Fighting Diabetes Worldwide.pdf",
    "page": 6
  },
  {
    "text": "ge Community Diabetes Prevention and Management",
    "source": "2. Diabetes Prevention and Management Author World Diabetes Foundation Fighting Diabetes Worldwide.pdf",
    "page": 6
  },
  {
    "text": "Community Diabetes Prevention and Management Page I 7",
    "source": "2. Diabetes Prevention and Management Author World Diabetes Foundation Fighting Diabetes Worldwide.pdf",
    "page": 7
  },
  {
    "text": "Risk factors of diabetes\nThe risk factors of diabetes can be grouped into 2\n1. Those that cannot be modified\na. Advancing age\nb. Family history of diabetes\n2. Those that are modifiable\na. Overweight and obesity\nb. Alcohol use\nc. Tobacco use\nd. Physical inactivity\ne. A stressful lifestyle\nf. Unhealthy diet\nDiagnosis\nDiagnosis of diabetes\nIn the majority of people presenting with the classical symptoms of\ndiabetes, the diagnosis is straightforward.\nA fasting blood sugar level of more than 7mmol/l ",
    "source": "2. Diabetes Prevention and Management Author World Diabetes Foundation Fighting Diabetes Worldwide.pdf",
    "page": 8
  },
  {
    "text": "is diagnostic (fasting\nmeans a person has not eaten overnight or for the last 8 hour)\nA random blood sugar of more than 11.1mmol/l is diagnostic of\ndiabetes.\n(A random blood sugar of between 7.1mmol/l and 11.1mmol/l refer to\nhospital to confirm diagnosis)\n8 I Page Community Diabetes Prevention and Management",
    "source": "2. Diabetes Prevention and Management Author World Diabetes Foundation Fighting Diabetes Worldwide.pdf",
    "page": 8
  },
  {
    "text": "Community Diabetes Prevention and Management Page I 9",
    "source": "2. Diabetes Prevention and Management Author World Diabetes Foundation Fighting Diabetes Worldwide.pdf",
    "page": 9
  },
  {
    "text": "Management of diabetes\n• The goal of diabetes management is to improve the quality of life\nand productivity of people living with diabetes.\n• There are two modalities of managing diabetes.\n(diabetes education goes hand in hand with these two methods)\n- Non drug method (use of proper diet and physical activity)\n- Use of Drugs e.g. diabetes tablets for lowering blood sugar and\ninsulin\n1. Education\nCommunity Members including People living with diabetes need to\nknow:\n• That diabetes is a serious li",
    "source": "2. Diabetes Prevention and Management Author World Diabetes Foundation Fighting Diabetes Worldwide.pdf",
    "page": 10
  },
  {
    "text": "felong disease that has no cure, but can\nbe controlled.\n• That the pillars of management include:\n- diabetes education\n- knowing what foods to eat, how much and how often to eat,\n- knowing the importance and precautions of exercise,\n- how and when to take diabetes medications\n• That community should know and be encouraged to seek regular\nmedical checkups which is essential for early detection of the\ndisease\n• People with diabetes need to know how to identify diabetes related\nemergencies arising ",
    "source": "2. Diabetes Prevention and Management Author World Diabetes Foundation Fighting Diabetes Worldwide.pdf",
    "page": 10
  },
  {
    "text": "from low or high blood sugar levels and when\nto seek medical help.\n• Pregnant mothers to be encouraged to check their blood sugars\nregularly .\n• Complications of diabetes are preventable.\n• Good blood sugar control is essential to prevent long term\ncomplications of diabetes.\n• That people with diabetes have to look after their feet to prevent\ninjuries and thus prevent ulcers and amputations\n10 I Page Community Diabetes Prevention and Management",
    "source": "2. Diabetes Prevention and Management Author World Diabetes Foundation Fighting Diabetes Worldwide.pdf",
    "page": 10
  },
  {
    "text": "LISHE BORA\nMUUGUZI\nCommunity Diabetes Prevention and Management Page I 11",
    "source": "2. Diabetes Prevention and Management Author World Diabetes Foundation Fighting Diabetes Worldwide.pdf",
    "page": 11
  },
  {
    "text": "2. Healthy diet\nEating a healthy diet and increasing the level of physical activity\nshould be the first steps in the management of newly diagnosed\npeople with diabetes, and have to be maintained.\nGood dietary practices in the management of diabetes mellitus\n• Appropriate diet and physical activity is important in maintaining\nan ideal body weight.\n• Reduced intake of animal fat, salt, and refined foods is\nrecommended.\n• Locally available foods high in fiber, vegetables and fruits should be\nencour",
    "source": "2. Diabetes Prevention and Management Author World Diabetes Foundation Fighting Diabetes Worldwide.pdf",
    "page": 12
  },
  {
    "text": "aged in the community\n• The nutritionist or a trained diabetes educator can help you know\nthe appropriate food portion sizes to meet your dietary\nrequirement.\n• Eat a variety of foods in at-least three meals a day.\n• Alcohol and tobacco products use should be avoided.\n• Water is essential for normal body functioning. At - least eight\nglasses of water should be taken per day.\n12 I Page Community Diabetes Prevention and Management",
    "source": "2. Diabetes Prevention and Management Author World Diabetes Foundation Fighting Diabetes Worldwide.pdf",
    "page": 12
  },
  {
    "text": "CHUMVI\nMAFUTA YA\nKUPIKIA\nCommunity Diabetes Prevention and Management Page I 13",
    "source": "2. Diabetes Prevention and Management Author World Diabetes Foundation Fighting Diabetes Worldwide.pdf",
    "page": 13
  },
  {
    "text": "3. Physical activity\n• Regular physical activity helps in;\n- Increasing insulin sensitivity thus improving blood sugar control\n- Controlling blood pressure\n- Improving blood flow in the heart and vessels\n- Weight loss and maintenance of healthy body weight,\n- Giving one a sense of well-being.\n• Physical activity should be regular (-3 days/week), lasting at least\n20-30 min. per session, and be of at least moderate intensity.\n• Examples of physical activities you can involve yourself include;\n- Ho",
    "source": "2. Diabetes Prevention and Management Author World Diabetes Foundation Fighting Diabetes Worldwide.pdf",
    "page": 14
  },
  {
    "text": "usework\n- Gardening\n- Walking\n- climbing stairs\n• Examples of exercises you can involve yourself include\n- Fast walking\n- Cycling\n- Jogging\n- Playing games\n- Weight lifting\n- Rope jumping\n- Swimming\n- Indoor exercises e.g sit ups and press ups.\n• Activities like walking, climbing steps (instead of taking lifts) should\nbe encouraged.\n• People with diabetes require proper medical assessment before\nengaging in vigorous physical activity\n• Proper shoes must always be worn during exercises to avoid i",
    "source": "2. Diabetes Prevention and Management Author World Diabetes Foundation Fighting Diabetes Worldwide.pdf",
    "page": 14
  },
  {
    "text": "njury\nto the feet.\n14 I Page Community Diabetes Prevention and Management",
    "source": "2. Diabetes Prevention and Management Author World Diabetes Foundation Fighting Diabetes Worldwide.pdf",
    "page": 14
  },
  {
    "text": "(facing page put poster ya mazoezi na ugonjwa wa….)\nCommunity Diabetes Prevention and Management Page I 15",
    "source": "2. Diabetes Prevention and Management Author World Diabetes Foundation Fighting Diabetes Worldwide.pdf",
    "page": 15
  },
  {
    "text": "4. Management of diabetes using drugs\nDiabetes is managed by use of medicines that can either be:\n- Oral blood sugar lowering tablets\n- Insulin injection\nIt is important to note that;\n• Oral Tablets are used when an individuals’ blood sugar control is\nnot achieved using the combination of dietary modifications and\nphysical activity/exercise.\n• Patients currently using tablets to control their blood sugar may at\none time in the future need insulin as these tablets may no longer\nwork in them.\n• In",
    "source": "2. Diabetes Prevention and Management Author World Diabetes Foundation Fighting Diabetes Worldwide.pdf",
    "page": 16
  },
  {
    "text": " some cases, oral tablets or insulin injection may be given\nat the time of diagnosis of diabetes if the blood sugar is extremely\nhigh. I.e. a fasting blood glucose level more than 11 mmol/L or\nrandom blood glucose level more than 15 mmol/L.\n• Individuals with type 1 diabetes must be on insulin for survival.\nPrinciples of insulin administration\n• The injection sites most commonly used for insulin are the\nabdomen, the thigh, and the outer upper arm.\n• The rate of absorption is fastest on the abdom",
    "source": "2. Diabetes Prevention and Management Author World Diabetes Foundation Fighting Diabetes Worldwide.pdf",
    "page": 16
  },
  {
    "text": "en.\n• The thigh should be avoided as an injection site when exercise is\ngoing to be done, as this will increase the rate of absorption of the\ninsulin.\n• One area should be used for an injection at a particular time of day,\ne.g. the abdomen is the site for the morning injection, and the thigh\nis the site for the evening injection.\n• Within these areas, the injection site is to be rotated. To avoid\nformation of a hard scar (seen as a lump)\n• Injection on these scars should be avoided as insulin ab",
    "source": "2. Diabetes Prevention and Management Author World Diabetes Foundation Fighting Diabetes Worldwide.pdf",
    "page": 16
  },
  {
    "text": "sorption is\nnot predictable\n• The injection should be done at a 90-degree angle with the skin\nusing the recommended insulin administration syringe and needle.\n• The needle should be held in place for 10 seconds after injection\nbefore withdrawal.\n16 I Page Community Diabetes Prevention and Management",
    "source": "2. Diabetes Prevention and Management Author World Diabetes Foundation Fighting Diabetes Worldwide.pdf",
    "page": 16
  },
  {
    "text": "Insulin injection technique\nInsulin injection sites\nFront Back\nCommunity Diabetes Prevention and Management Page I 17",
    "source": "2. Diabetes Prevention and Management Author World Diabetes Foundation Fighting Diabetes Worldwide.pdf",
    "page": 17
  },
  {
    "text": "Complications of Diabetes\nEarly diagnosis of diabetes, good management and regular screening\nfor complications can do much to reduce the burden that complica-\ntions can impose on people living with diabetes and the health care\nsystem.\nDiabetes complications are divided into two broad groups\n1. Short term complications\n2. Long term complications\nSHORT TERM COMPLICATIONS\nHypoglycemia (low blood sugar)\nOccurs when the blood sugar is too low; less than 3.5mmols/l\nIt requires immediate treatment.\nCau",
    "source": "2. Diabetes Prevention and Management Author World Diabetes Foundation Fighting Diabetes Worldwide.pdf",
    "page": 18
  },
  {
    "text": "ses:\n- Skipping or delaying meals - Wrong timings of medication\n- Eating inadequate meal portions - Drug overdose\n- Side effect of medication - Unplanned and excessive\n- Alcohol Intake physical activity\nSigns and Symptoms:\n- Dizziness - Confusion\n- Weakness - Reduced concentration\n- Cold , sweaty skin - Nervousness\n- Profuse sweating - Fast heartbeat\n- Hunger - Headache\n- Irritability - Numbness of tongue and mouth\n- Bad dreams - Fainting and loss of consciousness\n18 I Page Community Diabetes Pr",
    "source": "2. Diabetes Prevention and Management Author World Diabetes Foundation Fighting Diabetes Worldwide.pdf",
    "page": 18
  },
  {
    "text": "evention and Management",
    "source": "2. Diabetes Prevention and Management Author World Diabetes Foundation Fighting Diabetes Worldwide.pdf",
    "page": 18
  },
  {
    "text": "Community Diabetes Prevention and Management Page I 19",
    "source": "2. Diabetes Prevention and Management Author World Diabetes Foundation Fighting Diabetes Worldwide.pdf",
    "page": 19
  },
  {
    "text": "Prevention and Treatment of Hypoglycemia (low blood sugar)\nWhen the signs and symptoms of hypoglycemia are noted, eat or drink\na fast acting sugar e.g 3 teaspoons of sugar or honey (can be dissolved\nin water) ,3 sweets, 3 biscuits or 3/4 cup of juice or soda. Then eat a\nmeal.\nIn case of unconscious person DO NOT give fluids or food. Instead\napply moistened sugar or honey on the inner cheek lining (not on the\ntongue)\nIf symptoms persist or recur refer to the hospital.\nPrevention of hypoglycemia\n•",
    "source": "2. Diabetes Prevention and Management Author World Diabetes Foundation Fighting Diabetes Worldwide.pdf",
    "page": 20
  },
  {
    "text": " Avoid skipping or delaying meals\n• Eat adequate food portions\n• Use medications as prescribed (dosage and timing)\n• Avoid alcohol use\n• Avoid unplanned and excessive physical activity\nNOTE:\nTHE PATIENT SHOULD ALWAYS CARRY SOME SUGAR SOURCE\n(e.g. 3 sweets, 3 biscuits or a light meal)\nTHE PATIENT SHOULD ALWAYS CARRY OR WEAR AN\nIDENTIFICATION TAG/BRACELET/CARD STATING THAT THEY\nHAVE DIABETES\n*A note on hyperglycemia (high blood sugar)\nIn case the blood sugar remains persistently high despite follo",
    "source": "2. Diabetes Prevention and Management Author World Diabetes Foundation Fighting Diabetes Worldwide.pdf",
    "page": 20
  },
  {
    "text": "wing\nthe healthcare worker’s instructions on medication, please refer the\npatient urgently to see the nearest health facility.\n20 I Page Community Diabetes Prevention and Management",
    "source": "2. Diabetes Prevention and Management Author World Diabetes Foundation Fighting Diabetes Worldwide.pdf",
    "page": 20
  },
  {
    "text": "Community Diabetes Prevention and Management Page I 21",
    "source": "2. Diabetes Prevention and Management Author World Diabetes Foundation Fighting Diabetes Worldwide.pdf",
    "page": 21
  },
  {
    "text": "Long term complications of diabetes\nPoorly controlled blood sugar can lead to long term complications of\ndiabetes. Long term complications arise due to damage of the blood\nvessels resulting in;\n1. Diseases of the large blood vessels (affects the brain and heart)\n2. Diseases of the small blood vessels and nerves (affects the eyes,\nkidneys, sexual organs and feet)\nDiabetes and the Brain\nA person with diabetes is at higher risk for stroke than the general\npopulation. Persistently elevated blood sug",
    "source": "2. Diabetes Prevention and Management Author World Diabetes Foundation Fighting Diabetes Worldwide.pdf",
    "page": 22
  },
  {
    "text": "ar levels contribute to the\nbuildup of deposits in blood vessels thus leading to impaired blood\nflow or complete blockage and subsequently stroke.\nDiabetes and the Eye\nUncontrolled Diabetes damages the small blood vessels at the back of\nthe eye that enables one to see leading to poor vision and eventually\nto blindness. People with poorly controlled diabetes develops cataract\nat an earlier age than others.\nDiabetes and the Heart\nHigh blood sugar levels over time can lead to deposits causing the\nn",
    "source": "2. Diabetes Prevention and Management Author World Diabetes Foundation Fighting Diabetes Worldwide.pdf",
    "page": 22
  },
  {
    "text": "arrowing and the hardening of blood vessels that supply oxygen to\nthe heart. Therefore flow of blood to the heart can slow down or stop\ncausing a heart attack.\nHeart disease is the leading cause of death for people with diabetes\nDiabetes and the Kidney\nHigh blood sugar can overwork the kidneys causing them to stop\nworking properly and cause them to leak protein in the urine leading\nto kidney failure in the long run.\nDiabetes and the sexual function\nPoorly controlled diabetes damages nerves and b",
    "source": "2. Diabetes Prevention and Management Author World Diabetes Foundation Fighting Diabetes Worldwide.pdf",
    "page": 22
  },
  {
    "text": "lood vessels which\nare important for functioning of sexual organs. In women it may cause\nreduced urge to sex and painful intercourse.\nIn men, it may cause impotence and erectile dysfunction. This increas-\nes with age and has a major psychological impact.\n22 I Page Community Diabetes Prevention and Management",
    "source": "2. Diabetes Prevention and Management Author World Diabetes Foundation Fighting Diabetes Worldwide.pdf",
    "page": 22
  },
  {
    "text": "Community Diabetes Prevention and Management Page I 23",
    "source": "2. Diabetes Prevention and Management Author World Diabetes Foundation Fighting Diabetes Worldwide.pdf",
    "page": 23
  },
  {
    "text": "Diabetes and the feet\nUncontrolled diabetes can lead to nerve damage or poor blood supply\nto the feet and can lead to wounds on the feet which can get infected\nwhich if untreated can lead to amputation (cutting of the leg).\nThe Do’s of Diabetes Foot Management\n1. Wash your feet regulary and dry between the toes\n2. Cut nails straight with a nail cutter and file the sharp edges\n3. Examine your feet daily, using a mirror or use an assistant\n4. Seek medical attention for bruises, cuts or blisters\n5.",
    "source": "2. Diabetes Prevention and Management Author World Diabetes Foundation Fighting Diabetes Worldwide.pdf",
    "page": 24
  },
  {
    "text": " Examine your shoes daily for any foreign objects\n6. Moisturize your feet using creams or lotions\n(Avoid petroleum based jelly)\n7. Test bathing water with your elbow before washing your feet to\navoid burns\n8. Wear loose absorbent socks\n9. Shoes should be:\n• Closed and well fitting\n• Fastened with laces or velcro\n• Wide enough to accommodate the toe\n• Bought in the afternoon as feet tend to swell towards the\nevening\nThe Don’ts of Diabetes Foot Management\n1. Avoid walking bare foot\n2. Avoid smokin",
    "source": "2. Diabetes Prevention and Management Author World Diabetes Foundation Fighting Diabetes Worldwide.pdf",
    "page": 24
  },
  {
    "text": "g as it can harm blood circulation in your feet\n3. Avoid touching hot surfaces\n4. Avoid shoes with high heels and pointed toes.\n5. Avoid open shoes or sandals\n6. Avoid warming your feet infront of open fire\n7. Avoid wearing tight shoes without proper support and laces\n24 I Page Community Diabetes Prevention and Management",
    "source": "2. Diabetes Prevention and Management Author World Diabetes Foundation Fighting Diabetes Worldwide.pdf",
    "page": 24
  },
  {
    "text": "Community Diabetes Prevention and Management Page I 25",
    "source": "2. Diabetes Prevention and Management Author World Diabetes Foundation Fighting Diabetes Worldwide.pdf",
    "page": 25
  },
  {
    "text": "Tips on preventing diabetes\nEat healthy foods: more vegetables and fruits, less carbohydrates, fats,\nsugars and salts;\nExercise regularly:\nAt least 30 minutes of brisk walking every day will do you good.\nTake the stairs not the lift.\nWalk short distances; don’t board a vehicle\nEncourage children to have daily physical exercises.\nAvoid smoking, if a smoker seeks assistance to quit smoking;\nAvoid harmful use of alcohol: excessive use of alcohol is dangerous to\nhealth;\nIt’s good to know you are hea",
    "source": "2. Diabetes Prevention and Management Author World Diabetes Foundation Fighting Diabetes Worldwide.pdf",
    "page": 26
  },
  {
    "text": "lthy; Visit your nearest health facility for\ncheckups for diabetes and blood pressure.\nEarly diagnosis and proper treatment prevents complications of\ndiabetes;\nDON’T wait until you are feeling unwell;\nCheck your Body Mass Index (BMI):\nThis is the ration of Weight in Kg/height in Meters2 For example:\nif your weight is 75kg and height is 154cm\nBMI=75/ (1.54) 2 =75/2.3716=31.6\nLess than 18.5 18.5-24.9 25-29.9 30+ above\nUnderweight Normal Overweight Obese\n26 I Page Community Diabetes Prevention and ",
    "source": "2. Diabetes Prevention and Management Author World Diabetes Foundation Fighting Diabetes Worldwide.pdf",
    "page": 26
  },
  {
    "text": "Management",
    "source": "2. Diabetes Prevention and Management Author World Diabetes Foundation Fighting Diabetes Worldwide.pdf",
    "page": 26
  },
  {
    "text": "Matunda\nMaziwa\nNyama na\nMaharagwe\nMboga\nMboga\nVyakula vya\nnafaka na\nviazi\nCommunity Diabetes Prevention and Management Page I 27",
    "source": "2. Diabetes Prevention and Management Author World Diabetes Foundation Fighting Diabetes Worldwide.pdf",
    "page": 27
  },
  {
    "text": "Myths and Misconceptions About Diabetes\nThe following are some of the misconceptions and myths regarding\ndiabetes in Kenya;\nMyth: Diabetes is a disease of the rich\nFact: Diabetes knows no boundaries and affects all the people across\nthe board.\nMyth: Diabetes is the result of eating too much sugar\nFact: Diabetes is as a result of lack of insulin that is essential for the\ncontrol of blood sugar in the body. However, taking too much sugar\nmay lead to obesity and overweight that are risk factors for",
    "source": "2. Diabetes Prevention and Management Author World Diabetes Foundation Fighting Diabetes Worldwide.pdf",
    "page": 28
  },
  {
    "text": " develop-\ning diabetes.\nMyth: Only older people get diabetes\nFact: Diabetes knows no boundaries and affects all the people across\nthe board. Despite older people being at a higher risk of developing\ndiabetes, younger people also need to take precaution.\nMyth: Diabetes gets cured after a while\nFact: Diabetes results from gradual damage to the cells producing\ninsulin in the body. The damaged cells cannot be brought back to life.\nOnce an individual develops diabetes, he/she shall need lifelong trea",
    "source": "2. Diabetes Prevention and Management Author World Diabetes Foundation Fighting Diabetes Worldwide.pdf",
    "page": 28
  },
  {
    "text": "t-\nment that ranges from diet, exercises and or with drugs.\nMyth:If you look fat/obese you are healthy despite having diabetes\nFact: Obesity/overweight is a predisposing factor for diabetes. To\navoid developing diabetes, you should maintain a healthy weight.\n28 I Page Community Diabetes Prevention and Management",
    "source": "2. Diabetes Prevention and Management Author World Diabetes Foundation Fighting Diabetes Worldwide.pdf",
    "page": 28
  },
  {
    "text": "Myth: Diabetes is the result of a curses/witchcraft\nFact: Diabetes is as a result of lack of insulin that is essential for the\ncontrol of blood sugar in the body.\nMyth: Diabetes is cured through prayers since it is brought on by evil\nspirits\nFact: Diabetes is as a result of lack of insulin that is essential for the\ncontrol of blood sugar in the body. Spiritual support enhances good\ncontrol of blood sugar.\nMyth: Traditional healers can cure diabetes using nutritional and\nherbal supplements\nFact: ",
    "source": "2. Diabetes Prevention and Management Author World Diabetes Foundation Fighting Diabetes Worldwide.pdf",
    "page": 29
  },
  {
    "text": "Diabetes results from gradual damage to the cells producing\ninsulin in the body. Diabetes has no cure and can only be controlled by\na combination of diet, exercises or drugs.\nMyth: Alternative therapy preferred over scientific therapy.\nFact: Diabetes results from gradual damage to the cells producing\ninsulin in the body. Diabetes has no cure and can only be controlled by\na combination of diet, exercises or drugs.\nMyth: Having diabetes means eating different foods from others.\nFact: People with d",
    "source": "2. Diabetes Prevention and Management Author World Diabetes Foundation Fighting Diabetes Worldwide.pdf",
    "page": 29
  },
  {
    "text": "iabetes don’t need to follow a restricted diet but in-\nstead should follow the same healthy eating guidelines as every person\nin the community which can be provided by a nutritionist in your local\nhealth facility.\nCommunity Diabetes Prevention and Management Page I 29",
    "source": "2. Diabetes Prevention and Management Author World Diabetes Foundation Fighting Diabetes Worldwide.pdf",
    "page": 29
  },
  {
    "text": "MAFUTA YA\nKUPIKIA\n30 I Page Community Diabetes Prevention and Management",
    "source": "2. Diabetes Prevention and Management Author World Diabetes Foundation Fighting Diabetes Worldwide.pdf",
    "page": 30
  },
  {
    "text": "Community Diabetes Prevention and Management Page I 31",
    "source": "2. Diabetes Prevention and Management Author World Diabetes Foundation Fighting Diabetes Worldwide.pdf",
    "page": 31
  },
  {
    "text": "Division of Non-communicable Diseases\nAfya House, Cathedral Road\nP.O. Box 30016 – 00100\nNairobi, Kenya.\nTelephone: +254 202 71 7 077 ext 45048\nwww.pubhealth.go.ke\n32 I Page Community Diabetes Prevention and Management",
    "source": "2. Diabetes Prevention and Management Author World Diabetes Foundation Fighting Diabetes Worldwide.pdf",
    "page": 32
  },
  {
    "text": "cancer.org | 1.800.227.2345\nBreast Cancer Early Detection and\nDiagnosis\nCan Breast Cancer Be Found Early?\nBreast cancer is sometimes found after symptoms appear, but many women with breast\ncancer have no symptoms. This is why regular breast cancer screening is so important.\nLearn more.\nAmerican Cancer Society Recommendations for the Early Detection of Breast\nl\nCancer\nImaging Tests to Find Breast Cancer\nDifferent tests can be used to look for and diagnose breast cancer. If your doctor finds\nan ar",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 1
  },
  {
    "text": "ea of concern on a screening test (a mammogram), or if you have symptoms that\ncould mean breast cancer, you will need more tests to know for sure if it’s cancer.\nMammograms\nl\nBreast Ultrasound\nl\nBreast MRI\nl\nNewer and Experimental Breast Imaging Tests\nl\nSigns and Symptoms of Breast Cancer\nThe most common symptom of breast cancer is a new lump or mass, but other\nsymptoms are also possible. It's important to have any breast change checked by a\nhealth care provider.\n1",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 1
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nBreast Cancer Signs and Symptoms\nl\nBiopsy\nA biopsy is done when mammograms, other imaging tests, or a physical exam shows a\nbreast change that may be cancer. A biopsy is the only way to know for sure if it’s\ncancer.\nBreast Biopsy\nl\nFinding breast cancer during pregnancy\nBreast cancer during pregnancy is rare. But if you find a lump or notice any unusual\nchanges i",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 2
  },
  {
    "text": "n your breasts that concern you, tell your doctor or nurse right away.\nFinding Breast Cancer During Pregnancy\nl\nAmerican Cancer Society\nRecommendations for the Early\nDetection of Breast Cancer\nFinding breast cancer early and getting state-of-the-art cancer treatment are two of the\nmost important strategies for preventing deaths from breast cancer. Breast cancer that’s\nfound early, when it’s small and has not spread, is easier to treat successfully. Getting\nregular screening tests is the most rel",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 2
  },
  {
    "text": "iable way to find breast cancer early. The\nAmerican Cancer Society has screening guidelines for women at average risk of breast\ncancer, and for those at high risk for breast cancer.\nWhat are screening tests?\nScreening refers to tests and exams used to find a disease in people who don’t have\nany symptoms. The goal of screening tests for breast cancer is to find it early, before it\ncauses symptoms (like a lump in the breast that can be felt). Early detection means\n2",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 2
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nfinding and diagnosing a disease earlier than if you’d waited for symptoms to start.\nBreast cancers found during screening exams are more likely to be smaller and less\nlikely to have spread outside the breast. The size of a breast cancer and how far it has\nspread are some of the most important factors in predicting the prognosis (outlook) of\na woman with this dis",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 3
  },
  {
    "text": "ease.\nAmerican Cancer Society screening recommendations for women at\naverage breast cancer risk\nThe COVID-19 pandemic initially resulted in most elective procedures being put\non hold, leading to many people not getting screened for cancer. Learn how you\ncan talk to your doctor and what steps you can take to plan, schedule, and get\nyour regular cancer screenings in Cancer Screening & COVID-191.\nThese guidelines are for women at average risk for breast cancer. For screening\npurposes, a woman is co",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 3
  },
  {
    "text": "nsidered to be at average risk if she doesn’t have a personal\nhistory of breast cancer, a strong family history of breast cancer, or a genetic mutation\nknown to increase risk of breast cancer (such as in a BRCA gene), and has not had\nchest radiation therapy before the age of 30. (See below for guidelines for women at\nhigh risk.)\nWomen between 40 and 44 have the option to start screening with a mammogram\nl\nevery year.\nWomen 45 to 54 should get mammograms every year.\nl\nWomen 55 and older can switc",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 3
  },
  {
    "text": "h to a mammogram every other year, or they can\nl\nchoose to continue yearly mammograms. Screening should continue as long as a\nwoman is in good health and is expected to live at least 10 more years.\nAll women should understand what to expect when getting a mammogram for\nl\nbreast cancer screening – what the test can and cannot do.\nClinical breast exams are not recommended for breast cancer screening among\naverage-risk women at any age.\nMammograms\nMammograms are low-dose x-rays of the breast. Regul",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 3
  },
  {
    "text": "ar mammograms can help find\nbreast cancer at an early stage, when treatment is most likely to be successful. A\nmammogram can often find breast changes that could be cancer years before physical\nsymptoms develop. Results from many decades of research clearly show that women\n3",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 3
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nwho have regular mammograms are more likely to have breast cancer found earlier, are\nless likely to need aggressive treatments like surgery to remove the entire breast\n(mastectomy2) and chemotherapy3, and are more likely to be cured.\nMammograms are not perfect. They miss some breast cancers. And if something is\nfound on a screening mammogram, a woman will likely ",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 4
  },
  {
    "text": "need other tests (such as more\nmammograms or a breast ultrasound) to find out if it is cancer. There’s also a small\nchance of being diagnosed with a cancer that never would have caused any problems\nhad it not been found during screening. (This is called overdiagnosis.) It's important that\nwomen getting mammograms know what to expect and understand the benefits and\nlimitations of screening.\n2D vs. 3D mammograms\nIn recent years, a newer type of mammogram called digital breast tomosynthesis\n(common",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 4
  },
  {
    "text": "ly known as three-dimensional [3D] mammography) has become much\nmore common, although it’s not available in all breast imaging centers.\nMany studies have found that 3D mammography appears to lower the chance of being\ncalled back after screening for follow-up testing. It also appears to find more breast\ncancers, and several studies have shown it can be helpful in women with more dense\nbreasts. A large study is now in progress to better compare outcomes between 3D\nmammograms and standard (2D) mamm",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 4
  },
  {
    "text": "ograms.\nIt should be noted that 3D mammograms often cost more than 2D mammograms, and\nthis added cost may not be covered by insurance.\nThe American Cancer Society (ACS) breast cancer screening guidelines consider\nhaving had either a 2D or 3D mammogram as being in line with current screening\nrecommendations. The ACS also believes that women should be able to choose\nbetween 2D and 3D mammography if they or their doctor believes one would be more\nappropriate, and that out-of-pocket costs should not",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 4
  },
  {
    "text": " be a barrier to having either one.\nClinical breast exam (CBE) and breast self-exam (BSE)\nResearch has not shown a clear benefit of regular physical breast exams done by either\na health professional (clinical breast exams) or by women themselves (breast self-\nexams). There is very little evidence that these tests help find breast cancer early when\nwomen also get screening mammograms. Most often when breast cancer is detected\nbecause of symptoms (such as a lump in the breast), a woman discovers t",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 4
  },
  {
    "text": "he symptom\nduring usual activities such as bathing or dressing. Women should be familiar with\n4",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 4
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nhow their breasts normally look and feel and should report any changes to a\nhealth care provider right away.\nWhile the American Cancer Society does not recommend regular clinical breast exams\nor breast self-exams as part of a routine breast cancer screening schedule, this does\nnot mean that these exams should never be done. In some situations, particularly for\nwo",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 5
  },
  {
    "text": "men at higher-than-average risk, for example, health care providers may still offer\nclinical breast exams, along with providing counseling about risk and early detection.\nAnd some women might still be more comfortable doing regular self-exams as a way to\nkeep track of how their breasts look and feel. But it’s important to understand that there\nis very little evidence that doing these exams routinely is helpful for women at average\nrisk of breast cancer.\nAmerican Cancer Society screening recommen",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 5
  },
  {
    "text": "dations for women at\nhigh risk\nWomen who are at high risk for breast cancer based on certain factors should get a\nbreast MRI and a mammogram every year, typically starting at age 30. This includes\nwomen who:\nHave a lifetime risk of breast cancer of about 20% to 25% or greater, according to\nl\nrisk assessment tools that are based mainly on family history (see below)\nHave a known BRCA1 or BRCA2 gene mutation4 (based on having had genetic\nl\ntesting5)\nHave a first-degree relative (parent, brother, si",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 5
  },
  {
    "text": "ster, or child) with a BRCA1 or\nl\nBRCA2 gene mutation, and have not had genetic testing themselves\nHad radiation therapy to the chest when they were between the ages of 10 and 30\nl\nyears\nHave Li-Fraumeni syndrome, Cowden syndrome, or Bannayan-Riley-Ruvalcaba\nl\nsyndrome, or have first-degree relatives with one of these syndromes\nThe American Cancer Society recommends against MRI screening for women whose\nlifetime risk of breast cancer is less than 15%.\nThere’s not enough evidence to make a recomm",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 5
  },
  {
    "text": "endation for or against yearly MRI\nscreening for women who have a higher lifetime risk based on certain factors, such as:\nHaving a personal history of breast cancer, ductal carcinoma in situ (DCIS)6, lobular\nl\ncarcinoma in situ (LCIS)7, atypical ductal hyperplasia (ADH), or atypical lobular\n5",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 5
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nhyperplasia (ALH)8\nHaving “extremely” or “heterogeneously” dense breasts as seen on a mammogram\nl\nIf MRI is used, it should be in addition to, not instead of, a screening mammogram. This\nis because although an MRI is more likely to find cancer than a mammogram, it may still\nmiss some cancers that a mammogram would find.\nMost women at high risk should begin screen",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 6
  },
  {
    "text": "ing with MRI and mammograms when they\nare 30 and continue for as long as they are in good health. But this is a decision that\nshould be made with a woman's health care providers, taking into account her personal\ncircumstances and preferences.\nTools used to assess breast cancer risk\nSeveral risk assessment tools can help health professionals estimate a woman’s breast\ncancer risk. These tools give rough estimates of breast cancer risk, based on different\ncombinations of risk factors and different ",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 6
  },
  {
    "text": "data sets.\nBecause each of these tools uses different factors to estimate risk, they might give\ndifferent risk estimates for the same woman. A women's risk estimates can also change\nover time.\nRisk assessment tools that include family history in first-degree relatives (parents,\nsiblings, and children) and second-degree relatives (such as aunts and cousins) on both\nsides of the family should be used with the ACS guidelines to decide if a woman should\nhave MRI screening. The use of any of the risk",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 6
  },
  {
    "text": " assessment tools and its results should\nbe discussed by a woman with her health care provider.\nHyperlinks\n1. author-p64216-e543769.adobeaemcloud.com/content/cancer/en/healthy/find-\ncancer-early/cancer-screening-during-covid-19-pandemic.html\n2. www.cancer.org/cancer/breast-cancer/treatment/surgery-for-breast-\ncancer/mastectomy.html\n3. www.cancer.org/cancer/breast-cancer/treatment/chemotherapy-for-breast-\ncancer.html\n4. www.cancer.org/cancer/breast-cancer/risk-and-prevention/breast-cancer-risk-\nf",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 6
  },
  {
    "text": "actors-you-cannot-change.html\n5. www.cancer.org/cancer/breast-cancer/risk-and-prevention/genetic-testing.html\n6. www.cancer.org/cancer/breast-cancer/about/types-of-breast-cancer/dcis.html\n6",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 6
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\n7. www.cancer.org/cancer/breast-cancer/non-cancerous-breast-conditions/lobular-\ncarcinoma-in-situ.html\n8. www.cancer.org/cancer/breast-cancer/non-cancerous-breast-\nconditions/hyperplasia-of-the-breast-ductal-or-lobular.html\nReferences\nOeffinger KC, Fontham ET, Etzioni R, et al. Breast cancer screening for women at\naverage risk: 2015 guideline update From the Amer",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 7
  },
  {
    "text": "ican Cancer Society. JAMA.\n2015;314(15):1599-1614.\nSaslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast\nscreening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007 Mar-\nApr;57(2):75-89.\nLast Revised: January 14, 2022\nMammograms\nMammograms are low-dose x-rays that can help find breast cancer. If you've been told\nyou need a mammogram, or you're ready to start breast cancer screening, the topics\nbelow can help you know what to expect.\nGetting a mammogram\nFin",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 7
  },
  {
    "text": "d out what a mammogram is, why it's done, what doctors look for, and what it's like\nto get one.\nMammogram Basics\nl\nTips for Getting a Mammogram\nl\nWhat Does the Doctor Look for on a Mammogram?\nl\nGetting Called Back After a Mammogram\nl\nUnderstanding your results\n7",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 7
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nDoctors use a standard system called the Breast Imaging Reporting and Data System\n(BI-RADS) to describe what they see on a mammogram. Learn how to understand your\nresults, and what it means if your mammograms show dense breast tissue.\nUnderstanding Your Mammogram Report\nl\nBreast Density and Your Mammogram Report\nl\nLimitations of Mammograms\nl\nMammograms in special",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 8
  },
  {
    "text": " circumstances\nIf you have had breast cancer in the past, whether or not you need to keep getting\nmammograms might depend on the type of surgery you had. If you have breast\nimplants, you can and should get mammograms as recommended. But you might need\nto have extra pictures taken so the doctor can see as much breast tissue as possible.\nMammograms After Breast Cancer Surgery\nl\nMammograms for Women with Breast Implants\nl\nLast Revised: January 14, 2022\nMammogram Basics\nOn this page\nWhy do I need ma",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 8
  },
  {
    "text": "mmograms?\nl\nWhat are the main uses of mammograms?\nl\nWhat do mammograms show?\nl\nHow do mammograms work?\nl\nWhat are three-dimensional (3D) mammograms?\nl\nAre mammograms safe?\nl\nA mammogram is a low-dose x-ray that allows doctors called radiologists to look for\nchanges in breast tissue.\n8",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 8
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nWhy do I need mammograms?\nMammograms can be used to look for breast cancer, either as a screening test in\nwomen without symptoms or in women who have symptoms that might be from cancer.\nA mammogram can often find or detect breast cancer early, when it’s small and even\nbefore a lump can be felt. This is when it’s likely to be easiest to treat.\nWhat are the main us",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 9
  },
  {
    "text": "es of mammograms?\nScreening mammograms\nA screening mammogram is used to look for signs of breast cancer in women who\ndon’t have any breast symptoms or problems. X-ray pictures of each breast are taken,\ntypically from 2 different angles.\nDiagnostic mammograms\nMammograms are used to look at a woman’s breast if she has breast symptoms or if\nsomething unusual is seen on a screening mammogram. When used in this way, they\nare called diagnostic mammograms. They may include extra views (images) of the\nb",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 9
  },
  {
    "text": "reast that aren’t part of screening mammograms. Sometimes diagnostic mammograms\nare used to screen women who were treated for breast cancer in the past.\nWhat do mammograms show?\nMammograms can often show abnormal areas in the breast. They can’t tell for sure if an\nabnormal area is cancer, but they can help health care providers decide if more testing\n(such as a breast biopsy) is needed. The main types of breast changes found with a\nmammogram are:\nCalcifications\nl\nMasses\nl\nAsymmetries\nl\nDistortio",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 9
  },
  {
    "text": "ns\nl\nLearn more about these and other breast changes in What Does the Doctor Look for on\na Mammogram?\nHow do mammograms work?\n9",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 9
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nMammograms are done with a machine designed to look only at breast tissue. The\nmachine takes x-rays at lower doses than the x-rays done to look at other parts of the\nbody, like the lungs or bones. The mammogram machine has 2 plates that compress or\nflatten the breast to spread the tissue apart. This gives a better quality picture and\nallows less radiation to be u",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 10
  },
  {
    "text": "sed.\nTo learn more about how they are done, see Tips for Getting a Mammogram.\nIn the past, mammograms were typically printed on large sheets of film. Today, digital\nmammograms are much more common. Digital images are recorded and saved as\nfiles in a computer.\n10",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 10
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nWhat are three-dimensional (3D) mammograms?\nThree-dimensional (3D) mammography is also known as breast tomosynthesis or\ndigital breast tomosynthesis (DBT). As with a standard (2D) mammogram, each\nbreast is compressed from two different angles (once from top to bottom and once from\nside to side) while x-rays are taken. But for a 3D mammogram, the machine takes man",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 11
  },
  {
    "text": "y\nlow-dose x-rays as it moves in a small arc around the breast. A computer then puts the\nimages together into a series of thin slices. This allows doctors to see the breast tissues\nmore clearly in three dimensions. (A standard two-dimensional [2D] mammogram can\nbe taken at the same time, or it can be reconstructed from the 3D mammogram\nimages.)\nMany studies have found that 3D mammography appears to lower the chance of being\ncalled back for follow-up testing after screening. It also appears to fi",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 11
  },
  {
    "text": "nd more breast\ncancers, and several studies have shown it can be helpful in women with dense\nbreasts. A large study is now in progress to better compare outcomes between 3D\nmammograms and standard (2D) mammograms.\nFor more on 3D mammograms, see American Cancer Society Recommendations for\nthe Early Detection of Breast Cancer.\nAre mammograms safe?\nMammograms expose the breasts to small amounts of radiation. But the benefits of\nmammography outweigh any possible harm from the radiation exposure1. Mo",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 11
  },
  {
    "text": "dern\nmachines use low radiation doses to get breast x-rays that are high in image quality. On\naverage the total dose for a typical mammogram with 2 views of each breast is about\n0.4 millisieverts, or mSv. (A mSv is a measure of radiation dose.) The radiation dose\nfrom 3D mammograms can range from slightly lower to slightly higher than that from\nstandard 2D mammograms.\nTo put these doses into perspective, people in the US are normally exposed to an\naverage of about 3 mSv of radiation each year ju",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 11
  },
  {
    "text": "st from their natural surroundings.\n(This is called background radiation.) The dose of radiation used for a screening\nmammogram of both breasts is about the same amount of radiation a woman would get\nfrom her natural surroundings over about 7 weeks.\nIf there’s any chance you might be pregnant, let your health care provider and x-ray\ntechnologist know. Although the risk to the fetus is very small, and mammograms are\ngenerally thought to be safe during pregnancy, screening mammograms aren’t routin",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 11
  },
  {
    "text": "ely\ndone in pregnant women who aren't at increased risk for breast cancer.\n11",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 11
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nMammograms might also result in some women getting additional tests that don't result\nin a breast cancer diagnosis, but that might still have their own harms. For more on this,\nsee Limitations of Mammograms.\nHyperlinks\n1. www.cancer.org/healthy/cancer-causes/radiation-exposure/x-rays-gamma-\nrays.html\nReferences\nBahl M, Pinnamaneni N, Mercaldo S, et al. Digital 2D",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 12
  },
  {
    "text": " versus tomosynthesis screening\nmammography among women aged 65 and older in the United States. Radiology. 2019;\n291:582-590.\nHelvie MA, Patterson SK. Chapter 11: Imaging Analysis: Mammography. In: Harris JR,\nLippman ME, Morrow M, Osborne CK, eds. Diseases of the Breast. 5th ed.\nPhiladelphia, Pa: Lippincott Williams & Wilkins; 2014.\nHendrick RE. Radiation doses and cancer risks from breast imaging studies. Radiology.\n2010;257(1):246-253.\nLowry KP, Coley RY, Miglioretti DL, et al. Screening perfo",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 12
  },
  {
    "text": "rmance of digital breast\ntomosynthesis vs digital mammography in community practice by patient age, screening\nround, and breast density. JAMA Netw Open. 2020;3(7):e2011792.\nOeffinger KC, Fontham ET, Etzioni R, et al. Breast cancer screening for women at\naverage risk: 2015 guideline update from the American Cancer Society. JAMA.\n2015;314(15):1599-614.\nPuliti D, Duffey SW, Miccinesi G, et al. Overdiagnosis in mammographic screening for\nbreast cancer in Europe: A literature review. J Med Screen, 20",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 12
  },
  {
    "text": "12;19:Suppl 1:42-56.\nRadiological Society of North America (RSNA). Breast Tomosynthesis. 2020. Accessed\nat https://www.radiologyinfo.org/en/info/tomosynthesis on September 28, 2021.\nRadiological Society of North America (RSNA). Radiation Dose in X-Ray and CT\nExams. 2019. Accessed at https://www.radiologyinfo.org/en/info/safety-xray on\nSeptember 28, 2021.\n12",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 12
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nRose SL, Tidwell AL, Bujnoch LJ, et al. Implementation of breast tomosynthesis in a\nroutine screening practice: An observational study. AJR Am J Roentgenol.\n2013;200(6):1401-1408.\nSkaane P, Bandos AI, Gullien R, et al. Comparison of digital mammography alone and\ndigital mammography plus tomosynthesis in a population-based screening\nprogram. Radiology. 2013;267(1)",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 13
  },
  {
    "text": ":47-56.\nSvahn TM, Houssami N, Sechopoulos I, Mattsson S. Review of radiation dose\nestimates in digital breast tomosynthesis relative to those in two-view full-field digital\nmammography. Breast. 2015;24(2):93-99.\nLast Revised: January 14, 2022\nTips for Getting a Mammogram\nA mammogram is an important step in taking care of yourself and your breasts.\nWhether you’re a mammogram newbie or a veteran, knowing what to expect may help\nthe process go more smoothly.\nHow to prepare for your mammogram\nIf you",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 13
  },
  {
    "text": " have a choice, go to a facility that specializes in mammograms and does\nl\nmany mammograms a day.\nTry to go to the same facility every time so that your mammograms can easily be\nl\ncompared from year to year.\nIf you’re going to a facility for the first time, bring a list of the places and dates of\nl\nmammograms, biopsies, or any other breast procedures you’ve had before.\nIf you’ve had mammograms at another facility, try to get those records to bring with\nl\nyou to the new facility (or have them sen",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 13
  },
  {
    "text": "t there) so the old pictures can be\ncompared to the new ones.\nSchedule your mammogram for when your breasts aren't likely to be tender or\nl\nswollen, to help reduce discomfort and get good pictures. Try to avoid the week just\nbefore your period.\nOn the day of the exam, don’t apply deodorant, antiperspirant, powders, lotions,\nl\n13",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 13
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\ncreams, or perfumes under your arms, or on or under your breasts. Some of these\ncontain substances that can show up on the x-ray as white spots. If you’re not\ngoing home after your exam, you might want to take your deodorant or\nantiperspirant with you to put on after your exam. (Many centers will have cleaning\nand deodorant wipes to help you wipe off the deodoran",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 14
  },
  {
    "text": "t and then replace it after\nthe exam.)\nYou might find it easier to wear a skirt or pants, so that you’ll only need to remove\nl\nyour top and bra for the mammogram.\nDiscuss any recent changes or problems in your breasts with your health care\nl\nprovider before getting the mammogram. (If you have symptoms, you may need a\ndiagnostic mammogram so special images can be taken of the area of concern.)\nMake sure your provider is aware of any part of your medical history that could\nl\naffect your breast can",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 14
  },
  {
    "text": "cer risk—such as surgery, hormone use, breast cancer in\nyour family, or if you’ve had breast cancer before.\nDon’t be afraid of mammograms! Remember that only about 2 to 4 screening\nmammograms in 1,000 lead to a diagnosis of breast cancer.\nWhat to tell your technologist\nTo help ensure you have a good quality mammogram, make sure your technologist\nknows:\nAbout any breast changes or problems you’re having\nl\nIf you have breast implants\nl\nIf you have trouble standing and holding still alone (without ",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 14
  },
  {
    "text": "the aid of a cane or\nl\nwalker)\nIf you’re breastfeeding or if you think you might be pregnant.\nl\nTell the technologist right away if you start feeling lightheaded or dizzy during the\nmammogram.\nWhat to expect when getting a screening mammogram\nYou’ll have to undress above the waist to get a mammogram. The facility will give\nl\nyou a wrap to wear.\nYou and the technologist will be the only ones in the room during the mammogram.\nl\n14",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 14
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nTo get a high-quality picture, your breast must be flattened or compressed. You'll\nl\nstand in front of the machine, and the technologist will place your breast on the\nmachine. The plastic upper plate is then lowered to compress your breast for about\n10 to 15 seconds while the technologist takes an x-ray. You will then need to\nchange position so your breast is com",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 15
  },
  {
    "text": "pressed from side to side before the next x-\nray is taken.\nIf you're getting a 3D mammogram (also known as digital breast tomosynthesis, or\nl\nDBT), the procedure is the same as above, but you'll notice that the machine will\nmove in a small arc, either over the top of your breast or along the side of your\nbreast, for each image. You might be asked to hold your breath each time it's being\ndone.\nThe whole procedure takes about 20 minutes. The actual breast compression\nl\nonly lasts about 10 to 15 se",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 15
  },
  {
    "text": "conds for each image.\nYou might feel some discomfort when your breasts are compressed, and for some\nl\nwomen it can be painful. Tell the technologist if it hurts so they can try to adjust the\ncompression to your comfort.\nTwo views of each breast are taken for a screening mammogram. But for some\nl\nwomen, such as those with breast implants or larger breasts, more pictures may\nbe needed.\nWhat to expect when getting a diagnostic mammogram\nA diagnostic mammogram is often done if a woman has breast sym",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 15
  },
  {
    "text": "ptoms or if\nsomething unusual is seen on a screening mammogram. The basic procedure is similar\nto that for a screening mammogram, but there are some differences.\nMore pictures are taken during a diagnostic mammogram, with a focus on the area\nl\nthat looked different on the screening mammogram (or where the symptoms are).\nThese special images may be “spot views” or “magnification views,” which are used\nl\nto make the area of concern easier to see.\nAgain, if a 3D mammogram is being done, the procedu",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 15
  },
  {
    "text": "re is the same, but you\nl\nmight be asked to hold your breath while the machine moves in a small arc around\nyour breast to create each image.\nDuring a diagnostic mammogram, the images are checked by the radiologist while\nl\nyou’re there so that more pictures can be taken if needed to look more closely at\nany area of concern. (Depending on the findings, a breast ultrasound may also be\ndone to look at the area of concern.)\n15",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 15
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nHow will I get my mammogram results?\nA full report of the results of your mammogram will be sent to your health care\nprovider. If you don’t hear from your health care provider within 10 days, do not\nassume that your mammogram was normal. Call your provider or the facility where\nthe mammogram was done.\nThe mammography facility also must provide you with an easy-to",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 16
  },
  {
    "text": "-understand summary\nof your mammogram results within 30 days—or “as quickly as possible” if the\nresults suggest something abnormal is present. If you have online access to your\nmedical records, such as through a patient portal, your results might show up there at\nthe same time your health care provider gets them. This means you could get the\nresults before your health care provider contacts you. Be sure to go over the results with\nyour provider, especially if there's anything you don't understan",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 16
  },
  {
    "text": "d.\nWe can help you learn more about how to understand your mammogram report.\nReferences\nHelvie MA, Patterson SK. Chapter 11: Imaging Analysis: Mammography. In: Harris JR,\nLippman ME, Morrow M, Osborne CK, eds. Diseases of the Breast. 5th ed.\nPhiladelphia, Pa: Lippincott Williams & Wilkins; 2014.\nRadiological Society of North America (RSNA). Mammography. 2021. Accessed\nat https://www.radiologyinfo.org/en/info/mammo on September 29, 2021.\nRosenberg RD, Hunt WC, Williamson MR, et al. Effects of age",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 16
  },
  {
    "text": ", breast density, ethnicity,\nand estrogen replacement therapy on screening mammographic sensitivity and cancer\nstage at diagnosis: Review of 183,134 screening mammograms in Albuquerque, New\nMexico. Radiology 1998;209:511–518.\nUS Food and Drug Administration. Direct-to-Patient Mammogram Results: It’s the Law.\n2018. Accessed at https://www.fda.gov/radiation-emitting-products/mqsa-insights/direct-\npatient-mammogram-results-its-law on September 29, 2021.\nLast Revised: January 14, 2022\n16",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 16
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nWhat Does the Doctor Look for on a\nMammogram?\nA radiologist will look at your mammogram. Radiologists are doctors who diagnose\ndiseases and injuries using imaging tests such as x-rays.\nWhen possible, the doctor reading your mammogram will compare it to your old\nmammograms. This can help show if any findings are new, or if they were already there\non previous mammo",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 17
  },
  {
    "text": "grams. Findings that haven’t changed from older mammograms\naren’t likely to be cancer, which might mean you won't need further tests.\nThe doctor reading your mammogram will be looking for different types of breast\nchanges, such as small white spots called calcifications, abnormal areas called masses,\nand other suspicious findings that could be signs of cancer.\nCalcifications\nCalcifications are tiny calcium deposits within the breast tissue. They look like small\nwhite spots on a mammogram. They m",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 17
  },
  {
    "text": "ay or may not be caused by cancer. There are 2\ntypes of calcifications.\nMacrocalcifications\nMacrocalcifications are larger calcium deposits that are most likely due to changes\ncaused by aging of the breast arteries, old injuries, or inflammation. These deposits are\ntypically related to non-cancerous conditions and don’t need further testing with a\nbiopsy. Macrocalcifications become more common as women get older (especially after\nage 50).\nMicrocalcifications\nMicrocalcifications are tiny specks o",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 17
  },
  {
    "text": "f calcium in the breast. When seen on a\nmammogram, they are more of a concern than macrocalcifications, but they don’t\nalways mean that cancer is present. The shape and layout of microcalcifications (and\nwhether they are near a mass) help the radiologist judge how likely it is that the change\nis due to cancer.\nIn most cases, microcalcifications don’t need to be checked with a biopsy. But if they\nhave a suspicious look and pattern, a biopsy will be recommended to check for cancer.\n17",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 17
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nMasses\nA mass is an area of abnormal breast tissue with a shape and edges that make it look\ndifferent than the rest of the breast tissue on a mammogram. A mass might be seen\nwith or without calcifications. Masses can be many things, including cysts1 (non-\ncancerous, fluid-filled sacs) and non-cancerous solid tumors (such as fibroadenomas2),\nbut they may also be a",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 18
  },
  {
    "text": " sign of cancer.\nCysts are fluid-filled sacs. Simple cysts (fluid-filled sacs with thin walls) are not cancer\nand typically don’t need to be checked with a biopsy. If a mass is not a simple cyst, it’s\nof more concern, so a biopsy might be needed to be sure it isn’t cancer.\nSolid masses can be more concerning, but most solid breast masses are not cancer.\nA cyst and a solid mass can feel the same. They can also sometimes look the same on\na mammogram. The doctor must be sure it’s a cyst to know it’",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 18
  },
  {
    "text": "s not cancer, so a breast\nultrasound is often done (because it is better than a mammogram at showing if the\ninside of a mass is solid or filled with fluid).\nIf it isn’t clear if the mass is a cyst or a solid mass, a thin, hollow needle may be inserted\ninto the mass during an ultrasound to try to remove (aspirate) the fluid from the area. If\nthe mass goes away on the ultrasound as the fluid is removed, then it is most likely a\ncyst and no further work up is needed.\nIf a mass is not a simple cyst ",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 18
  },
  {
    "text": "(that is, if it’s at least partly solid, or if it has other\nconcerning features), more imaging tests might be needed to decide if it could be\ncancer. Some masses can be watched over time with regular mammograms or\nultrasound to see if they change, but others may need to be checked with a biopsy. The\nsize, shape, and margins (edges) of the mass can help the radiologist decide how likely\nit is to be cancer.\nAsymmetries\nAsymmetries are white areas seen on a mammogram that look different from the no",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 18
  },
  {
    "text": "rmal\nbreast tissue pattern. There are different types of asymmetries, including focal\nasymmetry, developing asymmetry, and global asymmetry.\nMost of the time, these findings do not mean you have breast cancer. But more imaging\ntests will likely be needed to make sure there is no cancer in this area.\nArchitectural distortion\n18",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 18
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nRadiologists use this term to describe when an area of the breast tissue appears\ndistorted or pulled toward a certain point. Sometimes this may just be due to how the\nbreast was positioned during the mammogram. It might also be caused by a prior injury\nor procedure done on the breast. But architectural distortion can also sometimes be a\nsign of a breast cancer, s",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 19
  },
  {
    "text": "o further imaging with diagnostic mammograms is typically\nneeded to get a better look at this area.\nBreast density\nYour mammogram report will also contain an assessment of your breast density. Breast\ndensity is a measure of how much fibrous and glandular tissue is in your breast,\ncompared to fatty tissue. It isn’t related to breast size or firmness.\nYour breast tissue may be called ‘dense’ if you have more fibrous and glandular tissue\ncompared to fatty tissue in the breast.\nAbout half of all wom",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 19
  },
  {
    "text": "en have dense breasts. Having dense breasts is not abnormal.\nHowever, women who have dense breasts have a slightly higher risk of breast cancer.\nDense breast tissue can also make it harder to see cancers on a mammogram. This is\nbecause fibrous and glandular tissue appear white on a mammogram, which can hide\nmany types of suspicious findings that also appear white. Still, experts don’t agree what\nother tests, if any, should be done along with mammograms in women with dense\nbreasts who aren’t othe",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 19
  },
  {
    "text": "rwise at higher risk for breast cancer (based on gene mutations,\nbreast cancer in the family, or other factors).\nHyperlinks\n1. www.cancer.org/cancer/breast-cancer/non-cancerous-breast-conditions/fibrosis-\nand-simple-cysts-in-the-breast.html\n2. www.cancer.org/cancer/breast-cancer/non-cancerous-breast-\nconditions/fibroadenomas-of-the-breast.html\nReferences\nEsserman LJ, Joe BN. Diagnostic evaluation of suspected breast cancer. UpToDate.\n2021. Accessed at https://www.uptodate.com/contents/diagnostic",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 19
  },
  {
    "text": "-evaluation-of-\nsuspected-breast-cancer on September 29, 2021.\n19",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 19
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nHelvie MA, Patterson SK. Chapter 11: Imaging Analysis: Mammography. In: Harris JR,\nLippman ME, Morrow M, Osborne CK, eds. Diseases of the Breast. 5th ed.\nPhiladelphia, Pa: Lippincott Williams & Wilkins; 2014.\nVenkataraman S, Slanetz PJ, Lee CI. Breast imaging for cancer screening:\nMammography and ultrasonography. UpToDate. 2021. Accessed at\nhttps://www.uptodate.c",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 20
  },
  {
    "text": "om/contents/breast-imaging-for-cancer-screening-\nmammography-and-ultrasonography on September 29, 2021.\nLast Revised: January 14, 2022\nGetting Called Back After a\nMammogram\nGetting called back after a screening mammogram is fairly common, and it doesn’t\nmean you have breast cancer. In fact, fewer than 1 in 10 women called back for more\ntests are found to have cancer. Often, it just means more mammograms or other tests\n(such as an ultrasound) need to be done to get a closer look at an area of con",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 20
  },
  {
    "text": "cern.\nIf you do need more tests, ask your doctor about how quickly these tests can be\nscheduled. This can vary based on a number of factors, such as how busy the testing\ncenters are in your area.\nGetting called back is more common after a first mammogram, or when there’s no\nprevious mammogram to compare to the new mammogram. It's also more common in\nwomen who haven’t gone through menopause.\nWhy might I be called back?\nYou could be called back after your mammogram because:\nThe pictures weren’t cl",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 20
  },
  {
    "text": "ear or didn't show some of your breast tissue, so they need\nl\nto be retaken.\nThe radiologist (doctor who reads the mammogram) sees something suspicious,\nl\nsuch as calcifications or a mass (which could be a cyst1 or solid mass).\n20",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 20
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nThe radiologist sees an area that just looks different from other parts of the breast.\nl\nSometimes when more mammograms are taken of an abnormal-looking area, or the\narea is compressed more, it no longer looks suspicious. In fact, most often the\nadditional images show the finding isn't cancer.\nWhat will happen at the follow-up appointment?\nYou’ll likely get anoth",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 21
  },
  {
    "text": "er mammogram called a diagnostic mammogram. (Your\nl\nprevious mammogram was called a screening mammogram.) A diagnostic\nmammogram is done just like a screening mammogram, but more pictures are\ntaken so that any areas of concern can be looked at more closely. A doctor called a\nradiologist will be on hand to advise the technologist (the person who operates the\nmammogram machine), to be sure they have all the images that are needed.\nYou may also get another imaging test, such as an ultrasound of the",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 21
  },
  {
    "text": " breast, which\nl\nuses sound waves to make pictures of the inside of your breast at the area of\nconcern.\nYou will most likely be given the results of your tests during the visit. You might be told\none of the following:\nThe suspicious area on the mammogram turned out to be nothing to worry about,\nl\nand you can return to your normal mammogram schedule.\nThe area is probably nothing to worry about, but you should have your next imaging\nl\ntest (mammogram and/or ultrasound) sooner than normal – usually",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 21
  },
  {
    "text": " in about 6\nmonths – to watch the area closely and make sure it's not changing over time.\nThe area could be cancer, so you will need a biopsy (see below) to know for sure.\nl\nYou’ll also get a letter with a summary of the findings that will tell you if you need more\ntests and/or when you should schedule your next mammogram.\nWhat if I need a biopsy?\nDuring a breast biopsy, small pieces of breast tissue are removed and checked for\ncancer under a microscope. Even if you need a biopsy, it doesn’t mea",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 21
  },
  {
    "text": "n you have\ncancer. Most biopsy results are not cancer, but a biopsy is the only way to find out.\nThere are different types of breast biopsies, some of which are done using a small,\n21",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 21
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nhollow needle and some that are done through a cut in the skin. The type you have\ndepends on things like how suspicious the area looks, how big it is, where it is in the\nbreast, other medical problems you might have, and your personal preferences.\nHow can I stay calm while waiting?\nWaiting for appointments and the results of tests can be frightening, especially i",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 22
  },
  {
    "text": "f you\nwere told the results of your first mammogram weren’t normal. You might have strong\nemotions, such as disbelief, anxiety, fear, anger, or sadness during this time. Here are\nsome things to remember:\nIt’s normal to have these feelings.\nl\nMost often, breast changes are not cancer and are not life-threatening.\nl\nTalking with a loved one or a counselor about your feelings may help.\nl\nTalking with other women who have been called back after a mammogram may\nl\nhelp.\nThe American Cancer Society is ",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 22
  },
  {
    "text": "available at 1-800-227-2345 around the clock to\nl\nanswer your questions and provide support.\nWhat if it’s cancer?\nIf you do have breast cancer and you’re referred to a breast specialist, use these tips to\nmake your appointment as useful as possible:\nMake a list of questions2 to ask.\nl\nTake a family member or friend with you. They can serve as an extra pair of ears,\nl\ntake notes, help you remember things later, and give you support.\nAsk if you can record the conversations. You might also want to ",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 22
  },
  {
    "text": "take notes.\nl\nIf someone uses a word you don’t know, ask them to spell it and explain it.\nl\nAsk the doctors or nurses to explain anything you don’t understand.\nl\nHyperlinks\n1. www.cancer.org/cancer/breast-cancer/non-cancerous-breast-conditions/fibrosis-\nand-simple-cysts-in-the-breast.html\n2. www.cancer.org/treatment/treatments-and-side-effects/planning-\nmanaging/questions-to-ask-your-doctor.html\n22",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 22
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nReferences\nHelvie MA, Patterson SK. Chapter 11: Imaging Analysis: Mammography. In: Harris JR,\nLippman ME, Morrow M, Osborne CK, eds. Diseases of the Breast. 5th ed.\nPhiladelphia, Pa: Lippincott Williams & Wilkins; 2014.\nLast Revised: May 17, 2022\nUnderstanding Your Mammogram\nReport\nA doctor called a radiologist will categorize your mammogram results using a\nnumbe",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 23
  },
  {
    "text": "red system. Talk to your doctor about your mammogram results and what you\nneed to do next.\nWhat is a BI-RADS assessment category?\nDoctors use a standard system to describe mammogram findings and results. This\nsystem (called the Breast Imaging Reporting and Data System or BI-RADS) sorts the\nresults into categories numbered 0 through 6.\nWith these categories, doctors can describe what they find on a mammogram using the\nsame words and terms. This makes communicating about the test results and follo",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 23
  },
  {
    "text": "wing\nup after the tests easier.\n(Note: These same BI-RADS categories can also be used to describe the results of a\nbreast ultrasound or breast MRI exam. However, the recommended next steps after\nthese tests might be slightly different.)\nWhat do the BI-RADS categories mean?\nCategoryDefinition What it means\n23",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 23
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nThis means the radiologist may have seen a possible abnormality, but it was\nIncomplete - not clear and you will need more tests, such as another mammogram with the\nAdditional imaging use of spot compression (applying compression to a smaller area when doing\nevaluation and/or the mammogram), magnified views, special mammogram views, and/or\n0 comparison to prior ul",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 24
  },
  {
    "text": "trasound. This may also suggest that the radiologist wants to compare your\nmammograms (or new mammogram with older ones to see if there have been changes in the\nother imaging tests) area over time.\nis needed.\nNegative This is a normal test result. Your breasts look the same (they are symmetrical)\n1 with no masses (lumps), distorted structures, or suspicious calcifications. In this\ncase, negative means nothing new or abnormal was found.\nThis is also a negative test result (there’s no sign of canc",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 24
  },
  {
    "text": "er), but the radiologist\nchooses to describe a finding that is not cancer, such as benign calcifications,\nBenign (non- masses, or lymph nodes in the breast. This can also be used to describe\n2\ncancerous) finding changes from a prior procedure (such as a biopsy) in the breast. This ensures\nthat others who look at the mammogram in the future will not misinterpret the\nbenign finding as suspicious.\nA finding in this category has a very low (no more than 2%) chance of being\ncancer. It is not expected",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 24
  },
  {
    "text": " to change over time. But since it’s not proven to\nProbably benign\nbe benign, it’s helpful to be extra safe and see if the area in question does\nfinding – Follow-up in\nchange over time.\na short time frame is\n3\nsuggested\nYou will likely need follow-up with repeat imaging in 6 to 12 months and\nregularly after that until the finding is known to be stable (usually at least 2\nyears). This approach helps avoid unnecessary biopsies, but if the area does\nchange over time, it still allows for early diagn",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 24
  },
  {
    "text": "osis.\nThese findings do not definitely look like cancer but could be cancer. The\nradiologist is concerned enough to recommend a biopsy. The findings in this\ncategory can have a wide range of suspicion levels. For this reason, this\ncategory is often divided further:\nSuspicious 4A: Finding with a low likelihood of being cancer (more than 2% but no more\n4 abnormality – Biopsy than 10%)\nshould be considered\n4B: Finding with a moderate likelihood of being cancer (more than 10% but no\nmore than 50%)\n4",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 24
  },
  {
    "text": "C: Finding with a high likelihood of being cancer (more than 50% but less than\n95%), but not as high as Category 5\n24",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 24
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nHighly suggestive of\nmalignancy – The findings look like cancer and have a high chance (at least 95%) of being\n5\nAppropriate action cancer. Biopsy is very strongly recommended.\nshould be taken\nKnown biopsy-proven\nThis category is only used for findings on a mammogram (or ultrasound or\nmalignancy –\n6 MRI) that have already been shown to be cancer by a previous bio",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 25
  },
  {
    "text": "psy. Imaging\nAppropriate action\nmay be used in this way to see how well the cancer is responding to treatment.\nshould be taken\nBI-RADS reporting breast density\nYour mammogram report will also include an assessment of your breast density, which\nis a description of how much fibrous and glandular tissue is in your breasts, as\ncompared to fatty tissue. The denser your breasts, the harder it can be to see abnormal\nareas on mammograms. (Having dense breasts also slightly raises your risk of getting\nbr",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 25
  },
  {
    "text": "east cancer.)\nBI-RADS classifies breast density into 4 groups, which are described in Breast Density\nand Your Mammogram Report.\nReferences\nAmerican College of Radiology. ACR BI-RADS ATLAS – Mammography. Reporting\nSystem, 2013. Accessed at https://www.acr.org/-/media/ACR/Files/RADS/BI-\nRADS/Mammography-Reporting.pdf on September 30, 2021.\nHelvie MA, Patterson SK. Chapter 11: Imaging Analysis: Mammography. In: Harris JR,\nLippman ME, Morrow M, Osborne CK, eds. Diseases of the Breast. 5th ed.\nPhilad",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 25
  },
  {
    "text": "elphia, Pa: Lippincott Williams & Wilkins; 2014.\nVenkataraman S, Slanetz PJ, Lee CI. Breast imaging for cancer screening:\nMammography and ultrasonography. UpToDate. 2021. Accessed at\nhttps://www.uptodate.com/contents/breast-imaging-for-cancer-screening-\nmammography-and-ultrasonography on September 30, 2021.\nLast Revised: January 14, 2022\n25",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 25
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nBreast Density and Your Mammogram\nReport\nRegular mammograms are the best way to find breast cancer early. But if your\nmammogram report says that you have dense breast tissue, you may be wondering\nwhat that means.\nWhat is dense breast tissue?\nBreast density is a measure of how much fibrous and glandular tissue (also known as\nfibroglandular tissue) there is in your",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 26
  },
  {
    "text": " breast, as compared to fat tissue. It isn’t related to\nbreast size or firmness.\nBreasts are made up of lobules, ducts, and fatty and fibrous connective tissue.\nLobules are the small glands that produce milk, while ducts are the tiny tubes that\nl\ncarry the milk from the lobules to the nipple. Together, the lobules and ducts are\nreferred to as glandular tissue.\nFibrous tissue and fat give breasts their size and shape and hold the other\nl\nstructures in place.\n26",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 26
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nFibrous and glandular tissue are harder to see through on a mammogram, so your\nbreast tissue may be called ‘dense’ if you have a lot of these tissues (and not as much\nfat).\nHaving dense breast tissue is common. Some women have more dense breast tissue\nthan others. For most women, breasts become less dense with age. But in some\nwomen, there’s little change.\n27",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 27
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nHow do I know if I have dense breasts?\nRadiologists are doctors who “read” mammograms (and other types of imaging tests).\nThey check your mammogram for abnormal areas, and they also look at breast density.\nThere are 4 categories of breast density. They go from almost all fatty tissue to\nextremely dense tissue with very little fat. The radiologist decides which of",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 28
  },
  {
    "text": " the 4\ncategories best describes how dense your breasts are:\nCategory A: Breasts are almost all fatty tissue.\n28",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 28
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nCategory B: There are scattered areas of dense glandular and fibrous tissue (seen as\nwhite areas on the mammogram).\n29",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 29
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nCategory C: More of the breast is made of dense glandular and fibrous tissue\n(described as heterogeneously dense). This can make it hard to see small masses in\nor around the dense tissue, which also appear as white areas.\n30",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 30
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nCategory D: Breasts are extremely dense, which makes it harder to see masses or\nother findings that may appear as white areas on the mammogram.\nMammogram reports sent to women often mention breast density. Your health care\nprovider can also tell you if your mammogram shows that you have dense breasts.\nIn many states, women whose mammograms show heterogeneously de",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 31
  },
  {
    "text": "nse or\nextremely dense breasts (which includes about half of all women) must be told that they\nhave dense breasts in the summary of the mammogram report that is sent to patients\n(sometimes called the lay summary).\nThe language used is mandated by each law, and may say something like this:\n“Your mammogram shows that your breast tissue is dense. Dense breast tissue is\ncommon and is not abnormal. However, dense breast tissue can make it harder to\nevaluate the results of your mammogram and may also ",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 31
  },
  {
    "text": "be associated with an increased\nrisk of breast cancer. This information about the results of your mammogram is given to\nyou so you will be informed when you talk with your doctor. Together, you can decide\nwhich screening options are right for you. A report of your results was sent to your\nprimary physician.”\n31",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 31
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nWhy is breast density important?\nBreast density is important for two main reasons:\nWomen who have dense breast tissue have a higher risk of breast cancer\nl\ncompared to women with less dense breast tissue. It’s unclear at this time why\ndense breast tissue is linked to breast cancer risk. It may be that dense breast\ntissue has more cells that can develop into abnor",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 32
  },
  {
    "text": "mal cells.\nDense breast tissue also makes it harder for radiologists to see cancer on\nl\nmammograms. Dense (fibrous and glandular) breast tissue looks white on a\nmammogram. Breast masses and cancers can also look white, so the dense tissue\ncan make it harder to see them. In contrast, fatty tissue looks almost black on a\nmammogram, so it’s easier to see a tumor that looks white if most of the breast is\nfat tissue.\nIf I have dense breasts, do I still need a mammogram?\nYes. Most breast cancers can b",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 32
  },
  {
    "text": "e seen on a mammogram even in women who have\ndense breast tissue, so it’s still important to get regular mammograms. Mammograms\ncan help save women’s lives.\nEven if you have a normal mammogram report, you should know how your breasts\nnormally look and feel. Anytime there’s a change, you should report it to a health care\nprovider right away.\nShould I have any other screening tests if I have dense breast tissue?\nAt this time, experts do not agree what other tests, if any, should be done in additio",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 32
  },
  {
    "text": "n to\nmammograms in women with dense breasts.\nDigital breast tomosynthesis (3D mammography) can find some cancers not seen on\nregular (2D) mammograms. Some studies have suggested 3D mammography might be\nparticularly helpful in women with dense breasts. It can be used as a screening test\nalong with or instead of standard mammography, although it isn’t yet available at all\nimaging centers.\nStudies have shown that breast ultrasound and possibly magnetic resonance imaging\n(MRI) can also help find som",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 32
  },
  {
    "text": "e breast cancers that can’t be seen on mammograms. But\n32",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 32
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nultrasound and MRI can also show more findings that are not cancer. This can lead to\nmore tests and unnecessary biopsies. And the cost of an ultrasound or MRI may not be\ncovered by insurance.\nTalk to your health care provider about whether you should consider any of these tests.\nWhat should I do if I have dense breast tissue?\nIf your mammogram report says that yo",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 33
  },
  {
    "text": "u have dense breast tissue, talk with your health\ncare provider about what this means for you. Be sure that your doctor or nurse knows if\nthere’s anything in your medical history that increases your risk for breast cancer. To\nlearn more about breast cancer risk factors, see Breast Cancer Risk and Prevention1.\nAny woman who’s already in a high-risk group (based on inherited gene mutations, a\nstrong family history of breast cancer, or other factors) should have an MRI along with\nher yearly mammogr",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 33
  },
  {
    "text": "am. To learn more about if you’re in a higher-risk group for breast\ncancer, see American Cancer Society Recommendations for the Early Detection of\nBreast Cancer.\nHyperlinks\n1. www.cancer.org/cancer/breast-cancer/risk-and-prevention.html\nReferences\nAmerican College of Radiology. BI-RADS ATLAS – Mammography. Reporting System,\n2013. Accessed at https://www.acr.org/-/media/ACR/Files/RADS/BI-\nRADS/Mammography-Reporting.pdf on October 1, 2021.\nHelvie MA, Patterson SK. Chapter 11: Imaging Analysis: Mam",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 33
  },
  {
    "text": "mography. In: Harris JR,\nLippman ME, Morrow M, Osborne CK, eds. Diseases of the Breast. 5th ed.\nPhiladelphia, Pa: Lippincott Williams & Wilkins; 2014.\nKerlikowske K, Ichikawa L, Miglioretti DL, et al. Longitudinal measurement of clinical\nmammographic breast density to improve estimation of breast cancer risk. J Natl\nCancer Inst. 2007;99(5):386-395.\nLee CI, Chen LE, Elmore JG. Risk-based breast cancer screening - Implications of\nbreast density. Medical Clinics of North America. 2017;101(4):725-74",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 33
  },
  {
    "text": "1.\n33",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 33
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nMelnikow J, Fenton JJ, Whitlock EP, et al. Supplemental screening for breast cancer in\nwomen with dense breasts: A systematic review for the US Preventive Services Task\nForce. Ann Intern Med. 2016;164(4):268-278.\nSaslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast\nscreening with MRI as an adjunct to mammography. CA Cancer J Clin. 200",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 34
  },
  {
    "text": "7 Mar-\nApr;57(2):75-89.\nVenkataraman S, Slanetz PJ, Lee CI. Breast imaging for cancer screening:\nMammography and ultrasonography. UpToDate. 2021. Accessed at\nhttps://www.uptodate.com/contents/breast-imaging-for-cancer-screening-\nmammography-and-ultrasonography on October 1, 2021.\nLast Revised: March 10, 2022\nLimitations of Mammograms\nMammograms are the best breast cancer screening tests we have at this time. But\nmammograms have their limits. For example, they aren’t 100% accurate in showing if a",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 34
  },
  {
    "text": "\nwoman has breast cancer. They can miss some cancers, and sometimes they find\nthings that turn out not to be cancer (but that still need further testing to be sure).\nFalse-negative results\nA false-negative mammogram looks normal even though breast cancer is present.\nOverall, screening mammograms miss about 1 in 8 breast cancers.\nWomen with dense breasts are more likely to get false-negative results.\nl\nFalse-negative mammograms can give women a false sense of security, thinking\nl\nthat they don’t ",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 34
  },
  {
    "text": "have breast cancer when in fact they do.\nIt’s important to see your doctor if you have new breast symptoms, even if you’ve\nl\nhad a normal screening mammogram recently. Additional tests such as a\ndiagnostic mammogram and/or a breast ultrasound may be needed to look more\nclosely at the area where you're having symptoms.\n34",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 34
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nFalse-positive results\nA false-positive mammogram looks abnormal even though there is no cancer in the\nbreast. Abnormal mammograms often require extra testing (diagnostic mammograms,\nultrasound, and sometimes MRI or even a breast biopsy) to find out if the change is\ncancer.\nFalse-positive results are more common in women who are younger, have dense\nl\nbreasts, hav",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 35
  },
  {
    "text": "e had breast biopsies, have breast cancer in the family, or are taking\nestrogen.\nAbout half of the women getting annual mammograms over a 10-year period will\nl\nhave a false-positive finding at some point.\nThe odds of a false-positive finding are higher for the first mammogram (or if\nl\nprevious mammograms aren't available for comparison). Women who have past\nmammograms available for comparison reduce their odds of a false-positive finding\nby about half.\nFalse-positive mammograms can cause anxiety",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 35
  },
  {
    "text": ". They can also lead to extra tests\nl\nto be sure cancer isn’t there, which cost time and money and maybe even physical\ndiscomfort.\nMammograms might not be helpful for all women\nThe value of a screening mammogram depends on a woman’s overall health. Finding\nbreast cancer early may not help her live longer if she has other serious or life-\nthreatening health problems, such as serious heart, kidney, liver, or lung disease. The\nAmerican Cancer Society breast cancer screening guidelines emphasize tha",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 35
  },
  {
    "text": "t women\nwith serious health problems or short life expectancies should discuss with their doctors\nwhether they should continue having mammograms. Our guidelines also stress that age\nalone should not be the reason to stop having regular mammograms.\nIt’s important to know that even though mammograms can often find breast cancers that\nare too small to be felt, treating a small tumor does not always mean it can be cured. A\nfast-growing or aggressive cancer might have already spread, even if the tumo",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 35
  },
  {
    "text": "r in the\nbreast is still small.\nOverdiagnosis and overtreatment\nScreening mammograms can often find invasive breast cancer and ductal carcinoma in\n35",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 35
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nsitu1 (DCIS, cancer cells in the lining of breast ducts) that need to be treated. But it’s\npossible that some of the invasive cancers and DCIS found on mammograms would\nnever grow or spread. (Finding cancers that would never cause problems is called\noverdiagnosis.) These cancers are not life-threatening, and never would have been\nfound or treated if the woman had",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 36
  },
  {
    "text": " not gotten a mammogram. The problem is that\ndoctors can’t tell these cancers from those that will grow and spread.\nOverdiagnosis leads to some women getting treatment that’s not really needed\n(overtreatment), because the cancer never would have caused any problems. Doctors\ncan’t always tell which cancers could be life-threatening and which would never cause\nproblems. Because of this, they advise treating all breast cancers. This exposes some\nwomen to the side effects of cancer treatment, even t",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 36
  },
  {
    "text": "hough it wasn't really needed.\nStill, overdiagnosis isn't thought to happen very often. There’s a wide range of estimates\nof the percentage of breast cancers that might be overdiagnosed by mammography, but\nthe most credible estimates range from 1% to 10%.\nRadiation exposure\nBecause mammograms are x-ray tests, they expose the breasts to radiation. The\namount of radiation from each mammogram is low, but it can still add up over time. For\nmore on this, see Mammogram Basics.\nHyperlinks\n1. www.cancer",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 36
  },
  {
    "text": ".org/cancer/breast-cancer/about/types-of-breast-cancer/dcis.html\nReferences\nElmore JG, Barton MB, Moceri VM, Polk S, Arena PJ, Fletcher SW. Ten-year risk of\nfalse positive screening mammograms and clinical breast examinations. N Engl J Med.\n1998;338(16):1089.\nElmore JG, Lee CI. Screening for breast cancer: Evidence for effectiveness and harms.\nUpToDate. 2021. Accessed at https://www.uptodate.com/contents/screening-for-breast-\ncancer-evidence-for-effectiveness-and-harms on October 1, 2021.\nHubbar",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 36
  },
  {
    "text": "d RA, Kerlikowske K, Flowers CI, et al. Cumulative probability of false-positive\nrecall or biopsy recommendation after 10 years of screening mammography: A cohort\nstudy. Ann Intern Med 2011;155:481-492.\n36",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 36
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nLauby-Secretan B, Scoccianti C, Loomis D, et al. Breast-cancer screening--viewpoint of\nthe IARC Working Group. N Engl J Med. 2015;372(24):2353-2358.\nLee CI, Elmore JG. Chapter 10: Breast Cancer Screening. In: Harris JR, Lippman ME,\nMorrow M, Osborne CK, eds. Diseases of the Breast. 5th ed. Philadelphia, Pa:\nLippincott Williams & Wilkins; 2014.\nPuliti D, Duffey SW",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 37
  },
  {
    "text": ", Miccinesi G, et al. Overdiagnosis in mammographic screening for\nbreast cancer in Europe: A literature review. J Med Screen, 2012;19:Suppl 1:42-56.\nRosenberg RD, Hunt WC, Williamson MR, et al. Effects of age, breast density, ethnicity,\nand estrogen replacement therapy on screening mammographic sensitivity and cancer\nstage at diagnosis: Review of 183,134 screening mammograms in Albuquerque, New\nMexico. Radiology 1998; 209:511–518.\nVenkataraman S, Slanetz PJ, Lee CI. Breast imaging for cancer scr",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 37
  },
  {
    "text": "eening:\nMammography and ultrasonography. UpToDate. 2021. Accessed at\nhttps://www.uptodate.com/contents/breast-imaging-for-cancer-screening-\nmammography-and-ultrasonography on October 1, 2021.\nLast Revised: January 14, 2022\nMammograms After Breast Cancer\nSurgery\nNearly all women with breast cancer will have surgery at some point as part of their\ntreatment. There are many different kinds of breast cancer surgery1. The type of surgery\nyou have had will affect if you need to get mammograms in the fu",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 37
  },
  {
    "text": "ture:\nIf you have had breast-conserving surgery (BCS), you will still need to get\nl\nmammograms of the treated breast.\nIf you have had a mastectomy, you most likely won't need a mammogram of that\nl\nbreast.\nHowever, if you had surgery (of any type) on only one breast, you will still need to get\n37",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 37
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nmammograms of the other breast. This is very important, because women who have\nhad breast cancer have a higher risk of developing a new cancer in the other breast.\nWhile the American Cancer Society does not have specific guidelines for\nmammograms or other breast imaging in women who have been treated for\nbreast cancer, there is information available about what th",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 38
  },
  {
    "text": "ese women will probably\nneed to do.\nMammograms after breast-conserving surgery\nMost experts recommend that women who have had breast-conserving surgery2 (BCS,\nsometimes called a partial mastectomy or lumpectomy) get a mammogram of the\ntreated breast 6 to 12 months after radiation treatment ends. Surgery and radiation both\ncause changes in the skin and breast tissues that will show up on the mammogram,\nwhich might make it harder to read.\nThe mammogram done at this time serves as a new baseline fo",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 38
  },
  {
    "text": "r the affected breast.\nFuture mammograms will be compared with this one, to help the doctor check on\nhealing and look for signs that the cancer might have come back (recurred).\nFollow-up mammograms of the treated breast are typically done at least yearly after\nthat, but some doctors may recommend that you have mammograms more often. You\nwill still need to have routine mammograms on the other (untreated) breast as well.\nMammograms after mastectomy\nWomen who have had a mastectomy3 (including simpl",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 38
  },
  {
    "text": "e mastectomy, modified radical\nmastectomy, and radical mastectomy) to treat breast cancer should not need further\nroutine screening mammograms on that side, but will still need regular mammograms\non the remaining breast. If both breasts have been removed (a double or bilateral\nmastectomy), mammograms should no longer be needed because there shouldn't be\nenough breast tissue left to do a mammogram. Cancer might come back in the skin or\nchest wall on that side, but if this happens it is usually fo",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 38
  },
  {
    "text": "und by feeling it (either during a\nphysical exam or a breast self-exam).\nIt’s possible for women with reconstructed breasts to get mammograms, but experts\nagree that women who have breast reconstruction4 after a simple, modified radical, or\nradical mastectomy don’t need routine mammograms of the affected breast(s). Still, if\nan area of concern is found during a physical exam on a woman who has had breast\nreconstruction, a diagnostic mammogram and breast ultrasound may be done. Breast\nMRI may als",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 38
  },
  {
    "text": "o sometimes be used to look at the area closely if the mammogram and\n38",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 38
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nultrasound results aren't clear.\nFor women who have had a nipple-sparing mastectomy, also called a subcutaneous\nmastectomy, some doctors might recommend follow-up mammograms because some\nbreast tissue can be left behind under the nipple.\nIf you're not sure what type of mastectomy you had or if you need to get\nmammograms, be sure to ask your doctor.\nHyperlinks\n1. ",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 39
  },
  {
    "text": "www.cancer.org/cancer/breast-cancer/treatment/surgery-for-breast-cancer.html\n2. www.cancer.org/cancer/breast-cancer/treatment/surgery-for-breast-cancer/breast-\nconserving-surgery-lumpectomy.html\n3. www.cancer.org/cancer/breast-cancer/treatment/surgery-for-breast-\ncancer/mastectomy.html\n4. www.cancer.org/cancer/breast-cancer/reconstruction-surgery.html\nReferences\nKhatcheressian JL, Hurley P, Bantug E, Breast cancer follow-up and management after\nprimary treatment: American Society of Clinical Onc",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 39
  },
  {
    "text": "ology clinical practice guideline\nupdate. J Clin Oncol. 2013;31(7):961-965.\nNahabedian M. Overview of breast reconstruction. UpToDate. 2021. Accessed at\nhttps://www.uptodate.com/contents/overview-of-breast-reconstruction on October 4,\n2021.\nNational Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in\nOncology. Breast Cancer. Version 2.2021. Accessed at\nwww.nccn.org/professionals/physician_gls/pdf/breast.pdf on October 4, 2021.\nRuddy KJ, Partridge AH. Approach to the patient follow",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 39
  },
  {
    "text": "ing treatment for breast cancer.\nUpToDate. 2021. Accessed at https://www.uptodate.com/contents/approach-to-the-\npatient-following-treatment-for-breast-cancer on October 4, 2021.\nVenkataraman S, Slanetz PJ. Breast imaging for cancer screening: Mammography and\nultrasonography. UpToDate. 2021. Accessed at\nhttps://www.uptodate.com/contents/breast-imaging-for-cancer-screening-\nmammography-and-ultrasonography on October 4, 2021.\n39",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 39
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nLast Revised: January 14, 2022\nMammograms for Women with Breast\nImplants\nIf you have breast implants, you should still get regular screening mammograms as\nrecommended (unless you had both breasts removed with a bilateral mastectomy\nbefore getting the implants).\nIt’s important to tell the technologist you have implants before your mammogram is\nstarted. In fact, it",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 40
  },
  {
    "text": "’s best to mention this when you make the appointment to have your\nmammogram done. This way you can find out if the facility has experience doing\nmammograms in women with breast implants.\nYou should be aware that both silicone and saline implants can make it hard for the\ndoctor to see the breast tissue that is in line with them on the mammogram.\nTo help the doctor see as much breast tissue as possible, women with implants have 4\nextra pictures done (2 on each breast), as well as the 4 standard p",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 40
  },
  {
    "text": "ictures taken during a\nscreening mammogram. In these extra pictures, called implant displacement (ID)\nviews, the implant is pushed back against the chest wall and the breast is pulled\nforward over it and then compressed. This allows better imaging of the front part of each\nbreast so the doctor can get a better look at the breast tissue.\nImplant displacement views are harder to do and can be uncomfortable if areas of scar\ntissue (called contractures) have formed around the implants. ID views are ",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 40
  },
  {
    "text": "easier if the\nimplants were placed underneath (behind) the chest muscles.\nVery rarely, the mammogram process can rupture an implant. This is another important\nreason to make sure the mammography facility knows you have implants.\nReferences\nElmore JG, Lee CI. Screening for breast cancer: Strategies and recommendations.\n40",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 40
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nUpToDate. 2021. Accessed at https://www.uptodate.com/contents/screening-for-breast-\ncancer-strategies-and-recommendations on October 4, 2021.\nHelvie MA, Patterson SK. Chapter 11: Imaging Analysis: Mammography. In: Harris JR,\nLippman ME, Morrow M, Osborne CK, eds. Diseases of the Breast. 5th ed.\nPhiladelphia, Pa: Lippincott Williams & Wilkins; 2014.\nNahabedian M. ",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 41
  },
  {
    "text": "Implant-based breast reconstruction and augmentation. UpToDate.\n2021. Accessed at https://www.uptodate.com/contents/implant-based-breast-\nreconstruction-and-augmentation on October 4, 2021.\nLast Revised: January 14, 2022\nBreast Ultrasound\nBreast ultrasound uses sound waves and their echoes to make computer pictures of the\ninside of the breast. It can show certain breast changes, like fluid-filled cysts, that can\nbe harder to see on mammograms.\nWhen is breast ultrasound used?\nUltrasound is not ty",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 41
  },
  {
    "text": "pically used as a routine screening test for breast cancer. But it can\nbe useful for looking at some breast changes, such as lumps (especially those that can\nbe felt but not seen on a mammogram). Ultrasound can be especially helpful in women\nwith dense breast tissue, which can make it hard to see abnormal areas on\nmammograms. It also can be used to get a better look at a suspicious area that was\nseen on a mammogram.\nUltrasound is useful because it can often tell the difference between fluid-fill",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 41
  },
  {
    "text": "ed masses\nlike cysts1 (which are very unlikely to be cancer) and solid masses (which might need\nfurther testing to be sure they're not cancer).\nUltrasound can also be used to help guide a biopsy needle into an area of the breast so\nthat cells can be taken out and tested for cancer. This can also be done in swollen\nlymph nodes under the arm.\nUltrasound is widely available and is fairly easy to have done, and it does not expose a\n41",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 41
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nperson to radiation. It also tends to cost less than other testing options.\nHow is a breast ultrasound done?\nMost often, ultrasound is done using a handheld, wand-like instrument called\natransducer. First a gel is put on the skin and/or the transducer, and then the transducer\nis moved around over the skin. It sends out sound waves and picks up the echoes as\nthey ",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 42
  },
  {
    "text": "bounce off body tissues deeper under the skin. These echoes are made into a\npicture on a computer screen. You might feel some pressure as the transducer is\nmoved around on your skin, but it should not be painful.\nAutomated breast ultrasound (ABUS) is an option at some imaging centers. This\ntechnique uses a much larger transducer to take hundreds of images that cover nearly\nthe entire breast. ABUS might sometimes be done as an added screening exam for\nwomen who have dense breasts. It might also b",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 42
  },
  {
    "text": "e used in women who have abnormal\nfindings on other imaging tests or who have breast symptoms. When ABUS is done, a\nsecond handheld ultrasound is often needed to get more pictures of any suspicious\nareas.\nHow are breast ultrasound results reported?\nDoctors use the same standard system to describe results of mammograms, breast\nultrasound, and breast MRI. This system (called the Breast Imaging Reporting and\nData System or BI-RADS) sorts the results into categories numbered 0 through 6.\nBy sorting ",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 42
  },
  {
    "text": "the results into these categories, doctors can describe what they find on an\nultrasound using the same words and terms. This makes communicating about these\ntest results and following up after the tests much easier.\nFor more details on the BI-RADS categories, see Understanding Your Mammogram\nReport. While the categories are the same for each of these imaging tests, the\nrecommended next steps after these tests might be different.\nHyperlinks\n1. www.cancer.org/cancer/breast-cancer/non-cancerous-bre",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 42
  },
  {
    "text": "ast-conditions/fibrosis-\nand-simple-cysts-in-the-breast.html\nReferences\n42",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 42
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nAmerican College of Radiology. ACR BI-RADS ATLAS – Breast Ultrasound. Reporting\nSystem. 2013. Accessed at https://www.acr.org/-/media/ACR/Files/RADS/BI-RADS/US-\nReporting.pdf on November 29, 2021.\nEsserman LJ, Joe BN. Diagnostic evaluation of women with suspected breast cancer.\nUpToDate. 2021. Accessed at https://www.uptodate.com/contents/diagnostic-\nevaluation-o",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 43
  },
  {
    "text": "f-women-with-suspected-breast-cancer on October 11, 2021.\nNational Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in\nOncology. Breast Cancer Screening and Diagnosis. Version 1.2021. Accessed at\nhttps://www.nccn.org/professionals/physician_gls/pdf/breast-screening.pdf on October\n11, 2021.\nRella R, Belli P, Giuliani M, et al. Automated breast ultrasonography (ABUS) in the\nscreening and diagnostic setting: Indications and practical use. Acad Radiol.\n2018;25(11):1457-1470.\nSedgwick ",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 43
  },
  {
    "text": "EL. Chapter 12: Imaging Analysis: Ultrasonography. In: Harris JR, Lippman\nME, Morrow M, Osborne CK, eds. Diseases of the Breast. 5th ed. Philadelphia, Pa:\nLippincott Williams & Wilkins; 2014.\nVenkataraman S, Slanetz PJ, Lee CI. Breast imaging for cancer screening:\nMammography and ultrasonography. UpToDate. 2021. Accessed at\nhttps://www.uptodate.com/contents/breast-imaging-for-cancer-screening-\nmammography-and-ultrasonography on October 11, 2021.\nLast Revised: January 14, 2022\nBreast MRI\nBreast M",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 43
  },
  {
    "text": "RI (magnetic resonance imaging) uses radio waves and strong magnets to\nmake detailed pictures of the inside of the breast.\nWhen is breast MRI used?\nBreast MRI might be used in different situations.\n43",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 43
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nTo screen for breast cancer: For certain women at high risk for breast cancer, a\nscreening breast MRI is recommended along with a yearly mammogram. MRI is not\nrecommended as a screening test by itself, because it can miss some cancers that a\nmammogram would find.\nAlthough MRI can find some cancers not seen on a mammogram, it’s also more likely to\nfind things that",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 44
  },
  {
    "text": " turn out not to be cancer (called a false positive). This can result in some\nwomen getting tests and/or biopsies that end up not being needed. This is why MRI is\nnot recommended as a screening test for women at average risk of breast cancer.\nTo look at the breasts if someone has symptoms that might be from breast\ncancer: Breast MRI might sometimes be done if breast cancer is suspected (based on\nsymptoms or exam findings, such as suspicious nipple discharge). Other imaging tests\nsuch as mammogra",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 44
  },
  {
    "text": "ms and breast ultrasound are usually done first, but MRI might be\ndone if the results of these tests aren’t clear.\nTo help determine the extent of breast cancer: If breast cancer has already been\ndiagnosed, breast MRI is sometimes done to help determine the exact size and location\nof the cancer, to look for other tumors in the breast, and to check for tumors in the other\nbreast. Breast MRI isn’t always helpful in this setting, so not every woman who has\nbeen diagnosed with breast cancer needs th",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 44
  },
  {
    "text": "is test.\nTo check for silicone breast implant leaks: In women with silicone breast implants1,\nbreast MRI can be used to check for implant leaks. This isn’t used for women with\nsaline breast implants.\nWhat you need to know about getting a breast MRI\nJust as mammograms are done using x-ray machines specially designed for the\nbreasts, breast MRI also requires special equipment. This MRI machine has a special\ndevice called a dedicated breast coil to image the breasts. Not all hospitals and imaging\nc",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 44
  },
  {
    "text": "enters have dedicated breast MRI equipment. If you are having a breast MRI, it’s\nimportant to have it at a facility that has dedicated equipment and can do an MRI-guided\nbreast biopsy if needed, or a facility that partners with one that can.\nMRI uses strong magnets instead of radiation to make very detailed, cross-sectional\npictures of the body. An MRI scanner takes pictures from many angles, as if someone\nwere looking at a slice of your body from the front, from the side, or from above your\nhea",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 44
  },
  {
    "text": "d. MRI creates pictures of soft tissue parts of the body that would sometimes be\nhard to see using other imaging tests.\n44",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 44
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nUnlike mammograms or breast ultrasound, breast MRI requires that you have a contrast\ndye injected into your vein (through an IV line) before the pictures are taken. This helps\nmake any abnormal areas in your breasts easier to see.\nTips for getting ready for the test\nCheck with your insurance provider before getting an MRI: Breast MRI can cost a\nlot, and it may ne",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 45
  },
  {
    "text": "ed to be approved by your insurance company before the scan is\ndone. Most private insurance plans that pay for mammogram screening also pay for\nMRI as a screening test if a woman is shown to be at high risk. It might help to go to a\ncenter with a breast health or high-risk clinic, where the staff has experience getting\napproval for breast MRIs.\nFollow all instructions: You don’t usually need a special diet or preparation before an\nMRI, but follow any instructions you’re given.\nIf you have troubl",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 45
  },
  {
    "text": "e with enclosed spaces: Breast MRI is most often done while you\nare lying on your belly with your arms above your head inside a long, narrow tube. If\nbeing in a tight space might be a problem for you, you might need to take medicine to\nhelp you relax while in the scanner. Talking with the technologist or a patient counselor\nor getting a tour of the MRI machine before the test can also help. You’ll be in the exam\nroom alone during the test, but you can talk to the MR technologist, who can see and",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 45
  },
  {
    "text": "\nhear what’s going on.\nRemove metal objects: Before the test, you'll be asked to undress and put on a gown\nor other clothes without zippers or metal. Be sure to remove any metal objects you can,\nlike hair clips, jewelry, dental work, and body piercings.\nIf you have metal in your body: Before the scan, the technologist will ask you if you\nhave any metal in your body. Some metallic objects will not cause problems, but others\ncan.\nLet your technologist know if you have any medical implants or clips",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 45
  },
  {
    "text": " in your body. If you\nhave any of these types of medical implants, you should not even enter the MRI\nscanning area unless you're told it's OK to do so by a radiologist or technologist:\nAn implanted defibrillator or pacemaker\nl\nClips used on a brain aneurysm\nl\nA cochlear (ear) implant\nl\nMetal coils inside blood vessels\nl\n45",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 45
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nWhat’s it like to get a breast MRI?\nMRI scans are usually done in an outpatient setting in a hospital or clinic. You'll first\nhave an IV line placed a vein in your arm so that contrast material can be injected\nduring the test.\nYou’ll lie face down on a narrow, flat table with your arms above your head. Your\nbreasts will hang down into an opening in the table so t",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 46
  },
  {
    "text": "hey can be scanned without\nbeing compressed. The technologist may use pillows to make you comfortable and help\nkeep you from moving. The table then slides into a long, narrow tube.\nThe test is painless, but you have to lie still inside the narrow tube. You may be asked\nto hold your breath or keep very still during certain parts of the test. The machine may\nmake loud thumping, clicking, and whirring noises, much like the sound of a washing\n46",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 46
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nmachine, as the magnet switches on and off. Some facilities give you earplugs or\nheadphones to help block noise out during testing.\nWhen breast MRI is done to look for breast cancer, a contrast material called\ngadolinium is injected into a vein in the arm during the exam, which helps show any\nabnormal areas of breast tissue. (This is different from the contrast d",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 47
  },
  {
    "text": "ye used in CT\nscans.) Let the technologist know if you have any allergies or have had problems before\nwith any contrast or dye used in imaging tests.\nIt’s important to stay very still while the test is being done, which helps ensure the\nimages will be of good quality.\nEach set of images usually takes a few minutes, and the whole test usually takes about\n30 to 45 minutes. After the test, you may be asked to wait while the pictures are\nchecked to see if more are needed.\nFor a newer MRI technique, ",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 47
  },
  {
    "text": "known as abbreviated breast MRI, fewer images are taken,\nso the scan takes less time (usually about 10 minutes).\nHow are breast MRI results reported?\nDoctors use the same standard system to describe results of mammograms, breast\nultrasound, and breast MRI. This system (called the Breast Imaging Reporting and\nData System or BI-RADS) sorts the results into categories numbered 0 through 6.\nBy sorting the results into these categories, doctors can describe what they find on a\nbreast MRI using the sa",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 47
  },
  {
    "text": "me words and terms. This makes communicating about these\ntest results and following up after the tests much easier.\nFor more details on the BI-RADS categories, see Understanding Your Mammogram\nReport. While the categories are the same for each of these types of imaging tests, the\nrecommended next steps after these tests might be different.\nHyperlinks\n1. www.cancer.org/cancer/breast-cancer/reconstruction-surgery/breast-\nreconstruction-options/breast-reconstruction-using-implants.html\nReferences\n4",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 47
  },
  {
    "text": "7",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 47
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nAmerican College of Radiology. ACR BI-RADS ATLAS – Breast MRI. Reporting\nSystem. 2013. Accessed at https://www.acr.org/-/media/ACR/Files/RADS/BI-\nRADS/MRI-Reporting.pdf on November 29, 2021.\nEsserman LJ, Joe BN. Diagnostic evaluation of suspected breast cancer. UpToDate.\n2021. Accessed at https://www.uptodate.com/contents/diagnostic-evaluation-of-\nsuspected-breas",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 48
  },
  {
    "text": "t-cancer on October 11, 2021.\nGupta D, Mendelson EB, Karst I. Nipple discharge: Current clinical and imaging\nevaluation. Am J Roentgenol. 2021;216(2):330-339.\nNational Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in\nOncology. Breast Cancer. Version 8.2021. Accessed at\nhttps://www.nccn.org/professionals/physician_gls/pdf/breast.pdf on October 11, 2021.\nSlanetz PJ. MRI of the breast and emerging technologies. UpToDate. 2021. Accessed\nat https://www.uptodate.com/contents/mri-of-t",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 48
  },
  {
    "text": "he-breast-and-emerging-technologies on\nOctober 11, 2021.\nWeinstein SP, Roth SO. Chapter 12: Imaging Analysis: Magnetic Resonance Imaging.\nIn: Harris JR, Lippman ME, Morrow M, Osborne CK, eds. Diseases of the Breast. 5th\ned. Philadelphia, Pa: Lippincott Williams & Wilkins; 2014.\nLast Revised: January 14, 2022\nNewer and Experimental Breast Imaging\nTests\nThe most commonly used breast imaging tests at this time are mammograms,\nultrasound, and breast MRI. Other tests, such as CT scans, bone scans, or",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 48
  },
  {
    "text": " PET scans\nmight sometimes be done to help find out if breast cancer has spread1.\nNewer types of tests are now being developed for breast imaging. Some of these, such\nas breast tomosynthesis (3D mammography), are already being used in some centers.\nOther tests are still being studied, and it will take time to see if they are as good as or\nbetter than those used today.\n48",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 48
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nAbbreviated breast MRI (fast breast MRI)\nThis is a newer technique that is done with a standard breast MRI scanner. But fewer\nimages are taken (over a shorter period of time) than with a standard breast MRI. As\nwith standard breast MRI, a contrast material called gadolinium is given through an IV\nline before some of the images are taken. Abbreviated breast MRI is",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 49
  },
  {
    "text": " now being studied\nas a possible screening test for breast cancer, especially in women with dense breasts,\nto see if it provides the same information as a standard breast MRI.\nNuclear medicine tests (radionuclide imaging)\nFor these tests, a small amount of radioactive material (known as a tracer) is injected\ninto the blood. The tracer is more likely to collect in cancer cells. A special camera can\nthen be used to see the tracer in the breast (or other parts of the body).\nFor molecular breast ima",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 49
  },
  {
    "text": "ging (MBI), also known as scintimammography or breast-\nspecific gamma imaging (BSGI), a tracer called technetium-99m sestamibi is injected\ninto the blood, and a special camera is then used to see the tracer while the breast is\ngently compressed. This test is being studied mainly as a way to follow up breast\nproblems (such as a lump or an abnormal mammogram), or to help determine the\nextent of breast cancer that has already been diagnosed. It’s also being studied as a\nscreening test for use along",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 49
  },
  {
    "text": " with mammograms to look for cancer in women with dense\nbreasts. One potential drawback is that it exposes the whole body to radiation, so it’s\nunlikely this test would be used for screening every year.\nFor a positron emission tomography (PET) scan, a different type of radioactive tracer\nis injected into the blood. Standard PET scans, which use a form of radioactive sugar\n(known as FDG), are sometimes done if there's a concern that breast cancer might\nhave spread to other parts of the body. A ne",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 49
  },
  {
    "text": "wer type of tracer, known as\nfluoroestradiol F-18, is now available to look for the spread of some advanced\nestrogen receptor (ER)-positive breast cancers.\nPositron emission mammography (PEM) is a newer imaging test of the breast that\ncombines some aspects of a PET scan and a mammogram. PEM uses the same type\nof radioactive tracer injected into the blood as a PET scan. The breast is then lightly\ncompressed while the images are taken, as with a mammogram. PEM may be better\nable to detect small cl",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 49
  },
  {
    "text": "usters of cancer cells within the breast than standard\nmammography. This is because it takes into account how active the breast cells are, as\nopposed to just their structure. PEM is being studied mainly in women with breast\ncancer to see if it can help determine the extent of the cancer. PEM exposes the whole\nbody to radiation, so it isn't likely to be used every year for breast cancer screening.\n49",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 49
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nContrast-enhanced mammography (CEM)\nAlso known as contrast-enhanced spectral mammography (CESM), this is a newer\ntest in which a contrast dye containing iodine is injected into the blood a few minutes\nbefore two sets of mammograms (using different energy levels) are taken. The contrast\ncan help the x-rays show any abnormal areas in the breasts. This test can be u",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 50
  },
  {
    "text": "sed to\nget a better look at areas that appear abnormal on a standard mammogram, or to help\nassess the extent of a tumor in women just diagnosed with breast cancer. Studies are\nnow comparing it to breast MRI in these settings (where it might be particularly useful if\nMRI can't be done for some reason), as well as possibly for use in screening women\nwith dense breasts. If it proves to be as good as MRI, CEM could become more widely\nused because it is quicker to do and is less expensive than MRI.\nE",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 50
  },
  {
    "text": "lastography\nThis is a test that can be done as part of an ultrasound exam. It’s based on the idea that\nbreast cancer tumors tend to be firmer and stiffer than the surrounding breast tissue.\nFor this technique, the breast is compressed slightly, and the ultrasound can show how\nfirm a suspicious area is. This test might prove to be useful in telling if the area is more\nlikely to be cancer or a benign (non-cancerous) tumor.\nOptical imaging tests\nThese tests pass light into the breast and then measu",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 50
  },
  {
    "text": "re the light that returns or passes\nthrough the tissue. The technique does not use radiation and does not require breast\ncompression. Early studies going on now are looking at combining optical imaging with\nother tests like MRI, ultrasound, or 3D mammography to help look for breast cancer.\nElectrical impedance tomography (EIT)\nEIT is based on the idea that breast cancer cells conduct electricity differently from\nnormal cells. For this test, small electrodes are taped to the skin to pass very sma",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 50
  },
  {
    "text": "ll\nelectrical currents through the breast and then detect them on the skin. EIT does not\nuse radiation or compress the breasts. This test might prove to be useful in helping to\nclassify tumors found on mammograms. But so far there hasn’t been enough clinical\ntesting to show if it's useful for breast cancer screening.\nHyperlinks\n1. www.cancer.org/cancer/breast-cancer/understanding-a-breast-cancer-\n50",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 50
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\ndiagnosis/tests-to-find-out-if-breast-cancer-has-spread.html\nReferences\nBruening W, Uhl S, Fontanarosa J, et al. Noninvasive Diagnostic Tests for Breast\nAbnormalities: Update of a 2006 Review [Internet]. Rockville (MD): Agency for\nHealthcare Research and Quality (US); 2012 Feb. Accessed at\nwww.ncbi.nlm.nih.gov/books/NBK84530/ on October 13, 2021.\nCaldarella C, Tr",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 51
  },
  {
    "text": "eglia G, Giordano A. Diagnostic performance of dedicated positron\nemission mammography using fluorine-18-fluorodeoxyglucose in women with\nsuspicious breast lesions: A meta-analysis. Clin Breast Cancer. 2014;14(4):241-248.\nComstock CE, Gatsonis C, Newstead GM, et al. Comparison of abbreviated breast MRI\nvs digital breast tomosynthesis for breast cancer detection among women with dense\nbreasts undergoing screening. JAMA. 2020;323(8):746-756.\nJochelson MS. Chapter 12: Imaging Analysis: New Breast I",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 51
  },
  {
    "text": "maging Techniques. In:\nHarris JR, Lippman ME, Morrow M, Osborne CK, eds. Diseases of the Breast. 5th ed.\nPhiladelphia, Pa: Lippincott Williams & Wilkins; 2014.\nLee CI, Elmore JG. Chapter 10: Breast Cancer Screening. In: Harris JR, Lippman ME,\nMorrow M, Osborne CK, eds. Diseases of the Breast. 5th ed. Philadelphia, Pa:\nLippincott Williams & Wilkins; 2014.\nNational Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in\nOncology. Breast Cancer. Version 8.2021. Accessed at\nhttps://www.nc",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 51
  },
  {
    "text": "cn.org/professionals/physician_gls/pdf/breast.pdf on October 13, 2021.\nPerry H, Phillips J, Dialani V, et al. Contrast-enhanced mammography: A systematic\nguide to interpretation and reporting. AJR Am J Roentgenol. 2019;212(1):222-231.\nRhodes DJ, Hruska CB, Phillips SW, Whaley DH, O'Connor MK. Dedicated dual-head\ngamma imaging for breast cancer screening in women with mammographically dense\nbreasts. Radiology. 2011;258(1):106-118.\nSlanetz PJ. MRI of the breast and emerging technologies. UpToDate.",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 51
  },
  {
    "text": " 2021. Accessed\nat https://www.uptodate.com/contents/mri-of-the-breast-and-emerging-technologies on\nOctober 13, 2021.\n51",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 51
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nWeigert JM, Bertrand ML, Lanzkowsky L, Stern LH, Kieper DA. Results of a multicenter\npatient registry to determine the clinical impact of breast-specific gamma imaging, a\nmolecular breast imaging technique. AJR Am J Roentgenol. 2012;198(1):W69-75.\nLast Revised: January 14, 2022\nBreast Cancer Signs and Symptoms\nKnowing how your breasts normally look and feel is an",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 52
  },
  {
    "text": " important part of your breast\nhealth. Although having regular screening tests for breast cancer is important,\nmammograms do not find every breast cancer. This means it's also important for you to\nknow what your breasts normally look and feel like, so you’ll be aware of any changes in\nyour breasts.\nThe most common symptom of breast cancer is a new lump or mass (although most\nbreast lumps are not cancer). A painless, hard mass that has irregular edges is more\nlikely to be cancer, but breast cance",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 52
  },
  {
    "text": "rs can be also soft, round, tender, or even painful.\nOther possible symptoms of breast cancer include:\nSwelling of all or part of a breast (even if no lump is felt)\nl\nSkin dimpling (sometimes looking like an orange peel)\nl\nBreast or nipple pain\nl\nNipple retraction (turning inward)\nl\nNipple or breast skin that is red, dry, flaking, or thickened\nl\nNipple discharge (other than breast milk)\nl\nSwollen lymph nodes under the arm or near the collar bone (Sometimes this\nl\ncan be a sign of breast cancer s",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 52
  },
  {
    "text": "pread even before the original tumor in the breast\nis large enough to be felt.)\nMany of these symptoms can also be caused by benign (non-cancerous) breast\nconditions1. Still, it’s important to have any new breast mass, lump, or other\nchange checked by an experienced health care professional so the cause can be\nfound and treated, if needed.\nRemember that knowing what to look for does not take the place of having regular\n52",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 52
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nscreening for breast cancer.Screening mammography can often help find breast cancer\nearly, before any symptoms appear. Finding breast cancer early gives you a better\nchance of successful treatment.\nHyperlinks\n1. www.cancer.org/cancer/breast-cancer/non-cancerous-breast-conditions.html\nReferences\nHenry NL, Shah PD, Haider I, et al. Chapter 88: Cancer of the Breast.",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 53
  },
  {
    "text": " In: Niederhuber\nJE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE, eds. Abeloff’s Clinical\nOncology. 6th ed. Philadelphia, Pa: Elsevier; 2020.\nMorrow M. Chapter 3: Physical Exam of the Breast. In: Harris JR, Lippman ME, Morrow\nM, Osborne CK, eds. Diseases of the Breast. 5th ed. Philadelphia: Wolters Kluwer\nHealth; 2014.\nNational Cancer Institute. Physician Data Query (PDQ). Breast Cancer Treatment\n(Adult) – Patient Version. 2021. Accessed at\nhttps://www.cancer.gov/types/breast/patient/breast-t",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 53
  },
  {
    "text": "reatment-pdq on October 13, 2021.\nSabel MS. Clinical manifestations, differential diagnosis, and clinical evaluation of a\npalpable breast mass. UpToDate. 2021. Accessed at\nhttps://www.uptodate.com/contents/clinical-manifestations-differential-diagnosis-and-\nclinical-evaluation-of-a-palpable-breast-mass on October 13, 2021.\nLast Revised: January 14, 2022\nBreast Biopsy\nIf breast symptoms or the results of an imaging test (such as a mammogram) suggest\nyou might have breast cancer, you may need a br",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 53
  },
  {
    "text": "east biopsy. During a biopsy, a doctor\nremoves small pieces of breast tissue from the suspicious area so they can be looked at\nin the lab to see if they contain cancer cells.\n53",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 53
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nNeeding a breast biopsy doesn’t necessarily mean you have cancer. Most biopsy\nresults are not cancer, but a biopsy is the only way to find out for sure.\nTypes of breast biopsies\nThere are different kinds of breast biopsies. Some are done using a hollow needle, and\nsome use an incision (cut in the skin). The type you have depends on a number of\nthings, like:\nHow s",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 54
  },
  {
    "text": "uspicious the breast change looks or feels\nl\nHow big it is\nl\nWhere it is in the breast\nl\nIf there is more than one suspicious area\nl\nYour overall health\nl\nYour personal preferences\nl\nMost of the time, a needle biopsy (rather than a surgical biopsy) can be done. Ask your\ndoctor which type of biopsy you will have and what you can expect during and after the\nprocedure.\nFine needle aspiration (FNA)\nFor a fine needle aspiration (FNA), a very thin, hollow needle attached to a syringe is\nused to withdr",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 54
  },
  {
    "text": "aw (aspirate) a small amount of tissue or fluid from a suspicious area.\nCore needle biopsy\nA core needle biopsy (CNB) uses a larger hollow needle to sample breast changes felt\nby the doctor or seen on an ultrasound, mammogram, or MRI. This is often the\npreferred type of biopsy if breast cancer is suspected.\nSurgical (open) biopsy\nIn rare cases, surgery is needed to remove all or part of the lump for testing. This is\ncalled a surgical or open biopsy. Most often, the surgeon removes the entire mas",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 54
  },
  {
    "text": "s or\nabnormal area as well as a surrounding margin of normal breast tissue.\nLymph node biopsy1\nThis type of biopsy might be done to check the lymph nodes under the arm for cancer\nspread. This might be done at the same time as a biopsy of the breast tumor, or when\n54",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 54
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nthe breast tumor is removed during surgery. Checking the lymph nodes can be done by\ncore needle biopsy, or with a sentinel lymph node biopsy (SLNB) and/or an axillary\nlymph node dissection.\nRegardless of which type of biopsy you have, the biopsy samples will be sent to a lab\nwhere a doctor called a pathologist will look at them. It typically will take at least a ",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 55
  },
  {
    "text": "few\ndays for you to find out the results.\nQuestions to Ask Before a Breast Biopsy\nIt’s important to ask questions if there’s anything you’re not sure about. Here you can\nfind a detailed list of questions to ask your doctor before getting a breast biopsy.\nIf the doctor doesn't think you need a biopsy, but you still feel there’s something wrong\nwith your breast, follow your instincts. Don’t be afraid to talk to the doctor about this or\ngo to another doctor for a second opinion2. If possible, try t",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 55
  },
  {
    "text": "o see someone who\nspecializes in breast health to discuss your concerns. A biopsy is the only sure way to\ndiagnose breast cancer.\nHyperlinks\n1. www.cancer.org/cancer/breast-cancer/treatment/surgery-for-breast-cancer/lymph-\nnode-surgery-for-breast-cancer.html\n2. www.cancer.org/treatment/treatments-and-side-effects/choosing-your-treatment-\nteam/seeking-a-second-opinion.html\nLast Revised: January 14, 2022\nFine Needle Aspiration (FNA) of the\nBreast\nDuring a fine needle aspiration (FNA), a small amou",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 55
  },
  {
    "text": "nt of breast tissue or fluid is\nremoved from a suspicious area with a thin, hollow needle and checked for cancer cells.\nThis type of biopsy is sometimes an option if other tests show you might have breast\ncancer (although a core needle biopsy is often preferred). lt might also be used in other\nsituations.\n55",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 55
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nWhat is an FNA of the breast?\nIn an FNA, the doctor uses a very thin, hollow needle attached to a syringe to withdraw\n(aspirate) a small amount of breast tissue or fluid from a suspicious area.\nFNA is most often done if the suspicious area is likely to be a fluid-filled sac (a cyst1). By\nremoving fluid, the FNA can often help relieve pain from the cyst. FNA can a",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 56
  },
  {
    "text": "lso be\nhelpful if the doctor is unsure if an area seen on an imaging test is a small cyst or a solid\nmass.\nIf the area to be biopsied can be felt, the needle can be guided into it while the doctor is\nfeeling it.\n56",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 56
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nIf the lump can't be felt easily, the doctor might watch the needle on an ultrasound\nscreen as it moves toward and into the area. This is called an ultrasound-guided FNA.\nIf an FNA is done to test a suspicious area in the breast, the sample is then checked for\ncancer cells. One drawback of FNA is that it only removes a small amount of tissue and\ncells, so the sam",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 57
  },
  {
    "text": "ple usually needs to be checked right away under a microscope to\nmake sure more samples don’t need to be taken.\nWhat should you expect if you have an FNA?\n57",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 57
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nDuring an FNA\nAn FNA is an outpatient procedure most often done in the doctor’s office. Your doctor\nmight use a numbing medicine (called a local anesthetic), but it's not needed in all\ncases. This is because the needle used for the biopsy is so thin that getting an\nanesthetic might hurt more than the biopsy itself.\nYou’ll lie on your back for the FNA, and you wil",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 58
  },
  {
    "text": "l have to be still while it’s being done.\nIf ultrasound is used, you may feel some pressure from the ultrasound wand and as the\nneedle is put in. Once the needle is in the right place, the doctor will use the syringe to\npull out a small amount of tissue and/or fluid. This might be repeated a few times. Once\nthe procedure is done, the area is covered with a sterile dressing or bandage.\nGetting each biopsy sample usually takes about 15 seconds. The entire procedure from\nstart to finish generally t",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 58
  },
  {
    "text": "akes around 20 to 30 minutes if ultrasound is used.\nAfter an FNA\nYour doctor or nurse will tell you how to care for the area where the biopsy was done\nand what you can and can’t do while it heals. You might be told to limit strenuous\nactivity for a day or so, but you should be able to go back to your usual activities after\nthat.\nBiopsies can sometimes cause bleeding, bruising, or swelling. This can make it seem\nlike a breast lump is larger after the biopsy. Most often, this is nothing to worry a",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 58
  },
  {
    "text": "bout,\nand the bruising and swelling will go away over time. Your doctor or nurse will give you\ninstructions on what to watch for and when you should call the office.\nWhat does an FNA show?\nA doctor called a pathologist will look at the biopsy tissue or fluid to find out if there are\ncancer cells in it.\nThe main advantages of FNA are that it is fairly quick, it often doesn't require\nanesthesia, and the skin doesn’t have to be cut, so no stitches are needed and there is\nusually no scar. Also, in s",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 58
  },
  {
    "text": "ome cases it’s possible to get the results the same day.\nHowever, an FNA can sometimes miss a cancer if the needle does not go into the\ncancer cells, or if it doesn't remove enough cells. Even if an FNA does find cancer, it\nmight not remove enough cancer cells to do some of the other lab tests that are\n58",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 58
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nneeded.\nIf the results of the FNA biopsy do not give a clear diagnosis, or if your doctor still has\nconcerns, you might need a more extensive type of biopsy, such as a core needle\nbiopsy or a surgical (open) biopsy.\nHyperlinks\n1. www.cancer.org/cancer/breast-cancer/non-cancerous-breast-conditions/fibrosis-\nand-simple-cysts-in-the-breast.html\nReferences\nJoe BN, Es",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 59
  },
  {
    "text": "serman LJ. Breast Biopsy. 2021. UpToDate. Accessed at\nwww.uptodate.com/contents/breast-biopsy on October 14, 2021.\nRadiological Society of North America. Ultrasound-Guided Breast Biopsy. 2021.\nAccessed at https://www.radiologyinfo.org/en/info/breastbius on October 14, 2021.\nLast Revised: January 14, 2022\nCore Needle Biopsy of the Breast\nIf exams or imaging tests show you might have breast cancer, your doctor might refer\nyou for a core needle biopsy (CNB) to help find out for sure. This is often ",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 59
  },
  {
    "text": "the preferred\ntype of biopsy if breast cancer is suspected, because it removes more breast tissue\nthan a fine needle aspiration (FNA), but it doesn't require surgery.\nDuring this procedure, the doctor uses a hollow needle to take out pieces of breast\ntissue from the area of concern. This can be done with the doctor either feeling the area\nor while using an imaging test to guide the needle.\nWhat is a core needle biopsy?\nFor a CNB, the doctor uses a hollow needle to take out pieces of breast tissu",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 59
  },
  {
    "text": "e from a\n59",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 59
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nsuspicious area the doctor has felt on exam or has seen on an imaging test. The needle\nmay be attached to a spring-loaded tool that moves the needle in and out of the tissue\nquickly, or it may be attached to a suction device that helps pull breast tissue into the\nneedle (known as a vacuum-assisted core biopsy).\nA small cylinder (core) of tissue is taken out in th",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 60
  },
  {
    "text": "e needle. Several cores are often\nremoved.\nThe doctor might put the needle into the abnormal area by feeling the lump. But usually\nsome type of imaging test is used to guide the needle into the right place. Some of the\nimaging tests a doctor may use include:\nMammogram (or breast tomosynthesis) (known as a stereotactic biopsy)\nl\nUltrasound\nl\n60",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 60
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nMRI\nl\nThe type of imaging test used to guide the biopsy depends on which test can best see\nthe abnormal area, as well as which is most comfortable for the patient.\nWhat should you expect if you have a CNB?\nDuring the CNB\nA CNB is most often done as an outpatient procedure, such as in a doctor’s office.\nTheprocedure itself is usually fairly quick, though it may ta",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 61
  },
  {
    "text": "ke more time if imaging tests\nare needed or if one of the special types of CNB described below is used.\nIf your biopsy is done using image guidance, you may be sitting up, lying flat or on your\nside, or lying face down on a special table with openings for your breasts to fit into. This\ndepends on which type of imaging (mammography, ultrasound, or MRI) is done. You\nwill have to be still while the biopsy is done.\nFor any type of CNB, a thin needle will be used first to put numbing medicine (local\n",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 61
  },
  {
    "text": "anesthesia) into the area to be biopsied. Sometimes a small cut (about ¼ inch) is then\nmade in the breast. The biopsy needle is put into the breast tissue through this cut to\nremove the tissue sample. You might feel pressure as the needle goes in. Again, an\nimaging test may be used to guide the needle to the right spot.\nTypically, a tiny tissue marker (also called a clip) is put into the area where the biopsy\nis done. This marker will show up on mammograms or other imaging tests so the exact\nare",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 61
  },
  {
    "text": "a can be located for further treatment (if needed) or follow up. You can’t feel or see\nthe marker. It can stay in place and is safe during MRIs, and it will not set off metal\ndetectors.\nOnce the tissue is removed, the needle is taken out. Stitches aren't usually needed, but\npressure may be applied for a short time to help limit bleeding. The area is then covered\nwith a sterile dressing.\nFor more on what it's like to have each type of CNB, see \"Types of image-guided core\nneedle biopsies\" below.\nA",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 61
  },
  {
    "text": "fter the CNB\nYou might be told to limit strenuous activity for a day or so, but you should be able to go\n61",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 61
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nback to your usual activities after that. Your doctor or nurse will give you instructions on\nthis.\nA CNB can cause some bleeding, bruising, or swelling. This can make it seem like the\nbreast lump is larger after the biopsy. Most often, this is nothing to worry about, and any\nbruising or swelling will go away over time. Your doctor or nurse will tell you how to ca",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 62
  },
  {
    "text": "re\nfor the biopsy site and when you might need to contact them if you’re having any issues.\nA CNB usually doesn’t leave a scar.\nTypes of image-guided core needle biopsies\nThere are 3 main types of image-guided biopsies:\nStereotactic (mammogram- or tomosynthesis-guided)\nl\nUltrasound-guided\nl\nMRI-guided\nl\nThe type of image-guided biopsy that is best for you will depend on which type of\nimaging test will show the abnormal area best, as well as your comfort.\nStereotactic (mammogram- or tomosynthesis",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 62
  },
  {
    "text": "-guided) core needle biopsy\nFor this procedure, a doctor uses mammogram pictures taken from different angles to\npinpoint the biopsy site. A computer analyzes the breast x-rays and shows where the\nneedle tip needs to go in the abnormal area. This type of biopsy is often used to check\nsuspicious microcalcifications (tiny calcium deposits) or small masses or other abnormal\nareas that can’t be seen clearly on an ultrasound.\nYou may be sitting up, lying on your side, or lying on your belly with your ",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 62
  },
  {
    "text": "breast hanging\nthrough a hole in the table for this procedure.\nThe breast will be positioned in the mammography machine and compressed, and an\nimage will be taken to make sure the area in question can still be seen. The breast is\nthen cleaned, and numbing medicine (local anesthesia) is given. The biopsy device is\nplaced into the breast, and more images are taken to confirm that the device is in the\ncorrect spot to take samples. Several biopsy samples are then taken.\nAfterwards, the device is rem",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 62
  },
  {
    "text": "oved from the breast, and a biopsy marker (clip) is placed\nin the area. Another mammogram is then done to confirm the marker is in the right\nplace.\n62",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 62
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nUltrasound-guided core needle biopsy\nFor this procedure, a doctor uses breast ultrasound to view the area that needs to be\nbiopsied. Typically this is done while you are lying down or slightly on your side, with\nyour arm above your head.\nAn ultrasound is done first to view the area. Then the skin is cleaned and numbing\nmedicine (local anesthesia) is injected. Ult",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 63
  },
  {
    "text": "rasound is then used to guide the needle into\nthe correct area. You might feel pressure as the needle goes in. Several biopsy\nsamples are usually taken.\nA biopsy marker (clip) is placed in the area of the biopsy. Most often, a mammogram is\ndone after the biopsy to confirm the clip is in the right place.\nMRI-guided core needle biopsy\nFor this procedure, a doctor uses breast MRI to locate and biopsy the suspicious area.\nThis is most often done when something is seen on a breast MRI that is unlikel",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 63
  },
  {
    "text": "y to be\nseen on mammogram or ultrasound. As with a breast MRI, you will be asked to lie on\nyour belly on the MRI table with your arms above your head. However, the breast will be\ncompressed during the procedure.\nThe table will slide into the MRI scanner and images will be taken. Then you’ll be given\ncontrast through an IV line (which can help make the abnormal area easier to see), and\nmore images will be taken.\nOnce the suspicious area has been located, the skin is cleaned and numbing medicine\n(",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 63
  },
  {
    "text": "local anesthesia) is injected into the area. The biopsy device is then gently inserted into\nthe breast. It’s normal to feel pressure while this is being done.\nMore MRI images will then be taken to confirm to that the device is in the correct spot to\ntake samples. Several biopsy samples are then taken, and the device is removed from\nthe breast.\nA biopsy marker (clip) is then placed in the area of the biopsy. Most often, a\nmammogram is done after the biopsy to confirm the clip is in the right plac",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 63
  },
  {
    "text": "e.\nWhat does a CNB show?\nA doctor called apathologist will look at the biopsy tissue and/or fluid to check if there\nare cancer cells in it. A CNB is likely to clearly show if cancer is present (and often\n63",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 63
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nprovides enough of a sample if other lab tests are needed), but it can still miss some\ncancers.\nAsk your doctor when you can expect to get the results of your biopsy. If the results of\nthe CNB do not give a clear diagnosis, or if your doctor still has concerns, you might\nneed to have a second CNB or a more extensive type of biopsy, such as a surgical\n(open) biops",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 64
  },
  {
    "text": "y.\nReferences\nJoe BN, Esserman LJ. Breast Biopsy. 2021. UpToDate. Accessed at\nwww.uptodate.com/contents/breast-biopsy on October 14, 2021.\nRadiological Society of North America. Stereotactic Breast Biopsy. 2021. Accessed\nat https://www.radiologyinfo.org/en/info/breastbixr on October 14, 2021.\nRadiological Society of North America. Ultrasound-Guided Breast Biopsy. 2021.\nAccessed at https://www.radiologyinfo.org/en/info/breastbius on October 14, 2021.\nSung JS, Comstock CE. Chapter 15: Image-Guided",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 64
  },
  {
    "text": " Biopsy of Nonpalpable Breast\nLesions. In: Harris JR, Lippman ME, Morrow M, Osborne CK, eds. Diseases of the\nBreast. 5th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2014.\nLast Revised: January 14, 2022\nSurgical Breast Biopsy\nIf exams or imaging tests show you might have breast cancer, your doctor may refer\nyou for a breast biopsy to help find out for sure. Most often this will be a core needle\nbiopsy (CNB) or a fine needle aspiration (FNA). But in some situations, such as if the\nresults",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 64
  },
  {
    "text": " of a needle biopsy aren’t clear, you might need a surgical biopsy (sometimes\ncalled an open biopsy).\nWhat is a surgical biopsy?\n64",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 64
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nFor this type of biopsy, surgery is used to remove all or part of a suspicious area so it\ncan be checked for cancer cells.\nThere are 2 types of surgical biopsies:\nAn incisional biopsy removes only part of the abnormal area.\nl\nAn excisional biopsy removes the entire tumor or abnormal area. An edge\nl\n(margin) of normal breast tissue around the tumor may be removed ",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 65
  },
  {
    "text": "as well,\ndepending on the reason for the biopsy.\nPreoperative localization to guide surgical biopsy\nIf the change in your breast can be felt, the surgeon can do the biopsy using their sense\nof touch as a guide.\nBut if the change can’t be felt and/or is hard to find, an imaging test such as a\nmammogram, ultrasound, or MRI may be done before the surgery to help place a wire\nor other localizing device (such as a radioactive or magnetic seed, or a radiofrequency\nreflector) into the suspicious area. ",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 65
  },
  {
    "text": "This can help guide the surgeon the right spot. This\nis called preoperative localization.\nFor wire localization, your breast is numbed, and an imaging test is used to guide a\nthin, hollow needle into the abnormal area. Once the tip of the needle is in the right spot,\na thin wire is put in through the center of the needle. A small hook at the end of the wire\nkeeps it in place, while the other end of the wire remains outside of the breast. The\nneedle is then taken out. You then go to the operating",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 65
  },
  {
    "text": " room with the wire in your breast.\nThe surgeon uses the wire as a guide to the area to be removed. When this method is\nused, it is done the same day as your surgery.\nIn newer methods of localization, a localizing device is put into the suspicious area\nbefore the day of your surgery, so you don’t have to have it done the morning of your\noperation. Radioactive or magnetic seeds (tiny pellets that give off a very small amounts\nof radiation or that create small magnetic fields) or radiofrequency re",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 65
  },
  {
    "text": "flectors (small\ndevices that give off a signal that can be picked by a device held over the breast) can\nbe placed completely inside the breast (unlike the wire used for localization). Your\nsurgeon can then find the suspicious area by using a handheld detector in the operating\nroom.\nWhat to expect if you have a surgical biopsy\n65",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 65
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nDuring a surgical biopsy\nRarely, a surgical biopsy might be done in the doctor's office. But most often it's done in\na hospital’s outpatient department or a surgical center. You are typically given local\nanesthesia (numbing medicine), along with intravenous (IV) sedation to make you\ndrowsy. Another option is to have the biopsy done under general anesthesia (where",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 66
  },
  {
    "text": "\nyou’re given medicine to put you in a deep sleep and not feel pain).\nThe skin of the breast is cut, and the doctor removes the suspicious area. You will likely\nneed stitches after a surgical biopsy, and pressure may be applied for a short time to\nhelp limit bleeding. The area is then covered with a sterile dressing.\nAfter a surgical biopsy\nThe biopsy can cause bleeding, bruising, or swelling. This can make it seem like the\nbreast is larger after the biopsy. Most often, this is nothing to worry ",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 66
  },
  {
    "text": "about, and the\nbruising and swelling will go away over time. Your doctor or nurse will tell you how to\ncare for the biopsy site, how much (and for how long) you might need to limit your\nactivities, and when you might need to contact them if you’re having any issues.\nA surgical biopsy may leave a scar. You might also notice a change in the shape of your\nbreast, depending on how much breast tissue is removed.\nWhat does a surgical biopsy show?\nA doctor called a pathologist will look at the biopsy t",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 66
  },
  {
    "text": "issue under a microscope to check\nit for cancer cells.\nAsk your doctor when you can expect to get the results of your biopsy. The next steps\nwill depend on the biopsy results.\nIf no cancer cells are found in the biopsy, your doctor will talk to you about whether any\nother tests are needed, as well as when you need to have your next mammogram and\nany other follow-up visits.\nIf breast cancer is found, other lab tests might be done on the tissue to learn more\nabout the cancer and how best to treat ",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 66
  },
  {
    "text": "it. Your doctor will talk to you about these tests\nand about what the next steps will be. You might need to see other doctors, too. For\nmore on this, see Understanding a Breast Cancer Diagnosis1.\nHyperlinks\n66",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 66
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\n1. www.cancer.org/cancer/breast-cancer/understanding-a-breast-cancer-\ndiagnosis.html\nReferences\nChagpar AB. Techniques to reduce positive margins in breast-conserving surgery.\n2021. UpToDate. Accessed at www.uptodate.com/contents/techniques-to-reduce-\npositive-margins-in-breast-conserving-surgery on October 14, 2021.\nJoe BN, Esserman LJ. Breast Biopsy. 2021. UpTo",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 67
  },
  {
    "text": "Date. Accessed at\nwww.uptodate.com/contents/breast-biopsy on October 14, 2021.\nLast Revised: January 14, 2022\nQuestions to Ask Before a Breast\nBiopsy\nThere are different types of breast biopsies. It's important to understand the type of\nbiopsy you’ll have and what you can expect during and after the biopsy.\nHere are some questions you might want to ask before having a breast biopsy:\nWhat type of biopsy do you think I need? Why?\nl\nWill the size of my breast affect the way the biopsy is done?\nl\nWh",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 67
  },
  {
    "text": "ere will the biopsy be done?\nl\nWhat exactly will you do?\nl\nHow much breast tissue will you remove?\nl\nHow long will it take?\nl\nWill I be awake or asleep during the biopsy?\nl\nWill the biopsy area be numbed?\nl\nIf you can’t feel the abnormal area in my breast, how will you find it?\nl\nIf you are using a guide wire to help find the abnormal area, how will you make sure\nl\nit’s in the right place (with ultrasound or a mammogram)?\n67",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 67
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nWill I need someone to help me get home afterward?\nl\nWill I have a hole there afterward? Will it show?\nl\nWill my breast have a different shape or look different afterward?\nl\nWill you put a clip or marker in my breast? If so, what will happen to it?\nl\nWill I have a scar? Where will it be? What will it look like?\nl\nWill I have bruising or changes in the color of my",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 68
  },
  {
    "text": " skin? If so, how long will it last?\nl\nWill I be sore? If so, how long will it last?\nl\nMight I have any other types of problems after the biopsy? Are there any I'd need to\nl\ncall your office about?\nWhen can I take off the bandage?\nl\nWhen can I take a shower or bath?\nl\nWill I have stitches? Will they dissolve or will I need to come back to the office and\nl\nhave them removed?\nWhen can I go back to work? How will I feel when I do?\nl\nDo I need to limit activities like lifting things or raising my ar",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 68
  },
  {
    "text": "m? If so, for how long?\nl\nHow soon will we know the biopsy results?\nl\nShould I call you or will you call me with the results?\nl\nWill you or someone else explain the biopsy results to me?\nl\nLast Revised: January 14, 2022\nFinding Breast Cancer During\nPregnancy\nBreast cancer during pregnancy isn't common. But if you find a lump or notice any\nchanges in your breasts that concern you, tell your doctor or nurse right away. There\nare a variety of tests a pregnant woman can have if breast cancer is susp",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 68
  },
  {
    "text": "ected. And\nthere are options for treating breast cancer if you are pregnant1.\nIf you are pregnant and breast cancer is found, it may be called gestational breast\ncancer or pregnancy-associated breast cancer (PABC).\nHow common is breast cancer during pregnancy?\n68",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 68
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nBreast cancer is found in about 1 in every 3,000 pregnant women. It is the most\ncommon type of cancer found during pregnancy.\nBreast cancers can be harder to find when you’re pregnant\nChanges in hormone levels during pregnancy cause the breasts to change. The breasts\nmay become larger, lumpy, and/or tender. This can make it harder for you or your\ndoctor to notice",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 69
  },
  {
    "text": " a lump caused by cancer until it gets quite large.\nAnother reason it may be hard to find breast cancers early during pregnancy is that\nmany women put off breast cancer screening with mammograms until after the\npregnancy. Even when women do get mammograms, pregnancy and breastfeeding can\nmake breast tissue denser, which can make it harder to see an early cancer on a\nmammogram.\nBecause of these challenges, when a pregnant woman develops breast cancer, it’s\noften diagnosed at a later stage than it",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 69
  },
  {
    "text": " usually is in women who are not pregnant. For\nexample, it’s more likely to have already spread to lymph nodes.\nWhat to look for\nIf you find a lump or other changes in your breasts that concern you, don’t ignore them.\nTell your doctor or nurse right away. Any suspicious breast changes should be checked\nout or even biopsied (see below) before assuming they are a normal response to\npregnancy.\nAlong with a clinical breast exam, several types of imaging tests can be used to look for\nbreast abnormali",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 69
  },
  {
    "text": "ties, if needed. Typically a breast ultrasound and/or mammogram can\nbe done. A breast biopsy (removing a piece of the abnormal area to check it for cancer\ncells) is often another option, especially if imaging tests show a suspicious finding. (See\nbelow.)\nAre mammograms and other imaging tests safe during pregnancy?\nA main concern with any imaging test during pregnancy is whether it exposes the\ndeveloping fetus to radiation, which could be harmful, especially during the first\ntrimester.\nMammogram",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 69
  },
  {
    "text": "s can find most breast cancers that start when a woman is pregnant, and\nit’s generally thought to be safe to have a mammogram during pregnancy. The amount\n69",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 69
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nof radiation needed for a mammogram is small, and the radiation is focused on the\nbreasts, so most of it doesn’t reach other parts of the body. For extra protection, a lead\nshield is placed over the lower part of the belly to help keep radiation from reaching the\nwomb. Still, small amounts of radiation might reach the fetus, and scientists can’t be\ncertain about ",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 70
  },
  {
    "text": "the effects of even a very small dose of radiation on an unborn baby.\nUltrasound exams of the breast do not use radiation and are thought to be safe during\npregnancy. This is typically an easy test to have, so it’s often the first test used to\nevaluate a change in the breast (such as a lump) during pregnancy.\nOther tests, such as PET scans, bone scans, and computed tomography (CT)\nscans are more likely to expose the fetus to radiation (see below).\nMagnetic resonance imaging (MRI) does not use ra",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 70
  },
  {
    "text": "diation. However, breast MRIs\ntypically require that a contrast material called gadolinium is injected into the blood in\norder to get useful images. This contrast can cross the placenta (the organ that\nconnects the mother to the fetus) and has been linked with fetal abnormalities in lab\nanimals. Because of this, doctors typically don’t recommend breast MRI during\npregnancy.\nBreast biopsy during pregnancy\nIf a new breast lump or abnormal imaging test result raises concerns about a breast\nchange p",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 70
  },
  {
    "text": "ossibly being cancer, a biopsy is typically done. During a biopsy, small pieces\nof breast tissue are taken from the area of concern.\nThe most common breast biopsy technique is a core needle biopsy, which uses a\nhollow needle to remove the pieces of breast tissue. This is usually done as an\noutpatient procedure, even if you’re pregnant. Most often, numbing medicine (local\nanesthesia) is used to numb just the area of the breast where the biopsy will be done.\nThis causes little risk to the fetus.\nI",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 70
  },
  {
    "text": "f a core needle biopsy doesn’t give a clear answer, a surgical biopsy is typically the\nnext step. For this type of biopsy, a larger piece of breast tissue is removed through a\nsmall cut (incision) in the breast. Surgical biopsies are often done under general\nanesthesia (where you are given medicine to put you into a deep sleep), which carries a\nsmall risk to the fetus.\nImaging tests to stage breast cancer\nIf breast cancer is found, you might need other tests to find out if cancer cells have\n70",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 70
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nspread within the breast or to other parts of the body. This process is called staging2.\nDifferent staging tests may be needed, depending on your situation.\nAs noted above, ultrasound scans do not use radiation and are safe during pregnancy.\nChest x-rays are sometimes needed to help make treatment decisions. They use a\nsmall amount of radiation to create the imag",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 71
  },
  {
    "text": "es. They’re generally thought to be safe to\nhave when you’re pregnant, as long as your belly is shielded.\nOther tests, such as PET scans, bone scans, and computed tomography (CT)\nscans are more likely to expose the fetus to radiation. These tests are not often needed\nto stage breast cancer, especially if the cancer is thought to be just in the breast. If one\nof these tests is needed, doctors might be able to make adjustments to limit the amount\nof radiation exposure to the fetus.\nTreating the ca",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 71
  },
  {
    "text": "ncer\nThe treatment of breast cancer in pregnant women is typically similar to that used for\nnon-pregnant women, especially for early-stage disease, although some adjustments\nmight be needed to help protect the fetus. Learn more in Treating Breast Cancer During\nPregnancy3.\nCan breast cancer spread to the baby?\nBreast cancer has never been found to spread from the mother to the fetus. But in a few\nrare cases, the cancer has reached the placenta (the organ that connects the mother to\nthe fetus). Th",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 71
  },
  {
    "text": "is could affect the amount of nutrition the fetus gets from the mother.\nFor answers to some common questions about pregnancy after having had breast\ncancer, see Pregnancy After Breast Cancer4.\nHyperlinks\n1. www.cancer.org/cancer/breast-cancer/treatment/treating-breast-cancer-during-\npregnancy.html\n2. www.cancer.org/treatment/understanding-your-diagnosis/staging.html\n3. www.cancer.org/cancer/breast-cancer/treatment/treating-breast-cancer-during-\npregnancy.html\n4. www.cancer.org/cancer/breast-canc",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 71
  },
  {
    "text": "er/living-as-a-breast-cancer-\nsurvivor/pregnancy-after-breast-cancer.html\n71",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 71
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nReferences\nLitton JK. Gestational breast cancer: Epidemiology and diagnosis. UpToDate. 2021.\nAccessed at https://www.uptodate.com/contents/gestational-breast-cancer-\nepidemiology-and-diagnosis on October 15, 2021.\nLitton JK, Theriault RL. Chapter 65: Breast Cancer During Pregnancy and Subsequent\nPregnancy in Breast Cancer Survivors. In: Harris JR, Lippman ME, Mor",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 72
  },
  {
    "text": "row M, Osborne\nCK, eds. Diseases of the Breast. 5th ed. Philadelphia, Pa: Lippincott Williams & Wilkins;\n2014.\nNational Cancer Institute. Breast Cancer Treatment During Pregnancy (PDQ). 2019.\nAccessed at https://www.cancer.gov/types/breast/hp/pregnancy-breast-treatment-pdq\non October 15, 2021.\nNational Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in\nOncology. Breast Cancer Screening and Diagnosis. Version 1.2021. Accessed at\nhttps://www.nccn.org/professionals/physician_gls/pdf",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 72
  },
  {
    "text": "/breast-screening.pdf on\nDecember 1, 2021.\nSechopoulos I, Suryanarayanan S, Vedantham S, D'Orsi CJ, Karellas A. Radiation dose\nto organs and tissues from mammography: Monte Carlo and phantom study. Radiology.\n2008;246(2):434-443.\nTaylor D, Lazberger J, Ives A, Wylie E, Saunders C. Reducing delay in the diagnosis of\npregnancy-associated breast cancer: How imaging can help us. J Med Imaging Radiat\nOncol. 2011;55(1):33-42.\nVenkataraman S, Slanetz PJ, Lee CI. Breast imaging for cancer screening:\nMam",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 72
  },
  {
    "text": "mography and ultrasonography. UpToDate. 2021. Accessed at\nhttps://www.uptodate.com/contents/breast-imaging-for-cancer-screening-\nmammography-and-ultrasonography on October 15, 2021.\nViswanathan S, Ramaswamy B. Pregnancy-associated breast cancer. Clin Obstet\nGynecol. 2011;54(4):546-555.\nYang WT, Dryden MJ, Gwyn K, et al. Imaging of breast cancer diagnosed and treated\nwith chemotherapy during pregnancy. Radiology. 2006;239(1):52-60.\nLast Revised: January 14, 2022\n72",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 72
  },
  {
    "text": "_A_m__e_ri_ca_n_ _C_a_n_c_e_r_ S_o_c_i_e_ty_________________________________________c_a_n_c_e_r._o_rg_ _| _1_.8_0_0_._2_2_7_.2_3_4_5__\nWritten by\nThe American Cancer Society medical and editorial content team\n(www.cancer.org/cancer/acs-medical-content-and-news-staff.html)\nOur team is made up of doctors and oncology certified nurses with deep knowledge of\ncancer care as well as journalists, editors, and translators with extensive experience in\nmedical writing.\nAmerican Cancer Society medical info",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 73
  },
  {
    "text": "rmation is copyrighted material. For reprint\nrequests, please see our Content Usage Policy (www.cancer.org/about-\nus/policies/content-usage.html).\ncancer.org | 1.800.227.2345\n73",
    "source": "3. Breast Cancer Early Detection and Diagnosis author American Cancer Society.pdf",
    "page": 73
  },
  {
    "text": "Strasbourg, 19 June 2003 CDBI-CO-GT3 (2003) 13\nSTEERING COMMITTEE ON BIOETHICS\n(CDBI)\nTTHHEE PPRROOTTEECCTTIIOONN OOFF TTHHEE HHUUMMAANN EEMMBBRRYYOO\nIINN VVIITTRROO\nReport by the Working Party on the Protection\nof the Human Embryo and Fetus\n(CDBI-CO-GT3)",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 1
  },
  {
    "text": "Table of contents\nI. General introduction on the context and objectives of the report...............................................3\nII. General concepts...............................................................................................................................4\nA. Biology of development.......................................................................................................................4\nB. Philosophical views on the “nature” and status of the embryo........",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 2
  },
  {
    "text": "....................................................4\nC. The protection of the embryo...............................................................................................................8\nD. Commercialisation of the embryo and its parts...................................................................................9\nE. The destiny of the embryo...................................................................................................................9\nF. “Freedom of procreati",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 2
  },
  {
    "text": "on” and instrumentalisation of women............................................................10\nIII. In vitro fertilisation (IVF)..................................................................................................................12\nA. Presentation of the procedure...........................................................................................................12\nB. Critical discussion on IVF................................................................................",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 2
  },
  {
    "text": "..................................14\nC. Number of embryos created for IVF..................................................................................................16\nD. Information and consent....................................................................................................................19\nE. Embryo “donation”.............................................................................................................................20\nIV. Research.....................",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 2
  },
  {
    "text": "......................................................................................................................22\nA. Introduction to research on the embryo.............................................................................................22\nB. The principle of “freedom of research”..............................................................................................22\nC. Embryonic stem cells: scientific aspects.............................................................",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 2
  },
  {
    "text": "..............................23\nD. Use of embryos that are no longer part of a parental project for research (including for collection of\nstem cells).........................................................................................................................................24\nE. Creation of embryos for research (including for the collection of stem cells)....................................28\nV. Preimplantation diagnosis (PGD) (for genetic diagnostic purposes).......................",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 2
  },
  {
    "text": ".................30\nA. Presentation of PGD: procedures and conditions.............................................................................30\nB. Ethical aspects and social consequences, in particular the issue of eugenics.................................31\nC. Selection of sex.................................................................................................................................35\nD. PGD use for immunocompatibility analysis..........................................",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 2
  },
  {
    "text": ".............................................36\nVI. Conclusion........................................................................................................................................37\nAPPENDIX I................................................................................................................................................38\nFigure 1......................................................................................................................................",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 2
  },
  {
    "text": ".................38\nChronology of embryo development until implantation..............................................................................38\nFigure 2.......................................................................................................................................................39\nFirst stages of embryo development..........................................................................................................39\nAPPENDIX II................................",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 2
  },
  {
    "text": "...............................................................................................................40\nGlossary......................................................................................................................................................40\nAPPENDIX III..............................................................................................................................................42\nSelected European reference documents...............................",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 2
  },
  {
    "text": ".....................................................................42\nAPPENDIX IV.............................................................................................................................................43\nExperts........................................................................................................................................................43\n2",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 2
  },
  {
    "text": "Report on the protection of the human embryo in vitro\nI. General introduction on the context and objectives of the report\nReflecting on ethical questions concerning the protection of the human embryo in vitro and the use of\nmedically assisted procreation have formed an important part of the Council of Europe’s work in bioethics\nfor nearly fifteen years. The extent of this reflection is a measure of the complexity and difficulty of the\nethical questions concerned, of the significant scientific de",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 3
  },
  {
    "text": "velopments that have taken place over that\nperiod, and of the evolution of opinion on these difficult matters.\nIn 1989, the Ad hoc Committee of Experts on Bioethics (CAHBI), the predecessor to the current Steering\nCommittee on Bioethics (CDBI) issued a report on human artificial procreation. Although not a legally\nbinding text, that report set out a number of principles that were useful as a source of guidance to member\nStates in an area which was still at a relatively early stage of development",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 3
  },
  {
    "text": ".\nIn 1992, the CAHBI, and then the CDBI, began its work to develop a framework convention, setting out\ncommon general standards for the protection of the human person in the context of the biomedical sciences.\nThat work culminated in the opening for signature of the Convention for the Protection of Human Rights and\nDignity of the Human Being with regard to the Application of Biology and Medicine (Convention on Human\nRights and Biomedicine; ETS 164) in April 1997.\nArticle 14 of that Convention se",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 3
  },
  {
    "text": "ts out the general principle of prohibition of the use of techniques of\nmedically assisted procreation for the purposes of sex selection except in very restricted health-related\ncircumstances. Article 18 of the Convention is a general provision concerning research on embryos in vitro.\nThe general standards set by the Convention on matters such as consent, professional obligations and\nstandards and the prohibition of financial gain from the human body and its parts, as such, would be as\nrelevant ",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 3
  },
  {
    "text": "to medically assisted procreation as they are to other health care interventions.\nThe need to undertake a more wide ranging reflection on questions concerning the protection of the embryo\nin vitro and the use of medically assisted procreation lead to the setting up in 1995 of a Working Party,\nchaired initially by Mr Jean MICHAUD (France) and then by Professor Daniel SERRAO (Portugal), to\nexamine these questions. (The membership of the Working Party, as well as the experts not members of the\nWork",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 3
  },
  {
    "text": "ing Party who contributed to the report, can be found in Appendix IV).\nTo confront the different opinions on these questions and to contribute to the reflection to be undertaken by\nthe Working Party, a symposium on medically assisted procreation and protection of the human embryo was\norganised on 15 – 18 December 1996 (see the proceedings of the symposium on the web site:\nhttp://www.coe.int/bioethics).\nThe birth of Dolly the sheep in 1997 lead to worldwide concerns about the possibility of the r",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 3
  },
  {
    "text": "eproductive\ncloning of human beings. These concerns were addressed by the Working Party which was then entrusted\nwith the task of preparing a draft additional Protocol to the Convention on cloning. The Protocol to the\nConvention on Human Rights and Biomedicine on the Prohibition of Cloning Human Beings (ETS 168) was\nopened for signature in January 1998.\nAfter the symposium, to further assist the reflections of the Working Party, a comparative study of the\nposition of the then member States, and ",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 3
  },
  {
    "text": "those States having observer status with the CDBI on relevant\nissues was conducted and published in 1998 (see document CDBI-INF(98)8 Medically assisted procreation\nand the protection of the human embryo: comparative study on the situation in 39 States; Cloning:\ncomparative study on the situation in 44 States).\nWhilst on many of the issues covered by this report there is a broad consensus at European level, on other\nmatters a considerable diversity of opinion exists, which makes it difficult to i",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 3
  },
  {
    "text": "dentify common approaches at\nthe present time. In this context, the elaboration of a report on the protection of the human embryo in vitro\nwas considered as a useful step to progress in the ethical discussion around these issues. The Working\nParty started the elaboration of this report in September 2002.\nIts purpose is to aid reflection on these topics, by outlining the various existing positions on the subjects\ncovered by the Report and the arguments on which those positions are based, without ",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 3
  },
  {
    "text": "taking a stance on\n3",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 3
  },
  {
    "text": "the issues raised. The Report provides a brief introduction to the scientific issues involved as an aid to\nunderstanding of the ethical questions raised, but does not intend to provide a comprehensive scientific\nreview of the relevant topics.\nIn developing laws and regulations concerning in vitro fertilisation, it is recognised that legal questions within\nthe field of family law, for example concerning the parentage of a child to be born, will need to be\nconsidered. However such questions, which",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 4
  },
  {
    "text": " are beyond the scope of the protection of the embryo, are also\nbeyond the scope of this Report.\nThe Report is organised in four main sections. The first section addresses issues of principle concerning the\nprotection of the human embryo in vitro that are relevant to all of the topics discussed in this report. It is then\nfollowed by three sections discussing the issues raised respectively by in vitro fertilisation, by research on\nthe embryo in vitro and by preimplantation genetic diagnosis.\nII. ",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 4
  },
  {
    "text": "General concepts\nA. Biology of development\nFertilisation occurs 24 hours after ovulation in the upper segment of the Fallopian tube. The male and\nfemale pronuclei come together in the ovum, and the two sets of chromosomes – one from the male and\none from the female gamete – join. The single-cell zygote then undergoes cleavage through a series of\nmitotic divisions. The first cleavage of the zygote occurs in the tube, 1.5-2.5 days after fertilisation (see\nfig. 1, in Appendix I).\nThe two cells (bla",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 4
  },
  {
    "text": "stomeres) of the embryo possess equal potential for development, that is both\nblastomeres are totipotent. Each blastomere is still able to form an entire embryo and then a fetus on its\nown, with all cell types required for differentiation into foetal tissues and extraembryonic membranes after\nfertilisation. By 3-4 days, the multicellular morula is formed. Blastomeres in the mouse embryo are not\ntotipotent after the 2-cell stage, but sheep and cattle blastomeres are totipotent even at the 8-cell ",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 4
  },
  {
    "text": "stage, with\nhuman embryos perhaps intermediate. At all stages up to implantation, the human embryo is surrounded by\na non-cellular transparent membrane, the zona pellucida. By 5 days the blastocyst is formed (see fig. 2, in\nAppendix I). A fluid-filled cavity (the blastocyst cavity, or blastocoele) is formed among the blastomeres. At\none of its poles an agglomeration of cells is noted (the inner cell mass – ICM). The outer one-cell layer of\nthe blastocyst forms the trophectoderm. Thus for the fir",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 4
  },
  {
    "text": "st time in the developing human embryo two\ndifferent cell types appear: the functions of the trophectoderm are the nutritional supply and the implantation\nof the embryo, while the ICM contains all the cells that will generate the fetus. The cells of the ICM are\npluripotent. They are not totipotent because they cannot make a fetus on their own.\nAt 6-7 days the embryo separates from the zona pellucida “by hatching” and begins implanting through the\nuterine epithelium and more deeply into the uteri",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 4
  },
  {
    "text": "ne wall. The trophoblast, differentiated from the\ntrophectoderm, establishes contact with uterine cells and maternal blood vessels, building up the placenta.\nAt the beginning of the second week the primitive (embryonic) endoderm cells separate from the rest of the\nICM to line the blastocoele cavity. This primitive endoderm (hypoblast, an extraembryonic tissue) gives rise\nto the yolk sac endoderm (see fig. 2, in Appendix I). The remaining ICM cells are now called the epiblast or\nectoderm.\nDuring ",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 4
  },
  {
    "text": "days 7-14 the blastocyst becomes more deeply implanted in the uterine endometrium. The amniotic\nand exocoelomic cavities are formed. The primitive streak is formed in the midline, at the posterior end of\nthe ectoderm. The precursor cells of foetal endoderm and mesoderm split off from the ectoderm and migrate\nthrough the primitive streak. Gastrulation is characterized by the formation of three definitive embryo layers:\nectoderm, endoderm and mesoderm which are required for further organogenesis.\n",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 4
  },
  {
    "text": "B. Philosophical views on the “nature” and status of the embryo\nThe status of the embryo is fundamental to the ethical controversy about the protection to which it should be\nentitled. Different assumptions about the status of an embryo have led to different conclusions about the\nappropriate protection of the embryo in vitro both in terms of its starting point and its level. These different\narguments have been combined in various ways. As a result of these combinations different moral positions\n4",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 4
  },
  {
    "text": "on the status of the embryo are defined. Four main moral positions can be identified. However, among\nindividuals or groups that would broadly accept a particular position, there may be variations in the status\naccorded to an embryo, and hence the distinctions between positions are not necessarily as sharp as they\nmight appear. Some people may therefore not recognise their own views in any of these four positions.\nNevertheless, attempts are often made to draw clear boundaries, not least because s",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 5
  },
  {
    "text": "uch boundaries are\nnecessary for the development of clear and enforceable legislation.\nThe four main moral positions on the status of the embryo\nThe two more opposite positions\nThey are both clear, simple and unambiguous.\nIn the first case, a fertilised egg is regarded as a human being. Therefore, in principle a fertilised egg, or an\nembryo, has inviolable value (as do all human beings), and a right to life. Therefore, nothing should be done\nto prevent, or make difficult or impossible, the furth",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 5
  },
  {
    "text": "er development of the embryo. If natural processes may\njeopardise such further development, there may be an obligation to attempt to counteract such processes, in\nthe same way that there may be an obligation to counteract life-threatening diseases of individuals.\nHowever, in the same way that there can be no obligation on a State to ensure implementation of all forms\nof life-prolonging treatment, such an obligation cannot be absolute.\nBecause each fertilised egg or embryo has equal value, it fol",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 5
  },
  {
    "text": "lows that any form of selection between\nindividual fertilised eggs or embryos is impermissible. Those who support this position consider that in\nprinciple termination of pregnancy or embryo research that entails the destruction of the embryo would be\nunacceptable. The only possible exception may arise when the continuation of pregnancy poses a definite\nthreat to the life of the mother.\nIn the other position the embryo is considered to have very little or no moral value. Hence, it is not\nconsider",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 5
  },
  {
    "text": "ed to need any particular protection, nor would it be regarded as having a right to life.\nIn consequence, those who hold this position consider that in principle it may be acceptable to carry out\nresearch that may entail the destruction of the embryo. If, for some reason, a selection between embryos or\nfertilised eggs has to be made, it should be done on the basis of the interests at stake, and fertilised eggs as\nsuch have no interests; the interests concerned are those of the other stakeholders",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 5
  },
  {
    "text": ". Thus this position\nleaves the embryo without any protection.\nThe “gradualist” positions\nHolders of these types of positions note that both the sperm and the egg are living entities before the\nfertilisation process, and consider that the fertilised egg is gradually developing into a human being. The\nembryo is considered to have significant, but not absolute, value. With regard to the right to life, a range of\nopinions may be held; some may consider that the embryo has a right to life, whereas o",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 5
  },
  {
    "text": "thers will refer to a\nright to develop.\nHolders of gradualist positions consider that the rights of the embryo are reinforced in the course of the\ndevelopment process. Hence, other rights or interests, such as the health of the mother, may override\nthese rights provided they are stronger. Critics of the position express concern that a gradualist position may\nundermine respect for human dignity and the equal moral value of persons because of the variable degrees\nof protection afforded to the embr",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 5
  },
  {
    "text": "yo/fetus. In a gradualist position, if a selection has to be made between\nembryos for some reason, this should only be made on the basis of stronger and overriding interests.\nAs has been indicated, within the gradualist position different shades of opinion exist about the implications\nof the position for the protection of the embryo which differ on the period at which a maximum level of\nprotection is granted. Two positions can be considered.\nIn the first case, as development is a continuous proc",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 5
  },
  {
    "text": "ess, entitlement to rights and protection increases\nprogressively throughout development, with full protection and rights being applied at the time of viability.\nThe interests and rights of others should also be taken in to account, and hence there may be ethical\ndilemmas arising from conflicts of interests.\n5",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 5
  },
  {
    "text": "Therefore, under certain conditions it may be acceptable - for example - to use post-coital contraception,\nselect between fertilised eggs, conduct embryo research and perform abortion. In clarifying the nature of\nthose conditions sharp borderlines often need to be drawn (such as the stage of development after which\nembryo research is prohibited). Particular stages in embryonic development, such as the development of\nthe primitive streak, have been retained as determinant criteria. However, some ",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 6
  },
  {
    "text": "consider such conventional\nborderlines relatively arbitrary, given the continuous nature of the developmental process. Even the time of\nviability may vary depending on the technical assistance (such as intensive care) that may be available.\nIn the other position, as with the first gradualist position, entitlement to rights and protection increases\nprogressively throughout development, but full rights are only achieved at birth. Again, the interests and\nrights of others may also be taken in to ac",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 6
  },
  {
    "text": "count and hence it may be justifiable to conduct – for example –\nembryo research. Holders of this position may find abortion acceptable at a later stage of pregnancy than\nwould holders of the preceding position. Some people consider that the arguments used to support this\nposition could also be used to support infanticide, and that therefore the application of this position may lead\nto a “slippery slope”.\nIn conclusion, it can be seen that in most of the positions taken on the status of the embr",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 6
  },
  {
    "text": "yo, the embryo is\nconsidered to warrant at least some level of protection.\nThese different positions are supported by various arguments based on, amongst other things, biology,\npotential, and personhood, which can be reviewed.\nBasis of the assumptions\nFundamental to the assumptions about the status of the embryo is the question of when an individual life\nbegins and when it begins to matter morally.\nArguments based on biology\nThis type of argument identifies a key point as the moment when a uniqu",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 6
  },
  {
    "text": "e human being begins to exist. At\nthe moment of fertilisation a new unique entity, in particular with regard to its genetic make-up, exists. For\nsome, it is from this moment on that reference can be made to a unique human being.\nOthers considered that the defining moment comes later in development. During a certain period that ends\napproximately fifteen days after fertilisation and before the appearance of the primitive streak, the embryo\nsubsequently develops in a manner that could lead to the ",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 6
  },
  {
    "text": "formation of one, two or three individual embryos.\nThose who hold this position consider that it is only at the end of this period when the embryo has lost this\npotential, that reference can be made to a unique human being.\nThose taking the first position argue that whether a genetic identity is ultimately shared – for example by\ntwins – is not important, given that it is already clear that at least one individual human being with a unique\ngenetic identity is in the process of development.\nAlso,",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 6
  },
  {
    "text": " given that the proportion of pregnancies which lead to a monozygotic multiple pregnancy is only a\nsmall fraction of all pregnancies, it can be argued that it is disproportionate to focus on the abstract\npossibility of such an outcome when it will not be relevant in the great majority of cases.\nPhilosophical arguments based on “potentiality”\nAt the basis of these types of argument is a view that an embryo and a human being at a later stage of\ndevelopment may be considered different but are relat",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 6
  },
  {
    "text": "ed through development. However, from this position\ndifferent arguments can be developed, which may even be in opposition.\nOne argument suggests that whilst an embryo and a human being at a later stage of development (“a\nperson”) may be considered different, the embryo has the potential to become a person. Because it has this\npotential, it should be respected as if it was already a person, and hence selection between embryos for the\npurposes of determining which should have the chance to live (f",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 6
  },
  {
    "text": "or example, by being placed in the uterus in\nin vitro fertilisation) would be as unacceptable as a corresponding selection among persons.\n6",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 6
  },
  {
    "text": "On the other hand, others would stress that if “a” has the potential to become “A”, they are not ontologically\nthe same. They would therefore argue that just because a has the potential to become A does not mean\nthat we should treat a as if it was already A.\nFurther, in nature many fertilised human eggs do not implant successfully in the uterus. Given the\nfrequency of such natural loss, it could be argued that it is incorrect to suggest that all fertilised eggs are\npotential human beings, as thi",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 7
  },
  {
    "text": "s takes no account of the actual probability of such an outcome. However, the\nfact that nature may appear to provide limited protection for a fertilised egg or early embryo does not\nnecessarily mean that we should take the same approach. Man is a moral agent, whereas nature is not.\nImplantation in the uterus is only one of the events that have to happen if an embryo is to fulfil its potential to\nbecome a person. Some of these events reflect the process of natural development, but others may depe",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 7
  },
  {
    "text": "nd\non the existence of technical support – such as surgery or neonatal intensive care – to enable the fetus to\nsurvive.\nArguments based on personhood\nIn these arguments, “mere” membership of the human species is distinct from the concept of personhood.\nHere, the term personhood is being used as a definition of a member of the human species worthy of moral\nrespect. This implies that membership of the human species is insufficient as a basis for moral respect, but\nthat some additional qualities ar",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 7
  },
  {
    "text": "e required.\nSuch a viewpoint has the implication that there might be two categories of members of the human species,\none of which could be used, or instrumentalised, for the benefit of the others (i.e. for the “persons”).\nWithin such approaches, the nature of the additional qualities required for personhood is clearly central.\nGiven that the qualities are to be used as the basis for according moral respect, it may be considered that\nthe relevant qualities must themselves have a moral basis. For ",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 7
  },
  {
    "text": "example, a distinction made on the quality of\n“height” would be inappropriate, as it is difficult if not impossible to see why a person’s height of itself should\nmake a moral difference as to the treatment to be accorded to the person. Stronger justifications could be\nmade for qualities such as “autonomy” considering that autonomy may be the basis for the moral judgments\nmade by an individual, and hence enables the person to act as a moral agent.\nHowever, members of the human species could not b",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 7
  },
  {
    "text": "e considered to attain any complete autonomy until a\nconsiderable time after birth. Further, some individuals may never acquire complete autonomy – for\nexample persons with profound learning disability. Other individuals may develop such autonomy, but as a\nresult of disease, such as dementia, or a severe head injury, may subsequently lose it partially or\ncompletely.\nSuch an approach clearly has wider ramifications than the appropriate treatment of the embryo and fetus. If\nbeing entitled to moral",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 7
  },
  {
    "text": " respect were equated with entitlement to legal protection, the legal implications would\nbe of considerable complexity. It can also be argued that such an approach fails to respect the most\nvulnerable members of society.\nIn contrast, others argue that all human beings possess human dignity, which is worthy of moral respect, by\nvirtue of being human. Although all those taking this position would agree that living, born human individuals\npossess human dignity, differences of opinion exist as to wh",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 7
  },
  {
    "text": "ether, or at what stage, an embryo or fetus\npossesses human dignity. Some of these differences derive from the biological arguments about the\nexistence of a specific individual as discussed above.\nFinally, other positions based on the identification of a clear point when an embryo or fetus becomes morally\nworthy of protection derive from several cultural traditions which refer to “successive animation” of the\nembryo and fetus. Although the details of such approaches are beyond the scope of this ",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 7
  },
  {
    "text": "report, an\nillustration of the approach would be the belief that an embryo/fetus is animated by a series of progressively\nhigher souls throughout its development. Another interpretation argues that “successive animation” should\nnot be equated to chronological animation.\nIn some traditions, a further distinction has been made in which, for example, the intellectual soul is\nconsidered to begin at 40 days for males and 90 days for females. It has been suggested that this distinction\nmay have cultur",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 7
  },
  {
    "text": "al roots in that the cultures concerned required women after birth to undergo 40 days of\npurification for boys and 90 for girls. Biological knowledge has however shown that development was a\nprogressive process.\n7",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 7
  },
  {
    "text": "Embryo created by nuclear transfer\nA more recent aspect of the debate concerns the very nature of the embryo. With regard to in vitro cloning\nof embryos to enable the development of organs and tissue from stem cells – independently of any position\ntaken on the moral acceptability of this process – arguments based on the method used have been\ndeveloped to counter the objection that embryos are actually being created.\nIt has been argued that an embryo cloned by the method used to create Dolly the ",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 8
  },
  {
    "text": "sheep (cell nuclear\ntransfer) cannot be considered the same as an embryo defined as the completed union of sperm and egg\ncells. The cloned embryo is the result of the introduction in an enucleated egg cell of the nucleus of a\nsomatic cell and does not involve a fertilisation process with gametes. The view expressed then is that\nnotwithstanding their development potential, the different origin of “natural” and “cloned” embryos means\nthat they need to be considered differently.\nOn this view an emb",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 8
  },
  {
    "text": "ryo that does not arise from natural reproduction (or an imitation of it, as in in vitro\nfertilisation) would not be an embryo with the rights that may be attached to that status (as discussed\nabove). Whether or not the product of cell nuclear transfer is an embryo is a key question in particular for\nthose who have strict positions against any interventions on embryos in vitro. If the status of the embryo\nderives from its developmental potential, the status of a “cloned” embryo would be the same",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 8
  },
  {
    "text": " as that of a\n\"natural\" embryo. However, if its status depends on its originating from a “natural”, albeit assisted\nfertilisation, as well as on its developmental potential, the status of a “cloned” embryo would be different.\nIf in fact a cloned embryo was not actually capable of developing into a born human being the situation\nmight again be different. If the cloned embryo lacked full developmental potential, some of the arguments\nused to support the status of an embryo would be inapplicable, a",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 8
  },
  {
    "text": "s would fears about the development of\ncloning for babies. However, some might have concerns about the use of egg cells in this way and consider\nthis an inappropriate manipulation of fertility. At present, the many philosophical and moral questions raised\nby cloning have not been answered. Furthermore, scientific knowledge and technical expertise arising from\nwork with embryonic stem cells derived from “natural” embryos, where this is permitted, may affect answers\nto some of the questions about ",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 8
  },
  {
    "text": "stem cells derived from cloned embryos.\nC. The protection of the embryo\nEven if positions differ on the status of the embryo and the creation of embryos in vitro, there is general\nagreement on the need for protection. Measures taken to ensure that protection and the level of protection\nmay however vary, in particular depending on the stage of development and on whether the embryo\nconcerned is part or no longer part of a parental project. Furthermore, not all countries have adopted\nspecific legal",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 8
  },
  {
    "text": " instruments. More detailed information on the protection of the embryo in specific\ncircumstances is provided in the other sections of this report.\nHowever, two positions can be generally identified. In both cases, measures provided usually offer\nprotection of the embryo in vitro from the fertilisation stage onwards. The aim in general is to ensure optimal\nconditions for fertilisation and embryo culture, and respect for good medical practice (see Chapter III. In vitro\nfertilisation). One of the ",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 8
  },
  {
    "text": "aims of protection is to ensure that the embryo is not subjected to experimental\nprocedures that could damage it or put at risk its developmental potential.\nIn the first position, maximum protection is granted starting from the completion of fertilisation. Any\nmanipulation of the human embryo in vitro that does not directly serve its preservation is prohibited.\nCreation of embryos in vitro for any purpose other than establishment of a pregnancy is also prohibited (see\nChapters III. In vitro fert",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 8
  },
  {
    "text": "ilisation and IV. Research). Such an approach precludes any human embryo\nresearch projects and derivation of embryonic stem cells. Furthermore, the removal of a totipotent cell\ncapable of dividing and developing into an individual human being would be unacceptable. A cell from the 8-\ncell stage of the embryo has to be removed if preimplantation genetic diagnosis (PGD) is to be carried out. If\nsuch cells are regarded as potentially totipotent, PGD may then not be allowed. However, problems may\nar",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 8
  },
  {
    "text": "ise if the woman is unable to continue with the parental project.\nIf at the same time termination of pregnancy is permissible, such a degree of protection for embryos is\nconsidered by some people as being disproportionate to the degree of protection accorded to the fetus after\nimplantation.\n8",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 8
  },
  {
    "text": "In the second position, protective measures applied do not always imply such prohibitions. In these\ncountries, other views are expressed for example with regard to preimplantation diagnosis (PGD), not least\nbecause the cells of the 8 cell stage embryo are not considered to be totipotent (see Chapter V.\nPreimplantation diagnosis). Furthermore, the number of embryos created by IVF in one treatment cycle\nmay not be limited and embryos not transferred may be cryopreserved.\nIf the embryo is to be cry",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 9
  },
  {
    "text": "opreserved, specific protective measures aim at ensuring proper methods of\nfreezing and thawing and uninterrupted supply of liquid nitrogen. Those embryos that are no longer part of\nthe initial parental project and are not being donated for transfer to another couple may be subject to\ndifferent measures of protection than those that are part of such a project. The measures may vary in\ndifferent circumstances.\nCryopreservation of these embryos is usually limited in time. One argument given in sup",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 9
  },
  {
    "text": "port of such a\ndecision takes into account the interests of the embryo itself, which is not to be cryopreserved but to\ndevelop. Even though this is not in the scope of the report, economic considerations may be relevant to\nsuch a choice. However, some people would question the legitimacy of such limitation and would favour\npermanent cryopreservation as a duty to the embryos to ensure that they are not destroyed.\nIn certain countries, these embryos that are no longer part of a parental project ma",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 9
  },
  {
    "text": "y be donated for\nresearch, which may include the derivation of stem cells. The measures provided to protect embryos\ndonated for research (where such research is permitted) are aimed particularly at ensuring that the research\naims are appropriate and that the embryos are maintained under appropriate conditions for as long as is\nconsistent with the aims of the research project (see Chapter IV. Research). Permissible research aims are\noften strictly limited.\nD. Commercialisation of the embryo and i",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 9
  },
  {
    "text": "ts parts\nThere is a well-established principle that a person cannot be bought or sold. In the same way that people\nare not generally regarded as a good it is difficult to see why an embryo should be so regarded.\nTo a certain extent, this principle has been extended to the human body, be it the body of a person alive or\nalready deceased. In legal terms, the human body is classically considered as « res extra commercium ».\nIt could be suggested that liberal economic theory accepts the principle th",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 9
  },
  {
    "text": "at all goods have a price. Hence,\nany human organ on embryonic stem cell used for someone’s benefit should be paid for at a price\nproportional to the benefit. However, not everything that would benefit an individual or society, whether an\nobject or a service, necessarily has a market price, and the usefulness of an object, even if necessary for a\nmarket price to exist, is not measured by its price, the latter being more directly determined by the rarity of\nthe object or by its production cost.\nT",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 9
  },
  {
    "text": "he principle of non-commercialisation of the human body is stated in Article 21 of the Convention on\nHuman Rights and Biomedicine as follows : “The human body and its parts shall not, as such, give rise to\nfinancial gain”. The use of “as such” makes clear that technical acts (such as sampling, testing, storage or\nculture) on those items may give rise to reasonable remuneration. Similarly, when a tissue has been\ntransformed by a process of work and skill in to – for example – an immortal cell lin",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 9
  },
  {
    "text": "e, that process of work\nand skill can be the subject of remuneration.\nE. The destiny of the embryo\nIndependently from the principle of non-commercialisation, the question is raised as to who can decide over\nthe embryo’s destiny.\nIf an embryo in vitro exists, it is advisable to have legal clarity on the person or persons who may decide the\ndestination of that embryo.\n9",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 9
  },
  {
    "text": "Although as was shown in Section II. B. above, there may be some disagreement about when exactly life\nbegins, it can be argued that at the very least it can be inferred from the Convention that the embryo or its\nparts should not, as such, be commercialised.\nIn that respect, it should be recalled that contrary to an organ, tissue or cells coming from the body of a\nsingle individual, in the case of an embryo resulting from the fusion of gametes coming from two different\npersons, more complex quest",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 10
  },
  {
    "text": "ions would be raised with regard to the rights of those individuals.\nThe central involvement of those whose gametes have been used to create the embryo as part of a parental\nproject means that whilst such a parental project exists, the interests of that couple in determining the use of\nthat particular embryo will be greater than any interest others may have in that embryo. However, the State\nmight choose to place limits to that control, for example by specifying a maximum period of storage in a\n",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 10
  },
  {
    "text": "cryopreserved state for an embryo. The reason for such limits might be, for example, that the state of\nscientific knowledge at the time is such that the safety of more prolonged storage for the embryo, or the\neffects of a prolonged storage period on a future child, is not known.\nIf there is no longer a parental project, the question of the rights to determine further use of the embryo will\narise. As noted previously in this report, different views on the status of the embryo may lead to differen",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 10
  },
  {
    "text": "t\nconclusions about the protection to which it is entitled. Thus, the State may choose to limit certain uses of\nembryos in all cases – for example by specifying that embryos may not be used for research, or may not be\ndestroyed. As a result of the general principles laid down by the State for the protection of all embryos in\nvitro, there may or may not be a range of options offered to the parent couple for the destiny of an embryo\nonce it is no longer part of the initial parental project – for e",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 10
  },
  {
    "text": "xample disposal, donation for transfer into\nanother woman, or use in research, within any possible constraints of the scope of the consent given by any\nthird party whose gametes were donated and used in the creation of the embryo concerned for the parental\nproject.\nIt would be possible to argue that once there is no longer a parental project, then the interests of each\nmember of the parent couple in the subsequent use of the embryo are lessened, and the interests of others\nmight be given a great",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 10
  },
  {
    "text": "er importance. Hence, there might be a greater role for others in determining the\nultimate fate of the embryos. On the other hand, for an embryo to be used for a purpose with which the\nmembers of the parent couple did not agree – particularly if this was use in IVF by another person – would\nbe likely to be highly traumatic for the persons concerned. It is therefore usually considered that the parent\ncouple should have the right to choose the final fate of the embryo and its parts within the opti",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 10
  },
  {
    "text": "ons laid down\nby the State.\nWhere a State bans the use of embryos in vitro for purposes other than procreation by the couple\nconcerned, the question of commercialisation will not arise. Where the use of embryos for other purposes\ncan be authorised, the principle of non-commercialisation can be dealt with as part of the authorisation\nprocedure.\nF. “Freedom of procreation” and instrumentalisation of women\nThe concept of “freedom of procreation”, which is sometimes used as a slogan, and questions c",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 10
  },
  {
    "text": "oncerning\ninstrumentalisation of women, are not directly relevant to the protection of the embryo. However, they are\nrelevant to the social context in which decisions about the protection of the embryo are taken. Further, they\nraise issues such as the right to non-interference in reproductive choices and the legitimacy of controlling\naccess to medically assisted procreation (MAP), which have to be taken into account when considering the\nprotection of the embryo in vitro. These issues will not be",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 10
  },
  {
    "text": " developed here but may be briefly mentioned\nconsidering their relevance to the general reflection around medically assisted procreation in particular.\nOne approach to “freedom of procreation” interprets it as a right to non-interference in reproductive choices.\nArguments in favour of women’s moral rights to freedom of procreation have highlighted the possible\nconsequences for a woman’s self-realisation and for her social situation of having a child early in life, or of\nhaving a child with sever",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 10
  },
  {
    "text": "e health problems.\nThe social influences on women, and questions concerning social reforms to improve women’s quality of\nlife, including economic and other issues that are relevant to the timing of procreation, are beyond the scope\nof this report. Issues concerning freedom of choice in the field of reproductive medicine, and of the impact of\n10",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 10
  },
  {
    "text": "progress in this medical field, are relevant to wider questions concerning women’s self-actualisation, but\ncannot offer a comprehensive answer to such questions. Nevertheless, we can note that at present,\nlifestyles - such as balancing maternity with work - appear to be leading women in Europe to, on average,\ngive birth at a later age than in previous generations. Similarly, the average age of women using IVF\nappears to be increasing. Because the risk of infertility increases with age, and the s",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 11
  },
  {
    "text": "uccess rate of IVF\ndeclines with age (particularly over the age of 40), women may not be able to achieve their procreative\naims.\nAs this report highlights, free and informed consent plays a central role in all ethical considerations, and in\nchoices made about the use of techniques of medically assisted procreation (MAP). However, some have\nargued that social pressures on women may limit the extent to which their choice is “free”, and have\nsuggested that in some situations a woman could be instru",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 11
  },
  {
    "text": "mentalised by others. Other parts of this report\nhighlight situations where there is a risk of instrumentalisation of women.\nHowever, some would reply that, without necessarily having to recourse to the notion of “social pressures”,\nthe current way of life largely influences the decision of some women to delay maternity. While the\npossibility for young women to pursue their studies is viewed positively, other economic and social\nconditions, such as those concerning work or housing have a decisiv",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 11
  },
  {
    "text": "e impact in limiting the choice of when\nto have a child. Those supporting these views argue that efforts should be made to improve these\nconditions.\nConcerns about the possible limits to women’s free choice have highlighted the risks and constraints to\nwomen of assisted procreation procedures, which have to be set against the probability of a successful\noutcome of those procedures. Ensuring that appropriate procedures are in place to ensure that consent is\ntruly free and informed, as discussed i",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 11
  },
  {
    "text": "n Section V.D, helps to address such concerns.\nInternational legal texts, such as the European Convention on Human Rights, refer to “the right to found a\nfamily” rather than the right to procreate. However, the question of freedom of procreation may be\nconsidered in the context of respect for private and family life.\nTaking into account the distinction generally made with respect to human rights, the “freedom of\nprocreation” as a possible right of both men and women, could be claimed as a more d",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 11
  },
  {
    "text": "efensive - negative -\nright or as a positive right. In the first case, a woman or a man should be protected against interventions that\ninappropriately interfere in the process of reproduction without her or his consent. Such interference can\noccur directly or indirectly either by intervening in the process of natural procreation or, more commonly, by\nhindering access to MAP techniques. There is a well-established doctrine in both legislation and case-law to\nthe effect that in order to be justifi",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 11
  },
  {
    "text": "ed, any restriction on fundamental rights must fulfill a number of specific\nconditions, including the following: it must correspond to a legitimate aim (e.g. protecting another\nfundamental right), it must be necessary in a democratic society (or in other words fulfill a pressing social\nneed), the means of restriction used must be proportional to the objective pursued, and the restriction must\nbe provided for by law. On the other hand, a positive right would entail unlimited access to medically\na",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 11
  },
  {
    "text": "ssisted reproduction, with in particular the resulting economic consequences.\nInternational legal texts regard the right to found a family mainly as a negative right, and hence that\nrestrictions on the right must be justified in accordance with the principles described above. Although such\nprinciples are relevant to decisions on categories of persons who may have access to the techniques of\nmedically assisted reproduction, such texts are not seen as conferring a general right of access to medica",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 11
  },
  {
    "text": "lly\nassisted reproduction in the sense of requiring a State to make such treatment widely available. Generally\nspeaking, the principle of equitable access to healthcare implies also that choices need to be made for a fair\nallocation of limited resources. However, some would argue that the concept of freedom of procreation,\neven if regarded as a negative right, also appeals for the solidarity of society with the case of those suffering\nfrom infertility.\nIn current national legal systems, a person",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 11
  },
  {
    "text": "’s access to medically assisted procreation (MAP) is often subject\nto certain restrictions (see replies to the 1998 questionnaire on medically assisted procreation and the\nprotection of the human embryo1). For instance, several countries restrict such access to heterosexual\ncouples, denying it to single women or homosexual couples, while other countries permit MAP for the latter\n1 CDBI/INF (98)8 Medically assisted procreation and the protection of the human embryo: comparative study on the\nsitua",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 11
  },
  {
    "text": "tion in 39 States; Cloning: comparative study on the situation in 44 States\n11",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 11
  },
  {
    "text": "categories. Without wishing here to go into the merits of either of these solutions, we might point out that\nrestrictions on medically assisted procreation are much more numerous and widespread than those on\nnatural procreation. The latter involve actual physical interventions and so are no doubt considered too\nintrusive to be anything other than exceptional, whereas MAP restrictions concern medical services\nprovided by professionals, regulation of which does not impose the same level of constra",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 12
  },
  {
    "text": "int.\nIn conclusion, we can note that it is important that questions concerning the protection of the embryo in vitro\nare not seen in isolation. Rather, wider social conditions, and the opportunities and choices open to\nmembers of a society will need to be taken into consideration as forming a background to medically assisted\nprocreation and the reflection on the protection of the embryo.\nIII. In vitro fertilisation (IVF)\nA. Presentation of the procedure\nIn vitro fertilisation and embryo transfer",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 12
  },
  {
    "text": " (IVF-ET) is a medical treatment intended to restore fertility. Infertility\nis a disease of the reproductive system that affects the male, the female or both. Infertility affects about 10%\nof the reproductive age population in western societies. In these days, approximately 5% of infertile couples\nin treatment use IVF.\nIn vitro fertilisation (IVF) is usually the treatment of choice for women with blocked, severely damaged, or\nabsent Fallopian tubes. IVF is also used to circumvent infertility cau",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 12
  },
  {
    "text": "sed by endometriosis or a male factor.\nMany programs also use IVF to treat couples with unexplained infertility or long duration infertility which has\nfailed to respond to other infertility treatments.\nIVF is a complex biological procedure in which we can identify four steps in the method:\nObtaining gametes\nRetrieval of mature oocytes\nIn rare cases, oocyte retrieval can be carried out during a spontaneous cycle. Then, only one oocyte\ncan be obtained. In most cases, it follows an ovarian stimulat",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 12
  },
  {
    "text": "ion during about 12 days with ultrasound\nmonitoring and hormonal control to identify the most appropriate moment for the oocyte retrieval. An\naverage of 9 oocytes are obtained per treatment cycle. However, this may vary depending in particular on\nthe response to hormonal treatment. Almost 90% of collected oocytes are mature. Gametes may also be\nobtained from a donor in those countries where such donation is allowed (utilised in only 1% of IVF in these\ncountries).\nHormonal stimulation allows the ",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 12
  },
  {
    "text": "recovery of several oocytes which increased the pregnancy rate per cycle.\nHowever, it involves the creation of an embryo which may not be immediately transferred to the uterus.\nFurthermore, there is a risk of ovarian hyperstimulation syndrome and concerns have been expressed with\nregard to the potential risk of breast or ovarian cancer development.\nA number of births have been reported from mature oocytes following freezing and thawing. This method is\nhowever still experimental. The possibility ",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 12
  },
  {
    "text": "to conserve in particular ovarian tissues, in case of treatment\nleading to sterility (e.g. radiotherapy for cancer treatment), is considered promising but would require in vitro\ngametogenesis.\nObtaining and treating spermatozoa\nMale gametes (spermatozoa) are obtained from the patient’s partner or donor ejaculate in more\nthan 90% of the cases. After collection, sperm is treated in the laboratory to keep and concentrate those\nspermatozoa with best mobility and normal morphology.\nSpermatozoa can al",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 12
  },
  {
    "text": "so be obtained by surgical means from vas deferens, epididymis or testes. In some\ncases spermatozoa are freeze stored prior to fertilisation. In 5% of the cases, spermatozoids come from a\ndonor, in countries where such donation is allowed.\nFertilisation and culture of the embryos\nIn most cases, one or more oocytes and spermatozoa at an appropriate concentration (50.000 to 100.0000\nper ml) are brought together. When spermatozoa are in insufficient number or are functionally deficient,\n12",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 12
  },
  {
    "text": "fertilisation can be assisted through intra cytoplasmic sperm injection (ICSI) (see Special IVF procedures\nbelow).\nThe process of fertilisation leads to the formation of a fertilised egg with normally two pronuclei, one female\nand one male. After 15 to 17 hours, the peripheral cells of the fertilised oocytes are eliminated to check the\nresult of the process and detect possible abnormality (one or more than two pronuclei). The first cellular\ndivisions of the embryo usually occur the day after. Th",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 13
  },
  {
    "text": "e embryo can then be transfer into the uterus or\ncryopreserved. The vast majority of embryos formed in vitro, that do not present polyploidy (more than two\npronuclei and as a consequence too many chromosomes) and no other morphologically assessed\nanomalies (about 60%), are cultivated in artificial media and transferred to the uterus on the second-third\nday after fertilisation. In certain cases, culture can be prolonged for 3 to 4 days until preimplantation stage\n(blastocyst) (see special IVF pro",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 13
  },
  {
    "text": "cedures below).\nEmbryo transfer\nEmbryos formed in vitro are introduced through the cervix to the uterus. Ultrasound guidance can be used,\nin certain cases, for proper placement of the embryo in the cavity.\nIn order to minimize the risk of multiple pregnancies, the number of embryos transferred is generally two or\nthree per attempt. However, this number may be increased to four in certain countries or reduced to one in\nfew others. With the improvement of the techniques, the tendency is however to",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 13
  },
  {
    "text": " transfer fewer embryos. If\nnot transferred in the first treatment cycle, the embryos are frozen for a future transfer, either if the treatment\nfails or if the couple wants another child. Some countries however, do not allow the creation of more\nembryos than can be transferred in one treatment cycle (see Section III.C).\nIVF future development\nKnowledge acquired and improvement of the different technical steps of the procedure has led to an\nevolution in IVF programmes. Currently, a decrease in th",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 13
  },
  {
    "text": "e number of created embryos and in the number of\nembryos transferred can be noted, which has been made possible by the improvement of the ability to\nevaluate in vitro the implantation and development capacities of the latter.\nAccess to medically assisted procreation techniques, in particular IVF, continues to develop in the majority\nof European countries. However, it seems important to highlight, in this context, the importance of socio-\neconomical aspects, which could contribute to disparities ",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 13
  },
  {
    "text": "encountered between these countries – disparities\nthat have another dimension if, beyond the European level, we consider a North-South perspective.\nSpecial IVF procedures\nIntra cytoplasmic sperm injection (ICSI)\nICSI is aimed at facilitating the fertilisation process in case of a male infertility problem related to a very low\nnumber of spermatozoa or functional deficit of the latter. A spermatozoid is injected into an oocyte specially\nprepared by eliminating the layer of peripheral cells. Sperma",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 13
  },
  {
    "text": "tozoa come either from ejaculated sperm or\nfrom epididymis fluid or from testis biopsy, which may all have been previously frozen. The pregnancy rate\nafter ICSI is about 30 to 40%. Embryo creation rates are 60 to 70% with spermatozoa coming from\nejaculated sperm, 45 to 50 % for those coming from epididymis fluid, and 30 to 45% when testis biopsy is\nused.\nInjection of germ cells (spermatid, spermatocyte), when spermatogenesis is blocked, remains experimental\nand much debated with regard to the ri",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 13
  },
  {
    "text": "sks for the future child.\nCo-culture and assisted hatching to improve implantation success\nCulture of embryos in vitro with embryotrophic factors can be prolonged until blastocyst stage. This enables\nthe identification of embryos with development problem not kept for transfer. Among them, about 40%\npresent cytogenetic abnormality. The implantation rate of the remaining blastocysts is almost doubled\ncompared to transfer of an embryo two or three days after fertilisation. By diminishing the number",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 13
  },
  {
    "text": " of\nembryos transferred at that stage, it allows a reduction of multiple pregnancies.\nAssisted hatching\nImplantation requires the opening of the zona pellucida which envelops the fertilised egg (see figure 2, in\nAppendix I). In certain cases, the zona pellucida seems to thicken and to harden, making this process\ndifficult. A hole created in the zona pellucida, either mechanically or chemically, seems to solve this\n13",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 13
  },
  {
    "text": "problem. However, further research needs to be done in this field to specify the indications and to improve\nthe techniques.\nGamete donation\nSperm donation\nIVF with sperm coming from a donor is usually considered in case of unsuccessful attempts with\nartificial insemination with sperm coming from a donor (male infertility) or in case of infertility problem in both\nman and woman.\nOocyte donation\nIt is mainly considered in cases of early menopause, following treatment affecting fertility, or\nabnorm",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 14
  },
  {
    "text": "al gonad development often related to genetic diseases (e.g. Turner syndrome), successive failures\nof homologous IVF, and risk of transmission of severe diseases. Donated oocytes, in contrast to sperm and\nembryos, may not be previously frozen (see paragraph on cryopreservation).\nThe embryo created after oocyte donation may have then been frozen or just created, donor and\nrecipient cycles being then synchronised. The pregnancy rate per cycle after transfer is around 20 to 40%.\nResults of IVF\nThe ",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 14
  },
  {
    "text": "results of IVF may vary according to the indications (Fallopian tube problem, male fertility problem,\nendometriosis, absence of ovulation, male and female infertility problems, etc.) and the age of the woman.\nFurthermore, results may also vary from one medical team to another and from one period to another with\nthe same medical team. In this context, general statistics on IVF when it comes to evaluating the chance of\nsuccess for an individual couple, may not be relevant. However, they are intere",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 14
  },
  {
    "text": "sting for evaluation of the\ntechniques in terms of general risks and efficiency.\nThe success rate of IVF is 20 - 25% pregnancy per oocyte retrieval. This success rate is similar to the\nchance that a healthy reproductive couple has of achieving a pregnancy that results in a live born child in\nany given month. When considering pregnancies per transfer, the success rates are on average: 25 - 29%\nfor standard IVF, 26 - 30% for ICSI, 15 - 16% for standard IVF with previously frozen embryos and\napprox",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 14
  },
  {
    "text": "imately 40% with donated oocytes.\nThe patient’s age is one of the most determinant criteria influencing the success rate. Indeed, the\nimplantation rate decreases with age: by almost 10% per embryo at 38 years old, to reach less than 3% at\n42 years old.\nCryopreservation\nEmbryos can be cryopreserved in liquid nitrogen at -196º C in straw or glass flasks, for a period of several\nyears. The majority of states that have regulations on this topic, allow embryos to be kept frozen up to five\nyears. This",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 14
  },
  {
    "text": " technique has been routinely used for nearly 20 years with successful transfer, and avoids the\nneed for further ovarian stimulation treatment and oocyte retrieval attempts. No harmful consequence to the\nresulting child caused by freezing and cryopreservation of embryos has been noted to date.\nIVF team\nIVF teams are usually multidisciplinary and combine in particular the different clinical and biological\ncompetencies and skills necessary to carry out the different steps of the procedure.\nB. Crit",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 14
  },
  {
    "text": "ical discussion on IVF\nThe possibility of obtaining gametes - the man’s sperm and the woman’s oocytes - has made it possible to\ndevise solutions based on medically assisted procreation for infertile couples who want a child or couples\nwho have a risk of passing on a particularly serious disease to their children. Although artificial insemination\nin human beings has been practised for two centuries, the first in vitro fertilisation goes back a mere quarter\nof a century.\nFertility problems and dif",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 14
  },
  {
    "text": "ficulty in having a child have been recognised as calling for medical help and for the\nestablishment of research and clinical institutions in this field. However, society, which is involved when new\ntechnologies are instituted and may have to provide financial resources, is not required to ensure totally\nunconditional access to these technologies. IVF has now become an integral part of clinical practice in\n14",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 14
  },
  {
    "text": "reproductive medicine in many European countries and all countries where IVF is provided insist by law on\nstrict control and on specific conditions.\nHowever, three major arguments have been expressed against IVF. One concerns the destruction of\nembryos resulting from embryo research carried out to develop and improve IVF methods. Two others make\nreference to “nature“. The first such argument opposes any form of technical interference in the “natural\nprocess“ of procreation. The second argument s",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 15
  },
  {
    "text": "uggests that IVF provides a lower level of protection for an\nindividual embryo than does “nature“. On this view, in “nature“ there is usually only one embryo per cycle\nthat may potentially implant in to a uterus whereas in contrast in IVF several embryos are transferred to a\nuterus. However, it is probable that only one of them will actually implant and therefore, it is argued, the\nprotection (in terms of protection of the potential for development) of each individual embryo is lower than\nthat p",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 15
  },
  {
    "text": "rovided by “nature“.\nBut others note that the protection of the embryo provided by “nature“ is not absolute. “Nature”, from the\nperspective of the embryo, could not then be considered ideal. Hence, it may be possible to manipulate\n“nature“ to the benefit of mankind. It is interesting in this context to note that “nature“ also constitutes a\nreference point for the development and improvement of IVF, the aim of which is to get as close as possible\nto the optimal conditions offered by nature for th",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 15
  },
  {
    "text": "e creation and development of the embryo. Furthermore, it\nhas been stressed that if this technique is a means to respond to infertility problems, it does not treat their\ncause.\nIn the current critical discussion around IVF, other arguments are now developed which, besides the results,\nrisks and benefits of the methods, take into account social context, in particular the evolution of the mode of\nlife and its influence on infertility problems, as well as psychological aspects.\nIn the countries whe",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 15
  },
  {
    "text": "re it is allowed, fertilisation outside the body was developed as a therapeutic response\nto infertility situations that were previously impossible to remedy. Initially, IVF was used as an answer to\nsterility due to blocked Fallopian tubes: the gametes were brought together in vitro to achieve fertilisation\nand the embryos obtained were transferred. The use of hormonal treatment to stimulate ovulation and the\nmonitoring of such treatment helps to optimise the egg harvest, the time at which the ga",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 15
  },
  {
    "text": "metes meet in order\nto produce embryos and the synchronous preparation of the endometrium for the transfer of the embryo.\nThe results of this practice have made it easier to decide when to use surgery in cases of sterility caused by\nblocked Fallopian tubes and to avoid operating and re-operating to no purpose.\nSimplification of the method in both biological and clinical terms has made it possible to extend the\nindications for IVF to include the failure of treatment for other causes of female inf",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 15
  },
  {
    "text": "ertility such as\nendometriosis, certain types of ill-explained infertility and infertility caused by moderately serious male\nfactors, particularly after the failure of artificial insemination.\nA bare ten years ago, microinjection of sperm into the oocyte cytoplasm (ICSI), was to male sterility the\ntherapeutic revolution that IVF was to sterility of tubal origin 15 years previously. It now enables nearly 70%\nof couples who only recently would have had to resort to an outside sperm donor to concei",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 15
  },
  {
    "text": "ve a child which\nis biologically 100% their own.\nHowever, when IVF and particularly ICSI are used to overcome an infertility (or subfertility) problem in men,\nwomen may be subject to invasive interventions despite the absence of a personal cause for an infertility\nproblem. Although in many instances infertility problems whether of male or female origin, are felt as a\n“couple problem“, concerns have been expressed about such situations and the possible difficulties in\nensuring full respect for th",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 15
  },
  {
    "text": "e autonomy of the women and that she is really making a free choice to undergo\nthe interventions.\n15",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 15
  },
  {
    "text": "Results\nAs a result of medically assisted procreation, nearly 2% of children in France, for instance, are born every\nyear following IVF or ICSI, from nearly 7,000 couples. These results are considered by many people as real\nscientific progress, offering infertile or sub-fertile couples a fertility (ability to conceive per cycle) comparable\nto that provided by nature to fertile couples (who have already had a child). They could also be considered\nto reflect an ethical progress on the basis of the",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 16
  },
  {
    "text": " principle of beneficence, in relieving these couples of\nanxiety, supporting their autonomy in their desire for a child and sparing them any feeling of being different,\nand maximising benefits to what is considered to be a health problem.\nHowever, with regard to these results, it is also suggested that the success rate of IVF is relatively low and\nis perceived as being associated with more and more difficulties by the couples over the course of a number\nof failed attempts.\nRisks\nIt has been sugg",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 16
  },
  {
    "text": "ested that IVF entails risks for the women, in particular due to the hormonal ovarian\nstimulation treatment and in particular a higher risk of cancer. However, on the latter, scientific studies\ncarried out so far have failed to demonstrate such implications and the knowledge acquired has enabled\nsubstantial improvement of treatment and limitation of its secondary effects.\nMore frequent premature birth and risks attached to such early birth have been linked to the use of IVF. It is\nargued however",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 16
  },
  {
    "text": " that IVF methods are not responsible. The two main reasons put forward are the more\nadvanced age of women involved in IVF procedures and an increase in the proportion of multiple\npregnancies. The latter should however now be more limited given the improved success of transfer which\nenables the number of embryos introduced in the uterus to be decreased.\nThere seems to be wider agreement however on the fact that not all prerequisites, in particular very limited\npreclinical studies, were fulfilled",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 16
  },
  {
    "text": " before ICSI was introduced in clinical practice. In that respect, concerns are\ncurrently expressed with regard to the potential use of non-mature spermatozoids (e.g. spermatid).\nIn general, the limited health related data on children born after such procedures have been a reason for\nscientists to suggest improved follow-up of those children, whilst being conscious of the need to prevent any\nstigmatisation.\nOne specific concern has been expressed regarding the health, and in particular the ferti",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 16
  },
  {
    "text": "lity, of children born\nfrom ICSI when this technique is used to overcome certain types of male infertility. If the infertility has a\ngenetic cause, it is likely that a male child born as a result of ICSI will carry the same genetic abnormality.\nHence that child will have to face the same fertility problems as did his father beforehand. Therefore, some\nhave argued that it is wrong to bring a child in to the world that will have what might be regarded as a form\nof disability.\nOn the other hand, ot",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 16
  },
  {
    "text": "hers consider that the problem does not affect the health of the child as such and\nmethods may exist that would ameliorate the effect of the problem. Hence for them, the extent of the\nproblem is not sufficient to justify interference with the autonomy of the parents in the desire to have their\nown biological child.\nFinally, it has to be noted that the possibility to create an embryo in vitro opened the door to new techniques\nenabling intervention on and/or selection of the embryo as well as to r",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 16
  },
  {
    "text": "esearch. This raises other related\nissues which are further developed together with the arguments supporting the different positions expressed\nin the following chapters.\nC. Number of embryos created for IVF\nIVF consists of fertilising in vitro the oocytes from the group of follicles developed after hormonal ovarian\nstimulation treatment. Current folliculogenesis physiology data suggest that ovarian stimulation treatment\ntargets a set of follicles whose maturity is such that they have receptors e",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 16
  },
  {
    "text": "ssential for hormonal action.\nThese follicles begin to develop nearly 70 days before ovarian stimulation by intra-ovarian mechanisms,\nabout which little is known as yet.\n16",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 16
  },
  {
    "text": "The ovarian stimulation treatment does not therefore affect the ovary’s reserve, since it concerns only\nfollicles that have already begun to develop; in other words, it is not in itself likely to speed up the onset of\nthe menopause.\nBut, this also means that:\n- it is not possible to predict the size of the group of follicles that would develop for a given cycle;\n- the quality of the oocytes and the number of oocytes harvested vary from one cycle to the next for\nthe same woman subjected several t",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 17
  },
  {
    "text": "imes to the same ovulation stimulation treatment.\nThe number of embryos obtained2 (see Section III. A) and their “ability to develop”3, the receptiveness of the\nendometrium and hence the likelihood of a pregnancy and resulting birth of a child, are therefore difficult to\npredict precisely.\nSeveral oocytes suitable for fertilisation are therefore harvested each time from an ovary from the group of\nfollicles (oocyte retrieval) that has been stimulated for IVF. Their number depends on various facto",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 17
  },
  {
    "text": "rs,\nincluding the natural intra-ovarian mechanism which leads to the development of a certain number of\nfollicles and the quantity of hormone given to the follicles already recruited.\nIt sometimes happens that the number of embryos obtained is larger than the number that can reasonably\nbe transferred at the same time if multiple pregnancy is to be avoided, as multiple pregnancy may have\ntragic consequences for the couple concerned and the children, with a risk of a miscarriage, often at a late\ns",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 17
  },
  {
    "text": "tage, or a somewhat or even very premature birth. The embryos that are not used for an immediate\ntransfer may be cryopreserved after freezing (see Section III. A).\nIn certain countries (e.g. Germany, Austria), however, the law prohibits the creation by IVF of more embryos\nthan can be transferred in one treatment cycle. Their number is then limited to a maximum of three embryos\nto reduce the risk of multiple pregnancy. To create more embryos is prohibited by penal law.\nThe possibility of freezing",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 17
  },
  {
    "text": " embryos means that there are, strictly speaking, no oocytes that are not used\n(unless some are not fertilised in order to avoid producing embryos), that would possibly be cryopreserved.\nThe difficulty of estimating the fertilisation rate and therefore the number of embryos that will be obtained in\nadvance means, however, that:\n- either too few oocytes are used in the fertilisation procedure and the embryonic transfer rate or the\npregnancy rate per transfer procedure is reduced;\n- or that too ma",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 17
  },
  {
    "text": "ny embryos are transferred, with the result that the couple is inevitably exposed to the\nrisk of multiple pregnancy.\nBut in those countries where the number of embryos per cycle is limited, such as Germany, if more\n“embryos” are created, in small numbers, by accident they would be frozen before the fertilisation of the\noocytes is completed. At that stage, until the complete fusion of the two pronuclei and termination of the\nfecundation process, they would not be considered as embryos, according ",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 17
  },
  {
    "text": "to the definition in the law.\nIn the countries where cryopreservation of embryos is allowed, the possibility of freezing embryos with a\nview to their subsequent transfer applies in the case of nearly 94% of embryos. In these countries, it is\nrequired that couples be traceable and embryos be clearly identified in relation to the parent couple.\nIt should be noted that oocytes, unlike spermatozoids and embryos, cannot as yet be routinely\ncryopreserved without there being an unevaluated risk to the ",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 17
  },
  {
    "text": "unborn child. Research is carried out however\nin this field which, if successful, would make it possible to limit cryopreservation of embryos.\nThe tendency today is to reduce the hormonal input used to stimulate the ovary and therefore the number of\noocytes produced. The number of embryos transferred each time – even reduced to one in certain cases –\ntends also to be reduced, limiting thereby the risk of multiple pregnancy. However, the creation of more\nembryos than can be transferred at once is",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 17
  },
  {
    "text": " considered, where allowed, as good IVF practice, given the\ncurrent state of our knowledge.\n2 Fertilisation rate, ratio of the number of embryos obtained to the number of oocytes fertilised\n3 This is assessed optically, and sometimes also by prolonging culture of the embryo until it reaches the\nblastocyst stage of development\n17",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 17
  },
  {
    "text": "A remaining problem that is not solved by legislation nor regulation in several countries, is the time-limit that\nshould apply to storage of embryos (see Section II. C).\nHowever, other concerns are raised by the future of these embryos when they are no longer kept as part of\na parental project. The fate of those embryos whose parents have decided not to go ahead is usually\ndecided by the parental couple, in accordance with what is legally possible: the embryos may simply no\nlonger be stored, the",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 18
  },
  {
    "text": "y may be used for authorised research, or they may be donated to another couple.\nIt is the question of the future – outside of a parental project - of embryos created in large numbers by IVF\nwith the aim of a higher success rate of the whole procedure, which led certain countries to favour the\nlimited creation of embryos per treatment cycle. The question of the number of embryos to be created is\nthen not considered primarily with a view to the success of the treatment and the individual needs of",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 18
  },
  {
    "text": " the\ncouple, even if these needs are accepted as high ranking needs. Rather, it is considered from the point of\nview of general values in society (often claimed as based on the country’s Constitution in particular) and of\nthe assessment of the outcome for embryos that are not longer part of a parental project. The individual\ndemand to have a child with the help of society, as understandable and morally acceptable as it is, is not\nconsidered as a strict negative nor positive right (see Section II",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 18
  },
  {
    "text": ".F.). Hence, in this context, the solidarity of\nsociety is not demanded on the basis of rights but only by more or less accepted compassion.\nAneuploidy screening\nWhere there is no limitation on the number of embryos created by IVF per treatment cycle, an appropriate\nnumber of these embryos can be selected with a view to benefit from the best likelihood of implantation and\ndevelopment. When carried out, such selection is done on the basis of observational criteria without any\nintervention on the ",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 18
  },
  {
    "text": "embryos. However, in certain countries, in the case of women with a history of repeated\nmiscarriages or IVF failure, a cytogenetic analysis, involving a more invasive procedure (biopsy of one or\ntwo cells), can be carried out to detect potential types of aneuploidy which would affect the ability of the\nembryo to develop or to implant.\nSuch aneuploid embryos contain an abnormal number of chromosomes, leading almost always to failure of\nimplantation or miscarriage. In general, the frequency of ane",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 18
  },
  {
    "text": "uploidy appears to be rather high in human\nembryos, and increases with advancing maternal age. Aneuploidy may be identified in embryos in vitro,\nusing the techniques of biopsy and fluorescent in-situ hybridisation (FISH). The aim of the procedure is to\nimprove the success rate of IVF, and it has been shown to reduce the rate of miscarriage. The possibility to\nselect embryos free from aneuploidy makes it also possible for fewer embryos to be transferred and\ntherefore enables a decreased risk of m",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 18
  },
  {
    "text": "ultiple pregnancy.\nHowever, although the technique has been implemented in a number of clinics around the world, it is still in\nthe early stage of development. Furthermore, aneuploidy may affect some cells of the embryo but not all\n(mosaicism), leading to both positive and negative errors in diagnosis.\nEthical concerns have also been expressed with regard to such a screening procedure, in relation to the\nvery principle of selection of embryos and to the actual invasive procedure involved (biopsy",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 18
  },
  {
    "text": "). In that respect,\npreimplantation diagnosis (PGD) and aneuploidy screening can be considered as being comparable in\nsome respects, and argumentation developed around PGD be considered equally relevant to aneuploidy\nscreening (see Section V.B). However, it has also been argued that a fundamental difference between both\nprocedures would justify them being considered differently from an ethical point of view. Indeed, PGD is\naimed at identifying a genetic condition in an embryo which may not affec",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 18
  },
  {
    "text": "t its development in the uterus and\nthe ultimate birth of a child, but could lead to a disease or disorder in this future child. Aneuploidy screening\nis aimed at identifying embryos which would, on the contrary, naturally not develop or implant and is\ntherefore directly relevant to the success of the IVF procedure.\n18",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 18
  },
  {
    "text": "D. Information and consent\nRespect for autonomy of persons is one of the fundamental ethical principles in medicine. It includes\nrespecting the self-determination and choices of autonomous persons and protecting those persons with\ndiminished autonomy. The rule of free and informed consent is directly linked to this principle. Article 5 of\nthe Convention on Human Right and Biomedicine lays down the following basic rules on these points:\n“An intervention in the health field may only be carried out",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 19
  },
  {
    "text": " after the person concerned has given free\nand informed consent to it.\nThis person shall beforehand be given appropriate information as to the purpose and nature of the\nintervention as well as on its consequences and risks.\nThe person concerned may freely withdraw consent at any time.”\nAs pointed out in the Explanatory Report to this Article: ” This rule [of informed consent] makes clear\npatients’ autonomy in their relationship with health care professionals and restrains the paternalist\napproac",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 19
  },
  {
    "text": "hes which might ignore the wish of the patient.”\nArticle 6, paragraphs 3 to 5 of the Convention, adapts the requirements of information and consent to\npersons of full age who do not have the capacity to consent.\nThe request for free and informed consent is an integral part of the requirements applied to IVF.\nHowever in this context several points can be stressed, in particular regarding the type and form in which\ninformation is communicated, as well as with the consent, including its scope and l",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 19
  },
  {
    "text": "ength of validity.\nInformation\nIt is agreed that informed consent requires prior communication of objective information in particular on the\nprocedure, including a description of the entire process and of interventions involved and a forecast of its\npossible duration, the implications and risks involved, the expected results (in terms both of failure and\nsuccess), as well as to possible existing alternatives.\nConcerns have been expressed however in relation to the amount of information provided.",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 19
  },
  {
    "text": " This is the case\nin particular for information on the possible future of embryos which may be no longer kept as part of the\ninitial parental project (e.g., in accordance with national legislation, the possibility of donation, research, end\nof storage). If it is agreed that such implications need to be referred to, concerns are expressed that, as they\nmay not be directly relevant to the consent requested – indeed, consent would be requested for any\ndecision with regard to the future of such embr",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 19
  },
  {
    "text": "yos if the parental project ends - they might actually be a\nsource of confusion. Hence, it is argued that the difference between this information and that directly related\nto the consent requested should be made clear to the person concerned and possibly be communicated at a\ndifferent time.\nIn practice, further information is also given on legal provisions applicable, such as situations where the\nconsent could be invalidated (e.g. separation of the members of the couple) or where authorisation b",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 19
  },
  {
    "text": "y a\njudge would be required (e.g. sperm donation in France). Where appropriate, information on legal effects\n(e.g. in terms of filiation) is also provided.\nThe way and form in which information is provided is also determinant to enable the provision of free and\ninformed consent. The rule of free and informed consent implies that any information be given in a non-\ndirective way and in comprehensible terms to the person concerned. There is agreement on the need for the\nperson who would be giving t",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 19
  },
  {
    "text": "his information to have appropriate knowledge and skills to present it in clear\nand suitable words for the persons concerned.\nWith regard to IVF, a difference is generally made between the information which is common to all cases\n(the procedures involved in IVF, their chronology, the legal provisions etc.) and the information which is\ntailored to each individual situation and concerns clinical and biological aspects. If in practice the first type of\ninformation may be given in written form, this",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 19
  },
  {
    "text": " is usually not the case for the second category. The latter is\nusually communicated by a member of the medical team.\n19",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 19
  },
  {
    "text": "Independently of the information provided prior to consent, it is also agreed that during treatment the\npersons concerned also have the possibility to seek and obtain additional information and be informed of\nany developments and intermediate results in the procedure; in particular, where appropriate:\n- the number of oocytes actually removed;\n- the number of embryos obtained;\n- the number of embryos to be transferred;\n- the development of the pregnancy.\nConsent\nWith regard to the consent, concer",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 20
  },
  {
    "text": "ns have been expressed in relation to the form in which it should be\ngiven. In this respect, it has been argued that express consent in written form should be requested\nconsidering in particular possible disagreement between the persons concerned regarding alteration of the\ninitial decisions or possible legal implications.\nFurthermore, in accordance with internationally agreed principles, consent may be freely withdrawn at all\ntimes. However, professional obligations and standards may be relevan",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 20
  },
  {
    "text": "t to the immediate action to be\nundertaken by the professional where such withdrawal would seriously endanger the health of the woman\nand/or embryo or fetus.\nConsent is usually requested from both members of the couple concerned. However, due to her biological\nrole in the procreation process, the woman will be much more physically involved in the procedure in being\nsubmitted to invasive interventions. Even though both consents are equally valid with regard to the IVF\nprocedure as a whole, this m",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 20
  },
  {
    "text": "ight be seen as supporting a difference in practice in the way both consents\nmight be regarded. In particular, an intervention on the woman’s body would not be carried out without the\nwoman’s consent. This is particularly relevant when considering consent in relation to prenatal diagnosis\n(PND) and preimplantation genetic diagnosis (PGD). In the first case, the procedure would involved an\ninvasive intervention on a pregnant woman whereas in the other the intervention is carried out on an embryo\n",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 20
  },
  {
    "text": "in vitro. In the first case, discussion would be primarily between the physician and the woman concerned.\nWith PGD, both members of the couple would be involved and discussion will generally take place with the\nmultidisciplinary medical team.\nWith regard to the future of embryos which would not have been transferred at the end of the parental\nproject, it is agreed that the decision always remains subject to the consent of the parents who initiate the\nproject, even if the embryo is not the produc",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 20
  },
  {
    "text": "t of their own gametes (in the case of sperm donation for\nexample). However, embryo donation may be subject to some conditions that the couple should be informed\nabout prior to the beginning of the IVF procedure.\nThe following outcomes may be considered, provided that they are permitted by law:\n- embryo donation to another couple;\n- permission to use the embryos in a biomedical research project;\n- end of storage.\nHowever, the difficulties which the couple could face in taking such decisions as w",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 20
  },
  {
    "text": "ell as the irreversibility of\ncertain procedures once undertaken have to be acknowledged. Taking these elements into account, support\nhas been expressed in favour of imposing a period of reflection between the communication of information\nin relation to the different outcomes, seeking consent and the time frame following consent in which such\nconsent may be withdrawn.\nE. Embryo “donation”\nIn certain countries, couples who went through an IVF procedure where embryos were created using their\ngamet",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 20
  },
  {
    "text": "es have the possibility to “donate” one or more of these embryos to another couple for transfer. Such\nembryo “donation” is not authorised in certain countries.\n20",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 20
  },
  {
    "text": "In those countries where it is authorised, it usually only concerns embryos created by IVF for a parental\nproject, that are no longer part of this initial project. However, in a few countries, creation of embryos for\ndonation is authorised.\nIt should be noted that the concept of “donation” occasionally raises a problem as it entails the underlying\nidea of “property”. In France, for example, the choice was therefore made not to use the word “don”\n(donation) but “accueil” (reception).\nMost ethical",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 21
  },
  {
    "text": " concerns expressed around “donation” of embryos are related to the respect for the dignity of\nthe human being. It is argued that the practice could lead to the instrumentalisation of the embryos which\ncould be considered as mere means to respond to infertility problems without treating the cause of these\nproblems. In this respect, for the holders of this position, embryo donation is seen as increasing the ethical\nproblems raised by sperm and oocyte donation, and creation of embryos purely for d",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 21
  },
  {
    "text": "onation is considered\nby some totally unacceptable. For this reason, concern is also expressed with regard to the possibility of\ncreating, by IVF, more embryos than necessary for the success of an IVF procedure.\nThose supporting the principle of embryo donation oppose to such arguments, that “embryo donation” is in\nfact respectful of human dignity, and benefits the embryos in giving them the possibility to develop in\nappropriate conditions which are strictly defined, rather than destroying them ",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 21
  },
  {
    "text": "(see Section III.D). For the\nholders of this position, provided that strict conditions are respected in particular for the protection of the\nfuture child, embryo donation could be considered as an alternative to embryo destruction while giving an\nacceptable answer to a couple with infertility problems.\nIn the countries where embryo donation is allowed, it usually remains an infrequent practice. In the United\nKingdom for example, where embryo donation is allowed, many couples with infertility pro",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 21
  },
  {
    "text": "blems would\nprefer to receive a donated oocyte than a donated embryo.\nIf donation has often been viewed in a similar way as adoption, the fundamental debate remains in certain\ncountries as to whether it should also follow the same legal regime – adoption could then be considered for\nany embryo- or if, on a legal level, it should rather be considered closer to gamete donation – with the\npossibility to define criteria to pair the donor and recipient couples.\nThe main conditions defined for embryo ",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 21
  },
  {
    "text": "donation are the absence of financial gain, health protection\nmeasures and legal protective procedures. The prohibition of financial gain on all parts of the human body\nas such is a fundamental principle laid down in Article 21 of the Convention on Human Rights and\nBiomedicine. Couple are requested to go through a certain number of tests to check in particular the\npresence of certain conditions which could affect the future child’s health or the recipient woman and would\ntherefore preclude donat",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 21
  },
  {
    "text": "ion. Finally, formalities are carried out to ensure that the legal terms of the donation\nand their consequences are known particularly in relation to legal filiation. Independently from the consent of\nthe donor couple, the consent of the recipient couple (or woman in countries where donation to single\nwoman may be permissible) is requested. Embryo donation often involves a decision by an authority or a\nguarantee that the relevant substantive and legal conditions are met.\nBesides those conditions",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 21
  },
  {
    "text": " on which there is general agreement, the question of anonymity of the donation\nhas recently been questioned. The anonymity of embryo donation is generally the rule. It is argued that\nrespect of this rule is aimed at protecting both the donor and recipient parents as well as the future child as\ninformation on identity of the donor and recipient parents could only be a psychologically disruptive factor for\nthemselves and the child. It is further argued that biological filiation is less relevant f",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 21
  },
  {
    "text": "or the establishment of\nthe parental bond and the development of personal identity than social filiation.\nHowever, argumentation around anonymity has been developed supporting the opposite view on the issue.\nIn that respect, a parallel can be drawn with the discussion on anonymity in the case of adoption. Two main\nreasons have been put forward against anonymous donation. The first one is the risk of psychological\nsuffering for the child in the search for his or her origin. The second is based on",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 21
  },
  {
    "text": " the development of genetic\napplications for medical purposes and therefore the importance for the child to have access to information\nabout his or her biological parents, including genetic details, which can be determinant for his or her health.\nConsidering the importance of these data, those who support the principle of anonymity may also consider\nthat access to non-identifiable information relevant to the health of the child.\n21",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 21
  },
  {
    "text": "IV. Research\nA. Introduction to research on the embryo\nThe question of whether, and if so under what conditions, to permit research on the embryo in vitro is one of\nthe most sensitive ethical questions that need to be addressed. At present, different member States of the\nCouncil of Europe have resolved this question in different ways. Other States are contemplating the\ndevelopment of legislation on this matter.\nAlthough the question of the status of the embryo (discussed in Section II.B above) i",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 22
  },
  {
    "text": "s fundamental to\nresolving the question of embryo research, in this section other issues that will also impact on the debate on\nembryo research are discussed.\nB. The principle of “freedom of research”\nIt has been said that any regulation that restricts research simultaneously impacts on freedom of scientific\nresearch. However, research may also have the potential to infringe fundamental rights. Therefore\nagreement has been reached at international level on the need to respect a balance between t",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 22
  },
  {
    "text": "he need to\nprotect fundamental rights and to protect the freedom of research. This is clearly stated in Article 2 of the\nConvention on Human Rights and Biomedicine, which affirms the primacy of the interest and welfare of the\nhuman being over the sole interest of society or science. Article 15 of the Convention applied this principle\nto research in stating that “scientific research in the field of biology and medicine shall be carried out freely,\nsubject to the provisions of this Convention and ",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 22
  },
  {
    "text": "the other legal provisions ensuring the protection of the\nhuman being.” As mentioned in the Explanatory Report in relation to the latter, if “freedom of scientific\nresearch is justified not only by humanity’s right to knowledge, but also by the considerable progress its\nresults may bring in terms of health and well being of patients”, it is “not absolute… it is limited by the\nfundamental rights of individuals …which protect the human being”.\nHowever, there are differences in the method used to p",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 22
  },
  {
    "text": "rotect freedom of research from one country to\nanother.\nIn some European countries such freedom is explicitly enshrined (like other fundamental rights) in the\nConstitution. Sometimes science and research are both mentioned together, whereas in constitutions that\ndeal exclusively with \"scientific freedom\", the latter is seen as also covering research (as the basic scientific\nworking method). Furthermore, a number of constitutions expressly require the State to develop and\npromote science.\nIn othe",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 22
  },
  {
    "text": "r countries, freedom of scientific research is not explicitly protected but can be indirectly derived from\nprotections of individual freedom (of action), freedom of opinion, freedom of intellectual creation and/or\nacademic freedom. However, it may be agreed that if freedom of thought and freedom of opinion should be\nas wide as possible, research, and particularly experimental research, is not comparable to the expression\nof an opinion.\nThe diversity of situations in approaches to the “freedom of",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 22
  },
  {
    "text": " scientific research” may in part arise from\ndifferent conceptions of the scope of the concept. For instance, freedom of intellectual creation and to state\none’s views can be seen as distinct from scientific experimentation, even though the latter is usually\nconsidered an integral part of any broad definition of science. Hence, a distinction between basic or\nfundamental research and experimental or applied research is often made, with restrictions in particular\nbeing applied to the latter. Howev",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 22
  },
  {
    "text": "er, this distinction is not absolute. Many types of basic biomedical\nresearch do not only involve contemplative speculation, but experimental methods. Such basic research\nmay also entail a requirement to obtain bodily materials to be used in the research, bringing in to question\nissues concerning the rights and protection of those from whom material has been obtained.\nMoreover, there are a variety of interpretations of the scope of the personal protection contemplated in the\nconcept of freedom o",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 22
  },
  {
    "text": "f scientific research.\n22",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 22
  },
  {
    "text": "C. Embryonic stem cells: scientific aspects\nStem cells are cells which have the unique capacity to renew themselves and to differentiate into\nspecialised cell types. Based on their origin, three main categories of stem cells can be identified: adult,\nfoetal and embryonic stem cells. Stem cells are not totally undifferentiated cells and can differentiate,\ndepending on their origin, into one or more tissues.\nThe presence of adult stem cells has been shown in different tissues of adult organisms an",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 23
  },
  {
    "text": "d it is probable\nthat a large number of tissues contain such cells. They have the capacity to differentiate into a limited\nnumber of specialised cell types. However, recent studies seem to indicate the presence in the adult\norganism of stem cells which would have a much higher capacity for differentiation.\nFetal stem cells can be obtained from fetal tissues or umbilical cord blood. Like adult stem cells, their\ncapacity to differentiate seems more limited than that of embryonic stem cells. Resear",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 23
  },
  {
    "text": "ch on these cells with\na view to therapeutic applications concerned mainly stem cells obtained from fetal nervous tissue and\nhaematopoietic stem cells from umbilical cord blood.\nEmbryonic stem cells (ES cells) are derived from an embryo at the blastocyst stage (5 – 7 days). They have\nthe ability to differentiate into a wide variety of tissues (pluripotence). However, they cannot on their own\nmake an embryo.\nCurrent knowledge on embryonic stem cells mainly results from research carried out animal",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 23
  },
  {
    "text": "s. The isolation\nand manipulation of mouse ES cells is now a routine procedure. These cell lines can be induced to\ndifferentiate both in vitro and in vivo (in mice) into recognizable tissues and various cell types (from\nectoderm, mesoderm and endoderm).\nES cell differentiation can be prevented by growing the ES cells on a layer of feeder cells, which produce a\nfactor or factors that prevent differentiation and maintain ES cell proliferation and pluripotency. A factor that\nis able to substitute f",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 23
  },
  {
    "text": "or feeder layer activity was isolated in 1988: leukaemia inhibitory factor (LIF). ES cells\ncan be maintained for long periods in the absence of feeder layers using LIF in the culture medium, but\neventually they accumulate aneuploidies or other chromosomal aberrations.\nHistory\nIn 1981, the first two reports were published concerning the derivation of embryonic stem (ES) cells from the\ninner cell mass (ICM) of 3.5 day old mouse blastocysts. When ICM cells were cultivated in vitro, they gave\nrise t",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 23
  },
  {
    "text": "o cell lines that were capable of indefinite self-renewal. These ES cells were capable of differentiating\ninto many cell types: ES cells while in culture gave rise to the stem cells of adult tissues, haematopoietic,\nmuscle, nerve, stratified squamous epithelia, intestine, etc.\nThe first report concerning human ES cells was published in 1998, by Dr J. Thomson and colleagues. The\ncell lines expressed cell surface markers characteristic of ES cells. Four cell lines tested produced\nteratomas when gr",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 23
  },
  {
    "text": "own in immunocompromised mice. Embryos were cultured to the blastocyst stage, 14\nICM were isolated, and five ES cell lines originating from five separate embryos were derived. Four of the\ncell lines were cryopreserved after five to six months of continuous undifferentiated proliferation. The other\ncell line retained a normal karyotype after six months of culture and has now been passaged continuously\nfor more than eight months (32 passages)…” (Thomson et al., 1998). Human ES cell lines have sinc",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 23
  },
  {
    "text": "e been\nmade in other countries, including Australia, Sweden and Israel.\nInterest in stem cell study and its possible applications\nThe following examples are among the arguments put forward to support the potential benefits of studying\nsuch cells:\n- ES cells are in a state of instability similar to that of pre-cancerous cells and could serve as a model\nfor finding out more about how a cell becomes cancerous;\n- if it could be controlled, the potential for differentiation of ES cells in vitro would",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 23
  },
  {
    "text": " make it possible to\nestablish models for pharmacological cell studies which are lacking today because they are\nrestricted to animal tissues and human cells which are usually different from the normal type;\n23",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 23
  },
  {
    "text": "- on the therapeutic front, there are prospects of a branch of regenerative medicine that could\ngenerate substitute tissues for degenerative and metabolic diseases and those involving cell\nnecrosis, which are incurable today.\nCurrent limits\nKnowledge about stem cells, either embryonic, adult or foetal, still remain limited, in particular when it\nconcerns differentiation mechanisms, their isolation (adult stem cells) or determination of their culture\nconditions. Futhermore there is, with embryoni",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 24
  },
  {
    "text": "c stem cells, a significant risk of tumour (teratoma)\ndevelopment when transplanted into a host organism. Finally, the risk of immune rejection of cells coming\nfrom a particular organism when transplanted into a different one remains an important problem when\nconsidering the potential use of stem cells for therapeutic purposes.\nReports have shown the possibility of deriving stem cells intended for cell-based therapies in various human\ndiseases. However, a large number of scientists seem to agree",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 24
  },
  {
    "text": " on the difficulty, in the current state of\nknowledge, to take a position on the comparative interest of the different stem cell types with regard to\npossible therapeutic applications.\nHowever, the issue of the use of human embryos to derive ES cells and its ethical acceptability remains at\nthe centre of the debate on stem cell. (see Section IV.D).\nD. Use of embryos that are no longer part of a parental project for research (including for\ncollection of stem cells)\nThe permissibility of research ",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 24
  },
  {
    "text": "on the embryo\nThere are two central ethical concerns about the use of embryos that are no longer part of a parental project\nfor research. The first concerns the ethics of using an embryo for any purpose other than procreation and\nthe second is that such research will result in the destruction of the embryo. These concerns form the\nstarting point for critical reflection, and for the need to justify such research.\nThe central philosophical and juridical question is whether or not there are benefit",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 24
  },
  {
    "text": "s that may be achieved, or\nvalues served, by destructive embryo research that outweigh considerations of the good of the embryo. As\ndiscussed in Section II.B, positions on the status of the embryo differ. For certain people, there is no good,\nthat can be achieved that could outweigh the status accorded to the embryo, or in other words that could\noutweigh its good.\nIn such contexts, it is argued, that rather than choosing between two different methods of destroying an\nembryo that was no longer pa",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 24
  },
  {
    "text": "rt of a parental project (research or the usual procedure), it would be better to\nensure that there were no such embryos in existence, and hence the ethical dilemma would be avoided (see\nSection III.C).\nHowever, for those who take a gradualist position – as is the case with States that permit research on\nembryos that are no longer part of a parental project - the status of the early embryo is seen as a status\n“between” the understanding of the embryo as a part of “human life” and as a human pers",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 24
  },
  {
    "text": "on with human\nrights. This has lead to the principle of “respect for human life”, which is a constant and to be respected\nthroughout the period in which the embryo/fetus is developing (see Section II.B). Such respect provides\nrecognition of the embryo as more than merely a part of the human body or a bundle of cells. However, the\nquestion of a “right to life” is separate, and for holders of a gradualist perspective, the extent to which an\nembryo or fetus can be considered to possess such a right",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 24
  },
  {
    "text": " will progressively develop.\nThis principle means that, for those who hold it, “respect for life” can, under certain circumstances, be\noutweighed by the “good” of health. For those, the fact that such outweighing can take place is not\nnecessarily in conflict with recognition of the dignity of the embryo; that dignity can be seen as fundamental,\neven if it does not entail a right to life. The outweighing of respect for the life of the embryo by other potential\nbenefits to humankind is supported b",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 24
  },
  {
    "text": "y the fact that embryos that are no longer part of a parental project will\ninevitably die. In contrast, this could be seen by others as a consequentialist approach. This raises however,\nthe question of whether the end would justify the means.\nA distinction may also be made between embryos which were created in the setting of IVF treatment with\nthe aim of utilising only those most likely to develop after transfer (in other words, in situations where it\n24",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 24
  },
  {
    "text": "would always have been envisaged that not all of the embryos would form part of a parental project), and\nembryos created to be all transferred. The latter might occur in countries whose law prohibits the creation by\nIVF of more embryos than can be transferred in one treatment cycle (such as Austria and Germany) when,\nfor example, a mother died during treatment. In such systems, the aim is that embryos should only be used\nfor procreative purposes.\nProponents of such an approach also note that, if",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 25
  },
  {
    "text": " some use the term “embryo” before the appearance of the\nprimitive streak (after about 15 days (see figure 2, in Appendix I)) and then refer to “fetus”, other researchers\nuse the term “pre-embryo“ to make a distinction between early stages of embryonic development and the\nlater ones, and that this might be considered as a way of “disguising” that the subject of research is in fact\nan embryo. Indeed the term “pre-embryo” is not used in research on other mammals than the human being.\nSome people, ",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 25
  },
  {
    "text": "holders of a gradualist approach, might in turn argue that the term “pre-embryo” is a practical\nway of distinguishing different stages of embryonic life which may warrant different levels of protection.\nPurposes of research on the embryo\nIf research on the embryo in vitro is not ruled out in principle, the question arises as to the aims of research\nthat might justify the use of an embryo. Research on embryos that are no longer part of a parental project is\nestablished in several European countri",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 25
  },
  {
    "text": "es. Not all of these countries have legislation about this practice.\nHowever, whether or not there is a law, there seems to be general agreement that such research must be\nfor what might be broadly described as health purposes, whether directly (applied research) or indirectly\n(basic research, the results of which would have a potential direct benefit for human health).\nEarlier forms of legislation, such as the United Kingdom’s 1990 Human Fertilisation and Embryology Act,\ntook a relatively narro",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 25
  },
  {
    "text": "w view of health purposes and permitted embryo research only for purposes that, in\nbroad terms, might be considered to concern reproductive health and the reproductive process (including\nassisted procreation). More recently however, speculation about the potential for research on embryonic\nstem cells to lead to treatments for diseases unrelated to the reproductive process (such as Parkinson’s\ndisease) has lead certain countries to allow using embryos that are no longer part of a parental project",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 25
  },
  {
    "text": " for\nwider health purposes.\nResearch into human reproduction and medically assisted procreation\nThere are two main types of research in this field using embryos that are no longer part of a parental project:\n- research which relates more specifically to the improvement of medically assisted procreation\ntechniques, in particular IVF treatment and procedures. This may include studies designed to\nimprove fertilisation, or investigations of prolonged culture, freezing and the viability of the embryo",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 25
  },
  {
    "text": ";\nor the development of embryonic analyses for diagnostic or therapeutic purposes. The results of the\nlatter may assist potential future parents who carry or have a genetic disease in their desire for a\nhealthy child, and recognises the suffering and dilemmas that they may experience as a result of\nthe risk of having a child with that disease. Such suffering may result from their actual experience of\na child or a relative with the relevant disease. The recognition of this issue by law or practic",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 25
  },
  {
    "text": "e is the\nbackground of research for improvement of PGD.4\n- basic research, for example certain embryonic development studies, particularly at molecular level in\nthe early stages of development, in respect of which little is known about significant differences\nbetween human beings and animals. Such research could also be seen as serving wider health\npurposes, which are discussed further below.\nIt is generally agreed that an embryo that has been the subject of research must not be subsequently\ntra",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 25
  },
  {
    "text": "nsferred to the uterus of a woman. Exception is made for research which is confined to observation of the\ndevelopment of the embryo where it is usually supposed that the risk to either the embryo or the mother\nposed by the research would not be any greater than if the research had not taken place. Another exception\nimplies however a more invasive intervention on the embryo, in countries where preimplantation genetic\ndiagnosis is allowed and considered as a research procedure (see Chapter V).\n4 T",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 25
  },
  {
    "text": "here is some variability between countries on whether or not certain procedures which are being developed\nare considered as research for the purposes of the relevant legislation. This has, for example, been the case with the\ndevelopment of PGD in some countries.\n25",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 25
  },
  {
    "text": "In contrast, with other types of research the possibility of an adverse effect on the embryo or its subsequent\ndevelopment may be considered much greater. Nevertheless, it is also argued that if some potential\nimprovements in IVF are to be of benefit in clinical practice, the transfer of embryos that have been subject\nto a research technique would, at one stage, be necessary.\nRecent research purposes\nProducing an exact, brief, definition of health purposes is difficult. However, such purposes cl",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 26
  },
  {
    "text": "early serve –\nimmediately or at length - the health of concerned patients. Over very recent years, increasing attention has\nbeen focused on the potential for research on embryonic stem cells or ES cells to lead to benefits for human\nhealth. Potential benefits have been suggested in the treatment of patients suffering from Parkinson’s\ndisease, diabetes, and for those who may require an organ or tissue transplant. Others point out that these\nare just hopes, and that what is in fact being promoted ",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 26
  },
  {
    "text": "is more research – in which embryos may be used.\nThey draw the parallel with gene therapy, from which much has been hoped over the last fifteen years,\nwhereas the results have been, in clinical terms, very limited.\nIn this difficult debate, the importance of being clear about what is a fact, and what is merely a hope, has\nbeen emphasised, as have the dangers of predicting dates by which therapeutically useful interventions will\nbe available. On the other hand, others have emphasised the importan",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 26
  },
  {
    "text": "ce of the freedom of research, as\ndiscussed earlier in this report (see Section IV.B).\nObtaining embryonic stem cells entails extracting them from an embryo, which will be destroyed by this\nprocedure5. At present knowledge of embryonic stem cells is limited. However they have two key\nproperties: plasticity (the ability to differentiate into blood, brain, liver or muscle cell lines depending on the\nculture conditions in vitro) and the capacity for self-renewal (the ability to replicate themselves",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 26
  },
  {
    "text": " almost\nindefinitely) (see Section IV.C).\nThe potential benefits of studying such cells were mentioned in Section IV.C. However, it is clear that there\nare still many questions to be answered in relation to human beings about ways of renewing ES cells and\nhow to direct them at will to form differentiated tissues and to control their proliferation. Beyond this,\nquestions about the interaction between ES cells and the immune system and any harm that might be\ncaused by transplanting such cells woul",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 26
  },
  {
    "text": "d require investigation.\nMoreover, there are increasingly high hopes of using, for therapeutic purposes, stem cells from umbilical\ncord blood and from adult tissues. Certain recent studies suggest that progenitor cells, particularly from\nadult bone marrow, behave very similarly in vitro to ES cells. For those who do not consider research on the\nembryo acceptable, this has led to suggestions that we should not study ES cells until the hope of achieving\nthe same benefits from adult stem cells has ",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 26
  },
  {
    "text": "been exhausted. Others, who do find embryo research\nacceptable in certain circumstances, but only if the results cannot be achieved by any other method, have\nalso taken this position.\nIn contrast, given the current state of our knowledge, a number of arguments are given that suggest that the\nadult source cannot be considered as an alternative to the embryonic source6 and therefore it has been\nsuggested that both ought to be studied. Proponents of this position point to the suffering of patients ",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 26
  },
  {
    "text": "with\ndisease that might be alleviated by the results of ES research, and that to delay conducting such research\nmight prolong suffering. On the other hand, it has been argued that consideration of the rights of patients\nwho can be probably healed by cell transplantation is inappropriate, as any relevant rights they could have\ncan only exist in the future, given that a number of scientists estimate that the possibility of therapy utilising\ncell transplants is likely to be a minimum of 10-15 years",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 26
  },
  {
    "text": " in the future. Further, it may be ethically problematic\nto hold out such future promises to patients suffering from serious diseases, as this does not help them\ncope better with their disease in the present. Moreover, there can be no right to be healed by an immoral\nmeans. In contrast, if the embryo that will be destroyed in the relevant research has any rights, those rights\nexist now. If a patient in the future may be helped by a therapy developed as a result of research conducted\nnow, the spe",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 26
  },
  {
    "text": "cific identity of that individual is not known – and so there is no one to whom we could be said\nto have a specific duty – whereas there will be a specific, identifiable embryo that is destroyed by the\nresearch.\n5 There are a few countries (e.g. the United Kingdom, Japan) where the production of embryos by fertilisation or\nby cloning for this purpose is provided for by law; a few others are considering it; elsewhere such research is only done\nusing embryos which are no longer part of a parental ",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 26
  },
  {
    "text": "project.\n6 For example: lesser division potential; small quantity in any tissue; possibly absent from certain tissues; would also\nrequire genetic modification in the event of a genetic disease.\n26",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 26
  },
  {
    "text": "Regulation of research\nAs is evident, the ultimate resolution of the question of the permissibility of research on embryos which are\nno longer part of a parental project depends centrally on the conclusion drawn on the status of the embryo.\nIt is important that the arguments both for and against such research are fully discussed in reaching such\nconclusions.\nThose States which have concluded that research on these embryos may be permissible have clearly\nrecognised the ethical dilemmas involved. ",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 27
  },
  {
    "text": "Both the procedures and the institutions involved in such\nresearch are subject to regulations, and the individual research projects are both authorised and supervised\nby the relevant competent body.\nA final question concerning the regulation of research may be briefly raised. Whilst a State may choose to\nban embryo research completely, if it does so the question arises as to whether it should permit on its\nterritory techniques, or use of materials or even results that have been developed or prod",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 27
  },
  {
    "text": "uced using such\nresearch carried out in another state where they are allowed. Should, for example, research that has made\nICSI7 or PGD8 possible and is essential before such techniques are put into practice, continue in some\ncountries and then benefit others which have already condemned such research? If so, is there a duty to\ninform patients who might benefit from the techniques in clinical practice of the means by which the\ntechnique has been developed?\nImport of embryonic stem cell lines\nFor ",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 27
  },
  {
    "text": "countries in which research on embryos is forbidden, such as Germany, the question of whether or not\nthe import of embryonic stem cell lines should be permitted has raised difficult questions. The issue of\nimport of stem cells may also arise in countries in which the scientific resources to develop embryonic stem\ncell lines are not yet available.\nAs noted previously, it has been argued that it is important to continue the promising experiments with stem\ncells and animal models using both embryon",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 27
  },
  {
    "text": "ic and adult stem cell lines.\nCertain countries with strict positions with regard to embryo research have taken the decision to allow import\nof embryonic stem cells from other countries. This was the case in France with a Governmental order in\nFebruary 2000 (this possibility has however been suspended since then. The issue is now being\nreexamined in the framework of the revision of the bioethics legislation of 1994).\nAnother example is Germany. According to the German Embryo Protection Act, the ",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 27
  },
  {
    "text": "production of human\nembryonic stem cells is prohibited in Germany. The German Stem Cell Act, which entered into force on 1st\nJuly 2002, poses a general ban on import and use of human embryonic stem cells. An exception is made\nonly for publicly and privately funded research purposes subject to strict conditions and approval by a\ngovernment agency.\nAs noted in the previous section, there are different approaches to the creation of embryos in the context of\nIVF. In some countries there is essential",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 27
  },
  {
    "text": "ly an acknowledgment that embryos will exist that may not form part\nof a parental project, in that more embryos are created than can be replaced in the uterus in a single cycle\nand which may not be transferred in the future. In countries such as Germany and Austria legally the\nnumber of embryos created shall not exceed the number which can be transferred within one treatment\ncycle, and therefore it is not intended that any such embryos should exist. As a result, it is estimated that in\nGermany l",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 27
  },
  {
    "text": "ess than 70 stored embryos are thought to exist that are no longer part of a parental project, by\ncontrast to the remainder of Europe, in which more than 100,000 such embryos are thought to exist and to\nbe cryopreserved.\nCurrent discussion and decisions with regard to embryonic stem cells show the difficulty in finding an\nappropriate balance between the wish to keep an active role in a research field the results of which are\nsuggested as potentially determinant in terms of medical progress and t",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 27
  },
  {
    "text": "o benefit from these potential\napplications whilst seeking to maintain a generally highly restrictive approach to the question of embryo\n7 Intra cytoplasmic sperm injection\n8 Pre-implantation diagnosis\n27",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 27
  },
  {
    "text": "research. Current legal initiatives taken in several European countries acknowledge the wish for coherence\nin the approach taken.\nE. Creation of embryos for research (including for the collection of stem cells)\nTo deliberately create an embryo for the purposes of a research project is prohibited by the Convention on\nHuman Rights and Biomedicine (Article 18(2)) and is widely regarded worldwide as not ethically\nacceptable. It would involve using the embryo purely as a means to an end. This degree ",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 28
  },
  {
    "text": "of\ninstrumentalisation of the embryo is rejected even by many of those who accept the use of embryos which\nare no longer part of a parental project for properly regulated research. As seen in Section IV.D above, it is\nargued that unless such an embryo is to be transferred to a uterus, it will in any case not survive, so to use it\nfor worthwhile research that might bring benefit or help to reduce suffering might be regarded as a better\noption than just discarding it. This argument would not apply",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 28
  },
  {
    "text": " to embryos created for research, since they\nwould not have existed had it not been for the research project. However, it is argued that certain specific\nresearch intended to benefit human health cannot be carried out on existing embryos and requires creation\nof embryos outside of a parental project. It is on that basis and subject to very strictly defined criteria and\npurposes that in the United Kingdom and in Belgium, for example, creation of embryos for research has\nbeen authorised.\nThe statu",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 28
  },
  {
    "text": "s of the embryo itself, once it has come into existence, is presumably the same whether it was\ncreated directly to alleviate infertility (IVF) or to avoid the birth of babies with serious disorders (PGD) - or for\nresearch aimed ultimately also to alleviate infertility or to avoid or treat serious disorders or illness. In\nprinciple, all embryos that are created, for whatever purpose, have the capacity to develop. The range of\nviews on the status of an embryo were reviewed earlier in this report (",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 28
  },
  {
    "text": "see Section II.B).\nThe proximate intention in creating an embryo may, of course, differ: on the one hand the birth of a baby,\nand on the other hand to create an embryo that will be destroyed in the course of the research. When more\nembryos are created than can safely be transferred to the uterus in a single cycle, it is almost certain that\nsome of those embryos will perish, but it is hoped that this will reinforce the chance of a successful parental\nproject. When embryos are deliberately produce",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 28
  },
  {
    "text": "d for research, the hope for beneficent consequence is\nboth less direct and more long-term.\nFrom the proportionality point of view, there are research projects that are considered worthwhile and\nnecessary that cannot be carried out on embryos that are no longer part of a parental project. There are\nseveral examples. Cryopreservation of embryos today is safe and relatively efficient. It would be preferable\non both clinical and ethical grounds to be able to cryopreserve unfertilised oocytes, for i",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 28
  },
  {
    "text": "nstance for young\nwomen who are receiving cancer treatment that is likely to endanger their fertility and who wish to preserve\nsome reproductive potential. Unfortunately chromosome stability is lower in oocytes than in embryos, so\nthat to develop optimal methods of oocyte freezing and thawing it is necessary to fertilise the experimental\noocytes and then test the resulting embryos for normal cleavage chromosomes and patterns. This entails\ntheir destruction, but the alternative is to transfer emb",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 28
  },
  {
    "text": "ryos derived from experimentally frozen oocytes\ndirectly to the uterus, thus in effect subjecting the fetus and mother to experimentation. Similarly, embryos\nderived by intracytoplasmic sperm injection (ICSI) of immature, as opposed to mature, spermatozoa require\nto be tested for normality before ICSI with immature spermatozoa is introduced into clinical practice. This\nwould require the creation of embryos which would not be subsequently transferred into a uterus.\nA significant proportion of int",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 28
  },
  {
    "text": "ernational research into human reproductive biology now concerns the early\nstages of fertilisation leading to the conception of embryos which need to be analysed by invasive\ntechniques. The creation of embryos is thus an integral part of such research, or necessary for analysing\nthe results of such research. It is argued that, in such cases, embryos created could be considered as\nhaving been created “by research” as distinct from “for research”. For some people this is a significant\ndistinction,",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 28
  },
  {
    "text": " with some considering that the creation of embryos for non-procreative purposes is only\nacceptable in the context of research on fertilisation.\nThe tens of thousands of embryos cryopreserved in Europe at the present time make it unlikely that there\nwould be any need to fertilise donated oocytes specifically in order to derive new stem cell lines. It is\nargued however that, at some stage, it might become relevant that the frozen embryos come, in the vast\nmajority of cases, from a selected sample",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 28
  },
  {
    "text": " of the population with fertility problems, and they are often of poor\ndevelopmental potential since the embryos appearing most likely to develop will be transferred to the\n28",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 28
  },
  {
    "text": "woman's uterus first. Also as IVF becomes more efficient and fewer oocytes are recovered, the number of\nembryos that no longer form part of a parental project could fall and fewer could be cryopreserved.\nIn countries which have authorised the creation of embryos for research, the relevant regulations have laid\ndown restrictions on the procedure. As with research on embryos that are no longer part of a parental\nproject, such regulations aim to ensure that the aims of the research project are wort",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 29
  },
  {
    "text": "hwhile and cannot be\nachieved in any other way. In practice, the number of embryos that have been created for research\npurposes are extremely small compared to the number initially created for reproductive purposes.\nOocyte donation\nConcerns have also been expressed about the risk of instrumentalisation of human beings and, in particular,\ndonors of oocytes for the purposes of this type of research (e.g. improvement of fertilisation and\ncryopreservation technique for oocytes). Given that the resea",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 29
  },
  {
    "text": "rch may not benefit the donor of the oocytes, it\nhas been suggested that there are analogies with research without potential benefit on persons not able to\nconsent. On the other hand, from the perspective of certain patients, it could be argued that participation in\nthis research involves no greater risk or degree of instrumentalisation than any other research project. From\nthe perspective of donors, if a donor is given all the necessary information about the risks that may be\nentailed in donati",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 29
  },
  {
    "text": "ng oocytes, and about the ways in which their oocytes will subsequently be used, the\ndonor should be in a position to choose whether or not to give free and informed consent. However, some\nconcerns have been expressed about the risk of commercialisation, in particular for women in difficult\nfinancial situations who might be tempted to sell their oocytes. The possibility of oocytes being diverted from\nthe purpose for which they were originally obtained has been suggested. However, if a woman has ",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 29
  },
  {
    "text": "given\nsuch consent it may be inappropriate to regard her as being instrumentalised. In this respect, the accuracy\nand extent of the information given will clearly be vital. In this context, it has sometime been suggested that\nafter having given consent, the couple/woman should be given time to reconsider their/her decision.\nSimilarly, it has been proposed that consent be requested by somebody else than the doctor in charge of\nthe treatment. Furthermore, in general, the imperative need to make su",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 29
  },
  {
    "text": "re that the consent of the\ncouple/woman is free, has been stressed.\nCloning\nArguments are also developed in favour of a possible future category of embryos created for research by\nsomatic cell nuclear transfer, a procedure leading to cloning. As noted previously, there is debate about the\nmoral significance of different methods of creating an “embryo” (see Section II.B). In this case, the definition\nof an embryo is taken to be the earliest stage of development, rather than the product of fertili",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 29
  },
  {
    "text": "sation of an\noocyte by a spermatozoid. At present there is little evidence that such a procedure would work in the\nhuman. If it did work, one possible line of research which could be considered worthwhile, might be the\nproduction of embryonic stem cell lines from patients suffering from rare and poorly understood metabolic or\ngenetic diseases, to provide material to study the biochemistry or physiology of the disease. A further aim\nmight be to derive embryonic stem cell lines from individual pat",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 29
  },
  {
    "text": "ients suffering from degenerative diseases,\nwith the aim of therapeutic use of the stem cells on the same individual, thus circumventing the risk of\ntransplant rejection. However, it is argued that the difficulties already met with embryonic stem cells (e.g.\ncontrol of differentiation and of proliferation) would first need to be solved before considering such a\ntechnique. Furthermore, this approach, sometimes misleadingly termed \"therapeutic cloning\" (see below),\nseems unlikely to be developed f",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 29
  },
  {
    "text": "or clinical use for economic reasons. The chief objection to \"therapeutic\ncloning”, in addition to the more fundamental objection, namely the ethical unacceptability of creating\nembryos for research and the resulting instrumentalisation of the embryos, is that it would facilitate the\ndevelopment of \"cloning for babies\" (often termed \"reproductive cloning\"). “Reproductive” cloning is almost\nuniversally rejected on ethical grounds and is prohibited in several European countries (as well as by the\n",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 29
  },
  {
    "text": "Council of Europe's \"Additional Protocol to the Convention on Human Rights and Biomedicine on the\nprohibition of cloning human beings\").\nThose who have concerns about the use of embryos in research have also highlighted what might be\ndescribed as “language politics” with regard to ES cells. In particular, they express concerns about the term\n“therapeutic”. The term “therapeutic” is only used because the intention is to derive embryonic stem cells\nwhich could potentially be used for therapeutic p",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 29
  },
  {
    "text": "urposes. But for those who believe that the product of cell\nnuclear transfer is an embryo, the fact that the purpose of the procedure of “therapeutic” cloning is not to\nproduce a baby is to ignore the fact that the embryo so produced does indeed have that potential and\ntherefore its creation does raise ethical concerns. Further, they would argue that the term “therapeutic” is\nalso misleading, given that there is nothing therapeutic about the cloning procedure itself and that, at\npresent, there i",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 29
  },
  {
    "text": "s no guarantee of producing a result of therapeutic use. It is argued therefore that it would be\nmore accurate to refer to “cloning for stem cells” and in the same way to talk about “cloning for a baby”\n29",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 29
  },
  {
    "text": "rather than “reproductive cloning”. Finally, others anxious not to use misleading terminology have proposed\nthat reference be made each time to the purpose of the cloning: research, therapeutic, reproductive.\nV. Preimplantation diagnosis (PGD) (for genetic diagnostic purposes)\nA. Presentation of PGD: procedures and conditions\nPreimplantation genetic diagnosis (PGD) allows the detection of genetic defects before implantation. PGD\nwas initially developed to offer an alternative to prenatal diagnos",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 30
  },
  {
    "text": "is for couples at risk of transmitting a\nparticularly severe genetic defect, avoiding the difficult decision of whether or not to terminate a pregnancy.\nThe first indication for PGD was the detection of specific genetic anomalies that will lead to the development\nof a genetic condition in a future child (including sex-linked diseases), or chromosomal abnormalities which\nwould lead to early miscarriage or major health problems in the child. PGD indications have recently evolved\nto include improvi",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 30
  },
  {
    "text": "ng IVF success for infertile couples by screening embryos for common or age-related\naneuploidies. The practice of screening for aneuploidy is discussed in Section III.C. Clinical PGD\napplications started in 1990 in England and since then it has been offered in a very large number of\ncountries, but by a limited number of centres.\nPGD procedure\nPGD procedures combine an in vitro fertilisation and a genetic analysis of the embryo obtained in order to\nselect and transfer to the uterus of the women o",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 30
  },
  {
    "text": "nly embryos not affected by the abnormalities concerned.\nThe first part of the procedure is hence no different from normal IVF/ICSI treatment, producing for these\nusually fertile couples, sufficient embryos to give a high probability of obtaining unaffected embryos, even in\nsituations where the risk of an embryo being affected is 25 to 50%. The vast majority of PGD cycles use\nICSI to avoid contamination with “foreign” DNA coming from other spermatozoa. The biopsy on the embryo\nis carried out thr",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 30
  },
  {
    "text": "ee days after fertilisation by gentle aspiration of one or two cells (blastomeres) or, less\noften, on the fifth day by biopsy of the trophectoderm (future placenta) of the blastocyst (embryonic stage\njust before implantation). An alternative to blastomere biopsy is the biopsy of the first and/or the second\npolar body. Such a strategy has the advantage of avoiding the pick up of embryonic material, but the major\nlimitation comes from the fact that only the maternal genome can be analysed. Most PG",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 30
  },
  {
    "text": "D procedures are\ncarried out on blastomeres.\nThe genetic analysis, according to the indication, can be performed by two different techniques:\n1) PCR (polymerase chain reaction) which amplifies the small amount of DNA obtained from the\nblastomeres determines the presence or absence of the gene defect involved by molecular analysis.\n2) FISH (fluorescent in situ hybridisation) identifies particular chromosomes with a specific colour to look for\nsuspected numerical or morphological chromosome abnorm",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 30
  },
  {
    "text": "alities.\nIn all cases, only unaffected embryos are transferred. The others may be donated for research in countries\nwhere such research is allowed.\nRegulation\nIn some countries PGD is regarded as a research technique, whereas in others it is considered as clinical\npractice. Considerable legal differences exist among countries, ranging from total bans to the almost\ncomplete absence of any regulations. In the majority of countries offering PGD, an authority regulates and\nensure respect for good pr",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 30
  },
  {
    "text": "actice, for PGD as well as for prenatal diagnosis (PND).\nPGD requires a multidisciplinary medical team which combined the necessary competencies and skills to\ncarry out the different steps of the procedure. It should be possible for the couples to be offered adequate\nindependent and non directive counselling and psychological support before and after PGD.\nPGD results\nPreimplantation genetic diagnosis is used for couples at risk of transmitting a severe genetic disease,\nusually identified on the ",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 30
  },
  {
    "text": "basis of family history or the birth of affected children. Technically embryos can be\nchecked for more than twenty genetically determined monogenic diseases, as well as for chromosomal\n30",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 30
  },
  {
    "text": "abnormalities9. The biopsy of blastomeres is successful in 97% of cases and a diagnosis obtained in 86% of\nsuccessfully biopsied blastomeres10.\nThe scientific and medical information that is presently available suggests that the use of PGD does not\npose a risk to the health of the future child. However, because the technique has been in use for relatively\nfew years, a follow up of children born after the use of PGD has been suggested to establish the position in\nrelation to safety more clearly.\n",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 31
  },
  {
    "text": "PGD’ future development\nMost centres offering PGD have tests for the most frequent genetic disorders. The advances will now come\nin the ability to develop diagnosis for rare diseases and in the improvement of the existing diagnosis.\nHowever, an increasing range of potential uses for PGD is being suggested. As well as gender selection for\na range of purposes, these have included using PGD to screen for susceptibility to certain cancers, and\nmore controversially for HLA matching with an existing s",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 31
  },
  {
    "text": "ibling. The latter is discussed further in Section D\nbelow. Fears have also been expressed about the possibility of “designer babies”, although the term is\nmisleading. Rather than a potential child being “designed” as such, a selection would be made on the basis\nof particular characteristics – that may have nothing to do with health, such as hair colour, if the genetic\nbasis of the characteristics is known – and only embryos with the desired characteristics would be replaced\nin the uterus and he",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 31
  },
  {
    "text": "nce have a chance to develop.\nB. Ethical aspects and social consequences, in particular the issue of eugenics\nPreimplantation diagnosis (PGD) can be seen by some, as an anticipatory form of prenatal diagnosis (PND)\neven if each has its own indications. If seen as such it does then raise ethical issues which are common to\nother types of prenatal diagnosis, in particular when it comes to discrimination and stigmatisation. However,\nas PGD implies creation of embryos by IVF, intervention on embryos ",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 31
  },
  {
    "text": "and their selection for transfer,\nadditional concerns are expressed in relation to the status of the embryo and reference is made to eugenics.\nThe consequences of PGD and PND procedures for the couple and in particular the mother, are very\ndifferent. PND is carried out during pregnancy. As a result of the test the couples have the dilemma of\nwhether or not to terminate the pregnancy if the relevant genetic abnormality is present.\nPreimplantation genetic diagnosis (PGD) offers the possibility of ",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 31
  },
  {
    "text": "identifying affected embryos before the\npregnancy is established. Only unaffected embryos will be transferred to the uterus. This technique obviates\nthe need for screening for this purpose during a pregnancy, and therefore avoids the physical and\npsychological trauma associated both with the consideration of a possible termination and, where such an\noutcome is chosen, with the termination itself. However, PGD results are currently routinely controlled by a\nlater PND.\nWithout access to PGD couple",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 31
  },
  {
    "text": "s that are aware that they are carriers of a genetically transmitted disease,\nand wish to avoid passing on that disease to a child, will be faced with the options of choosing not to have a\nchild or to undertake PND and possible termination of pregnancy. For those who would find termination of\npregnancy unacceptable, this may mean giving up the hope of having a child that is biologically their own.\nThe potential benefits of PGD to such couples are to enable them to consider a pregnancy without th",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 31
  },
  {
    "text": "e\n9 The ESHRE PGD Consortium steering committee, Geraedts J, Handyside A, Harper J, Liebaers I, Sermon K,\nStaessen C, Thornhill A, Vanderfaeillie A, Viville S, Wilton L. ESHRE preimplantation genetic diagnosis (PGD)\nconsortium: data collection III (May 2001). Hum. Reprod. 2002; 17 : 233-246.\n(Indication for PCF diagnosis for 2001)\nCentral core disease, Charcot-Marie-Tooth 1A, Charcot-Marie-Tooth 2A, Crouzon syndrome, FAP-Gardner, HD-\nexclusion, Huntington’s disease, Marfan’s syndrome, Myotonic d",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 31
  },
  {
    "text": "ystrophy, Neurofibromatosis, Osteogenesis imperfecta\nI, Osteogenesis imperfecta IV, Stickler syndrome, Tuberous sclerosis, Beta-thalassemia, CDG1C, Cystic fibrosis,\nEpidermolysis bullosa, Gaucher’s disease, Hyperinsulinemic hypoglycemia PHH1, Sickle cell, Spinal muscular atrophy,\nTay-Sachs disease, Agammaglobulinemia, Alport syndrome, Duchenne’s muscular dystrophy, Hunter’s syndrome\nMPSII, Spinal and Bulbar muscular atrophy, Alport syndrome, Fragile X syndrome, Oro-facial-digital syndrome type 1",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 31
  },
  {
    "text": ",\nMELAS, CF+FRAXA, CF+XL mental retardation\n10 Hum. Reprod. 2002 17: 3260-3274.\n31",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 31
  },
  {
    "text": "anxiety associated with the risk of passing on a serious genetic disease to allow them to have children who\nare both biologically their own and free from that specific disease.\nOn the other hand, a number of concerns have been expressed about the practice which are discussed\nbelow. Indeed, to those who regard an embryo as a human being with a right to life from the moment of\nconception (see Section II.B), PGD is objectionable because it involves a morally impermissible selection\namongst those wi",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 32
  },
  {
    "text": "th an equal right to life.\nThere has also been debate about the capacities of the blastomere removed from the embryo and subjected\nto the process of genetic testing. If such a blastomere was totipotent, or in other words itself had the\ncapacity to form an embryo, to undertake testing that would result in the destruction of the blastomere could\nbe regarded as equivalent to destroying an embryo, and, for certain people, a human being. However, most\nscientists consider that a blastomere derived fro",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 32
  },
  {
    "text": "m the embryo at the 8-cell stage is pluripotent (i.e. has the\ncapacity to differentiate into different tissues but no longer the capacity to form an embryo) rather than\ntotipotent.\nOthers have pointed out that if an embryo with a genetic abnormality is allowed to mature and be born alive,\nthe abnormality may not necessarily result in a disorder or disease in the person concerned. Genetic\nvariations (alleles) have a penetrance factor, which is a measure of their effectiveness or power. For\nexampl",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 32
  },
  {
    "text": "e, the allele that causes Huntington’s disease has a 100% penetrance, so that if someone has the\nallele, s/he will – assuming they live long enough – develop the disease. Other genetically determined\nconditions have a much lower penetrance: for example, 15% for left-handedness. Thus it is argued that\nmany embryos will be destroyed even though the abnormality that they carry would never have caused a\ndisease or disorder if PGD were to be allowed for such low penetrance conditions.\nPGD has also ar",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 32
  },
  {
    "text": "oused particular concern with regard to its social consequences and in particular the\npossibility of eugenics (see below).\nAssumptions underlying PGD\nThe assumption underlying prenatal diagnosis, and therefore PGD as a particular category of such\ndiagnosis, is that certain conditions or characteristics are classified as diseases or malformations or\notherwise unwanted. This emphasises the need to clarify relevant concepts – for example of disease,\nnormality, genetic variation, and eugenics. In pa",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 32
  },
  {
    "text": "rticular, there needs to be clarity about the misleading\nnotion of “genetic perfection”, in contrast to the reality of genetic “abnormality” as an integral part of the\ncharacteristics of all human beings. Clarifying these concepts will mean that underlying conceptions of\ndisease and quality of life are made explicit, and that reasons for and against the potential approaches to\nthe indications for PGD can be considered. Questions concerning the status of the embryo, and ensuring\nthe voluntary bas",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 32
  },
  {
    "text": "is of decision-making will also be relevant in such debates.\nThe distinction between diseases, disorders and characteristics warrants scrutiny. If it could be considered\nmorally acceptable to use PGD for severe genetic diseases, some concerns are expressed with the\npossibility of using PGD to select an embryo on the basis of certain characteristics.\nThis may give rise to several kinds of risks: in particular, a risk for children with those characteristics\n(handicap, for instance) that are born t",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 32
  },
  {
    "text": "o be or feel stigmatised, and a risk of pressure on the parents who,\nsince the technique is available, could have arguably avoided a child with this particular handicap or genetic\ndisorder.\nSome people are already arguing that the current use of PGD will lead to discrimination and stigmatisation.\nOthers have expressed concern that the use of PGD will have such negative social consequences, or at\nleast that it is not unlikely that PGD will lead to such consequences.\nThe problems of definition and",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 32
  },
  {
    "text": " classification should be considered in this context. In many countries PGD is\nonly allowed for diagnosis of severe genetic diseases. But differences are met in how the seriousness of a\ngiven disorder is classified. Certain patient’s organisations have objected to the use of PGD and other\nmethods for prenatal diagnosis on the ground that they undermine the equal value of human beings, and\nhave stressed that notions like “severe genetic diseases” are social constructions.\nIt has been replied that",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 32
  },
  {
    "text": " one must distinguish between a particular genetic disease and the person having\nthat disease. That the disease is negatively valued, and that it is desirable and legitimate to try to avoid it,\n32",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 32
  },
  {
    "text": "does not mean that the person having the disease is negatively. In that way there is no conflict of interest\nbetween attempts to eradicate (or diminish the prevalence of) a disease and help to those who suffer from it.\nHowever, it has been stressed that the use of PGD, even though this is not intended, will have stigmatising\nconsequences because it will reduce the number of people with certain genetic diseases. Social pressure\nmay be enough to exert the effect. If the values underlying these def",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 33
  },
  {
    "text": "initions, classifications and social and\nreproductive practices are more generally supported in society, such evaluations may lead to more obvious\nand straightforward discrimination - which in its turn may increase the pressure on future parents to use\nPGD and other similar techniques to avoid embryos with certain diseases or characteristics.\nThe risk of widening the indications, so that the method is first used to avoid children with severe genetic\ndiseases, and then less and less severe diseas",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 33
  },
  {
    "text": "es are included as time goes by, has been stressed. Some\nargued that the risk cannot be excluded, particularly as increased weight is attached to respecting the\nautonomy of the couple/woman. If the method can be stigmatising and discriminatory when used\nrestrictively, it may be even more so when the indications are wider.\nAs will be seen below, in the context of eugenics issues have arisen about the promotion of desirable\ncharacteristics. It can be noted that human beings can seek to improve the",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 33
  },
  {
    "text": "ir own capabilities, for example\nby training in sports, or parents the capabilities of their children by providing them with extra facilities for\neducation. Some people have questioned whether the difference between undertaking such activities, and\nconducting PGD – should the genetic basis of the characteristics sought ever be sufficiently elucidated –\nwith the aim of producing a child who has the potential to develop high capabilities in certain fields, is\nmorally relevant.\nThe reference to “eu",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 33
  },
  {
    "text": "genics”\nThe term “eugenics” arouses strong emotion, and it is particularly important to try to clarify what is meant by\nthe term. Eugenics involves selection on the basis of genetic characteristics. Some people would argue that\nany selection of human beings, each with certain rights, is eugenics - the question of eugenics in relation to\nPGD being thus mainly related to the question of the status of the embryo (see Section II.B). However,\nothers would consider that not all selection involve eugen",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 33
  },
  {
    "text": "ics. Eugenics presupposes that a selection is\nmade on the basis of some type of genetic characteristic and that the moral basis in terms of the purpose\nand/or consequences of the selection is unacceptable, involving discrimination and stigmatisation of certain\nindividuals or groups. Furthermore, eugenics has been historically associated with the notions of coercion\nand third party influence in reproductive choices. This notion is therefore perceived as a strongly negatively-\nvalued term.\nA disti",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 33
  },
  {
    "text": "nction has traditionally been made between positive and negative eugenics. In the first, parents with\nwhat is considered to be a good genetic heritage are encouraged to produce children. In the second, people\nwith what are considered to be “bad genes” are dissuaded or prevented (sometimes by compulsory\nsterilisation) from having children.\nConcerns have been expressed about the morality of eugenics on two grounds. Firstly, because it\nundermines respect for human dignity and for the equal value of",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 33
  },
  {
    "text": " human beings. The second ground is more\nhistorically based. In the context of PGD, it has been suggested that we should learn from past experiences\nand for the potential for a progressive increase in the scope of the indications for PGD to lead to the practice\nof eugenics.\nIn the context of PGD, it is clear that although the practice is used to prevent the passage of a serious\ndisorder to a child, there is at least the possibility of using the technique for the purpose of selecting\n“positive” q",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 33
  },
  {
    "text": "ualities, rather than purely the absence of diseases or disorders. Furthermore, it is the choice of\nan individual couple which is supposed to be taken freely without the intervention of a third party. The\nquestion is therefore whether or not PGD is always, or may be in some circumstances, a eugenic practice.\nEugenics is usually also used as a term for a practice which may be applied to all members of a particular\ngroup. However, questions of discrimination and stigmatisation of individual member",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 33
  },
  {
    "text": "s of a particular group\nare also important, whether or not any forms of intervention are applied to that group as a whole. The need\nto address such discrimination at a European level is highlighted by Article 11 of the Convention on Human\nRights and Biomedicine, which prohibits discrimination on grounds of genetic heritage. Similarly, at a global\nlevel, Article 6 of UNESCO’s Universal Declaration on the Human Genome and Human Rights states: “No\none shall be subjected to discrimination based on g",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 33
  },
  {
    "text": "enetic characteristics that is intended to infringe or has\nthe effect of infringing human rights, fundamental freedoms and human dignity”. These concerns have lead\n33",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 33
  },
  {
    "text": "countries to develop laws and guidelines to reduce the risk of eugenics, and of undermining respect for\nhuman dignity. In some countries, explicit restrictions have been placed to the effect that PGD must only be\nused for couples with serious, progressive, hereditary diseases which can lead to premature death and\nwhere no cure or treatment is currently available. Other countries have not considered it necessary to\nrequire that the disease be “progressive” or that it specifically lead to prematur",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 34
  },
  {
    "text": "e death and have only\nreferred to the high probability for the child to be born with an incurable serious genetic disease. Some other\ncountries have taken a more flexible approach, limiting the use of PGD for the purposes of establishing\nwhether an embryo might suffer from a serious genetic condition.\nThree different approaches can be taken with regard to the diseases concerned:\n- a fixed list of diseases for which PGD is allowed\nThis is the least flexible approach. As our knowledge of the genet",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 34
  },
  {
    "text": "ic basis of disorders increases, such a list\nwould need to be regularly reviewed if it was to remain appropriate. Equally, as the possibility of treatment\nfor different disorders develops there may be a need to review whether the indication remains appropriate.\nDetermining the criteria for inclusion on the list may be problematic for the same reasons discussed in\nrelation to the second potential approach. A specific list would give rise to particular concerns about\ndiscrimination and stigmatisat",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 34
  },
  {
    "text": "ion of those suffering from the conditions concerned.\n- PGD only used for serious non-curable diseases, but no fixed list\nThe difficulty with this approach is determining how, or by whom, the seriousness of a disorder should be\ndetermined. Even within a single genetic disorder, the way in which the life of an individual is affected by\nthat disorder may vary considerably. Another issue is whether or not the views of the couple concerned\nshould be taken into account in determining the seriousness ",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 34
  },
  {
    "text": "of a disorder. Those who have experience of a\ndisorder within their family, or who already have one or more affected offspring, may have different views\nabout their ability to cope with a child with that particular disorder. A rigid approach may make it more\ndifficult to take individual perceptions into account. Furthermore, geneticists may also have different views\non precisely which conditions are “serious”. This might mean that a couple might be able to obtain PGD for\na particular condition i",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 34
  },
  {
    "text": "n some places but not in others.\n- examination on a case-by-case basis, on the assumption that what is a serious disease will vary to\ndifferent people, as will their ability and willingness to cope with various diseases\nThis is the most flexible approach and enables a more individualised approach to be made to the couple.\nHowever, the results may be criticised as being somewhat arbitrary.\nIn relation to the restrictions placed on PGD, the coherence between the protection offered to the embryo in",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 34
  },
  {
    "text": "\nvitro (the subject of PGD) and the fetus in vivo (the subject of PND) within an individual national system has\nalso been questioned. For example, if PGD is only permitted for a very restricted range of disorders, but\nPND and subsequent termination of pregnancy can be undertaken for a broader range of disorders, this\ncould be interpreted by some as suggesting that the embryo is offered a higher level of protection than the\nfetus. For those who take a gradualist approach, as described in Section ",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 34
  },
  {
    "text": "II.B above, and consider that the\nprotection and rights afforded to an embryo/fetus increase throughout the process of development, this\nwould appear anomalous.\nThe importance of voluntariness\nAutonomy is an important value, and it provides the basis of the requirement of free and informed consent.\nVoluntariness – an expression of autonomy - is generally considered crucial in health care, and is\nemphasised in Article 5 of the Convention on Human Rights and Biomedicine.\nConcerns have been express",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 34
  },
  {
    "text": "ed that health care professionals, including genetic counsellors, whether\nconsciously or unconsciously, may transmit social pressures and “eugenic attitudes” to patients. Hence,\ninfluence could be exerted on the choices made by a couple, diminishing the voluntariness of consent and\nleading to eugenic consequences in the sense that the purpose – as well as the effect – of the selection will\nbe to reduce the number of people with certain genetic diseases, or with an increased risk of getting certa",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 34
  },
  {
    "text": "in\nhereditary diseases.\nAlthough it is generally considered vital that individuals make a voluntary choice about undergoing PGD,\nconcern has been expressed about particular cases in which there has been a request for affected embryos\nonly to be selected for replacement in the uterus. Such requests may derive from a desire that the child of a\ncouple affected with a disorder may “fit in” to the family or social culture where s/he will be living (for\n34",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 34
  },
  {
    "text": "example in to the “deaf community”). However, it would then generally be argued that the welfare of the\npotential child should be given paramount importance and the impact the relevant disorder may have on the\nchild in terms of that child’s functioning and opportunities as a whole should be considered.\nC. Selection of sex\nAs has been noted above, it is possible to use PGD to select the sex of the embryos that will be replaced in\nthe woman’s uterus. There are three main reasons why this may be co",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 35
  },
  {
    "text": "nsidered desirable:\ni) for medical reasons\nThis is the most straightforward indication. Where a genetic disease is linked to gender, rather than the\nneed to identify the specific gene responsible for the disorder, it would be sufficient to identify the presence\nof the relevant sex chromosome as a basis for selecting embryos that will be free of the disease. Such an\napproach does not raise differences in principle from selecting on the basis of the presence of a specific\ngene. Article 14 of the C",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 35
  },
  {
    "text": "onvention on Human Rights and Biomedicine permits the use of medically assisted\nprocreation techniques for the purpose of choosing a future child’s sex if the aim is to avoid a serious\nhereditary sex-related disease. PGD could be considered as part of such techniques.\nHowever, as noted in the previous section, defining what constitutes a “serious” disease is not\nstraightforward. The same issues discussed in Section V.B would also apply to gender linked disorders.\nii) for societal reasons\nIn some",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 35
  },
  {
    "text": " societies children of one sex may be considered inherently more desirable than children of the\nother sex. Alternatively, it may be considered particularly desirable for the first child to be of a particular sex.\nIn such societies, it is usually a male child that has been preferred. Concerns have been raised about the\nidentification of fetal sex during pregnancy in such countries using non-invasive techniques such as\nultrasound, as there have been reports of healthy female fetuses subsequently b",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 35
  },
  {
    "text": "eing aborted. The\nexistence of such preferences raises issues concerning discrimination on grounds of sex in such societies. It\ncan be argued that permitting sex selection in support of such preferences is likely to reinforce\ndiscrimination and be contrary to human dignity and the respect for equality to which all human beings\nshould be entitled.\nIn contrast, it has been argued that the use of PGD in such situations may prevent termination of the fetus at\na later stage of pregnancy, and from a g",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 35
  },
  {
    "text": "radualist approach to the rights and protections of the embryo and\nfetus this might be considered desirable. Nevertheless, to allow PGD to be used in this way could also be\nseen as an implicit endorsement of the practice of terminations of fetuses of an undesired sex, and of the\ndiscrimination that such practices reflect. Furthermore, Article 14 of the Convention on Human Rights and\nBiomedicine would prohibit the use of medically assisted procreation techniques for this purpose.\niii) for family ",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 35
  },
  {
    "text": "balancing\nWhen a couple has one or more children of a particular sex, they may desire to “balance” their family by\nhaving a child of the opposite sex. This might be seen as a variant of the social reasons discussed above,\nbut in this case it has been argued that the risks of reinforcing discrimination, or of the approach leading to\neugenic practices, are considerably reduced. This is because the sex of the first child will not be deliberately\nchosen, and PGD is only used to choose a child of the",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 35
  },
  {
    "text": " “opposite” sex, rather than being used in a\nsystematic way to select embryos of a specific sex.\nGiven that the risks to the values of society should be limited or non-existent, if parents wish to exercise\ntheir autonomy by choosing to have a balanced family some argue why should they not do so? On the other\nhand, the deliberate selection of embryos with particular characteristics may give rise to fears about\ninstrumentalisation of a child and of a slippery slope to selecting children on the bas",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 35
  },
  {
    "text": "is of other\ncharacteristics. For example, if two children of the family were good at sport would it be acceptable to select\n– should this be technically possible – a future child on the basis of potential for musical talent? It could also\nbe considered, with regard to the proportionality principle, that implications for the parents of not having\n35",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 35
  },
  {
    "text": "access to a such procedure for family balancing would be limited with regard to the possible risks of\nextending such selection.\nWorldwide the morality of family balancing continues to be debated, and there is a greater divergence of\nviews on this issue than on sex selection for other social reasons, which is generally regarded as\nunacceptable. Article 14 of the Convention on Human Rights and Biomedicine would however prohibit the\nuse of medically assisted procreation techniques for this purpose.",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 36
  },
  {
    "text": "\nD. PGD use for immunocompatibility analysis\nAnother application of PGD has been found which although it may serve a health purpose for the embryo\nitself also has another purpose. An example might be the situation where a child of a family suffers from an\nextremely serious illness, such as Fanconi anaemia. A treatment has been developed that involves the\nremoval and transplant of blood cells from the umbilical cord of another child free of the illness and having\nmatching HLA in order to prevent ",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 36
  },
  {
    "text": "problems arising from rejection of the transplant. PGD could be used in\norder to establish whether a future child would meet these criteria. Consequently, in vitro fertilisation is also\nnecessary, although the question of parental infertility does not arise. PGD in this situation has two\nobjectives: to ensure HLA compatibility with the existing child, and to confirm that the future child is free from\nthe relevant illness.\nSome argue that this is a distortion of the original purpose of PGD. It is",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 36
  },
  {
    "text": " argued that the unborn child,\nsometimes referred to as a “designer baby” (although as noted previously this term is misleading) will not be\nconceived for his/her own sake, but for another person’s benefit. This is the first ethical objection. However,\na parent might answer that they desire to have another, healthy, child in any event. Some commentators\nhave emphasised the importance of the motivations of the parents in determining whether PGD in a specific\nsituation would be ethically acceptabl",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 36
  },
  {
    "text": "e.\nHowever, more practically, it would be very difficult to truly establish what the motivations of the parents\nmight be prior to initiating the procedure. For example, in a situation where PGD was undertaken and those\nembryos that were found to be free of disease were not HLA compatible with the existing child, if the couple\nrefused to permit the transfer of any of those embryos it could be inferred that their original motivation –\nwhatever they might have said previously – was not purely to ha",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 36
  },
  {
    "text": "ve a healthy child. Although it may be\ndifficult to establish the exact motivation of the parents, as with all IVF treatment, it is generally agreed that\nnon-directive counselling should be undertaken to ensure the welfare of any future child is carefully\nconsidered. In particular, parents need to consider in advance their potential reactions should an umbilical\ncord blood transplant be undertaken, if it failed to produce a benefit.\nA second ethical objection highlights the fact that in such cir",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 36
  },
  {
    "text": "cumstances if an embryo was found to be\nhealthy but not HLA-compatible, transfer to the uterus could not assist the existing child – the question\nraised then would be the fate of that embryo. The options might include transfer to the uterus in any event,\nconservation for a possible transfer at a later moment or destruction. If the latter were the case, it is argued\nthat this would be a clear “instrumentalisation” of the embryo.\nIn addition, if an embryo was transferred that was both free of the ",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 36
  },
  {
    "text": "illness and HLA compatible, there are\npotential concerns about the welfare of the future child. For example, should it prove impossible to obtain\nthe umbilical cord blood – or a sufficient amount of it – the parents might seek to have bone marrow\nremoved from the child to be used in the treatment of the sick child, or indeed to commence a further\nPGD/IVF procedure for the purpose of obtaining another embryo to obtain the necessary material to treat\nthe sick child. Again, concerns about instrumen",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 36
  },
  {
    "text": "talisation arise.\nIt should also be noted that umbilical cord blood transplants could be used to treat a wide range of diseases,\nincluding some that are not genetically based. In such cases, some would consider it desirable to use PGD\npurely for the purposes of establishing HLA compatibility. Unlike in the first example, where PGD could be\nconsidered to offer potential benefits for the embryo concerned by establishing that the latter did not carry a\nserious disease, in such a case PGD would offe",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 36
  },
  {
    "text": "r no benefits to the embryo.\nSome argue that the duty of family solidarity means that it is appropriate to use PGD in this way to promote\nsuch solidarity. Further, it is argued that the duty of social solidarity means that society should not make it\nimpossible for a parent to access a life saving treatment for his or her child. In contrast, others argue that to\n36",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 36
  },
  {
    "text": "use PGD in this way, particularly when it serves no health purpose for the embryo concerned, is a distortion\nof both PGD and of medically assisted procreation, and that furthermore the use of such techniques for\nthese purposes would involve an unacceptable instrumentalisation of a child.\nVI. Conclusion\nThis report aimed at giving an overview of current positions found in Europe regarding the protection of the\nhuman embryo in vitro and the arguments supporting them.\nIt shows a broad consensus on ",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 37
  },
  {
    "text": "the need for the protection of the embryo in vitro. However, the definition of\nthe status of the embryo remains an area where fundamental differences are encountered, based on strong\narguments. These differences largely form the basis of most divergences around the other issues related to\nthe protection of the embryo in vitro.\nNevertheless, even if agreement cannot be reached on the status of the embryo, the possibility of re-\nexamining certain issues in the light of the latest developments in t",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 37
  },
  {
    "text": "he biomedical field and related potential\ntherapeutic advances could be considered. In this context, while acknowledging and respecting the\nfundamental choices made by the different countries, it seems possible and desirable with regard to the\nneed to protect the embryo in vitro on which all countries have agreed, that common approaches be\nidentified to ensure proper conditions for the application of procedures involving the creation and use of\nembryos in vitro. The purpose of this report is to ",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 37
  },
  {
    "text": "aid reflection towards that objective.\n37",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 37
  },
  {
    "text": "APPENDIX I\nFigure 1\nChronology of embryo development until implantation\n38",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 38
  },
  {
    "text": "Figure 2\nFirst stages of embryo development\n39",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 39
  },
  {
    "text": "APPENDIX II\nGlossary\n§ Aneuploidy a condition in which the number of chromosomes in the cell differs from the normal\nnumber.\n§ Blastomeres cells into which an embryo divides during cleavage stage.\n§ Blastocyst the stage normally reached 5 to 7 days after fertilisation; the stage at which implantation\nprocess in the uterus begins.\n§ Embryonic stem cells (ES cells) embryonic cells that can proliferate indefinitely and differentiate into\nmany different tissues.\n§ Cell nuclear transfer cloning techn",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 40
  },
  {
    "text": "ique where the nucleus of a cell from the organism (e.g. animal)\nwhich we want to clone is transferred into an oocyte whose own nucleus has been removed.\n§ Cell differentiation the progressive restriction in potential cell fates, until acquisition of a specialised\nfunction is achieved.\n§ Endometriosis presence of endometrial tissue (normally restricted to uterus) in abnormal locations\nsuch as Fallopian tubes, ovaries or the peritoneal cavity.\n§ Fertilisation begins when the male gamete penetrate",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 40
  },
  {
    "text": "s the oocyte and ends when male and female\nchromosomes come together to form the zygote.\n§ Folliculogenesis the entire maturation process of the follicle in the ovary.\n§ Implantation process which lasts about one week, beginning when the blastocyst attaches to the wall\nof the uterus of the woman and ending when the embryo is fully embedded in the wall of the uterus, or\nexceptionally in an extrauterine place.\n§ Inner cell mass group of cells in the blastocyst which would make up the fetus and som",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 40
  },
  {
    "text": "e of the\nsurrounding membranes.\n§ Karyotype analysis of the number, size and shape of an individual’s chromosomes.\n§ Meiosis the process by which germ cells (i.e. reproductive cells from the ovary or the testes) divide to\nproduce haploid gametes (i.e. which contain only one set of chromosomes which results from the\nrecombination between the maternal and paternal chromosome set).\n§ Monozygotic derived from one zygote.\n§ Ovarian hyperstimulation syndrome results from an overstimulation of the ovar",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 40
  },
  {
    "text": "y by hormonal\ntreatment. In its moderate form, it is characterised in particular by enlarged ovaries due to big ovarian\ncysts. In its more severe form it can be potentially life threatening.\n§ Oocyte the mature oocyte, also called ovum or egg, is the female gamete, possessing a genome\nreduced by half (haploid genome), ie normally 23 chromosomes.\n§ Oocyte in the process of fertilisation the result of the penetration of a male gamete into an oocyte; it\ncontains two nuclei (pronuclei), a male pronu",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 40
  },
  {
    "text": "cleus containing the set of chromosomes of the male\ngamete, and a female pronucleus, containing the set of chromosomes of the female gamete.\n§ Penetrance factor the frequency with which persons carrying a genetic characteristic responsible for a\ndisease show signs of the disease.\n40",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 40
  },
  {
    "text": "§ Polyploid which contains three or more sets of chromosomes rather that the normal two sets (more\nthan 46 chromosomes in human beings).\n§ Pronuclei the haploid nuclei of the oocyte and the spermatozoa after fertilisation but before the\ndissolution of their membrane and the first division of the fertilised egg.\n§ Pluripotent a cell possessing the potential to become any tissue in the final organism.\n§ Somatic cells all body cells that are not part of the germ line.\n§ Spermatid haploid (one set o",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 41
  },
  {
    "text": "f chromosomes) germ cell resulting from the second meiotic division of\nspermatogenesis which will then differentiate into spermatozoa.\n§ Spermatocyte diploid (two sets of chromosomes) germ cell which will undergo two meiotic divisions to\ngive haploid spermatids.\n§ Totipotent a cell from which an entire organism can be formed.\n§ Zygote the final stage of fertilisation, the single cell formed when the two sets of chromosomes, one\nfrom the male gamete, the other from the female gamete, have joined.",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 41
  },
  {
    "text": "\n41",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 41
  },
  {
    "text": "APPENDIX III\nSelected European reference documents\n• Convention for the protection of human rights and dignity of the human being with regard to the\napplication of biology and medicine: Convention on human rights and biomedicine (Oviedo, 4.iv.1997)\n..........................................................................................................................................ETS n° 164\nhttp://conventions.coe.int/Treaty/EN/WhatYouWant.asp?NT=164&CM=7&DF=\n• Additional Protocol to the Conv",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 42
  },
  {
    "text": "ention for the protection of human rights and dignity of the human being\nwith regard to the application of biology and medicine, on the prohibition of cloning human beings..............\n..........................................................................................................................................ETS n° 168\nhttp://conventions.coe.int/Treaty/EN/WhatYouWant.asp?NT=168&CM=7&DF=\n• Medically assisted procreation and the protection of the human embryo: comparative study on th",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 42
  },
  {
    "text": "e\nsituation in 39 states\nCloning comparative study on the situation in 44 states........................................................CDBI/INF (98) 8\nhttp://www.coe.int/T/E/Legal%5FAffairs/Legal%5Fco%2Doperation/Bioethics/Texts%5Fand%5Fdocuments/\nCDBI-INF(98)8PMA.pdf\n• IIIrd Symposium on Medically Assisted Procreation and Protection of the Human Embryo...........\n.....................................................................................................................15-18 December ",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 42
  },
  {
    "text": "1996\nhttp://www.coe.int/T/E/Legal%5FAffairs/Legal%5Fco%2Doperation/Bioethics/Conferences%5Fand%5Fsym\nposium/Symposium%20Embryo%201996%20Programme.asp#TopOfPage\n• Ethical aspects on cloning .................................................................Opinion no. 9 of 28 May 1997\n...................................from the European Group on Ethics in Science and New Technologies (EGE)\nhttp://europa.eu.int/comm/european_group_ethics/gaieb/en/opinion9.pdf\n• Ethical aspects of human stem cells re",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 42
  },
  {
    "text": "search and use............Opinion no. 15 of 14 November 2000\n.................................. from the European Group on Ethics in Science and New Technologies (EGE)\nhttp://europa.eu.int/comm/european_group_ethics/docs/avis15_en.pdf\n• Report on human embryonic stem cell research (European Commission).............SEC(2003)441\nhttp://europa.eu.int/comm/research/conferences/2003/bioethics/pdf/sec2003-441report_en.pdf\n• Universal Declaration on the Human Genome and Human Rights..................11",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 42
  },
  {
    "text": " November 1997\nhttp://unesdoc.unesco.org/images/0010/001096/109687eb.pdf\n42",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 42
  },
  {
    "text": "APPENDIX IV\nExperts\nMEMBERS OF THE WORKING PARTY ON THE PROTECTION OF THE HUMAN EMBRYO AND FETUS\nProf. Yvon ENGLERT, Président du Groupe HEF, Clinique de Fertilité Erasme, Route de Lennik 808, B-\n1070 BRUXELLES (until 2001)\nMme Sylviane FRIART, Conseiller, Ministère de la Justice, 115 bd de Waterloo, B-1000 BRUXELLES\nMrs Grete GJERTSEN, Adviser, Ministry of Health and Social Affairs, PO Box 8011 Dep., N-0030 OSLO 1\nMrs Ellen A. M. DE HILSTER, Counsellor of Legislation, Ministry of Justice, Sched",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 43
  },
  {
    "text": "eldoekshaven 100,\nPostbox 20301, 2500 EH DEN HAGUE (until 2001)\nMrs Ljubov KURILO, National Research Centre for Medical Genetics Russian Academy of Medical\nSciences, PO Box Moskvorechie str. 1, 115478 MOSCOW\nDr Anne McLAREN, Principal Research Associate, Wellcome/CRC Institute, Tennis Court Road, Cambridge\nCB2 1QR\nM. Jean MICHAUD, ancien Conseiller à la Cour de Cassation, membre du Comité Consultatif National\nd’Ethique, 2 rue Ernest Renan, 75015 PARIS\nProf. Dr. theol. Dietmar MIETH, Abteilung f.",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 43
  },
  {
    "text": " Theologische Ethik, der Universität Tübingen, Blumenstrasse 3,\n72149 TÜBINGEN\nDr Miguel PARDO, Scientific Director, Centro Internacional Medicine Avanzada, C/Osi, 14-16, 1°1a 08034\nBARCELONA\nM. Daniel SERRÃO (Chair), M. D., Ph. D, Professeur de bioéthique et d’éthique médicale à la Faculté de\nMédecine de Porto, Laboratoire d’Anatomie pathologique, Rua de São Tomé 746, P-4200 PORTO\nMs Sylvia TOMOVA, Conseiller juridique en chef, Université de Médecine, 15 bd Dimitar Nestorov 15, BG-\n1000 SOFIA\nC",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 43
  },
  {
    "text": "OMITE EUROPEEN DE LA SANTE (CDSP) : Professor Helge BOMAN, Department of Medical Genetics,\nHaukeland University Hospital, University of Bergen, PO BOX 1, 5021 BERGEN, Norway\n(until 2000)\nEUROPEAN COMMISSION\nDr. Line MATTHIESSEN, Principal Scientific Officer, Commission Européenne, Direction Générale de la\nRecherche, Direction B.0 – Biotechnology, agriculture and food, SDME Bureau 9/8, Rue de la Loi 200, B-\n1049 Bruxelles\nM. Hugh WHITTALL, Scientific Officer, DG XII-E5, Office SDME 8/03, Commissi",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 43
  },
  {
    "text": "on des Communautés\nEuropéennes, rue de la Loi 200, B-1049 BRUXELLES (until 1999)\n43",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 43
  },
  {
    "text": "EXPERTS NOT MEMBERS OF THE WORKING PARTY HAVING CONTRIBUTED TO THE REPORT\nProf. Göran HERMEREN, President of the European Group on Ethics, Dept. of Medical Ethics, Lund\nUniversitySt. Gräbrödersgatan 16, 22222 LUND, Sweden\nDr Jacques MONTAGUT, Directeur de l'IFREARES, 20 route de Revel, 31400 TOULOUSE, France\nProf. Dr. Jochen TAUPITZ, Managing Director, Institute for German, European and International Medical\nLaw, Public Health Law and Bioethics of the Universities of Heidelberg an Mannheim, D-68",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 44
  },
  {
    "text": "131 Mannheim\nDr Stéphane VIVILLE, Head of PGD Center at Strasbourg University Hospital, IGBMC, 1 rue Laurent Fries,\nBP 10142, 67404 ILLKIRCH Cedex, France\n44",
    "source": "3. Report on the Protection of the Human Embryo in Vitro Author Council of Europe.pdf",
    "page": 44
  }
]